,CAS,URL,Highest Development Event Status and Year,Highest Development Event Source ID,Highest Development Event Source URL,Earliest Approved Event Status and Year,Earliest Approved Event Source ID,Earliest Approved Event Source URL,conditions,phases
0,623-84-7,https://drugs.ncats.io/drug/5Z492UNF9O,Possibly Marketed Outside US 1996,ANDA040166,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0ec47b7-c13a-4fa0-91fe-d7a03c70aec9,Possibly Marketed Outside US 1996,ANDA040166,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0ec47b7-c13a-4fa0-91fe-d7a03c70aec9,Bacillus cereus infection,Basic research
1,36653-82-4,https://drugs.ncats.io/drug/936JST6JCN,US Previously Marketed 1990,EXOSURF NEONATAL by GLAXOSMITHKLINE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020044,Possibly Marketed Outside US 1984,"NU-DERM SUNFADER  Skin Lightener with Sunscreen (SPF 15) PABA FREE by OMP, INC.",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c67b0629-5529-412d-99ee-186df4ecad5a,"Dry, itchy skin; Respiratory distress syndrome, neonatal",Approved; Approved
2,112-92-5,https://drugs.ncats.io/drug/2KR89I4H1Y,US Previously Marketed ,"21 CFR 310.545(a)(18)(i)(B) skin protectant:w/ sales less than $25,000 stearyl alcohol",https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-545.xml,Possibly Marketed Outside US 1970,Ala Quin by Crown Laboratories,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2ae30c6-ad64-47ed-b371-778eaebeeddf,SUNBURN,Approved
3,328-50-7,https://drugs.ncats.io/drug/8ID597Z82X,Possibly Marketed Outside US ,ALPHA-KETOGLUTARATE,http://naturaldatabase.therapeuticresearch.com/nd/PrintVersion.aspx?id=144&AspxAutoDetectCookieSupport=1 | http://www.webmd.com/vitamins-supplements/ingredientmono-144-alpha-ketoglutarate.aspx?activeingredientid=144&activeingredientname=alpha-ketoglutarate,,,,Osteoporosis; Gastrointestinal microbiota imbalance; Short bowel syndrome; Burn; Kidney failure,Not Provided; Not Provided; Not Provided; Approved; Approved
4,67-63-0,https://drugs.ncats.io/drug/ND2M416302,US Approved OTC ,21 CFR 344.12 otic:ear drying aid isopropyl alcohol,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec344-12.xml,US Previously Marketed 1921,Rubbing Alcohol,https://books.google.com/books?id=1n4gAQAAMAAJ&newbks=1&newbks_redir=0&dq=alcohol%20rubbing%20usp&pg=PA85#v=onepage&q=alcohol%20rubbing%20usp&f=false,,
5,56-12-2,https://drugs.ncats.io/drug/2ACZ6IPC6I,Possibly Marketed Outside US ,Theracodeine-300 by Physician Therapeutics Llc,https://www.drugbank.ca/drugs/DB02530,Possibly Marketed Outside US 2009,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1725b5af-fe03-4372-beaf-d6fd9088a1f1,Type 1 diabetes mellitus; Stress; Vascular diseases of the brain; Atherosclerosis of cerebral arteries; Chronic cerebrovascular insufficiency; Partial Seizures,Phase II; Phase I; Approved; Approved; Approved; Not Provided
6,566-19-8,https://drugs.ncats.io/drug/2334LJD2E9,Possibly Marketed Outside US 2015,21 CFR 348,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c5854bb-b51a-4583-9148-6f76c59ff24c,Possibly Marketed Outside US 2015,21 CFR 348,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c5854bb-b51a-4583-9148-6f76c59ff24c,,
7,148-24-3,https://drugs.ncats.io/drug/5UTX5635HP,US Previously Marketed ,21 CFR 310.545(a)(18)(ii) skin protectant:astringent oxyquinoline sulfate,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-545.xml,Possibly Marketed Outside US 1964,UDDER BALM by H. W. Naylor Company Inc.,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2907f343-4457-bf36-2e0b-aa074e63a4bd,Unknown,
8,136470-78-5,https://drugs.ncats.io/drug/WR2TIP26VS,US Approved Rx 2017,ANDA204990,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204990,US Previously Marketed 1998,ZIAGEN by VIIV HLTHCARE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020977,HIV-1 infection,Approved
9,247062-33-5,https://drugs.ncats.io/drug/AVK0I6HY2U,US Approved Rx 2017,NDA208743,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208743,US Approved Rx 2017,NDA208743,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208743,Osteoporosis,Approved
10,183552-38-7,https://drugs.ncats.io/drug/W486SJ5824,US Previously Marketed 2003,PLENAXIS by SPECIALITY EUROPEAN,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021320,US Previously Marketed 2003,PLENAXIS by SPECIALITY EUROPEAN,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021320,Advanced prostate cancer,Approved
11,332348-12-6,https://drugs.ncats.io/drug/7D0YB67S97,US Approved Rx 2005,BLA125118,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125118,US Approved Rx 2005,BLA125118,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125118,,
12,143653-53-6,https://drugs.ncats.io/drug/X85G7936GV,US Approved Rx 1994,BLA103575,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103575,Possibly Marketed Outside US 1993,BLA103575,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=033d4c3b-4630-4256-b8f7-9ed5f15de9a3,,
13,1231929-97-7,https://drugs.ncats.io/drug/60UAB198HK,US Approved Rx 2017,NDA208716,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716,US Approved Rx 2017,NDA208716,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716,Breast cancer; Melanoma; Glioblastoma; Non-small cell lung cancer; HER2-negative advanced breast cancer,Phase III; Phase II; Phase II; Phase III; Approved
14,154229-18-2,https://drugs.ncats.io/drug/EM5OCB9YJ6,US Approved Rx 2023,NDA216793,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216793,US Approved Rx 2011,NDA202379,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202379,Metastatic castration-resistant prostate cancer,Approved
15,1420477-60-6,https://drugs.ncats.io/drug/I42748ELQW,US Approved Rx 2022,NDA216387,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216387,US Approved Rx 2017,NDA210259,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210259,Chronic lymphocytic leukemia; Rheumatoid arthritis; Glioblastoma multiforme; Mantle cell lymphoma; Head and neck squamous cell carcinoma; mantle cell lymphoma,Phase III; Phase II; Phase II; Phase II; Phase II; Approved
16,77337-76-9,https://drugs.ncats.io/drug/N4K14YGM3J,US Approved Rx 2013,ANDA202229,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202229,US Previously Marketed 2004,CAMPRAL by FOREST LABS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021431,Alcohol addiction,Approved
17,56180-94-0,https://drugs.ncats.io/drug/T58MSI464G,US Approved Rx 2009,ANDA078441,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=078441,US Previously Marketed 1995,PRECOSE by BAYER HLTHCARE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020482,Type 2 diabetes mellitus,Approved
18,37517-30-9,https://drugs.ncats.io/drug/67P356D8GH,US Approved Rx 1995,ANDA074007,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=074007,US Previously Marketed 1984,SECTRAL by PROMIUS PHARMA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018917,Ventricular arrhythmia; Hypertension,Approved; Approved
19,110042-95-0,https://drugs.ncats.io/drug/UZ29E6L2X8,Possibly Marketed Outside US 2014,21 CFR 347,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=122273ec-d670-4606-baf8-c9fe3fddebed,Possibly Marketed Outside US 2014,21 CFR 347,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=122273ec-d670-4606-baf8-c9fe3fddebed,,
20,61-00-7,https://drugs.ncats.io/drug/54EJ303F0R,Possibly Marketed Outside US ,Canada:ACEPROMAZINE MALEATE,https://tripod.nih.gov/npc/#Download,Possibly Marketed Outside US 2011,NADA015030,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11ee8981-46eb-4791-8e40-727c991341fe,Agitation (veterinary); Schizophrenia,Approved; Not Provided
21,33665-90-6,https://drugs.ncats.io/drug/MA3UYZ6K1H,Possibly Marketed Outside US 2012,21 CFR 334,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=62cbf4ea-5ae5-4f4d-b054-6fe4635a93fe,Possibly Marketed Outside US 2002,NDA022410,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16695a4c-9e32-4a4d-8aa9-e10fd2412a46,Obesity,Approved
22,59-66-5,https://drugs.ncats.io/drug/O3FX965V0I,US Approved Rx 2023,ANDA211151,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211151,US Previously Marketed 1953,DIAMOX by TEVA BRANDED PHARM,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=008943,Open-angle glaucoma; Acute mountain sickness,Approved; Approved
23,64-19-7,https://drugs.ncats.io/drug/Q40Q9N063P,US Approved Rx 1978,ANDA085998,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=085998,US Previously Marketed 1921,Sodium Chloride U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Otitis externa; Cyanide poisoning,Approved; Approved
24,968-81-0,https://drugs.ncats.io/drug/QGC8W08I6I,US Previously Marketed 1986,ACETOHEXAMIDE by USL PHARMA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=070754,US Previously Marketed 1964,DYMELOR by LILLY,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=013378,Type 2 diabetes mellitus,Approved
25,546-88-3,https://drugs.ncats.io/drug/4RZ82L2GY5,US Approved Rx 1983,NDA018749,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018749,US Approved Rx 1983,NDA018749,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018749,chronic urea-splitting urinary infection,Approved
26,67-64-1,https://drugs.ncats.io/drug/1364PS73AF,US Previously Marketed 1921,Acetone U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Acetone U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,,
27,3040-38-8,https://drugs.ncats.io/drug/6DH1W9VH8Q,US Approved Rx 1985,NDA018948,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018948,US Approved Rx 1985,NDA018948,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018948,Systemic primary carnitine deficiency; Ulcerative colitis; Peripheral arterial occlusive disorders; Congestive heart failure,Approved; Phase III; Approved; Phase III
28,51-84-3,https://drugs.ncats.io/drug/N9YNS0M02X,US Approved Rx 1993,NDA020213,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020213,US Previously Marketed 1966,MIOCHOL by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016211,Mydriasis,Approved
29,616-91-1,https://drugs.ncats.io/drug/WYQ7N0BPYC,US Approved Rx 2012,ANDA203853,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203853,US Previously Marketed 1963,MUCOMYST by APOTHECON,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=013601,Cystic fibrosis; Hepatic injury,Approved; Approved
30,50-78-2,https://drugs.ncats.io/drug/R16CO5Y76E,US Approved OTC ,21 CFR 343.13(b) internal analgesic:rheumatologic aspirin (buffered),https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec343-13.xml,US Previously Marketed 1899,"Aspirin by Friedr. Bayer & Co., Elberfeld, Germany",https://catalog.hathitrust.org/Record/100782317,Headache; Pain; Stroke; Myocardial infarction,Approved; Approved; Approved; Approved
31,80-74-0,https://drugs.ncats.io/drug/WBT5QH3KED,US Previously Marketed 1949,Gantrisin by Hoffmann-La Roche,DeHaen 1940-1975 NMEs,US Previously Marketed 1948,GANTRISIN by ROCHE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006525,Acute otitis media,Approved
32,977000-16-0,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
33,59277-89-3,https://drugs.ncats.io/drug/X4HES1O11F,US Approved Rx 2019,ANDA210774,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210774,US Approved Rx 1982,NDA018604,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018604,Cold sores; Genital herpes; Herpes zoster infections; Herpes simplex infection; Herpes zoster infections,Approved; Approved; Approved; Approved; Approved
34,55079-83-9,https://drugs.ncats.io/drug/LCH760E9T7,US Approved Rx 2013,ANDA202897,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202897,US Previously Marketed 1996,SORIATANE by STIEFEL LABS INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019821,Psoriasis,Approved
35,320345-99-1,https://drugs.ncats.io/drug/UQW7UF9N91,US Approved Rx 2019,NDA210595,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210595,US Approved Rx 2012,NDA202450,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202450,Bronchospasm associated with chronic obstructive pulmonary disease,Approved
36,87848-99-5,https://drugs.ncats.io/drug/A20F9XAI7W,US Previously Marketed 1994,SEMPREX-D by AUXILIUM PHARMS LLC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019806,US Previously Marketed 1994,SEMPREX-D by AUXILIUM PHARMS LLC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019806,Seasonal allergic rhinitis,Approved
37,331731-18-1,https://drugs.ncats.io/drug/ad622025,,,,,,,,
38,106685-40-9,https://drugs.ncats.io/drug/1L4806J2QF,US Approved Rx 2018,ANDA206959,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206959,US Approved Rx 1996,NDA020380,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020380,Acne vulgaris,Approved
39,142340-99-6,https://drugs.ncats.io/drug/U6Q8Z01514,US Approved Rx 2013,ANDA202051,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202051,US Previously Marketed 2002,HEPSERA by GILEAD,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021449,Chronic hepatitis B,Approved
40,29908-03-0,https://drugs.ncats.io/drug/7LP2MPO46S,Possibly Marketed Outside US ,WHO-ATC:A16AA02,https://ginas.ncats.nih.gov/ginas/app/substance/7LP2MPO46S,,,,"Non-alcoholic fatty liver disease; Liver disease, alcoholic; Depression; Osteoarthritis; Fibromyalgia",Phase III; Phase III; Approved; Approved; Approved
41,58-61-7,https://drugs.ncats.io/drug/K72T3FS567,US Approved Rx 2005,ANDA077133,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077133,US Previously Marketed 1976,VIRA-A by PARKEDALE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050486,Keratoconjunctivitis; Epithelial keratitis; Herpes simplex infection; Paroxysmal supraventricular tachycardia,Approved; Approved; Phase III; Approved
42,56-65-5,https://drugs.ncats.io/drug/8L70Q75FXE,Possibly Marketed Outside US ,Japan:Adenosine 5'-Triphosphate Disodium,https://tripod.nih.gov/npc/#Download,Possibly Marketed Outside US 2009,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1725b5af-fe03-4372-beaf-d6fd9088a1f1,,
43,606-17-7,https://drugs.ncats.io/drug/TKQ858A3VW,US Previously Marketed 1958,SINOGRAFIN by BRACCO,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011324,US Previously Marketed 1954,CHOLOGRAFIN MEGLUMINE by BRACCO,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=009321,Hepatobiliary disease,Approved
44,850140-72-6,https://drugs.ncats.io/drug/41UD74L59M,US Approved Rx 2013,NDA201292,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201292,US Approved Rx 2013,NDA201292,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201292,Non-small cell lung cancer,Approved
45,862111-32-8,https://drugs.ncats.io/drug/1567f7b0,,,,,,,,
46,104138-64-9,https://drugs.ncats.io/drug/2HLC17MX9G,US Approved Rx 2003,BLA103979,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103979,US Approved Rx 2003,BLA103979,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103979,,
47,56-41-7,https://drugs.ncats.io/drug/OF5P57N2ZX,US Previously Marketed ,21 CFR 310.532(a) benign prostatic hypertrophy alanine,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-532.xml,Possibly Marketed Outside US 1971,NDA016822,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6ea7ec73-403e-4303-8862-6380e2f1fda6,Fructose intolerance; Muscle atrophy; Low birth weight; Burns,Natural Metabolite; Natural Metabolite; Natural Metabolite; Approved
48,146961-76-4,https://drugs.ncats.io/drug/7QVV6I50DT,US Previously Marketed 1997,TROVAN PRESERVATIVE FREE by PFIZER,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020760,US Previously Marketed 1997,TROVAN PRESERVATIVE FREE by PFIZER,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020760,Complicated skin and skin structure infections; Pneumonia; Intra-abdominal infections; Complicated intra-abdominal infections; Skin infections; Pneumonia; Gynecologic infections; Nosocomial pneumonia,Approved; Approved; Approved; Withdrawn; Withdrawn; Withdrawn; Withdrawn; Withdrawn
49,54965-21-8,https://drugs.ncats.io/drug/F4216019LN,US Approved Rx 2019,ANDA208094,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208094,Possibly Marketed Outside US 1989,NADA110048,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94cf5818-f27d-4374-87ad-54a2d9ce6ef1,Neurocysticercosis; Hydatid disease,Approved; Approved
50,782500-75-8,https://drugs.ncats.io/drug/5E7U48495E,US Previously Marketed 2014,TANZEUM by GLAXOSMITHKLINE LLC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125431,US Previously Marketed 2014,TANZEUM by GLAXOSMITHKLINE LLC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125431,,
51,33069-62-4,https://drugs.ncats.io/drug/P88XT4IS4D,US Approved Rx 2018,ANDA205720,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205720,US Previously Marketed 1992,TAXOL by HQ SPCLT PHARMA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020262,Advanced carcinoma of the ovary; Non-small cell lung cancer; Breast cancer,Approved; Approved; Approved
52,1357448-54-4,https://drugs.ncats.io/drug/A57KX1VL5P,Possibly Marketed Outside US ,EU/1/16/1095/004,https://www.drugbank.ca/drugs/DB13884,Possibly Marketed Outside US 2016,BLA125582,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f74301bf-95e2-44ab-a8b6-98aa07b04683,,
53,147084-10-4,https://drugs.ncats.io/drug/7Z8O94ECSX,US Approved Rx 2024,ANDA209706,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209706,US Approved Rx 2010,NDA022134,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022134,Itching associated with allergic conjunctivitis,Approved
54,67452-97-5,https://drugs.ncats.io/drug/136H45TB7B,US Approved Rx 2005,ANDA076973,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=076973,US Previously Marketed 1982,ACLOVATE by FOUGERA PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018707,Corticosteroid-responsive dermatoses,Approved
55,110942-02-4,https://drugs.ncats.io/drug/M89N0Q7EQR,US Approved Rx 1992,BLA103293,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103293,US Approved Rx 1992,BLA103293,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103293,,
56,5579-81-7,https://drugs.ncats.io/drug/8T66I31YNK,US Approved OTC ,21 CFR 346.20(a) anorectal:keratolytic alcloxa,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec346-20.xml,US Previously Marketed 1961,ALLANTOMIDE ALLANTOIN by NATIONAL DRUG,https://www.govinfo.gov/content/pkg/FR-1972-02-12/pdf/FR-1972-02-12.pdf,Chaffing; Functional dyspepsia; Gastritis; Duodenal ulcer; Gastric ulcer,Not Provided; Preclinical; Approved; Approved; Approved
57,1256580-46-7,https://drugs.ncats.io/drug/LIJ4CT1Z3Y,US Approved Rx 2015,NDA208434,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208434,US Approved Rx 2015,NDA208434,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208434,"Anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer",Approved
58,222535-22-0,https://drugs.ncats.io/drug/ELK3V90G6C,US Previously Marketed 2003,Amevive,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125036,US Previously Marketed 2003,Amevive,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125036,,
59,216503-57-0,https://drugs.ncats.io/drug/3A189DH42V,US Approved Rx 2001,BLA103948,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103948,US Approved Rx 2001,BLA103948,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103948,,
60,66376-36-1,https://drugs.ncats.io/drug/X1J18R4W8P,US Approved Rx 2009,ANDA090258,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=090258,US Approved Rx 1995,NDA020560,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020560,Glucocorticoid-induced osteoporosis; Osteoporosis; Paget's disease,Approved; Approved; Approved
61,71195-58-9,https://drugs.ncats.io/drug/1N74HM2BS7,US Approved Rx 1986,NDA019353,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019353,US Approved Rx 1986,NDA019353,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019353,Pain,Approved
62,81403-80-7,https://drugs.ncats.io/drug/90347YTW5F,US Approved Rx 2012,ANDA079060,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=079060,US Approved Rx 2003,NDA021287,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021287,Benign prostatic hyperplasia,Approved
63,9005-32-7,https://drugs.ncats.io/drug/8C3Z4148WZ,US Previously Marketed ,21 CFR 310.545(a)(20) weight control alginic acid,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-545.xml,Possibly Marketed Outside US 2002,NDA013217,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e1ec092-4748-47c6-9b72-1b826da0ce02,,
64,143003-46-7,https://drugs.ncats.io/drug/27T56C7KK0,US Previously Marketed 1991,Ceredase by Genzyme,OB NME Appendix 1950-1993,US Previously Marketed 1991,Ceredase by Genzyme,OB NME Appendix 1950-1993,,
65,420784-05-0,https://drugs.ncats.io/drug/DTI67O9503,US Approved Rx 2010,BLA125291,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125291,US Approved Rx 2006,BLA125141,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125141,,
66,1245916-14-6,https://drugs.ncats.io/drug/PP0SHH6V16,US Approved Rx 2015,BLA125559,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125559,US Approved Rx 2015,BLA125559,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125559,,
67,173334-57-1,https://drugs.ncats.io/drug/502FWN4Q32,US Approved Rx 2019,ANDA206665,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206665,US Approved Rx 2007,NDA021985,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021985,Hypertension,Approved
68,5300-03-8,https://drugs.ncats.io/drug/1UA8E65KDZ,US Approved Rx 2019,ANDA211644,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211644,US Previously Marketed 1971,RETIN-A by VALEANT INTL,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016921,severe recalcitrant nodular acne; Acne vulgaris; Acute promyelocytic leukemia; AIDS-related Kaposi’s sarcoma,Approved; Approved; Approved; Approved
69,55-98-1,https://drugs.ncats.io/drug/G1LN9045DK,US Approved Rx 1999,NDA020954,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020954,US Previously Marketed 1954,Myleran by Burroughs Wellcome,OB NME Appendix 1950-1985,Chronic myeloid leukemia,Approved
70,97-59-6,https://drugs.ncats.io/drug/344S277G0Z,US Approved OTC ,21 CFR 346.20(a) anorectal:keratolytic alcloxa,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec346-20.xml,US Previously Marketed 1961,ALLANTOMIDE ALLANTOIN by NATIONAL DRUG,https://www.govinfo.gov/content/pkg/FR-1972-02-12/pdf/FR-1972-02-12.pdf,Chaffing; Functional dyspepsia; Gastritis; Duodenal ulcer; Gastric ulcer,Not Provided; Preclinical; Approved; Approved; Approved
71,315-30-0,https://drugs.ncats.io/drug/63CZ7GJN5I,US Approved Rx 2007,ANDA078253,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=078253,US Approved Rx 1966,NDA016084,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016084,Lymphoma; Gout; Leukemia,Approved; Approved; Approved
72,57-06-7,https://drugs.ncats.io/drug/BN34FX42G3,US Previously Marketed ,21 CFR 310.545(a)(6)(ii)(A) cough/cold:nasal decongestant allyl isothiocyanate,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-545.xml,,,,,
73,154323-57-6,https://drugs.ncats.io/drug/1O4XL5SN61,US Approved Rx 2015,ANDA205171,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205171,US Previously Marketed 2001,AXERT by JANSSEN PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021001,Migraine,Approved
74,1415-73-2,https://drugs.ncats.io/drug/648RW354S9,,,,,,,Non-small cell lung cancer; Myocardial ischemia-reperfusion injury; Ventricular arrhythmia,Preclinical; Preclinical; Preclinical
75,850649-61-5,https://drugs.ncats.io/drug/JHC049LO86,US Approved Rx 2013,NDA203414,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203414,US Approved Rx 2013,NDA203414,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203414,Type 2 diabetes mellitus,Approved
76,122852-42-0,https://drugs.ncats.io/drug/13Z9HTH115,US Approved Rx 2019,ANDA209180,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209180,US Approved Rx 2000,NDA021107,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021107,Irritable bowel syndrome,Approved
77,7493-95-0,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
78,9005-82-7,https://drugs.ncats.io/drug/7TDQ74Y18L,US Previously Marketed 1961,"SOLUSPONGE CONE AMYLOSE, UNSPECIFIED SOURCE by PANRAY",https://www.govinfo.gov/content/pkg/FR-1971-05-22/pdf/FR-1971-05-22.pdf,US Previously Marketed 1921,"amylose, unspecified source",https://catalog.hathitrust.org/Record/100163146,,
79,7488-99-5,https://drugs.ncats.io/drug/45XWE1Z69V,,,,,,,Lewis lung carcinoma,Preclinical
80,28981-97-7,https://drugs.ncats.io/drug/YU55MQ3IZY,US Approved Rx 2010,ANDA090248,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=090248,US Approved Rx 1981,NDA018276,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018276,Panic disorder; Anxiety,Approved; Approved
81,745-65-3,https://drugs.ncats.io/drug/F5TD010360,US Approved Rx 1996,NDA020700,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020700,US Approved Rx 1981,NDA018484,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018484,Peripheral vascular disorders; congenital heart defects,Phase III; Approved
82,105857-23-6,https://drugs.ncats.io/drug/1RXS4UE564,US Approved Rx 1987,BLA103172,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103172,US Approved Rx 1987,BLA103172,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103172,,
83,645-05-6,https://drugs.ncats.io/drug/Q8BIH59O7H,US Previously Marketed 1990,HEXALEN by EISAI INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019926,US Previously Marketed 1990,HEXALEN by EISAI INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019926,"Ovarian cancer, persistent or recurrent",Approved
84,7429-90-5,https://drugs.ncats.io/drug/CPD4NFA903,US Previously Marketed 1921,Solution of Aluminum Acetico-Tartrate N.F.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Solution of Aluminum Acetico-Tartrate N.F.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,,
85,110070-78-5,https://drugs.ncats.io/drug/A585MN1H2L,Possibly Marketed Outside US ,Canada:SODIUM BENTONITE,https://tripod.nih.gov/npc/#Download,Possibly Marketed Outside US 1946,M006,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=90f80e35-095d-88f9-8ea3-0fd54f1e916c,"Allergy due to ivy, oak and sumac",Approved
86,156053-89-3,https://drugs.ncats.io/drug/Q153V49P3Z,US Approved Rx 2023,ANDA216843,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216843,US Previously Marketed 2008,ENTEREG by CUBIST PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021775,Postoperative ileus,Approved
87,768-94-5,https://drugs.ncats.io/drug/BF4C9Z1J53,US Approved Rx 2018,NDA209410,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209410,US Previously Marketed 1966,SYMMETREL by ENDO PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016020,Influenza A virus infection; Parkinson's disease,Approved; Approved
88,7648-98-8,https://drugs.ncats.io/drug/L16PUN799N,US Previously Marketed 1956,MYTELASE by SANOFI AVENTIS US,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=010155,US Previously Marketed 1956,MYTELASE by SANOFI AVENTIS US,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=010155,Myasthenia gravis,Approved
89,177036-94-1,https://drugs.ncats.io/drug/HW6NV07QEC,US Approved Rx 2022,ANDA210701,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210701,US Approved Rx 2007,NDA022081,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022081,Pulmonary arterial hypertension,Approved
90,51022-69-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
91,90-84-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
92,300-62-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
93,20537-88-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
94,37517-28-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
95,2609-46-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
96,2097132-02-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
97,90-45-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
98,60-32-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
99,125-84-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
100,106-60-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
101,317-34-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
102,504-29-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
103,65-49-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
104,1951-25-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
105,50-48-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
106,68302-57-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
107,88150-42-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
108,7664-41-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
109,14798-03-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
110,57-43-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
111,14028-44-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
112,26787-78-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
113,300-62-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
114,1397-89-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
115,69-53-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
116,161814-49-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
117,60719-84-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
118,463-04-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
119,60-29-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
120,68475-42-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
121,143090-92-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
122,120511-73-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
123,1262449-58-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
124,482-27-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
125,138402-11-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
126,166663-25-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
127,117-37-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
128,471-34-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
129,91-75-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
130,977007-26-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
131,69-72-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
132,69-72-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
133,112-05-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
134,58-73-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
135,7440-36-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
136,9000-94-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
137,956104-40-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
138,503612-47-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
139,58-00-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
140,69-72-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
141,66711-21-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
142,608141-41-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
143,170729-80-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
144,9087-70-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
145,9036-66-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
146,91745-67-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
147,9041-08-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
148,67346-49-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
149,74863-84-6,https://drugs.ncats.io/drug/OCY3U280Y3,US Approved Rx 2021,NDA212035,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212035,US Previously Marketed 2000,ARGATROBAN by SANDOZ,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020883,Heparin-induced thrombocytopenia; Thrombosis,Approved; Approved
150,74-79-3,https://drugs.ncats.io/drug/94ZLA3W45F,US Approved Rx 1973,NDA016931,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016931,US Previously Marketed 1957,Argivine by Gray,DeHaen 1940-1975 NMEs,Gigantism; Acromegaly; Pituitary dwarfism; Panhypopituitarism; Type 2 diabetes mellitus; Hypertension; Preeclampsia,Approved; Approved; Approved; Approved; Phase III; Phase III; Phase III
151,129722-12-9,https://drugs.ncats.io/drug/82VFR53I78,US Approved Rx 2016,ANDA206383,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206383,US Approved Rx 2002,NDA021436,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021436,Major depressive disorder; Autism; Bipolar I disorder; Schizophrenia; Tourette's syndrome; Agitation associated with schizophrenia or bipolar mania,Approved; Approved; Approved; Approved; Approved; Approved
152,1259305-29-7,https://drugs.ncats.io/drug/B786J7A343,US Approved Rx 2016,ANDA206383,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206383,US Approved Rx 2002,NDA021436,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021436,Major depressive disorder; Autism; Bipolar I disorder; Schizophrenia; Tourette's syndrome; Agitation associated with schizophrenia or bipolar mania,Approved; Approved; Approved; Approved; Approved; Approved
153,112111-43-0,https://drugs.ncats.io/drug/V63XWA605I,US Approved Rx 2012,ANDA200043,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200043,US Approved Rx 1998,NDA020717,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020717,Obstructive sleep apnea; Narcolepsy; Sleep disorder,Approved; Approved; Approved
154,7440-38-2,https://drugs.ncats.io/drug/N712M78A8G,US Previously Marketed 1921,"Stronger Pills of Iron, Quinine, Strychnine, and Arsenic N.F.",https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,"Stronger Pills of Iron, Quinine, Strychnine, and Arsenic N.F.",https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,,
155,71963-77-4,https://drugs.ncats.io/drug/C7D6T3H22J,US Approved Rx 2009,NDA022268,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022268,US Approved Rx 2009,NDA022268,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022268,,
156,1362-42-1,https://drugs.ncats.io/drug/OE5992O64P,,,,,,,Acute lung injury,Preclinical
157,23964-58-1,https://drugs.ncats.io/drug/D3SQ406G9X,US Approved Rx 2006,NDA022010,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022010,US Approved Rx 2000,NDA020971,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020971,Pain,Approved
158,7681-49-4,https://drugs.ncats.io/drug/8ZYQ1474W7,US Approved OTC ,21 CFR 355.10(c)(1)(ii) anticaries:dentifrices stannous fluoride,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec355-10.xml,US Previously Marketed 1921,Calcium Oxide U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Dental caries; Unknown,Approved
159,84775-78-0,https://drugs.ncats.io/drug/c9e81cc9,,,,,,,,
160,50-81-7,https://drugs.ncats.io/drug/PQ6CK8PD0R,US Approved Rx 2018,NDA209381,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209381,US Previously Marketed 1947,BEROCCA PN by ROCHE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006071,Scurvy; Vitamin C deficiency,Approved; Approved
161,65576-45-6,https://drugs.ncats.io/drug/JKZ19V908O,US Approved Rx 2009,NDA022117,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=22117,US Approved Rx 2009,NDA022117,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=22117,Bipolar I disorder (manic or mixed episodes); Schizophrenia,Approved; Approved
162,1174277-80-5,https://drugs.ncats.io/drug/Z633861EIM,US Approved Rx 2015,BLA125513,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125513,US Approved Rx 2015,BLA125513,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125513,,
163,9015-68-3,https://drugs.ncats.io/drug/D733ET3F9O,US Approved Rx 2021,BLA761179,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761179,US Previously Marketed 2011,Erwinaze,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125359,,
164,22839-47-0,https://drugs.ncats.io/drug/Z0H242BBR1,Possibly Marketed Outside US ,CFR:21 CFR 201.21,https://ginas.ncats.nih.gov/ginas/app/substance/Z0H242BBR1,Possibly Marketed Outside US 2001,21 CFR 334,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d7655c03-8a47-4349-940c-f51c876ebeef,Osteoarthritis; Sickle cell anemia; sweetener,Preclinical; Not Provided; Approved
165,56-84-8,https://drugs.ncats.io/drug/30KYC7MIAI,US Previously Marketed 1961,Spartase by Wyeth,DeHaen 1940-1975 NMEs,US Previously Marketed 1921,potassium aspartate,https://catalog.hathitrust.org/Record/100163146,Opiate abstinence syndrome; Neonatal jaundice; Unknown,Natural Metabolite; Natural Metabolite
166,472-61-7,https://drugs.ncats.io/drug/8XPW32PR7I,Possibly Marketed Outside US ,Astaxanthin by Josun International Limited,https://www.drugbank.ca/drugs/DB06543,Possibly Marketed Outside US 2010,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5996f9b2-18c1-4c8f-a0ab-eca180db61ad,Aging; Genitourinary cancer; Neurological disorders,Not Provided; Basic research; Basic research
167,68844-77-9,https://drugs.ncats.io/drug/7HU6337315,US Previously Marketed 1988,Hismanal by Janssen,OB NME Appendix 1950-1993,US Previously Marketed 1988,Hismanal by Janssen,OB NME Appendix 1950-1993,Seasonal allergic rhinitis; Chronic idiopathic urticaria,Withdrawn; Withdrawn
168,486-66-8,https://drugs.ncats.io/drug/6287WC5J2L,Clinical 2011,NCT01556737: Not Applicable Interventional Completed Postmenopause,https://clinicaltrials.gov/ct2/show/NCT01556737,,,,Unknown,
169,198904-31-3,https://drugs.ncats.io/drug/QZU4H47A3S,US Approved Rx 2020,ANDA209717,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209717,US Approved Rx 2003,NDA021567,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021567,HIV-1 infection,Approved
170,29122-68-7,https://drugs.ncats.io/drug/50VV3VW0TI,US Approved Rx 2005,ANDA076900,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=076900,US Approved Rx 1981,NDA018240,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018240,Hypertension; Angina pectoris; Acute myocardial infarction,Approved; Approved; Approved
171,1380723-44-3,https://drugs.ncats.io/drug/52CMI0WC3Y,US Approved Rx 2016,BLA761034,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761034,US Approved Rx 2016,BLA761034,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761034,,
172,83015-26-3,https://drugs.ncats.io/drug/ASW034S0B8,US Approved Rx 2002,NDA021411,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021411,US Approved Rx 2002,NDA021411,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021411,Attention deficit hyperactivity disorder,Approved
173,134523-00-5,https://drugs.ncats.io/drug/A0JWA85V8F,US Approved Rx 2023,ANDA214344,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214344,US Approved Rx 1996,NDA020702,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020702,Cardiovascular diseases; Hyperlipidemia,Approved; Approved
174,94015-53-9,https://drugs.ncats.io/drug/ODU3ZAZ94J,US Approved Rx 2023,NDA216386,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216386,US Approved Rx 2023,NDA216386,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216386,,
175,64228-81-5,https://drugs.ncats.io/drug/40AX66P76P,US Approved Rx 1997,ANDA074900,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=074900,US Previously Marketed 1983,TRACRIUM PRESERVATIVE FREE by HOSPIRA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018831,Skeletal muscle relaxation,Approved
176,8007-93-0,https://drugs.ncats.io/drug/2ec3b2a1,,,,,,,,
177,51-55-8,https://drugs.ncats.io/drug/7C0697DR9I,US Approved Rx 2001,NDA021146,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021146,US Previously Marketed 1921,Atropine U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Bradyasystolic cardiac arrest; Muscarinic mushroom poisoning; Increased salivary flow; Vagus nerve activation; Organophosphorus poisoning,Approved; Approved; Approved; Approved; Approved
178,12174-11-7,https://drugs.ncats.io/drug/U6V729APAM,US Previously Marketed 1962,QUINTESS-N ATTAPULGITE by LILLY,https://cdn.loc.gov/service/ll/fedreg/fr035/fr035128/fr035128.pdf,US Previously Marketed 1962,QUINTESS-N ATTAPULGITE by LILLY,https://cdn.loc.gov/service/ll/fedreg/fr035/fr035128/fr035128.pdf,,
179,34031-32-8,https://drugs.ncats.io/drug/3H04W2810V,US Approved Rx 1985,NDA018689,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018689,Possibly Marketed Outside US 1985,NDA018689,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05c34ddf-a0f7-4267-83f5-d02be3defc37,Rheumatoid arthritis,Approved
180,10236-47-2,https://drugs.ncats.io/drug/N7TD9J649B,Clinical 2011,NCT01423019: Not Applicable Interventional Completed Weight Loss,https://clinicaltrials.gov/ct2/show/NCT01423019,,,,Liver cancer; Parkinson's disease,Basic research; Basic research
181,12192-57-3,https://drugs.ncats.io/drug/2P2V9Q0E78,US Previously Marketed 1949,Solganal by Schering,DeHaen 1940-1975 NMEs,US Previously Marketed 1949,Solganal by Schering,DeHaen 1940-1975 NMEs,Rheumatoid arthritis,Approved
182,33796-26-8,https://drugs.ncats.io/drug/ODU3ZAZ94J,US Approved Rx 2023,NDA216386,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216386,US Approved Rx 2023,NDA216386,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216386,,
183,330784-47-9,https://drugs.ncats.io/drug/DR5S136IVO,US Approved Rx 2012,NDA202276,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202276,US Approved Rx 2012,NDA202276,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202276,Erectile dysfunction,Approved
184,570406-98-3,https://drugs.ncats.io/drug/3H8GSZ4SQL,US Approved Rx 2018,NDA210238,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210238,US Approved Rx 2018,NDA210238,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210238,Chronic liver disease-associated thrombocytopenia,Approved
185,1537032-82-8,https://drugs.ncats.io/drug/KXG2PJ551I,US Approved Rx 2017,BLA761078,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761078,US Approved Rx 2017,BLA761078,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761078,,
186,1192500-31-4,https://drugs.ncats.io/drug/7352665165,,,,,,,,
187,70356-09-1,https://drugs.ncats.io/drug/G63QQF2NOX,US Approved Rx 2008,NDA022009,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022009,US Previously Marketed 1988,Photoplex by Herbert,OB NME Appendix 1950-1993,Sunburn,Approved
188,319460-85-0,https://drugs.ncats.io/drug/C9LVQ0YUXG,US Approved Rx 2012,NDA202324,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202324,US Approved Rx 2012,NDA202324,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202324,Renal cell carcinoma,Approved
189,320-67-2,https://drugs.ncats.io/drug/M801H13NRU,US Approved Rx 2020,NDA214120,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214120,US Approved Rx 2004,NDA050794,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050794,Myelodysplastic syndromes,Approved
190,25990-37-8,https://drugs.ncats.io/drug/N993G4LGD6,,,,,,,,
191,3964-81-6,https://drugs.ncats.io/drug/94Z39NID6C,US Previously Marketed 1977,OPTIMINE by SCHERING,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017601,US Previously Marketed 1977,OPTIMINE by SCHERING,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017601,Rashes; Hives; Itching; Sneezing,Approved; Approved; Approved; Approved
192,446-86-6,https://drugs.ncats.io/drug/MRK240IY2L,US Approved Rx 1996,ANDA074069,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=074069,US Approved Rx 1968,NDA016324,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016324,Rheumatoid arthritis,Approved
193,123-99-9,https://drugs.ncats.io/drug/F2VW3D43YT,US Approved Rx 2002,NDA021470,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021470,US Approved Rx 1995,NDA020428,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020428,Rosacea,Approved
194,58581-89-8,https://drugs.ncats.io/drug/ZQI909440X,US Approved Rx 2017,ANDA204660,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204660,US Previously Marketed 1996,ASTELIN by MYLAN SPCLT VIATRIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020114,Seasonal allergic rhinitis; Perennial allergic rhinitis,Approved; Approved
195,863031-21-4,https://drugs.ncats.io/drug/LL0G25K7I2,US Approved Rx 2011,NDA202331,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202331,US Approved Rx 2011,NDA202331,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202331,Hypertension; Hypertension,Approved; Phase III
196,83905-01-5,https://drugs.ncats.io/drug/J2KLZ20U1M,US Approved Rx 2018,ANDA208249,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208249,US Previously Marketed 1991,ZITHROMAX by PFIZER,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050670,Acute bacterial exacerbation of chronic bronchitis; Acute bacterial sinusitis; Acute otitis media; Skin structure infections; Urethritis; Community-acquired pneumonia,Approved; Approved; Approved; Approved; Approved; Approved
197,78110-38-0,https://drugs.ncats.io/drug/G2B4VE5GH8,US Approved Rx 2010,NDA050814,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050814,US Approved Rx 1986,NDA050580,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050580,Sepsis; Skin and skin structure infections; Gynecologic infections; Respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa; Intra-abdominal infections; Lower respiratory tract infections; Urinary tract infections,Approved; Approved; Approved; Approved; Approved; Approved; Approved
198,83-46-5,https://drugs.ncats.io/drug/S347WMO6M4,US Previously Marketed 1956,Cytellin by Lilly,DeHaen 1940-1975 NMEs,US Previously Marketed 1956,Cytellin by Lilly,DeHaen 1940-1975 NMEs,Benign prostatic hyperplasia; Breast cancer; Sitosterolemia; Cystic fibrosis; Cervical cancer,Natural Metabolite; Natural Metabolite; Natural Metabolite; Natural Metabolite; Natural Metabolite
199,64-17-5,https://drugs.ncats.io/drug/bfe60581,,,,,,,,
200,7704-34-9,https://drugs.ncats.io/drug/a781d1f2,,,,,,,,
201,68038-65-3,https://drugs.ncats.io/drug/ISK1LOY57E,Possibly Marketed Outside US 2019,Provad by TMIG Inc,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=302af4c2-78e2-4082-9b09-25ac2790762f,Possibly Marketed Outside US 2015,"BIOVITA by ILDONG PHARMACEUTICAL CO., LTD.",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1414abaf-1158-4d8b-8906-59dc85f17e1c,,
202,1405-87-4,https://drugs.ncats.io/drug/e830aaf7,,,,,,,,
203,1134-47-0,https://drugs.ncats.io/drug/H789N3FKE8,US Approved Rx 2007,ANDA077088,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077088,US Previously Marketed 1977,LIORESAL by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017851,Spasticity,Approved
204,1985606-14-1,https://drugs.ncats.io/drug/505CXM6OHG,US Approved Rx 2018,NDA210854,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210854,US Approved Rx 2018,NDA210854,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210854,Influenza,Phase II
205,80573-04-2,https://drugs.ncats.io/drug/P80AL8J7ZP,US Approved Rx 2000,NDA020610,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020610,US Approved Rx 2000,NDA020610,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020610,Ulcerative colitis,Approved
206,57-44-3,https://drugs.ncats.io/drug/5WZ53ENE2P,US Previously Marketed 1903,"Veronal by Friedr. Bayer 8: Co., Elberfeld, Germany, and E. Merck, Darmstadt, Germany.",https://catalog.hathitrust.org/Record/100782317,US Previously Marketed 1903,"Veronal by Friedr. Bayer 8: Co., Elberfeld, Germany, and E. Merck, Darmstadt, Germany.",https://catalog.hathitrust.org/Record/100782317,Insomnia,Approved
207,1187594-09-7,https://drugs.ncats.io/drug/ISP4442I3Y,US Approved Rx 2018,NDA207924,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207924,US Approved Rx 2018,NDA207924,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207924,Rheumatoid arthritis,Approved
208,7440-39-3,https://drugs.ncats.io/drug/24GP945V5T,Possibly Marketed Outside US 2010,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da19d3ec-3547-48c0-a08a-5b4e35d1db1d,Possibly Marketed Outside US 2010,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da19d3ec-3547-48c0-a08a-5b4e35d1db1d,,
209,179045-86-4,https://drugs.ncats.io/drug/9927MT646M,US Approved Rx 1998,BLA103764,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103764,US Approved Rx 1998,BLA103764,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103764,,
210,198481-32-2,https://drugs.ncats.io/drug/Q16TT9C5BK,US Approved Rx 2013,NDA022247,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022247,US Approved Rx 2013,NDA022247,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022247,Postmenopausal osteoporosis; Hot flashes,Approved; Approved
211,165101-51-9,https://drugs.ncats.io/drug/1B56C968OA,US Approved Rx 1997,BLA103691,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103691,US Approved Rx 1997,BLA103691,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103691,,
212,4419-39-0,https://drugs.ncats.io/drug/KGZ1SLC28Z,US Previously Marketed 1987,VANCENASE AQ by SCHERING,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019589,US Previously Marketed 1987,VANCENASE AQ by SCHERING,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019589,Asthma,Approved
213,843663-66-1,https://drugs.ncats.io/drug/78846I289Y,US Approved Rx 2012,NDA204384,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204384,US Approved Rx 2012,NDA204384,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204384,"Tuberculosis, multidrug-resistant",Approved
214,706808-37-9,https://drugs.ncats.io/drug/E3B2GI648A,US Approved Rx 2011,BLA125288,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125288,US Approved Rx 2011,BLA125288,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125288,,
215,356547-88-1,https://drugs.ncats.io/drug/73B0K5S26A,US Approved Rx 2017,BLA761043,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761043,US Approved Rx 2011,BLA125370,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125370,,
216,866323-14-0,https://drugs.ncats.io/drug/F4H96P17NZ,US Approved Rx 2014,NDA206256,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206256,US Approved Rx 2014,NDA206256,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206256,"Lymphoma, T-cell, peripheral",Approved
217,86541-75-5,https://drugs.ncats.io/drug/UDM7Q7QWP8,US Approved Rx 2004,ANDA076118,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=076118,Possibly Marketed Outside US 1991,NDA019851,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2abb091b-a53e-46b0-9b84-e5ee8f2bdd8e,Hypertension,Approved
218,16506-27-7,https://drugs.ncats.io/drug/9266D9P3PQ,US Approved Rx 2015,NDA208194,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208194,US Approved Rx 2008,NDA022303,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022303,Non-Hodgkin's lymphoma; Chronic lymphocytic leukemia,Phase III; Approved
219,73-48-3,https://drugs.ncats.io/drug/5Q52X6ICJI,US Previously Marketed 1983,CORZIDE by KING PHARMS LLC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018647,US Previously Marketed 1959,NATURETIN-2.5 by APOTHECON,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012164,Hypertension,Approved
220,1044511-01-4,https://drugs.ncats.io/drug/71492GE1FX,US Approved Rx 2017,BLA761070,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761070,US Approved Rx 2017,BLA761070,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761070,,
221,1302-78-9,https://drugs.ncats.io/drug/A3N5ZCN45C,Possibly Marketed Outside US ,Canada:SODIUM BENTONITE,https://tripod.nih.gov/npc/#Download,Possibly Marketed Outside US 1946,M006,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=90f80e35-095d-88f9-8ea3-0fd54f1e916c,"Allergy due to ivy, oak and sumac",Approved
222,1340-69-8,https://drugs.ncats.io/drug/7F465U79Q1,US Approved Rx 1996,NDA020532,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020532,US Approved Rx 1996,NDA020532,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020532,,
223,100-51-6,https://drugs.ncats.io/drug/LKG8494WBH,US Approved OTC ,21 CFR 346.10(b) anorectal:local anesthetic benzyl alcohol,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec346-10.xml,US Previously Marketed 1921,Benzyl Alcohol,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Head lice infestation,Approved
224,86-13-5,https://drugs.ncats.io/drug/1NHL2J4X8K,US Approved Rx 1989,ANDA072266,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=072266,US Previously Marketed 1954,COGENTIN by MERCK,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=009193,Parkinsonism; Extrapyramidal disorders,Approved; Approved
225,121-54-0,https://drugs.ncats.io/drug/PH41D05744,US Previously Marketed 1942,Phemerol Chloride by Parke-Davis,DeHaen 1940-1975 NMEs,US Previously Marketed 1942,Phemerol Chloride by Parke-Davis,DeHaen 1940-1975 NMEs,Head and neck cancer; Methicillin-resistant Staphylococcus aureus; Skin infections; Bacterial Infections,Preclinical; Basic research; Basic research; Approved
226,94-09-7,https://drugs.ncats.io/drug/U3RSY48JW5,US Approved OTC ,21 CFR 346.10(a) anorectal:local anesthetic benzocaine,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec346-10.xml,US Previously Marketed 1895,Americaine,https://catalog.hathitrust.org/Record/100782317,Otitis media; Burn; Canker sores; Sore mouth; Sore throat; Hemorrhoids,Approved; Approved; Approved; Approved; Approved; Approved
227,65-85-0,https://drugs.ncats.io/drug/8SKN0B0MIM,US Approved Rx 2016,ANDA207096,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207096,US Previously Marketed 1921,Benzoic Acid U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Unknown; Tinea capitis; Hyperammonemia; Tinea pedis,Approved; Approved; Approved
228,104-31-4,https://drugs.ncats.io/drug/5P4DHS6ENR,US Approved Rx 2019,ANDA211518,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211518,US Approved Rx 1958,NDA011210,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011210,Cough,Approved
229,119-61-9,https://drugs.ncats.io/drug/701M4TTV9O,Possibly Marketed Outside US ,part352,https://www.drugbank.ca/drugs/DB01878,Possibly Marketed Outside US 2009,21 CFR 333D,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d15560f-d8d1-4dfe-8eca-b16bb529ad87,Skin pigmentation,Approved
230,86-75-9,https://drugs.ncats.io/drug/GRE0P19C3Z,US Previously Marketed ,21 CFR 310.545(a)(18)(ii) skin protectant:astringent oxyquinoline sulfate,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-545.xml,Possibly Marketed Outside US 1964,UDDER BALM by H. W. Naylor Company Inc.,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2907f343-4457-bf36-2e0b-aa074e63a4bd,Unknown,
231,94-36-0,https://drugs.ncats.io/drug/W9WZN9A0GM,US Approved OTC ,21 CFR 333.310(a) acne benzoyl peroxide,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec333-310.xml,US Approved Rx 1984,NDA050557,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050557,Acne vulgaris,Approved
232,156-08-1,https://drugs.ncats.io/drug/0M3S43XK27,US Approved Rx 2010,ANDA090968,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=090968,US Previously Marketed 1960,DIDREX by PFIZER,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012427,Exogenous obesity,Approved
233,100-51-6,https://drugs.ncats.io/drug/LKG8494WBH,US Approved OTC ,21 CFR 346.10(b) anorectal:local anesthetic benzyl alcohol,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec346-10.xml,US Previously Marketed 1921,Benzyl Alcohol,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Head lice infestation,Approved
234,120-51-4,https://drugs.ncats.io/drug/N863NB338G,US Previously Marketed 1976,BENZYL BENZOATE by LANNETT,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=084535,US Previously Marketed 1921,Benzyl benzoate by Merck,https://books.google.com/books?id=3VM5AQAAMAAJ&newbks=1&newbks_redir=0&dq=benzyl%20benzoate%20van%20dyk&pg=PA61#v=onepage&q=benzyl%20benzoate%20van%20dyk&f=false,Scabies caused by the Sarcoptes scabiei mite.; Pediculosis caused by Pediculus capitis (head louse) and Phthirus pubis (pubic or crab louse); Sunburn,Withdrawn; Withdrawn; Approved
235,125602-71-3,https://drugs.ncats.io/drug/HYD2U48IAS,US Approved Rx 2023,ANDA214588,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214588,US Approved Rx 2009,NDA022288,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022288,Allergic conjunctivitis; Allergic rhinitis,Approved; Approved
236,64706-54-3,https://drugs.ncats.io/drug/755BO701MA,US Previously Marketed 1990,BEPADIN by MEDPOINTE PHARM HLC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019001,US Previously Marketed 1990,BEPADIN by MEDPOINTE PHARM HLC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019001,Chronic stable angina; Tachyarrhythmia; Atrial fibrillation; Hypertension,Approved; Approved; Approved; Approved
237,108778-82-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
238,141388-76-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
239,7235-40-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
240,5638-76-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
241,107-43-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
242,378-44-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
243,63659-18-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
244,674-38-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
245,330942-05-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
246,216974-75-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
247,153559-49-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
248,1246264-45-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
249,90357-06-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
250,1611493-60-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
251,155206-00-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
252,606143-89-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
253,153-18-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
254,58-85-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
255,514-65-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
256,603-50-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
257,7440-69-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
258,66722-44-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
259,30392-40-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
260,128270-60-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
261,11056-06-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
262,853426-35-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
263,394730-60-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
264,10043-35-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
265,179324-69-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
266,147536-97-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
267,380843-75-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
268,173740-48-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
269,914088-09-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
270,59-41-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
271,913611-97-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
272,1197953-54-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
273,633-03-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
274,59803-98-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
275,138890-62-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
276,357336-20-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
277,1174395-19-7,https://drugs.ncats.io/drug/6ZA31Y954Z,US Approved Rx 2017,BLA761032,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761032,US Approved Rx 2017,BLA761032,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761032,,
278,118-23-0,https://drugs.ncats.io/drug/T032BI7727,US Previously Marketed 1953,Ambodryl HCl by Parke-Davis,DeHaen 1940-1975 NMEs,US Previously Marketed 1951,Ambodryl by Parke Davis,OB NME Appendix 1950-1985,Allergy,Approved
279,91714-94-2,https://drugs.ncats.io/drug/864P0921DW,US Approved Rx 2024,ANDA211239,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211239,US Previously Marketed 1997,Duract,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=20535,Postoperative inflammation; Ocular pain,Approved; Approved
280,7726-95-6,https://drugs.ncats.io/drug/SBV4XY874G,US Previously Marketed 1921,Bromine N.F.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Bromine N.F.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,,
281,25614-03-3,https://drugs.ncats.io/drug/3A64E3G5ZO,US Approved Rx 2008,ANDA078899,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=078899,US Approved Rx 1978,NDA017962,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017962,Parkinson's disease; Acromegaly; Type 2 diabetes mellitus; Hyperprolactinemia-associated dysfunctions,Approved; Approved; Approved; Approved
282,86-22-6,https://drugs.ncats.io/drug/H57G17P2FN,US Approved OTC ,21 CFR 341.12(a) cough/cold:antihistamine brompheniramine maleate,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec341-12.xml,US Previously Marketed 1956,Dimetane by Robins,OB NME Appendix 1950-1985,Rhinitis; Nasal congestion and inflammations; Common cold,Phase III; Phase III; Approved
283,52-51-7,https://drugs.ncats.io/drug/6PU1E16C9W,US Approved Allergenic Extract 1994,BLA103738,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f082b68-dc74-418a-9e6f-b3c285b41d44,US Approved Allergenic Extract 1994,BLA103738,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f082b68-dc74-418a-9e6f-b3c285b41d44,Unknown,
284,51333-22-3,https://drugs.ncats.io/drug/Q3OKS62Q6X,US Approved Rx 2014,NDA205613,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205613,US Previously Marketed 1994,RHINOCORT by ASTRAZENECA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020233,Distal ulcerative colitis; Asthma; Crohn's disease; Perennial allergic rhinitis,Approved; Approved; Approved; Approved
285,28395-03-1,https://drugs.ncats.io/drug/0Y2S3XUQ5H,US Approved Rx 2008,ANDA079196,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=079196,US Previously Marketed 1983,BUMEX by VALIDUS PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018226,Edema,Approved
286,38396-39-3,https://drugs.ncats.io/drug/Y8335394RO,US Approved Rx 1988,ANDA071168,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=071168,US Approved Rx 1972,NDA016964,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016964,Pain,Approved
287,52485-79-7,https://drugs.ncats.io/drug/40D3SCR4GZ,US Approved Rx 2013,ANDA091422,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=091422,US Previously Marketed 1981,BUPRENEX by INDIVIOR,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018401,Rheumatoid arthritis; Opioid dependence; Osteoarthritis; Lower back pain; Chronic pain,Phase IV; Approved; Phase IV; Phase IV; Approved
288,34911-55-2,https://drugs.ncats.io/drug/01ZG3TPX31,US Approved Rx 2011,NDA022497,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022497,US Previously Marketed 1985,WELLBUTRIN by GLAXOSMITHKLINE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018644,Major depressive disorder; Nicotine dependence,Approved; Approved
289,1610833-03-8,https://drugs.ncats.io/drug/G9WJT6RD29,US Approved Rx 2018,BLA761068,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761068,US Approved Rx 2018,BLA761068,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761068,,
290,36505-84-7,https://drugs.ncats.io/drug/TK65WKS8HL,US Approved Rx 2015,ANDA202087,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202087,US Previously Marketed 1986,BUSPAR by BRISTOL MYERS SQUIBB,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018731,Anxiety,Approved
291,55-98-1,https://drugs.ncats.io/drug/G1LN9045DK,US Approved Rx 1999,NDA020954,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020954,US Previously Marketed 1954,Myleran by Burroughs Wellcome,OB NME Appendix 1950-1985,Chronic myeloid leukemia,Approved
292,22131-35-7,https://drugs.ncats.io/drug/140T9JTG43,Possibly Marketed Outside US ,WHO-ATC:C04AX23,https://ginas.ncats.nih.gov/ginas/app/substance/140T9JTG43,,,,,
293,77-26-9,https://drugs.ncats.io/drug/KHS0AZ4JVK,US Approved Rx 1987,ANDA089175,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=089175,US Previously Marketed 1929,Sandoptal by Sandoz,https://books.google.com/books?id=i9BQAAAAYAAJ&q=SANDOPTAL&dq=SANDOPTAL&hl=en&newbks=1&newbks_redir=0&sa=X&ved=2ahUKEwj_i7-Hg_TmAhVDU98KHX8dCOAQ6AEwAHoECAYQAg,Tension or muscle contraction headache,Approved
294,101828-21-1,https://drugs.ncats.io/drug/91Y494NL0X,US Approved Rx 2017,ANDA205181,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205181,Possibly Marketed Outside US 1993,NDA021307,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0eadac26-4619-4227-9dda-28e739d77a87,Tinea versicolor; Tinea,Approved; Approved
295,64872-76-0,https://drugs.ncats.io/drug/0Q771797PH,US Approved Rx 2012,ANDA200923,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200923,US Previously Marketed 1985,FEMSTAT by ROCHE PALO,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019215,Vulvovaginal candidiasis,Approved
296,42408-82-2,https://drugs.ncats.io/drug/QV897JC36D,US Approved Rx 2001,ANDA075759,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=075759,US Previously Marketed 1978,STADOL PRESERVATIVE FREE by APOTHECON,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017857,Pain,Approved
297,25013-16-5,https://drugs.ncats.io/drug/REK4960K2U,Possibly Marketed Outside US 1941,Morphine Sulfate by Padagis US LLC,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=649d731b-962a-45df-b043-7e0781e8a530,Possibly Marketed Outside US 1941,Morphine Sulfate by Padagis US LLC,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=649d731b-962a-45df-b043-7e0781e8a530,,
298,94-25-7,https://drugs.ncats.io/drug/EFW857872Q,Possibly Marketed Outside US ,"One Touch Advanced Topical Anesthetic Bubble Gum by Hager Worldwide, Inc.",https://www.drugbank.ca/drugs/DB11148,Possibly Marketed Outside US 1958,"Cetacaine Anesthetic by Cetylite Industries, Inc.",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=af1773c5-5d5b-4278-b551-30ad2df6d5b5,Topical anesthetic,Basic research
299,94-26-8,https://drugs.ncats.io/drug/3QPI1U3FV8,Possibly Marketed Outside US ,Canada:BUTYLPARABEN,https://tripod.nih.gov/npc/#Download,Possibly Marketed Outside US 1984,"NU-DERM SUNFADER  Skin Lightener with Sunscreen (SPF 15) PABA FREE by OMP, INC.",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c67b0629-5529-412d-99ee-186df4ecad5a,Depression; Unknown,Approved
300,80295-38-1,https://drugs.ncats.io/drug/5QS67N4551,Possibly Marketed Outside US ,WHO-ATC:B06AC04,https://ginas.ncats.nih.gov/ginas/app/substance/5QS67N4551,Possibly Marketed Outside US 2014,BLA125495,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b81613ee-506e-47eb-91a7-708dfc958ea3,,
301,183133-96-2,https://drugs.ncats.io/drug/51F690397J,US Approved Rx 2021,NDA207949,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207949,US Approved Rx 2010,NDA201023,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201023,Hormone-refractory metastatic prostate cancer,Approved
302,81409-90-7,https://drugs.ncats.io/drug/LL60K9J05T,US Approved Rx 2007,ANDA077750,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077750,US Previously Marketed 1996,DOSTINEX by PFIZER,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020664,"Hyperprolactinemic disorders, idiopathic; Hyperprolactinemic disorders, due to pituitary adenomas",Approved; Approved
303,849217-68-1,https://drugs.ncats.io/drug/1C39JW444G,US Approved Rx 2022,ANDA215942,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215942,US Approved Rx 2012,NDA203756,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203756,"Medullary thyroid cancer; Medullary thyroid cancer, metastatic; Renal cell carcinoma",Approved; Approved; Approved
304,94820-09-4,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
305,8013-10-3,https://drugs.ncats.io/drug/1Q84T0P2G3,US Approved OTC ,"21 CFR 346.16(b) anorectal:analgesic, anesthetic, antipruritic juniper tar",https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec346-16.xml,US Previously Marketed 1921,Oil of Cade U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,,
306,58-08-2,https://drugs.ncats.io/drug/3G6A5W338E,US Approved OTC ,21 CFR 340.10 stimulant caffeine,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec340-10.xml,US Previously Marketed 1921,Citrated Caffeine U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Migraine; Atopic dermatitis; Apnea of prematurity; Drowsiness,Approved; Not Provided; Approved; Approved
307,8011-96-9,https://drugs.ncats.io/drug/ODU3ZAZ94J,US Approved Rx 2023,NDA216386,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216386,US Approved Rx 2023,NDA216386,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216386,,
308,19356-17-3,https://drugs.ncats.io/drug/T0WXW8F54E,US Approved Rx 2016,NDA208010,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208010,US Previously Marketed 1980,CALDEROL by ORGANON USA INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018312,"Secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease; Hypocalcemia, chronic; Hypophosphatemia; Osteodystrophy",Approved; Approved; Approved; Approved
309,112965-21-6,https://drugs.ncats.io/drug/143NQ3779B,US Approved Rx 2020,NDA213422,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213422,US Previously Marketed 1993,DOVONEX by LEO PHARMA AS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020273,Plaque psoriasis; Unknown; Colon cancer; Lung cancer; Breast cancer,Approved; Preclinical; Preclinical; Preclinical
310,9007-12-9,https://drugs.ncats.io/drug/DF35I47HCM,Possibly Marketed Outside US 2020,NCT04445857: Phase 4 Interventional Completed Analgesia,https://clinicaltrials.gov/ct2/show/NCT04445857,,,,,
311,32222-06-3,https://drugs.ncats.io/drug/FXC9231JVH,US Approved Rx 2008,ANDA078066,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=078066,US Approved Rx 1978,NDA018044,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018044,Mild to moderate plaque psoriasis; Hypocalcemia; Secondary hyperparathyroidism; Unknown,Approved; Approved; Approved
312,7440-70-2,https://drugs.ncats.io/drug/SY7Q814VUP,US Approved OTC ,21 CFR 331.11(i)(2) antacid:calcium-containing calcium (mono or dibasic salt),https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec331-11.xml,US Previously Marketed 1921,Precipitated Calcium Phosphate N.F.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Unknown; Hypocalcemia; Chronic obstructive pulmonary disease; Cystic fibrosis; Unknown; Hypocalcemia,Not Provided; Phase I; Phase I; Approved
313,1492-18-8,https://drugs.ncats.io/drug/RPR1R4C0P4,US Approved Rx 2023,ANDA216590,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216590,US Previously Marketed 1952,Leucovorin by Lederle,OB NME Appendix 1950-1985,Megaloblastic anemia; Advanced colorectal cancer; Osteosarcoma,Approved; Approved; Approved
314,80433-71-2,https://drugs.ncats.io/drug/778XL6VBS8,US Approved Rx 2019,ANDA211003,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211003,Possibly Marketed Outside US 1952,NDA211226,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=344f65ac-9f04-49d7-b7c3-4ba19bd7b429,Methotrexate toxicity; Metastatic colorectal cancer,Approved; Approved
315,26560-38-3,https://drugs.ncats.io/drug/9I291HQ60G,Possibly Marketed Outside US ,vitaMedMD One Rx by vitaMedMD,https://www.drugbank.ca/drugs/DB04789,Possibly Marketed Outside US 2012,vitaMedMD One Rx by vitaMedMD,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c321dba6-eae6-42fa-8ff9-bdfa6ffabcd9,Methylenetetrahydrofolate reductase deficiency,Not Provided
316,183325-78-2,https://drugs.ncats.io/drug/Q4K217VGA9,US Approved Rx 1998,BLA020521,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020521,US Approved Rx 1998,BLA020521,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020521,,
317,474-62-4,https://drugs.ncats.io/drug/5L5O665639,Possibly Marketed Outside US 2012,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bae69545-3b5a-4994-a357-7f93c474340f,Possibly Marketed Outside US 2012,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bae69545-3b5a-4994-a357-7f93c474340f,,
318,76-22-2,https://drugs.ncats.io/drug/5TJD82A1ET,US Approved OTC ,"21 CFR 346.16(a) anorectal:analgesic, anesthetic, antipruritic camphor",https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec346-16.xml,US Previously Marketed 1921,Camphor U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Cough; Muscle pain; Pain,Approved; Approved; Approved
319,842133-18-0,https://drugs.ncats.io/drug/6S49DGR869,US Approved Rx 2014,NDA204353,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204353,US Approved Rx 2013,NDA204042,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204042,Type 2 diabetes mellitus,Approved
320,914613-48-2,https://drugs.ncats.io/drug/37CQ2C7X93,US Approved Rx 2009,BLA125319,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125319,US Approved Rx 2009,BLA125319,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125319,,
321,145040-37-5,https://drugs.ncats.io/drug/R85M2X0D68,US Approved Rx 2016,ANDA203813,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203813,US Approved Rx 1998,NDA020838,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020838,Heart failure; Hypertension,Approved; Approved
322,163706-06-7,https://drugs.ncats.io/drug/6AQ1Y404U7,US Approved Rx 2015,NDA204958,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204958,US Approved Rx 2015,NDA204958,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204958,Myocardial infarction; Blood clotting; Degenerative brain disease,Approved; Approved; Basic research
323,13956-29-1,https://drugs.ncats.io/drug/19GBJ60SN5,US Approved Rx 2018,NDA210365,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210365,Possibly Marketed Outside US 2018,M012,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a698502d-c1c5-41ca-8142-74338b834c8b,Tuberous sclerosis complex; Dravet syndrome; Lennox-Gastaut syndrome; Pain; Multiple sclerosis,Phase III; Phase III; Phase III; Approved; Approved
324,56-25-7,https://drugs.ncats.io/drug/IGL471WQ8P,US Approved Rx 2023,NDA212905,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212905,US Previously Marketed 2019,cantharidin,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23,Warts,Approved
325,56-25-7,https://drugs.ncats.io/drug/IGL471WQ8P,US Approved Rx 2023,NDA212905,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212905,US Previously Marketed 2019,cantharidin,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23,Warts,Approved
326,154361-50-9,https://drugs.ncats.io/drug/6804DJ8Z9U,US Approved Rx 2018,ANDA210604,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210604,US Approved Rx 1998,NDA020896,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020896,Breast cancer; Colorectal cancer,Approved; Approved
327,915810-67-2,https://drugs.ncats.io/drug/2R27AB6766,US Approved Rx 2019,BLA761112,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761112,US Approved Rx 2019,BLA761112,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761112,,
328,11003-38-6,https://drugs.ncats.io/drug/232HYX66HC,US Previously Marketed 2017,CAPREOMYCIN SULFATE by MYLAN LABS LTD,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202634,US Previously Marketed 1971,CAPASTAT SULFATE by EPIC PHARMA LLC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050095,Pulmonary infections,Approved
329,145464-28-4,https://drugs.ncats.io/drug/BDO5072GRX,US Approved Rx 1996,BLA103608,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103608,US Approved Rx 1996,BLA103608,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103608,,
330,404-86-4,https://drugs.ncats.io/drug/S07O44R1ZM,US Approved Rx 2009,NDA022395,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022395,Possibly Marketed Outside US 1988,21 CFR 348,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fbec6898-5417-dbce-e053-6294a90af139,Neuropathic pain associated with postherpetic neuralgia,Approved
331,977007-72-9,https://drugs.ncats.io/drug/ODU3ZAZ94J,US Approved Rx 2023,NDA216386,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216386,US Approved Rx 2023,NDA216386,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216386,,
332,8023-77-6,https://drugs.ncats.io/drug/ae5feb0e,,,,,,,,
333,62571-86-2,https://drugs.ncats.io/drug/9G64RSX1XD,US Approved Rx 2019,ANDA212809,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212809,US Previously Marketed 1981,CAPOTEN by STRIDES PHARMA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018343,Hypertension; Hypertension; Heart Failure; Left Ventricular Dysfunction; Diabetic Nephropathy,Preclinical; Approved; Approved; Approved; Approved
334,77-22-5,https://drugs.ncats.io/drug/97J7NP0XJY,US Previously Marketed 1949,Panparnit HCl by Geigy,DeHaen 1940-1975 NMEs,US Previously Marketed 1949,Panparnit HCl by Geigy,DeHaen 1940-1975 NMEs,Cough; Parkinson's disease,Approved; Approved
335,51-83-2,https://drugs.ncats.io/drug/8Y164V895Y,US Approved Rx 1972,NDA016968,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016968,US Approved Rx 1972,NDA016968,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016968,Elevated intraocular pressure,Approved
336,298-46-4,https://drugs.ncats.io/drug/33CM23913M,US Approved Rx 2005,ANDA077272,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077272,US Approved Rx 1968,NDA016608,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016608,Epilepsy; Trigeminal neuralgia,Approved; Approved
337,4697-36-3,https://drugs.ncats.io/drug/G42ZU72N5G,US Previously Marketed 1970,Pyopen by Beecham,DeHaen 1940-1975 NMEs,US Previously Marketed 1970,Pyopen by Beecham,DeHaen 1940-1975 NMEs,Urinary tract infections; Acute and chronic infections of the upper and lower urinary tract; Prostatitis,Approved; Approved; Approved
338,28860-95-9,https://drugs.ncats.io/drug/KR87B45RGH,US Approved Rx 2023,ANDA217961,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217961,US Approved Rx 1975,NDA017555,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017555,Idiopathic Parkinson's disease,Approved
339,486-16-8,https://drugs.ncats.io/drug/982A7M02H5,US Approved Rx 2003,ANDA040458,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=040458,US Previously Marketed 1953,CLISTIN by ORTHO MCNEIL PHARM,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=008915,Perennial allergic rhinitis; Vasomotor rhinitis; Allergic conjunctivitis; Angioedema; Urticaria; Anaphylaxis; Seasonal allergic rhinitis,Approved; Approved; Approved; Approved; Approved; Approved; Approved
340,111-90-0,https://drugs.ncats.io/drug/A1A1I8X02B,Possibly Marketed Outside US 2004,21 CFR 348,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff24f080-33ca-4c97-9739-625bb58a39fe,Possibly Marketed Outside US 1955,NDA021794,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8dbe1a41-6d9d-414f-aa9c-09bd95857e2a,,
341,638-23-3,https://drugs.ncats.io/drug/740J2QX53R,Possibly Marketed Outside US ,UK NHS:Carbocisteine,https://tripod.nih.gov/npc/#Download,Possibly Marketed Outside US 2008,21 CFR 333D,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de384124-cdb9-4d6b-ae4d-351214182c58,Chronic obstructive pulmonary disease,Approved
342,6347-01-9,https://drugs.ncats.io/drug/6YSS42VSEV,US Previously Marketed 1953,Levugen by Mead Johnson,DeHaen 1940-1975 NMEs,US Previously Marketed 1921,fructose,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Pain,Approved
343,9007-20-9,https://drugs.ncats.io/drug/K6MOM3T5YL,Possibly Marketed Outside US 2020,Hand Sanitizer by Solquim SA DE CV,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a2dc681d-ccc0-0a85-e053-2a95a90a90fb,Possibly Marketed Outside US 1998,ANDA075043,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=767df368-82fc-40ec-8faf-e6a3435c55b3,,
344,463-79-6,https://drugs.ncats.io/drug/67507691,,,,,,,,
345,41575-94-4,https://drugs.ncats.io/drug/BG3F62OND5,US Approved Rx 2004,ANDA077269,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077269,US Previously Marketed 1989,PARAPLATIN by CORDEN PHARMA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019880,Advanced ovarian cancer,Approved
346,35700-23-3,https://drugs.ncats.io/drug/7B5032XT6O,US Approved Rx 2022,ANDA215337,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215337,US Approved Rx 1979,NDA017989,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017989,Postpartum hemorrhage due to uterine atony; Aborting pregnancy,Approved; Approved
347,868540-17-4,https://drugs.ncats.io/drug/72X6E3J5AR,US Approved Rx 2012,NDA202714,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202714,US Approved Rx 2012,NDA202714,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202714,Multiple myeloma,Approved
348,1188-38-1,https://drugs.ncats.io/drug/5L0HB4V1EW,US Approved Rx 2010,NDA022562,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022562,US Approved Rx 2010,NDA022562,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022562,Acute hyperammonemia; Chronic hyperammonemia,Approved; Approved
349,108333-82-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
350,35531-88-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
351,839712-12-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
352,78-44-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
353,9000-11-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
354,154-93-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
355,8015-86-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
356,305-84-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
357,7235-40-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
358,11103-57-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
359,51781-06-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
360,72956-09-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
361,8024-48-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
362,9000-71-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
363,162808-62-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
364,606138-08-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
365,53994-73-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
366,50370-12-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
367,15686-71-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
368,34444-01-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
369,21593-23-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
370,25953-19-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
371,91832-40-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
372,117467-28-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
373,88040-23-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
374,79350-37-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
375,56796-20-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
376,61270-58-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
377,62893-19-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
378,63527-52-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
379,69712-56-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
380,35607-66-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
381,87239-81-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
382,92676-86-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
383,38821-53-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
384,229016-73-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
385,72558-82-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
386,97519-39-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
387,68401-81-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
388,689293-68-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
389,73384-59-5,https://drugs.ncats.io/drug/75J73V1629,US Approved Rx 2016,ANDA203702,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203702,US Previously Marketed 1984,ROCEPHIN by HOFFMANN LA ROCHE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050585,Acute bacterial otitis media; Lower respiratory tract infections; Urinary tract infections; Skin and skin structure infections; Pelvic inflammatory disease; Uncomplicated gonorrhea; Sepsis; Intra-abdominal infections; Bone and joint infections; Meningitis,Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved
390,55268-75-2,https://drugs.ncats.io/drug/O1R9FJ93ED,US Approved Rx 2010,ANDA065496,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=065496,US Previously Marketed 1983,ZINACEF by PAI HOLDINGS PHARM,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050558,Bacterial infections,Approved
391,64544-07-6,https://drugs.ncats.io/drug/Z49QDT0J8Z,US Approved Rx 2010,ANDA065496,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=065496,US Previously Marketed 1983,ZINACEF by PAI HOLDINGS PHARM,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050558,Bacterial infections,Approved
392,169590-42-5,https://drugs.ncats.io/drug/JCX84Q7J1L,US Approved Rx 2020,ANDA207872,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207872,Possibly Marketed Outside US 1998,NDA020998,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe09528e-a072-4bc8-84eb-e79ed06cd553,Juvenile rheumatoid arthritis; Ankylosing spondylitis; Acute pain; Osteoarthritis; Rheumatoid arthritis; Primary dysmenorrhea,Approved; Approved; Approved; Approved; Approved; Approved
393,9012-54-8,https://drugs.ncats.io/drug/7Q170212NX,,,,,,,,
394,9004-34-6,https://drugs.ncats.io/drug/1f970ca7,,,,,,,,
395,1801342-60-8,https://drugs.ncats.io/drug/6QVL057INT,US Approved Rx 2018,BLA761097,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761097,US Approved Rx 2018,BLA761097,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761097,,
396,5466-77-3,https://drugs.ncats.io/drug/4Y5P7MUD51,US Previously Marketed 1992,SHADE UVAGUARD by BAYER HEALTHCARE LLC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020045,Possibly Marketed Outside US 1984,"NU-DERM SUNFADER  Skin Lightener with Sunscreen (SPF 15) PABA FREE by OMP, INC.",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f439d77f-ec5b-4534-a005-08f2e7af8d0c,Sunburns,Approved
397,1032900-25-6,https://drugs.ncats.io/drug/K418KG2GET,US Approved Rx 2019,NDA211225,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211225,US Previously Marketed 2014,ZYKADIA by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205755,Non-small cell lung cancer,Approved
398,7440-45-1,https://drugs.ncats.io/drug/30K4522N6T,Clinical 2001,NCT00745108: Phase 3 Interventional Completed Postmenopausal Women,https://clinicaltrials.gov/ct2/show/NCT00745108,,,,,
399,145599-86-6,https://drugs.ncats.io/drug/AM91H2KS67,US Previously Marketed 1997,BAYCOL by BAYER PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020740,US Previously Marketed 1997,BAYCOL by BAYER PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020740,Hypercholesterolemia; Mixed dyslipidemia (Fredrickson types IIa and IIb),Withdrawn; Withdrawn
400,151662-36-1,https://drugs.ncats.io/drug/X8R2D92QP1,US Approved Rx 2017,BLA761052,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761052,US Approved Rx 2017,BLA761052,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761052,,
401,428863-50-7,https://drugs.ncats.io/drug/UMD07X179E,US Approved Rx 2008,BLA125160,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125160,Possibly Marketed Outside US 2008,BLA125160,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4c2c9dc-a0bb-4d64-a667-a67ebe88392d,,
402,10328-34-4,https://drugs.ncats.io/drug/FHG725432Z,US Previously Marketed ,21 CFR 310.545(a)(18)(vi)(A) skin protectant:poison ivy/oak/sumac cetalkonium chloride,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-545.xml,Possibly Marketed Outside US 1983,NDA214965,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c795cd2f-89da-78e3-e053-2a95a90a9422,Mouth ulcers; Cold sores; Dry eye syndrome,Approved; Approved; Approved
403,83881-51-0,https://drugs.ncats.io/drug/YO7261ME24,US Approved Rx 2018,ANDA210719,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210719,Possibly Marketed Outside US 1988,ANDA077170,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=20932906-e5bf-4858-ac54-2e5b96c20b37,Allergic rhinitis; Perennial allergic rhinitis; Seasonal allergic rhinitis,Approved; Approved; Approved
404,8044-71-1,https://drugs.ncats.io/drug/24QSH2NL8N,Possibly Marketed Outside US ,Cetrimide Cream 0.5% by Canadian Custom Packaging Company [Canada],https://www.drugbank.ca/drugs/DB01718,Possibly Marketed Outside US 1999,21 CFR 358H,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=afa58a8f-5cbf-408e-9900-668ad9355349,Seborrheic dermatitis; Skin infections,Approved; Approved
405,120287-85-6,https://drugs.ncats.io/drug/OON1HFZ4BA,US Approved Rx 2000,NDA021197,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021197,US Approved Rx 2000,NDA021197,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021197,Female infertility,Approved
406,205923-56-4,https://drugs.ncats.io/drug/PQX0D8J21J,US Approved Rx 2004,BLA125084,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084,US Approved Rx 2004,BLA125084,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084,,
407,7773-52-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
408,107233-08-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
409,16291-96-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
410,302-17-0,https://drugs.ncats.io/drug/418M5916WG,US Previously Marketed 1963,Beta-Chlor by Mead Johnson,DeHaen 1940-1975 NMEs,US Previously Marketed 1963,Beta-Chlor by Mead Johnson,DeHaen 1940-1975 NMEs,Insomnia,Approved
411,305-03-3,https://drugs.ncats.io/drug/18D0SL7309,US Approved Rx 1957,NDA010669,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=010669,US Approved Rx 1957,NDA010669,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=010669,Giant follicular lymphoma; Chronic lymphocytic leukemia; Lymphosarcoma; Hodgkin's lymphoma,Approved; Approved; Approved; Approved
412,56-75-7,https://drugs.ncats.io/drug/66974FR9Q1,US Approved Rx 1982,ANDA062365,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=062365,US Previously Marketed 1950,Chloromycetin by Warner-Lambert,OB NME Appendix 1950-1993,Eye infections,Approved
413,82-93-9,https://drugs.ncats.io/drug/M26C4IP44P,US Approved OTC ,21 CFR 341.12(b) cough/cold:antihistamine chlorcyclizine hydrochloride,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec341-12.xml,US Previously Marketed 1949,Perazil by Burroughs Wellcome,DeHaen 1940-1975 NMEs,Allergic rhinitis,Approved
414,58-25-3,https://drugs.ncats.io/drug/6RZ6XEZ3CR,US Approved Rx 2022,ANDA215835,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215835,US Previously Marketed 1960,LIBRIUM by VALEANT PHARM INTL,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012249,Major depressive disorder; Anxiety; Withdrawal symptoms of acute alcoholism,Phase III; Approved; Approved
415,55-56-1,https://drugs.ncats.io/drug/R4KO0DY52L,US Approved Rx 1976,NDA017768,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017768,US Previously Marketed 1959,Hibitane by Ayerst,DeHaen 1940-1975 NMEs,Gingivitis,Approved
416,7782-50-5,https://drugs.ncats.io/drug/4R7X1O2820,US Previously Marketed 1921,Compound Solution of Chlorine N.F.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Compound Solution of Chlorine N.F.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,,
417,51-75-2,https://drugs.ncats.io/drug/50D9XSG0VR,US Approved Rx 2013,NDA202317,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202317,US Previously Marketed 1949,MUSTARGEN by RECORDATI RARE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006695,,
418,57-15-8,https://drugs.ncats.io/drug/HM4YQM8WRC,US Previously Marketed 1961,OTOMIDE CHLOROBUTANOL by WHITE,https://www.govinfo.gov/content/pkg/FR-1972-02-12/pdf/FR-1972-02-12.pdf,US Previously Marketed 1911,Chloretone by Parke-Davis,https://catalog.hathitrust.org/Record/100782317,Pain,Not Provided
419,75-00-3,https://drugs.ncats.io/drug/46U771ERWK,US Previously Marketed 1921,Ethyl Chloride U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Ethyl Chloride U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,,
420,67-66-3,https://drugs.ncats.io/drug/7V31YC746X,US Previously Marketed 1847,chloroform,https://catalog.hathitrust.org/Record/100782317,US Previously Marketed 1847,chloroform,https://catalog.hathitrust.org/Record/100782317,,
421,1406-65-1,https://drugs.ncats.io/drug/00WNZ48OR9,US Previously Marketed 1945,Chloresium by Rystan,DeHaen 1940-1975 NMEs,US Previously Marketed 1945,Chloresium by Rystan,DeHaen 1940-1975 NMEs,Cancer,Approved
422,133-16-4,https://drugs.ncats.io/drug/5YVB0POT2H,US Approved Rx 1998,ANDA040273,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=040273,US Approved Rx 1955,NDA009435,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=009435,Pain,Approved
423,54-05-7,https://drugs.ncats.io/drug/886U3H6UFF,US Approved Rx 2021,ANDA214756,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214756,US Previously Marketed 1943,Aralen by Winthrop,DeHaen 1940-1975 NMEs,Extraintestinal amebiasis; HIV-1 infection; Acute attacks of malaria,Approved; Phase II; Approved
424,58-94-6,https://drugs.ncats.io/drug/77W477J15H,US Approved Rx 2011,ANDA091546,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=091546,US Previously Marketed 1958,DIUPRES-250 by MERCK,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011635,Congestive heart failure; Nephrotic syndrome,Approved; Approved
425,89-68-9,https://drugs.ncats.io/drug/LJ25TI0CVT,US Previously Marketed ,21 CFR 310.545(a)(22)(ii) antifungal:diaper rash chlorothymol,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-545.xml,Possibly Marketed Outside US 1950,21 CFR 347,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24682288-1be4-42af-e054-00144ff88e88,Otitis externa; Nasal congestion and colds,Approved; Approved
426,773-76-2,https://drugs.ncats.io/drug/2I8BD50I8B,US Previously Marketed 1976,CAPITROL by WESTWOOD SQUIBB,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017594,US Previously Marketed 1976,CAPITROL by WESTWOOD SQUIBB,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017594,Severe seborrheic dermatitis of the scalp,Approved
427,88-04-0,https://drugs.ncats.io/drug/0F32U78V2Q,US Previously Marketed 1960,Septiderm by Fougera,DeHaen 1940-1975 NMEs,US Previously Marketed 1960,Septiderm by Fougera,DeHaen 1940-1975 NMEs,Bacterial infections,Approved
428,132-22-9,https://drugs.ncats.io/drug/3U6IO1965U,US Approved OTC ,21 CFR 341.12(c) cough/cold:antihistamine chlorpheniramine maleate,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec341-12.xml,US Previously Marketed 1949,CHLOR-TRIMETON by SCHERING,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006921,Allergic rhinitis,Approved
429,104-29-0,https://drugs.ncats.io/drug/I670DAL4SZ,Possibly Marketed Outside US ,part333A,https://www.drugbank.ca/drugs/DB00856,Possibly Marketed Outside US 2013,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9e104ad0-088a-47ee-a037-3c9fa3af797c,Sunburns,Approved
430,34468-21-8,https://drugs.ncats.io/drug/8OBZ1M4V3V,US Approved Rx 2023,NDA214520,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214520,US Approved Rx 2023,NDA214520,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214520,,
431,94-20-2,https://drugs.ncats.io/drug/WTM2C3IL2X,US Previously Marketed 1984,CHLORPROPAMIDE by ANI PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=088919,US Previously Marketed 1958,DIABINESE by PFIZER,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011641,Type 2 diabetes mellitus,Approved
432,77-36-1,https://drugs.ncats.io/drug/Q0MQD1073Q,US Approved Rx 1984,NDA018760,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018760,US Previously Marketed 1960,HYGROTON by SANOFI AVENTIS US,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012283,Hypertension; Edema,Approved; Approved
433,95-25-0,https://drugs.ncats.io/drug/H0DE420U8G,US Approved Rx 2010,ANDA040861,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=040861,US Previously Marketed 1958,PARAFON FORTE DSC by JANSSEN R AND D,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011529,Muscle spasm,Approved
434,57-88-5,https://drugs.ncats.io/drug/97C5T2UQ7J,US Previously Marketed ,21 CFR 310.531(a) boil treatment cholesterol,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-531.xml,Possibly Marketed Outside US 1992,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ba50cf4-b3d3-4b87-80da-483a006f694e,Fatigue; Hypercholesterolemia; Gallbladder health,Not Provided; Natural Metabolite; Not Provided
435,62-49-7,https://drugs.ncats.io/drug/N91BDP6H0X,US Previously Marketed ,21 CFR 310.545(a)(20) weight control choline,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-545.xml,Possibly Marketed Outside US 2001,Vitamin B Complex 150 by Covetrus North America,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a7e15f37-7d33-40e8-b578-46e7549df257,Postoperative pain; anxiety disorder; Autism; Fatty liver disease,Phase IV; Approved; Phase IV; Phase IV
436,856676-23-8,https://drugs.ncats.io/drug/4BMH7IZT98,US Approved Rx 2015,ANDA200920,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200920,US Approved Rx 2008,NDA022224,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022224,hypertriglyceridemia,Approved
437,4499-40-5,https://drugs.ncats.io/drug/3K045XR58X,US Approved Rx 1983,ANDA087943,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=087943,US Previously Marketed 1921,Theophylline U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Airway obstruction,Approved
438,24967-94-0,https://drugs.ncats.io/drug/fd6596d5,,,,,,,,
439,9000-07-1,https://drugs.ncats.io/drug/5C69YCD2YJ,US Previously Marketed ,21 CFR 310.545(a)(20) weight control carrageenan,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-545.xml,Possibly Marketed Outside US 1984,Liquid Polibar Plus by E-Z-EM Canada Inc,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5b78c1b9-3013-4add-b439-663c419054b3,,
440,177073-44-8,https://drugs.ncats.io/drug/20ED16GHEB,US Approved Rx 1974,BLA017016,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017016,US Previously Marketed 1940,RIOGON by OJF,*!,,
441,9002-61-3,https://drugs.ncats.io/drug/20ED16GHEB,US Approved Rx 1974,BLA017016,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017016,US Previously Marketed 1940,RIOGON by OJF,*!,,
442,7440-47-3,https://drugs.ncats.io/drug/0R0008Q3JB,Possibly Marketed Outside US ,Formula Hh by Inno Vite Incorporated [Canada],https://www.drugbank.ca/drugs/DB11136,Possibly Marketed Outside US 1996,"Strovite Forte Caplet by Everett Laboratories, Inc.",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=add96910-9404-48aa-bb3c-945e321a11ab,,
443,480-40-0,https://drugs.ncats.io/drug/3CN01F5ZJ5,Possibly Marketed Outside US 2011,21 CFR 333D,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33fb5893-ea63-49a3-bb02-6b98c747c4fe,Possibly Marketed Outside US 2011,21 CFR 333D,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33fb5893-ea63-49a3-bb02-6b98c747c4fe,Neurological disorders; Inflammation,Basic research; Basic research
444,126544-47-6,https://drugs.ncats.io/drug/S59502J185,US Approved Rx 2006,NDA022004,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022004,US Approved Rx 2006,NDA022004,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022004,Asthma; Seasonal allergic rhinitis; Perennial allergic rhinitis,Approved; Approved; Approved
445,29342-05-0,https://drugs.ncats.io/drug/19W019ZDRJ,US Approved Rx 2005,ANDA077092,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077092,US Previously Marketed 1982,Loprox by Hoechst Roussel,OB NME Appendix 1950-1985,Onychomycosis of fingernails and toenails due to Trichophyton rubrum; Seborrheic dermatitis,Approved; Approved
446,59865-13-3,https://drugs.ncats.io/drug/83HN0GTJ6D,US Approved Rx 2022,ANDA216046,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216046,US Approved Rx 1983,NDA050574,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050574,"Psoriasis; Organ rejection in kidney, liver, and heart allogeneic transplants; Keratoconjunctivitis sicca; Rheumatoid arthritis",Approved; Approved; Approved; Approved
447,113852-37-2,https://drugs.ncats.io/drug/768M1V522C,US Approved Rx 2021,NDA214460,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214460,US Previously Marketed 1996,VISTIDE by GILEAD SCIENCES INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020638,Cytomegalovirus retinitis,Approved
448,82009-34-5,https://drugs.ncats.io/drug/141A6AMN38,US Approved Rx 2019,NDA212819,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212819,US Approved Rx 1985,NDA050587,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050587,Bacterial Infections,Approved
449,73963-72-1,https://drugs.ncats.io/drug/N7Z035406B,US Approved Rx 2004,ANDA077028,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077028,US Previously Marketed 1999,PLETAL by OTSUKA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020863,Intermittent claudication,Approved
450,51481-61-9,https://drugs.ncats.io/drug/80061L1WGD,US Approved Rx 1997,ANDA074553,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=074553,US Previously Marketed 1977,TAGAMET by GLAXOSMITHKLINE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017920,Stomach Ulcer; Gastroesophageal reflux disease,Approved; Approved
451,226256-56-0,https://drugs.ncats.io/drug/UAZ6V7728S,US Approved Rx 2020,ANDA211892,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211892,US Approved Rx 2004,NDA021688,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021688,Hypercalcemia in patients with parathyroid carcinoma; Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis,Approved; Approved
452,85-79-0,https://drugs.ncats.io/drug/L6JW2TJG99,US Approved OTC ,21 CFR 346.10(d) anorectal:local anesthetic dibucaine hydrochloride,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec346-10.xml,US Previously Marketed 1930,"Dibucaine; Nupercaine by Society of Chemical Industry in Basle, Basle, Switzerland (Ciba Company, Inc., New York, distributor).",https://archive.org/details/newnonofficialre39coun,Pain,Approved
453,470-82-6,https://drugs.ncats.io/drug/RV6J6604TK,US Previously Marketed 1921,Eucalyptol U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Eucalyptol U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Rhinosinusitis; Cough,Not Provided; Phase III
454,90-86-8,https://drugs.ncats.io/drug/Y1245J8012,Possibly Marketed Outside US ,https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Over-the-CounterOTCDrugs/StatusofOTCRulemakings/ucm071887.htm menstrual/diuretic:muscle relaxant cinnamedrine hydrochloride,https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Over-the-CounterOTCDrugs/StatusofOTCRulemakings/ucm071887.htm,,,,Dysmenorrhea,Not Provided
455,28657-80-9,https://drugs.ncats.io/drug/LMK22VUH23,US Previously Marketed 1992,CINOXACIN by TEVA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=073005,US Previously Marketed 1980,CINOBAC by LILLY,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018067,Urinary tract infections,Not Provided
456,104-28-9,https://drugs.ncats.io/drug/5437O7N5BH,US Previously Marketed 1961,Sundare Clear by Texas Pharmacal,OB NME Appendix 1950-1985,US Previously Marketed 1961,Sundare Clear by Texas Pharmacal,OB NME Appendix 1950-1985,Unknown,
457,85721-33-1,https://drugs.ncats.io/drug/5E8K9I0O4U,US Approved Rx 2004,ANDA076558,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=076558,US Approved Rx 1987,NDA019537,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019537,Infectious diarrhea; Urinary tract infections; Lower respiratory tract infections,Approved; Approved; Approved
458,81098-60-4,https://drugs.ncats.io/drug/UVL329170W,US Previously Marketed 1993,PROPULSID by JANSSEN PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020210,US Previously Marketed 1993,PROPULSID by JANSSEN PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020210,Gastroesophageal reflux disease; Megacolon; Constipation,Withdrawn; Not Provided; Not Provided
459,96946-42-8,https://drugs.ncats.io/drug/80YS8O1MBS,US Approved Rx 2018,ANDA203238,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203238,US Approved Rx 1995,NDA020551,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020551,Skeletal muscle relaxation,Approved
460,15663-27-1,https://drugs.ncats.io/drug/Q20Q21Q62J,US Approved Rx 1978,NDA018057,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018057,US Approved Rx 1978,NDA018057,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018057,Unknown; Advanced bladder cancer; Metastatic ovarian tumors; Metastatic testicular tumors; Non-small cell lung cancer; Unknown,Approved; Approved; Approved; Phase IV
461,59729-33-8,https://drugs.ncats.io/drug/0DHU5B8D6V,US Approved Rx 2006,ANDA077289,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077289,US Approved Rx 1998,NDA020822,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020822,Depression; Depression,Approved; Approved
462,987-78-0,https://drugs.ncats.io/drug/536BQ2JVC7,Possibly Marketed Outside US ,Japan:Citicoline,https://tripod.nih.gov/npc/#Download,Possibly Marketed Outside US 2023,Nerve Mushroom gummies by XIAN CHIANG COMPANY LIMITED,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=07a81afd-b86f-87af-e063-6294a90a65f9,Acute ischemic stroke; Alcohol addiction; Bipolar disorder; Cocaine addiction; Traumatic brain injury,Approved; Phase IV; Phase IV; Phase IV; Approved
463,77-92-9,https://drugs.ncats.io/drug/GQH5A01T0W,,,,,,,,
464,8000-29-1,https://drugs.ncats.io/drug/QYO8Q067D0,Possibly Marketed Outside US 2024,M017,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94fa1774-73ef-4b30-8069-617750dedc0c,Possibly Marketed Outside US 1966,21 CFR 348,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91bf3641-e83d-49e9-9b53-ce7c37452811,,
465,372-75-8,https://drugs.ncats.io/drug/29VT07BGDA,Possibly Marketed Outside US ,Lipovite by Perdido Key Health And Wellness Inc,https://www.drugbank.ca/drugs/DB00155,Possibly Marketed Outside US 2012,SPAI-SONSPROLAC-VIT by SPAI-SONS PHARMACEUTICAL INTERNATIONAL COSMETICS,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c294bea-5a61-4756-af3c-17ed30f2c0d8,,
466,90045-43-5,https://drugs.ncats.io/drug/2OYE00PC25,US Approved Rx 2023,NDA215830,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215830,US Approved Rx 2023,NDA215830,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215830,,
467,4291-63-8,https://drugs.ncats.io/drug/47M74X9YT5,US Approved Rx 2019,NDA022561,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022561,US Previously Marketed 1993,LEUSTATIN by JANSSEN PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020229,Hairy cell leukemia,Approved
468,81103-11-9,https://drugs.ncats.io/drug/H1250JIK0A,US Approved Rx 1993,NDA050697,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050697,US Previously Marketed 1991,BIAXIN by ABBVIE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050662,Community-acquired pneumonia; Uncomplicated skin and skin-structure infections; Disseminated mycobacterial infections; Bacterial pharyngitis; Bacterial tonsillitis; Acute bacterial maxillary sinusitis; Acute bacterial exacerbation of chronic bronchitis; Helicobacter pylori infection; Acute bacterial otitis media,Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved
469,58001-44-8,https://drugs.ncats.io/drug/23521W1S24,US Approved Rx 2023,ANDA209351,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209351,US Previously Marketed 1984,AUGMENTIN '250' by US ANTIBIOTICS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050564,Lower respiratory tract infections; Sinusitis; Skin and skin structure infections; Urinary tract infections; Otitis media,Approved; Approved; Approved; Approved; Approved
470,12141-46-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
471,15686-51-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
472,167221-71-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
473,7020-55-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
474,18323-44-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
475,130-26-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
476,22316-47-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
477,25122-41-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
478,4828-27-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
479,123318-82-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
480,2030-63-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
481,791-35-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
482,637-07-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
483,15690-55-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
484,303-49-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
485,1622-61-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
486,4205-90-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
487,113665-84-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
488,23887-31-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
489,23593-75-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
490,61-72-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
491,130-16-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
492,5786-21-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
493,8007-45-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
494,7440-48-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
495,13870-90-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
496,1004316-88-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
497,934660-93-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
498,50-36-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
499,154-87-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
500,124-87-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
501,76-57-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
502,8001-69-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
503,64-86-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
504,67-97-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
505,182815-43-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
506,50925-79-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
507,11041-12-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
508,66575-29-9,https://drugs.ncats.io/drug/1F7A44V6OU,Clinical ,INN:colforsin [INN],https://ginas.ncats.nih.gov/ginas/app/substance/1F7A44V6OU,,,,,
509,63-89-8,https://drugs.ncats.io/drug/319X2NFW0A,US Previously Marketed 1990,EXOSURF NEONATAL by GLAXOSMITHKLINE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020044,US Previously Marketed 1990,EXOSURF NEONATAL by GLAXOSMITHKLINE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020044,respiratory distress syndrome,Approved
510,1066-17-7,https://drugs.ncats.io/drug/Z67X93HJG1,US Approved Rx 1962,NDA050356,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050356,US Previously Marketed 1962,COLY-MYCIN S by PARKE DAVIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050355,Infections of mastoidectomy and fenestration cavities; Superficial bacterial infections of the external auditory canal,Approved; Approved
511,9007-34-5,https://drugs.ncats.io/drug/8JC99XGU4W,Possibly Marketed Outside US ,Ramosu Collagen Ampoule 200 by RaMoSu,https://www.drugbank.ca/drugs/DB14246,Possibly Marketed Outside US 1973,NDA022070,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6b45969-a64a-4ce3-b3b6-157d2568a301,,
512,9001-12-1,https://drugs.ncats.io/drug/9X7O8V25IT,US Approved Rx 1965,BLA101995,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=101995,US Approved Rx 1965,BLA101995,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=101995,,
513,9001-12-1,https://drugs.ncats.io/drug/9X7O8V25IT,US Approved Rx 1965,BLA101995,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=101995,US Approved Rx 1965,BLA101995,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=101995,,
514,80295-38-1,https://drugs.ncats.io/drug/5QS67N4551,Possibly Marketed Outside US ,WHO-ATC:B06AC04,https://ginas.ncats.nih.gov/ginas/app/substance/5QS67N4551,Possibly Marketed Outside US 2014,BLA125495,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b81613ee-506e-47eb-91a7-708dfc958ea3,,
515,210101-16-9,https://drugs.ncats.io/drug/0NJ98Y462X,US Approved Rx 2007,NDA022016,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022016,US Approved Rx 2005,NDA021697,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021697,Hyponatremia; Traumatic brain injury; Liver cirrhosis; Heart failure,Approved; Phase I; Phase II; Phase III
516,69-72-7,https://drugs.ncats.io/drug/O414PZ4LPZ,US Approved OTC ,21 CFR 358.110(b) wart remover:collodoin-like vehicle salicylic acid,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec358-110.xml,US Previously Marketed 1860,sodium salicylate,https://catalog.hathitrust.org/Record/100782317,Psoriasis; Ichthyosis vulgaris; Keratosis palmaris; Bruises; Arthritis; Strains and sprains; Simple backache,Approved; Approved; Approved; Approved; Approved; Approved; Approved
517,1032568-63-0,https://drugs.ncats.io/drug/WI6V529FZ9,US Previously Marketed 2017,ALIQOPA by BAYER HEALTHCARE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209936,US Previously Marketed 2017,ALIQOPA by BAYER HEALTHCARE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209936,Relapsed follicular lymphoma,Approved
518,7440-50-8,https://drugs.ncats.io/drug/789U1901C5,US Approved Rx 1984,NDA018680,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018680,US Previously Marketed 1921,copper,https://catalog.hathitrust.org/Record/100163146,Pregnancy prevention,Approved
519,829-74-3,https://drugs.ncats.io/drug/V008L6478D,US Previously Marketed 1961,NOV PONT W/NEOCOBEFRIN LEVONORDEFRIN by COOKE-WAITE,*!,US Previously Marketed 1952,RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN by EASTMAN KODAK,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=008592,Dental care,Approved
520,86784-80-7,https://drugs.ncats.io/drug/305OE8862Y,Possibly Marketed Outside US ,WHO-ATC:V04CD04,https://ginas.ncats.nih.gov/ginas/app/substance/305OE8862Y,,,,,
521,9002-60-2,https://drugs.ncats.io/drug/097da217,,,,,,,,
522,53-06-5,https://drugs.ncats.io/drug/V27W9254FZ,US Previously Marketed 1975,CORTISONE ACETATE by EVERYLIFE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=084246,US Previously Marketed 1950,CORTONE by MERCK,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=007110,Primary adrenocortical insufficiency; Severe or incapacitating allergic conditions; Rheumatic diseases,Approved; Approved; Approved
523,90-05-1,https://drugs.ncats.io/drug/6JKA7MAH9C,US Previously Marketed 1892,Guaiacol,https://books.google.com/books?id=T41MAQAAMAAJ&newbks=1&newbks_redir=0&dq=Guaiacol&pg=PA381#v=onepage&q=Guaiacol&f=false,US Previously Marketed 1892,Guaiacol,https://books.google.com/books?id=T41MAQAAMAAJ&newbks=1&newbks_redir=0&dq=Guaiacol&pg=PA381#v=onepage&q=Guaiacol&f=false,Cough,Approved
524,57-00-1,https://drugs.ncats.io/drug/MU72812GK0,Possibly Marketed Outside US ,"Ginsamin Energy by Biogrand Co., Ltd",https://www.drugbank.ca/drugs/DB00148,Possibly Marketed Outside US 2004,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b67a454-26ba-4049-854c-9335668236cd,,
525,60-27-5,https://drugs.ncats.io/drug/AYI8EX34EU,Possibly Marketed Outside US 1996,ANDA040069,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=580b36d2-1400-4096-aff1-cbc1f6d0ad4c,Possibly Marketed Outside US 1996,ANDA040069,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=580b36d2-1400-4096-aff1-cbc1f6d0ad4c,Renal failure; Sunburn,Natural Metabolite; Approved
526,8021-39-4,https://drugs.ncats.io/drug/3JYG22FD73,US Previously Marketed 1921,Creosote U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Creosote U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,,
527,906673-24-3,https://drugs.ncats.io/drug/Q2R47HGR7P,US Approved Rx 2016,NDA207695,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207695,US Approved Rx 2016,NDA207695,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207695,Atopic dermatitis,Approved
528,877399-52-5,https://drugs.ncats.io/drug/53AH36668S,US Approved Rx 2011,NDA202570,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202570,US Approved Rx 2011,NDA202570,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202570,Metastatic non-small cell lung cancer; Cancer,Approved; Basic research
529,148465-45-6,https://drugs.ncats.io/drug/PY79D6C8RX,US Approved Rx 2012,NDA202292,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202292,US Approved Rx 2012,NDA202292,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202292,HIV associated diarrhea,Approved
530,16110-51-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
531,124236-29-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
532,76-14-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
533,472-70-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
534,548-62-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
535,458-37-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
536,458-37-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
537,68-19-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
538,456-59-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
539,82-92-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
540,303-53-7,https://drugs.ncats.io/drug/69O5WQQ5TI,US Approved Rx 2020,ANDA213324,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213324,US Previously Marketed 1977,FLEXERIL by JANSSEN RES AND DEV,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017821,"Acute, painful musculoskeletal conditions",Approved
541,69430-24-6,https://drugs.ncats.io/drug/NMQ347994Z,Possibly Marketed Outside US ,EHP Cleansing by Miguhara,https://www.drugbank.ca/drugs/DB14124,Possibly Marketed Outside US 1983,NDA019555,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fbf56a50-741f-4d86-b995-e6f5fb454df4,,
542,541-02-6,https://drugs.ncats.io/drug/0THT5PCI0R,Possibly Marketed Outside US ,Bp by Miguhara,https://www.drugbank.ca/drugs/DB11244,Possibly Marketed Outside US 2005,"Lustra by Taro Pharmaceuticals U.S.A., Inc.",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c1d01301-70c3-484b-8967-2324afa1781e,Sunburn,Approved
543,512-15-2,https://drugs.ncats.io/drug/I76F4SHP7J,US Approved Rx 1974,ANDA084108,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=084108,US Previously Marketed 1953,Cyclogyl HCl by Schieffelin,DeHaen 1940-1975 NMEs,Eye diseases,Approved
544,50-18-0,https://drugs.ncats.io/drug/6UXW23996M,US Approved Rx 2023,ANDA211552,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211552,US Previously Marketed 1959,CYTOXAN by BAXTER HLTHCARE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012142,"Burkitt’s lymphoma; Acute myelogenous and monocytic leukemia; Mycosis fungoides; Hodgkin’s disease mixed-cell type lymphoma; Chronic granulocytic leukemia; Breast cancer; Retinoblastoma; Neuroblastoma; Multiple myeloma; Chronic lymphocytic leukemia; Adenocarcinoma of the ovary; Minimal change nephrotic syndrome; Hodgkin’s disease histiocytic lymphoma; Acute lymphoblastic leukemia; Hodgkin’s disease, lymphocytic lymphoma  (nodular or diffuse)",Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved
545,68-41-7,https://drugs.ncats.io/drug/95IK5KI84Z,US Approved Rx 1964,ANDA060593,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=060593,US Previously Marketed 1956,Seromycin by Lilly,DeHaen 1940-1975 NMEs,Tuberculosis,Approved
546,129-03-3,https://drugs.ncats.io/drug/2YHB6175DO,US Approved Rx 2006,ANDA040668,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=040668,US Previously Marketed 1961,PERIACTIN by MERCK,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012649,Cold urticaria; Vasomotor rhinitis; Uncomplicated allergic skin manifestations of angioedema; Perennial allergic rhinitis; Anaphylaxis; Vasomotor rhinitis; Angioedema; Urticaria; Seasonal allergic rhinitis; Allergic conjunctivitis,Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved
547,52-90-4,https://drugs.ncats.io/drug/K848JZ4886,US Approved Rx 2019,NDA210660,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210660,Possibly Marketed Outside US 1952,NDA008372,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b48ddec-e815-45f4-9ca0-5c0daaf56f30,Parenteral nutrition,Approved
548,56-89-3,https://drugs.ncats.io/drug/48TCX9A1VT,US Previously Marketed ,21 CFR 310.545(a)(20) weight control cystine,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-545.xml,Possibly Marketed Outside US 2008,BLA125265,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f3182470-1965-4e20-dbaf-e3506f893ea5,Colon cancer; Gastric cancer,Not Provided; Not Provided
549,147-94-4,https://drugs.ncats.io/drug/04079A1RDZ,US Approved Rx 1990,ANDA071868,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=071868,US Previously Marketed 1969,CYTARABINE by TEVA PARENTERAL,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016793,Chronic myelogenous leukemia; Lymphomatous meningitis,Phase III; Approved
550,10326-41-7,https://drugs.ncats.io/drug/3Q6M5SET7W,Possibly Marketed Outside US 2016,21 CFR 347,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2cea5bb8-9683-6957-e054-00144ff8d46c,Possibly Marketed Outside US 2016,21 CFR 347,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2cea5bb8-9683-6957-e054-00144ff8d46c,Unknown,
551,211915-06-9,https://drugs.ncats.io/drug/2E18WX195X,US Approved Rx 2020,ANDA207961,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207961,US Approved Rx 2010,NDA022512,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022512,Unknown; Deep venous thrombosis; Systemic embolism in patients with non-valvular atrial fibrillation; Pulmonary embolism,Approved; Approved; Approved
552,1195765-45-7,https://drugs.ncats.io/drug/QGP4HA4G1B,US Approved Rx 2023,NDA217514,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217514,US Approved Rx 2013,NDA202806,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202806,Melanoma,Approved
553,4342-03-4,https://drugs.ncats.io/drug/7GR28W0FJI,US Approved Rx 1999,ANDA075371,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=075371,US Previously Marketed 1975,DTIC-DOME by BAYER HLTHCARE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017575,Hodgkin's lymphoma; Malignant melanoma,Approved; Approved
554,1009119-64-5,https://drugs.ncats.io/drug/LI2427F9CI,US Previously Marketed 2015,DAKLINZA by BRISTOL-MYERS SQUIBB,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206843,US Previously Marketed 2015,DAKLINZA by BRISTOL-MYERS SQUIBB,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206843,Chronic hepatitis C virus genotype 3 infection,Approved
555,152923-56-3,https://drugs.ncats.io/drug/CUJ2MVI71Y,US Approved Rx 2016,BLA761029,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761029,US Previously Marketed 1997,Zenapax,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103749,,
556,1110813-31-4,https://drugs.ncats.io/drug/2XJX250C20,US Approved Rx 2018,NDA211288,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211288,US Approved Rx 2018,NDA211288,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211288,Non-small cell lung cancer; Glioblastoma; Esophageal squamous cell carcinoma; Head and neck squamous cell carcinoma,Approved; Phase II; Phase II; Phase II
557,50-76-0,https://drugs.ncats.io/drug/1CC1JFE158,US Approved Rx 2017,ANDA203385,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203385,US Previously Marketed 1964,Cosmegen by Merck Sharp & Dohme,OB NME Appendix 1950-1993,Locally recurrent and locoregional carcinomas; Locally recurrent and locoregional sarcomas; Wilms' tumor; Gestational trophoblastic neoplasia; Locally recurrent and locoregional adenocarcinomas; Ewing’s sarcoma; Metastatic nonseminomatous testicular cancer; Childhood rhabdomyosarcoma,Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved
558,94349-98-1,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
559,171500-79-1,https://drugs.ncats.io/drug/808UI9MS5K,US Approved Rx 2014,NDA021883,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021883,US Approved Rx 2014,NDA021883,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021883,Acute bacterial skin and skin structure infection,Approved
560,112362-50-2,https://drugs.ncats.io/drug/R9M4FJE48E,US Approved Rx 1999,NDA050748,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050748,US Approved Rx 1999,NDA050748,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050748,Complicated skin and skin structure infections caused by Staphylococcus aureus or Streptococcus pyogenes,Approved
561,9041-08-1,https://drugs.ncats.io/drug/19GW9E1WHN,Clinical ,INN:sevuparin sodium [INN],https://ginas.ncats.nih.gov/ginas/app/substance/19GW9E1WHN,,,,,
562,1363853-26-2,https://drugs.ncats.io/drug/BY4TSK952Y,Possibly Marketed Outside US ,Jivi by Bayer [Canada],https://www.drugbank.ca/drugs/DB14700,Possibly Marketed Outside US 2018,BLA125661,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f04e5bd5-d7e2-453b-a407-2616d81a695d,,
563,17230-88-5,https://drugs.ncats.io/drug/N29QWW3BUO,US Approved Rx 2005,ANDA077246,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077246,US Previously Marketed 1976,DANOCRINE by SANOFI AVENTIS US,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017557,Hereditary angioedema; Endometriosis; Fibrocystic breast disease,Approved; Approved; Approved
564,7261-97-4,https://drugs.ncats.io/drug/F64QU97QCR,US Approved Rx 1974,NDA017443,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017443,US Approved Rx 1974,NDA017443,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017443,Malignant hyperthermia; Chronic spasticity,Approved; Approved
565,117-10-2,https://drugs.ncats.io/drug/Z4XE6IBF3V,US Previously Marketed ,21 CFR 310.545(a)(12)(iv)(B) laxative:stimulant laxative danthron,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-545.xml,,,,Constipation in terminally ill patients,Withdrawn
566,461432-26-8,https://drugs.ncats.io/drug/1ULL0QJ8UC,US Approved Rx 2017,NDA209091,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209091,Possibly Marketed Outside US 2008,NDA202293,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01f90c94-71cb-4a1f-81ff-8004b850529b,Type 2 diabetes mellitus,Approved
567,72822-12-9,https://drugs.ncats.io/drug/5RNZ8GJO7K,US Previously Marketed 2019,DAPIPRAZOLE HYDROCHLORIDE by WOODWARD,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204902,US Previously Marketed 1990,DAPIPRAZOLE HYDROCHLORIDE by FERA PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019849,Pharmacologically induced mydriasis,Approved
568,80-08-0,https://drugs.ncats.io/drug/8W5C518302,US Approved Rx 2016,NDA207154,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207154,US Previously Marketed 1955,Avlosulfon by Ayerst,OB NME Appendix 1950-1985,Dermatitis herpetiformis; Acne vulgaris; Leprosy,Approved; Approved; Approved
569,103060-53-3,https://drugs.ncats.io/drug/NWQ5N31VKK,US Approved Rx 2017,NDA208385,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208385,US Previously Marketed 2003,CUBICIN by CUBIST PHARMS LLC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021572,Complicated skin and skin structure infections; Staphylococcus aureus bloodstream infections,Approved; Approved
570,945721-28-8,https://drugs.ncats.io/drug/4Z63YK6E0E,US Approved Rx 2015,BLA761036,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761036,US Approved Rx 2015,BLA761036,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761036,,
571,209810-58-2,https://drugs.ncats.io/drug/15UQ94PT4P,US Approved Rx 2001,BLA103951,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103951,US Approved Rx 2001,BLA103951,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103951,,
572,133099-04-4,https://drugs.ncats.io/drug/APG9819VLM,US Approved Rx 2017,ANDA207302,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207302,US Previously Marketed 2004,ENABLEX by ABBVIE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021513,Overactive bladder,Approved
573,206361-99-1,https://drugs.ncats.io/drug/YO603Y8113,US Approved Rx 2023,ANDA215389,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215389,US Approved Rx 2006,NDA021976,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=21976,HIV-1 infection,Approved
574,1132935-63-7,https://drugs.ncats.io/drug/DE54EQW8T1,US Previously Marketed 2016,VIEKIRA XR by ABBVIE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208624,US Previously Marketed 2014,VIEKIRA PAK (COPACKAGED) by ABBVIE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206619,Chronic hepatitis C,Approved
575,302962-49-8,https://drugs.ncats.io/drug/X78UG0A0RN,US Approved Rx 2006,NDA021986,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021986,Possibly Marketed Outside US 2006,NDA021986,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4764f37b-c9e6-4ede-bcc2-8a03b7c521df,Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML); Acute lymphoblastic leukemia,Approved; Approved
576,20830-81-3,https://drugs.ncats.io/drug/ZS7284E0ZP,US Approved Rx 2019,ANDA208759,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208759,US Previously Marketed 1979,CERUBIDINE by WYETH AYERST,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050484,Neuroblastoma; Acute lymphoblastic leukemia; Acute myeloblastic leukemia,Approved; Approved; Approved
577,108-01-0,https://drugs.ncats.io/drug/2N6K9DRA24,US Previously Marketed 1961,DEANER 100MG by RIKER,https://cdn.loc.gov/service/ll/fedreg/fr035/fr035095/fr035095.pdf,US Previously Marketed 1958,Deaner by Riker,DeHaen 1940-1975 NMEs,,
578,334-48-5,https://drugs.ncats.io/drug/4G9EDB6V73,Possibly Marketed Outside US 2010,"OHUI Wrinkle Science wrinkle repair eye by LG Household and Healthcare, Inc.",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b8e85860-f7ce-4e47-9321-4c916ce7e9da,Possibly Marketed Outside US 1968,NDA204017,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bcaf8db0-1750-425d-b008-255b5e7a9cc6,Seizure; Inherited metabolic diseases,Preclinical; Basic research
579,2353-33-5,https://drugs.ncats.io/drug/776B62CQ27,US Approved Rx 2013,ANDA203131,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203131,US Previously Marketed 2006,DACOGEN by OTSUKA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021790,Myelodysplastic syndromes,Approved
580,201530-41-8,https://drugs.ncats.io/drug/V8G4MOF2V9,US Approved Rx 2022,ANDA216229,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216229,US Approved Rx 2005,NDA021882,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021882,Beta-thalassemia; Transfusional hemosiderosis,Approved; Approved
581,30652-11-0,https://drugs.ncats.io/drug/2BTY8KH53L,US Approved Rx 2020,NDA212269,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212269,US Approved Rx 2011,NDA021825,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021825,Iron overload; Thalassemia syndrome,Approved; Approved
582,70-51-9,https://drugs.ncats.io/drug/J06Y7MXW4D,US Approved Rx 2017,ANDA207384,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207384,US Approved Rx 1968,NDA016267,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016267,Acute iron intoxication; Chronic iron overload,Approved; Approved
583,83712-60-1,https://drugs.ncats.io/drug/L7CHH2B2J0,US Approved Rx 2016,NDA208114,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208114,US Approved Rx 2016,NDA208114,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208114,,
584,14484-47-0,https://drugs.ncats.io/drug/KR5YZ6AE4B,US Approved Rx 2017,NDA208684,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208684,US Approved Rx 2017,NDA208684,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208684,Immune system diseases,Approved
585,214766-78-6,https://drugs.ncats.io/drug/SX0XJI3A11,US Approved Rx 2008,NDA022201,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022201,US Approved Rx 2008,NDA022201,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022201,Advanced prostate cancer,Approved
586,189279-58-1,https://drugs.ncats.io/drug/6315412YVF,US Approved Rx 2017,NDA208610,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208610,US Approved Rx 2017,NDA208610,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208610,Gonorrhea; Community-acquired bacterial pneumonia; Acute bacterial skin and skin structure infection,Phase III; Phase III; Approved
587,136817-59-9,https://drugs.ncats.io/drug/DOL5F9JD3E,US Previously Marketed 1997,RESCRIPTOR by VIIV HLTHCARE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020705,US Previously Marketed 1997,RESCRIPTOR by VIIV HLTHCARE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020705,HIV-1 infection,Approved
588,16505-84-3,https://drugs.ncats.io/drug/ILP8XJ8R5K,US Previously Marketed 1959,HUMORSOL by MERCK,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011860,US Previously Marketed 1959,HUMORSOL by MERCK,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011860,Accommodative esotropia; Open-angle glaucoma,Approved; Approved
589,64-73-3,https://drugs.ncats.io/drug/29O079NTYT,US Approved Rx 2008,ANDA065389,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=065389,US Previously Marketed 1959,Declomycin by Lederle,DeHaen 1940-1975 NMEs,Bacterial infections,Approved
590,173146-27-5,https://drugs.ncats.io/drug/25E79B5CTM,US Approved Rx 1999,BLA103767,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103767,US Approved Rx 1999,BLA103767,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103767,,
591,615258-40-7,https://drugs.ncats.io/drug/4EQZ6YO2HI,US Approved Rx 2010,BLA125320,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125320,US Approved Rx 2010,BLA125320,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125320,,
592,7631-97-2,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
593,83-44-3,https://drugs.ncats.io/drug/005990WHZZ,US Approved Rx 2021,ANDA212296,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212296,US Previously Marketed 1942,Doxychol by Breon,https://books.google.com/books?id=NwRGZTzHKRUC&lpg=PA9322&ots=xiCPzCwR9r&dq=doxychol%20breon&pg=PA9322#v=onepage&q=doxychol%20breon&f=false,Subcutaneous fat disorders; Lipoma,Approved; Phase II
594,131-01-1,https://drugs.ncats.io/drug/9016E3VB47,US Previously Marketed 1984,METHYCLOTHIAZIDE AND DESERPIDINE by WATSON LABS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=088452,US Previously Marketed 1957,HARMONYL by ABBVIE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=010796,Hypertension,Approved
595,57041-67-5,https://drugs.ncats.io/drug/CRS35BZ94Q,US Approved Rx 1992,NDA020118,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020118,US Approved Rx 1992,NDA020118,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020118,skeletal muscle relaxation,Approved
596,50-47-5,https://drugs.ncats.io/drug/TG537D343B,US Approved Rx 1987,ANDA071602,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=071602,US Approved Rx 1964,NDA014399,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=014399,Depression,Approved
597,120993-53-5,https://drugs.ncats.io/drug/U0JZ726775,US Previously Marketed 2003,IPRIVASK by BAUSCH,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021271,US Previously Marketed 2003,IPRIVASK by BAUSCH,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021271,Deep vein thrombosis,Approved
598,100643-71-8,https://drugs.ncats.io/drug/FVF865388R,US Approved Rx 2011,ANDA078365,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=078365,US Approved Rx 2001,NDA021165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021165,Seasonal allergic rhinitis; Perennial allergic rhinitis; Chronic idiopathic urticaria,Approved; Approved; Approved
599,16679-58-6,https://drugs.ncats.io/drug/ENR1LLB0FP,US Approved Rx 2020,ANDA210223,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210223,US Previously Marketed 1978,DDAVP by FERRING PHARMS INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017922,von Willebrand’s disease (Type I); Hemophilia A; Central cranial diabetes insipidus,Withdrawn; Approved; Approved
600,54024-22-5,https://drugs.ncats.io/drug/81K9V7M3A3,US Approved Rx 2013,ANDA202296,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202296,US Previously Marketed 1992,ORTHO-CEPT by JANSSEN PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020301,Pregnancy,Approved
601,638-94-8,https://drugs.ncats.io/drug/J280872D1O,US Approved Rx 2017,ANDA208836,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208836,US Approved Rx 1972,NDA017010,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017010,Contact dermatitis; Atopic dermatitis; Psoriasis; Seborrheic dermatitis; Eczema,Approved; Approved; Approved; Approved; Approved
602,140218-14-0,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
603,93413-62-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
604,1392826-25-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
605,50-02-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
606,51-64-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
607,132-21-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
608,25523-97-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
609,138530-94-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
610,113775-47-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
611,40431-64-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
612,81-13-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
613,24584-09-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
614,9004-54-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
615,56087-11-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
616,9004-53-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
617,125-71-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
618,469-62-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
619,51-49-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
620,117-96-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
621,439-14-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
622,78491-02-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
623,364-98-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
624,480-30-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
625,79-43-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
626,75-71-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
627,15307-86-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
628,120-97-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
629,3116-76-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
630,66-76-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
631,77-19-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
632,69655-05-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
633,13029-44-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
634,65928-58-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
635,56-53-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
636,134-62-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
637,28782-42-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
638,2557-49-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
639,22494-42-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
640,23674-86-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
641,71-63-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
642,20830-75-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
643,125-28-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
644,511-12-6,https://drugs.ncats.io/drug/436O5HM03C,US Approved Rx 2017,ANDA206621,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206621,US Previously Marketed 1946,D.H.E. 45 by BAUSCH,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=005929,Migraine,Approved
645,11032-41-0,https://drugs.ncats.io/drug/34HPE9Z8IP,US Approved Rx 1991,ANDA081113,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=081113,US Previously Marketed 1953,Hydergine by Sandoz,OB NME Appendix 1950-1993,Primary progressive dementia; Alzheimer's dementia; Multi-infarct dementia,Approved; Approved; Approved
646,67-96-9,https://drugs.ncats.io/drug/R5LM3H112R,US Previously Marketed 1940,Hytakerol by Winthrop-Stearns (Winthrop),DeHaen 1940-1975 NMEs,US Previously Marketed 1940,Hytakerol by Winthrop-Stearns (Winthrop),DeHaen 1940-1975 NMEs,Hypocalcemia; Hypoparathyroidism,Approved; Approved
647,96-26-4,https://drugs.ncats.io/drug/O10DDW6JOO,Possibly Marketed Outside US 1999,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c517222-35fe-4d93-8fc9-bd38ccda65fc,Possibly Marketed Outside US 1999,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c517222-35fe-4d93-8fc9-bd38ccda65fc,sunburn,Approved
648,7047-84-9,https://drugs.ncats.io/drug/P9BC99461E,Possibly Marketed Outside US ,Japan:Aluminum Monostearate,https://tripod.nih.gov/npc/#Download,Possibly Marketed Outside US 1993,NDA020215,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bf9e7e35-7707-42a0-88d6-6292fa52bbfa,Angina pectoris due to coronary artery disease; Unknown,Approved
649,83-73-8,https://drugs.ncats.io/drug/63W7IE88K8,US Previously Marketed 1953,BACULIN by AMFRE GRANT,"Federal Register v.40 (1975), page 12698, retrieved from: https://books.google.ru/books?id=Bs7A91z1w6sC",US Previously Marketed 1953,BACULIN by AMFRE GRANT,"Federal Register v.40 (1975), page 12698, retrieved from: https://books.google.ru/books?id=Bs7A91z1w6sC",Amebiasis,Withdrawn
650,56209-45-1,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
651,523-87-5,https://drugs.ncats.io/drug/JB937PER5C,US Approved OTC ,21 CFR 336.10(b) antiemetic dimenhydrinate,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec336-10.xml,US Previously Marketed 1949,Dramamine by Searle,DeHaen 1940-1975 NMEs,,
652,1118-68-9,https://drugs.ncats.io/drug/7797M4CPPA,,,,,,,Unknown,
653,624-49-7,https://drugs.ncats.io/drug/FO2303MNI2,US Approved Rx 2019,NDA211855,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211855,Possibly Marketed Outside US 1946,NDA006035,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1552d48-86f5-4184-810a-001e57e96c02,Arthritis; Multiple sclerosis; Ischemic stroke; Cancer; Periapical diseases; Unknown; Relapsing forms of multiple sclerosis; Unknown,Preclinical; Approved; Preclinical; Natural Metabolite; Not Provided; Approved
654,67-71-0,https://drugs.ncats.io/drug/9H4PO4Z4FT,Possibly Marketed Outside US ,Powerfulx Ginseng RecoveryCream by Powerful X,https://www.drugbank.ca/drugs/DB14090,Possibly Marketed Outside US 1988,21 CFR 348,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5f76bfc-6601-815a-e053-2995a90ac124,Dietary Supplements; Osteoarthritis,Approved; Approved
655,67-68-5,https://drugs.ncats.io/drug/YOW8V9698H,US Approved Rx 1978,NDA017788,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017788,Possibly Marketed Outside US 1972,NADA045512,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ae0564a-6c03-4848-88d0-621943d94ea1,interstitial cystitis,Approved
656,107-51-7,https://drugs.ncats.io/drug/9G1ZW13R0G,Possibly Marketed Outside US ,Canada:DIMETHICONE,https://tripod.nih.gov/npc/#Download,Possibly Marketed Outside US 2004,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b67a454-26ba-4049-854c-9335668236cd,Sunburn,Approved
657,363-24-6,https://drugs.ncats.io/drug/K7Q1JQR04M,US Approved Rx 1995,NDA020411,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020411,US Previously Marketed 1977,PROSTIN E2 by PFIZER,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017810,Unknown; Labor complications,Approved
658,1363687-32-4,https://drugs.ncats.io/drug/7SQY4ZUD30,US Approved Rx 2015,BLA125516,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125516,US Approved Rx 2015,BLA125516,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125516,,
659,520-27-4,https://drugs.ncats.io/drug/7QM776WJ5N,Possibly Marketed Outside US ,"Vasculera by Primus Pharmaceuticals, Inc.",https://www.drugbank.ca/drugs/DB08995,Possibly Marketed Outside US 2012,"Vasculera by Primus Pharmaceuticals, Inc.",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=563d3d34-a547-471e-aecd-f4a4a57cbf1d,Menorrhagia; Venous insufficiency; Hemorrhoids,Phase II; Not Provided; Not Provided
660,131-53-3,https://drugs.ncats.io/drug/B762XZ551X,US Previously Marketed 1966,Solhar by Person-Covey,OB NME Appendix 1950-1985,US Previously Marketed 1966,Solhar by Person-Covey,OB NME Appendix 1950-1985,Sunburn,Approved
661,58-73-1,https://drugs.ncats.io/drug/8GTS82S83M,US Approved OTC ,21 CFR 336.10(c) antiemetic diphenhydramine hydrochloride,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec336-10.xml,US Previously Marketed 1946,BENADRYL by MCNEIL CONS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=005845,Occasional sleeplessness; Seasonal allergic rhinitis,Approved; Approved
662,915-30-0,https://drugs.ncats.io/drug/73312P173G,US Approved Rx 1960,NDA012462,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012462,US Approved Rx 1960,NDA012462,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012462,Acute diarrhea,Approved
663,147-20-6,https://drugs.ncats.io/drug/33361OE3AV,US Previously Marketed 1961,PYRALINE HCL 2MG by NOPCO,https://www.govinfo.gov/content/pkg/FR-1977-09-02/pdf/FR-1977-09-02.pdf,US Previously Marketed 1953,Diafen by SchenLabs (Riker),OB NME Appendix 1950-1985,Rhinitis; Pruritus; Allergic rhinitis,Approved; Approved; Approved
664,52365-63-6,https://drugs.ncats.io/drug/8Q1PVL543G,US Previously Marketed 1995,AKPRO by EPIC PHARMA LLC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=074382,US Previously Marketed 1980,PROPINE by ALLERGAN,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018239,Chronic open-angle glaucoma,Approved
665,479-18-5,https://drugs.ncats.io/drug/263T0E9RR9,US Previously Marketed 1951,NEOTHYLLINE by TEVA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=007794,US Previously Marketed 1951,NEOTHYLLINE by TEVA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=007794,Acute bronchial asthma; Chronic bronchitis; Emphysema,Approved; Approved; Approved
666,25265-71-8,https://drugs.ncats.io/drug/E107L85C40,Possibly Marketed Outside US ,"Abelia green tea energy mask by Terrasun Co., Ltd.",https://www.drugbank.ca/drugs/DB14140,Possibly Marketed Outside US 1958,"Cetacaine Anesthetic by Cetylite Industries, Inc.",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=af1773c5-5d5b-4278-b551-30ad2df6d5b5,,
667,58-32-2,https://drugs.ncats.io/drug/64ALC7F90C,US Approved Rx 2017,ANDA206753,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206753,US Approved Rx 1961,NDA012836,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012836,Postoperative thromboembolic complications of cardiac valve replacement,Approved
668,62013-04-1,https://drugs.ncats.io/drug/1801D76STL,US Previously Marketed 1995,DYNABAC by LILLY RES LABS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050678,US Previously Marketed 1995,DYNABAC by LILLY RES LABS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050678,"Uncomplicated skin and skin structure infections due to Staphylococcus aureus (methiciIlin-susceptible strains) or Streptococcus pyogenes.; Chronic bronchitis due to Haemophilus in<U+FB02>uenzae, Moraxella catarrhalis, or Streptococcus pneumoniae",Approved; Approved
669,3737-09-5,https://drugs.ncats.io/drug/GFO928U8MQ,US Approved Rx 1985,ANDA070101,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=070101,US Approved Rx 1977,NDA017447,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017447,Ventricular arrhythmia,Approved
670,67-63-0,https://drugs.ncats.io/drug/ND2M416302,US Approved OTC ,21 CFR 344.12 otic:ear drying aid isopropyl alcohol,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec344-12.xml,US Previously Marketed 1921,Rubbing Alcohol,https://books.google.com/books?id=1n4gAQAAMAAJ&newbks=1&newbks_redir=0&dq=alcohol%20rubbing%20usp&pg=PA85#v=onepage&q=alcohol%20rubbing%20usp&f=false,,
671,97-77-8,https://drugs.ncats.io/drug/TR3MLJ1UAI,US Approved Rx 2013,ANDA091681,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=091681,US Previously Marketed 1951,ANTABUSE by TEVA WOMENS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=007883,Chronic alcoholism,Approved
672,1143-38-0,https://drugs.ncats.io/drug/U8CJK0JH5M,US Previously Marketed 1929,Anthralin by Abbott,https://books.google.com/books?id=TAhtAAAAMAAJ&q=anthralin+drug&dq=anthralin+drug,US Previously Marketed 1929,Anthralin by Abbott,https://books.google.com/books?id=TAhtAAAAMAAJ&q=anthralin+drug&dq=anthralin+drug,Quiescent or chronic psoriasis,Basic research
673,50-21-5,https://drugs.ncats.io/drug/3B8D35Y7S4,US Approved Rx 1971,NDA016679,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016679,US Previously Marketed 1921,Lactic Acid U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Metabolic acidosis,Approved
674,34368-04-2,https://drugs.ncats.io/drug/3S12J47372,US Approved Rx 1994,ANDA074277,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=074277,US Previously Marketed 1978,DOBUTREX by LILLY,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017820,Heart diseases,Approved
675,114977-28-5,https://drugs.ncats.io/drug/699121PHCA,US Approved Rx 2017,ANDA207563,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207563,US Approved Rx 1996,NDA020449,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020449,Non-small cell lung cancer; Head and neck squamous cell carcinoma; Breast cancer; Gastric adenocarcinoma; Hormone refractory prostate cancer,Approved; Approved; Approved; Approved; Approved
676,6217-54-5,https://drugs.ncats.io/drug/ZAD9OKH9JC,Possibly Marketed Outside US ,Ultra Omega 3 by Liberty Bioscience LLC,https://www.drugbank.ca/drugs/DB03756,Possibly Marketed Outside US 2007,"DHA by Exeltis USA, Inc",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0e273e2-0876-4830-a903-282085be7f32,Alzheimer’s disease; Coronary heart disease; Age-related macular degeneration; Pregnancy,Approved; Approved; Phase III; Phase III
677,6217-54-5,https://drugs.ncats.io/drug/ZAD9OKH9JC,Possibly Marketed Outside US ,Ultra Omega 3 by Liberty Bioscience LLC,https://www.drugbank.ca/drugs/DB03756,Possibly Marketed Outside US 2007,"DHA by Exeltis USA, Inc",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0e273e2-0876-4830-a903-282085be7f32,Alzheimer’s disease; Coronary heart disease; Age-related macular degeneration; Pregnancy,Approved; Approved; Phase III; Phase III
678,661-19-8,https://drugs.ncats.io/drug/9G1OE216XY,US Approved Rx 2022,ANDA212385,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212385,US Approved Rx 2000,NDA020941,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020941,Herpes labialis,Approved
679,24880-45-3,https://drugs.ncats.io/drug/NS3OZT14QT,,,,,,,,
680,10041-19-7,https://drugs.ncats.io/drug/M7P27195AG,US Previously Marketed 1956,Peri-Colace by Mead Johnson,OB NME Appendix 1950-1993,US Previously Marketed 1956,Peri-Colace by Mead Johnson,OB NME Appendix 1950-1993,Constipation,Approved
681,1847-58-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
682,115256-11-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
683,115956-12-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
684,60937-55-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
685,1051375-16-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
686,13900-14-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
687,57808-66-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
688,120014-06-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
689,51-61-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
690,1338225-97-0,https://drugs.ncats.io/drug/913P6LK81M,US Approved Rx 2018,NDA210807,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210807,Possibly Marketed Outside US 2018,NDA210806,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6084e889-6092-4d8d-b7d0-18aae29b6817,HIV-1 infection,Approved
691,148016-81-3,https://drugs.ncats.io/drug/BHV525JOBH,US Previously Marketed 2007,DORIBAX by SHIONOGI INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022106,US Previously Marketed 2007,DORIBAX by SHIONOGI INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022106,"Nosocomial pneumonia (NP), including ventilator associated pneumonia (VAP).; Complicated urinary tract infections; Complicated intra-abdominal infections",Withdrawn; Approved; Approved
692,143831-71-4,https://drugs.ncats.io/drug/953A26OA1Y,US Approved Rx 1993,BLA103532,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103532,US Approved Rx 1993,BLA103532,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103532,,
693,120279-96-1,https://drugs.ncats.io/drug/9JDX055TW1,US Approved Rx 2019,ANDA204778,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204778,US Previously Marketed 1994,TRUSOPT by MSD SUB MERCK,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020408,Open-angle glaucoma; Ocular hypertension,Approved; Approved
694,83348-52-1,https://drugs.ncats.io/drug/M78TVM3G5Z,US Previously Marketed 1991,NUROMAX by ABBVIE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019946,US Previously Marketed 1991,NUROMAX by ABBVIE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019946,Muscle spasm; Muscle spasm,Approved; Approved
695,309-29-5,https://drugs.ncats.io/drug/94F3830Q73,US Approved Rx 2003,ANDA076266,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=076266,US Approved Rx 1965,NDA014879,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=014879,Drug-induced postanesthesia respiratory depression; Chronic pulmonary disease associated with acute hypercapnia,Approved; Approved
696,74191-85-8,https://drugs.ncats.io/drug/NW1291F1W8,US Approved Rx 2017,ANDA208719,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208719,US Approved Rx 1990,NDA019668,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019668,Hypertension; Benign prostatic hyperplasia,Approved; Approved
697,1668-19-5,https://drugs.ncats.io/drug/5ASJ6HUZ7D,US Approved Rx 2023,ANDA217688,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217688,US Previously Marketed 1969,SINEQUAN by PFIZER,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016798,Depression; Psychoneurotic patients with anxiety; Moderate pruritus in adult patients with atopic dermatitis or lichen simplex chronicus,Approved; Approved; Approved
698,54573-75-0,https://drugs.ncats.io/drug/3DIZ9LF5Y9,US Approved Rx 2000,NDA021027,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021027,US Approved Rx 1999,NDA020862,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020862,Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis,Approved
699,23214-92-8,https://drugs.ncats.io/drug/80168379AG,US Approved Rx 2022,ANDA212219,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212219,US Previously Marketed 1974,DOXORUBICIN HYDROCHLORIDE by PFIZER,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050467,AIDS-related Kaposi’s sarcoma; Multiple myeloma; Ovarian cancer; Locally advanced or unresectable soft tissue sarcoma; Glioblastoma; Kaposi’s sarcoma; Metastatic non-small cell lung cancer; Pancreatic ductal adenocarcinoma,Approved; Approved; Approved; Phase III; Phase II; Phase II; Phase II; Phase II
700,564-25-0,https://drugs.ncats.io/drug/334895S862,US Approved Rx 2019,ANDA211343,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211343,US Approved Rx 1967,NDA050007,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050007,Bartonellosis; Periodontitis; Campylobacter fetus infections; Campylobacter fetus infections; Granuloma inguinale; Rocky Mountain spotted fever; Typhus fever; Bartonellosis,Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved
701,469-21-6,https://drugs.ncats.io/drug/95QB77JKPL,US Approved OTC ,21 CFR 341.12(h) cough/cold:antihistamine doxylamine succinate,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec341-12.xml,US Previously Marketed 1948,DECAPRYN by SANOFI AVENTIS US,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006412,Insomnia; Allergic rhinitis,Approved; Approved
702,1972-08-3,https://drugs.ncats.io/drug/7J8897W37S,US Approved Rx 1985,NDA018651,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018651,US Approved Rx 1985,NDA018651,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018651,Anorexia in AIDS; Nausea in cancer chemotherapy; Vomiting in cancer chemotherapy,Approved; Approved; Approved
703,141626-36-0,https://drugs.ncats.io/drug/JQZ1L091Y2,US Approved Rx 2024,ANDA205904,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205904,US Approved Rx 2009,NDA022425,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022425,Atrial fibrillation; Atrial flutter,Approved; Approved
704,548-73-2,https://drugs.ncats.io/drug/O9U0F09D5X,US Approved Rx 1988,ANDA072123,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=072123,US Previously Marketed 1968,INNOVAR by EPIC PHARMA LLC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016049,Nausea and vomiting associated with surgical and diagnostic procedures,Approved
705,67392-87-4,https://drugs.ncats.io/drug/N295J34A25,US Approved Rx 2012,ANDA201663,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201663,US Approved Rx 2001,NDA021098,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021098,Vulvar and vaginal atrophy symptoms due to menopause; Pregnancy; Vasomotor symptoms due to menopause,Approved; Approved; Approved
706,98530-76-8,https://drugs.ncats.io/drug/JGH8MYC891,US Previously Marketed 2001,Xigris,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125029,US Previously Marketed 2001,Xigris,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125029,,
707,23651-95-8,https://drugs.ncats.io/drug/J7A92W69L7,US Approved Rx 2018,ANDA210839,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210839,US Approved Rx 1950,NDA007513,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=007513,Hypotension; Cardiac arrest; Systemic inflammatory response syndrome; Neurogenic orthostatic hypotension,Approved; Approved; Phase IV; Approved
708,923950-08-7,https://drugs.ncats.io/drug/WTT295HSY5,US Approved Rx 2014,BLA125469,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125469,US Approved Rx 2014,BLA125469,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125469,,
709,116539-59-4,https://drugs.ncats.io/drug/O5TNM5N07U,US Approved Rx 2018,ANDA211310,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211310,US Approved Rx 2004,NDA021733,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021733,Fibromyalgia; Major depressive disorder; Generalized anxiety disorder,Approved; Approved; Approved
710,1190264-60-8,https://drugs.ncats.io/drug/420K487FSG,US Approved Rx 2017,BLA761055,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761055,US Approved Rx 2017,BLA761055,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761055,,
711,1428935-60-7,https://drugs.ncats.io/drug/28X28X9OKV,US Approved Rx 2017,BLA761069,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069,US Approved Rx 2017,BLA761069,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069,,
712,164656-23-9,https://drugs.ncats.io/drug/O0J6XJN02I,US Approved Rx 2015,ANDA203118,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203118,US Approved Rx 2001,NDA021319,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021319,Benign prostatic hyperplasia,Approved
713,1201438-56-3,https://drugs.ncats.io/drug/610V23S0JI,US Approved Rx 2018,NDA211155,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211155,US Approved Rx 2018,NDA211155,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211155,Relapsed or refractory follicular lymphoma; Relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma,Approved; Approved
714,586-60-7,https://drugs.ncats.io/drug/078A24Q30O,US Approved OTC ,21 CFR 346.10(e) anorectal:local anesthetic dyclonine hydrochloride,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec346-10.xml,US Previously Marketed 1955,DYCLONE by ASTRAZENECA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=009925,Friedreich ataxia; Cancer; Sore throat; Pain,Not Provided; Basic research; Approved; Approved
715,460738-38-9,https://drugs.ncats.io/drug/5Q6TZN2HNM,US Approved Rx 2009,BLA125277,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125277,US Approved Rx 2009,BLA125277,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125277,hereditary angioedema,Approved
716,27220-47-9,https://drugs.ncats.io/drug/6Z1Y2V4A7M,US Approved Rx 2013,NDA205175,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205175,US Previously Marketed 1982,SPECTAZOLE by ALVOGEN,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018751,Tinea pedis,Approved
717,6736-03-4,https://drugs.ncats.io/drug/0F350BVT6S,US Approved Rx 1960,NDA011963,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011963,Possibly Marketed Outside US 1959,NDA011963,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e4bb53c7-9061-43fc-878f-dc1b19801bfc,Accommodative esotropia; Open-angle glaucoma,Approved; Approved
718,219685-50-4,https://drugs.ncats.io/drug/A3ULP0F556,US Approved Rx 2007,BLA125166,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125166,US Approved Rx 2007,BLA125166,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125166,,
719,89-25-8,https://drugs.ncats.io/drug/S798V6YJRP,US Approved Rx 2017,NDA209176,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209176,US Approved Rx 2017,NDA209176,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209176,Acute ischemic stroke; Amyotrophic lateral sclerosis,Approved; Approved
720,60-00-4,https://drugs.ncats.io/drug/9G34HU7RV0,US Approved Rx 2023,ANDA216435,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216435,US Previously Marketed 1953,CALCIUM DISODIUM VERSENATE by BAUSCH,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=008922,Heavy metal poisoning; Hypercalcemia; Ventricular arrhythmias associated with digitalis toxicity; Lead encephalopathy; Lead poisoning,Approved; Not Provided; Not Provided; Approved; Approved
721,480449-70-5,https://drugs.ncats.io/drug/NDU3J18APO,US Approved Rx 2015,NDA206316,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206316,US Approved Rx 2015,NDA206316,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206316,Nonvalvular atrial fibrillation; Pulmonary embolism; Deep vein thrombosis,Approved; Approved; Approved
722,312-48-1,https://drugs.ncats.io/drug/70FP3JLY7N,US Previously Marketed 1985,ENLON by MYLAN INSTITUTIONAL,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=088873,US Previously Marketed 1951,TENSILON by PAI HOLDINGS PHARM,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=007959,Neuromuscular blockade; Myasthenia gravis,Approved; Approved
723,214745-43-4,https://drugs.ncats.io/drug/XX2MN88N5D,US Previously Marketed 2003,Raptiva,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125075,US Previously Marketed 2003,Raptiva,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125075,,
724,154598-52-4,https://drugs.ncats.io/drug/JE6H2O27P8,US Approved Rx 2018,NDA208255,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208255,US Previously Marketed 1998,SUSTIVA by BRISTOL MYERS SQUIBB,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020972,HIV-1 infection,Approved
725,164650-44-6,https://drugs.ncats.io/drug/J82SB7FXWB,US Approved Rx 2021,ANDA211969,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211969,US Approved Rx 2014,NDA203567,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203567,Onychomycosis,Approved
726,70052-12-9,https://drugs.ncats.io/drug/ZQN1G5V6SR,US Approved Rx 2023,NDA215500,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215500,US Previously Marketed 1990,ORNIDYL by SANOFI AVENTIS US,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019879,Facial hirsutism,Approved
727,1270012-79-7,https://drugs.ncats.io/drug/7PCM518YLR,Possibly Marketed Outside US ,Eloctate by Bioverativ Canada Inc [Canada],https://www.drugbank.ca/drugs/DB11607,Possibly Marketed Outside US 2014,BLA125487,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bec39fa0-1524-4e6b-897f-db0ef093085e,,
728,1270012-74-2,https://drugs.ncats.io/drug/02E00T2QDE,Possibly Marketed Outside US ,Alprolix by Bioverativ Canada Inc [Canada],https://www.drugbank.ca/drugs/DB11608,Possibly Marketed Outside US 2014,BLA125444,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2fb3fb92-379d-4683-80d6-b06c0a7dc063,,
729,834153-87-6,https://drugs.ncats.io/drug/5B2546MB5Z,US Approved Rx 2020,NDA213388,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213388,US Approved Rx 2018,NDA210450,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210450,Pain associated with endometriosis; Uterine Fibroids,Approved; Phase III
730,1709806-75-6,https://drugs.ncats.io/drug/9R3D3Y0UHS,US Approved Rx 2018,BLA761092,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761092,US Approved Rx 2018,BLA761092,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761092,,
731,9007-58-3,https://drugs.ncats.io/drug/VRC4754D50,Possibly Marketed Outside US 2016,"Shampoo for dyed and damaged hair with collagen, lanolin, biotin and arginine Horse Force by Zeldis-farma, Ooo",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=331c14e9-3b2e-1f4a-e054-00144ff88e88,Possibly Marketed Outside US 2016,"Shampoo for dyed and damaged hair with collagen, lanolin, biotin and arginine Horse Force by Zeldis-farma, Ooo",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=331c14e9-3b2e-1f4a-e054-00144ff88e88,,
732,1370468-36-2,https://drugs.ncats.io/drug/632L571YDK,US Approved Rx 2016,NDA208261,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208261,US Approved Rx 2016,NDA208261,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208261,Chronic hepatitis C,Approved
733,12125-02-9,https://drugs.ncats.io/drug/01Q9PC255D,US Approved Rx 1984,ANDA088366,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=088366,US Previously Marketed 1921,Ammonium Chloride U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Metabolic alkalosis,Approved
734,143322-58-1,https://drugs.ncats.io/drug/22QOO9B8KI,US Approved Rx 2002,NDA021016,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021016,US Approved Rx 2002,NDA021016,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021016,Migraine,Approved
735,977005-95-0,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
736,491833-29-5,https://drugs.ncats.io/drug/DR40J4WA67,US Approved Rx 2023,ANDA212420,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212420,US Approved Rx 2014,NDA205494,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205494,Gaucher's disease type I,Approved
737,9025-60-9,https://drugs.ncats.io/drug/ODJ69JZG85,US Approved Rx 2014,BLA125460,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125460,US Approved Rx 2014,BLA125460,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125460,,
738,915296-00-3,https://drugs.ncats.io/drug/1351PE5UGS,US Approved Rx 2015,BLA761035,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761035,US Approved Rx 2015,BLA761035,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761035,,
739,496775-61-2,https://drugs.ncats.io/drug/S56D65XJ9G,US Approved Rx 2008,NDA022291,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022291,US Approved Rx 2008,NDA022291,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022291,Immune thrombocytopenia; Severe aplastic anemia,Approved; Approved
740,864821-90-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
741,697761-98-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
742,1709815-23-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
743,87233-61-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
744,1610943-06-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
745,56-81-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
746,864070-44-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
747,143491-57-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
748,75847-73-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
749,76420-72-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
750,1446502-11-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
751,1269440-17-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
752,13838-16-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
753,159519-65-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
754,74011-58-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
755,679809-58-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
756,471-53-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
757,93106-60-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
758,130929-57-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
759,142217-69-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
760,915087-33-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
761,299-42-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
762,989-51-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
763,80012-43-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
764,51-43-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
765,56420-45-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
766,107724-20-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
767,11096-26-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
768,11096-26-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
769,35121-78-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
770,133040-01-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
771,188627-80-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
772,1207283-85-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
773,1582205-90-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
774,50-14-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
775,60-79-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
776,113-15-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
777,253128-41-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
778,183321-74-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
779,153832-46-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
780,1210344-57-2,https://drugs.ncats.io/drug/6C282481IP,US Approved Rx 2017,NDA209806,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209806,US Approved Rx 2017,NDA209806,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209806,Type 2 diabetes mellitus; type 2 diabetes mellitus,Phase III; Approved
781,114-07-8,https://drugs.ncats.io/drug/63937KV33D,US Approved Rx 2020,ANDA212015,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212015,US Previously Marketed 1952,Ilotycin by Lilly,DeHaen 1940-1975 NMEs,Acne; Pneumonia; Bacterial endocarditis; Staphylococcal dermatitis; Listeriosis; Diphtheria; Respiratory tract infections; Skin and skin structure infections; Erythrasma; Diphtheria; Skin and skin structure infections; Respiratory tract infections; Listeriosis; Erythrasma,Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved
782,128196-01-0,https://drugs.ncats.io/drug/4O4S742ANY,US Approved Rx 2002,NDA021323,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021323,US Approved Rx 2002,NDA021323,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021323,Generalized anxiety disorder; Major depressive disorder,Approved; Approved
783,33643-46-8,https://drugs.ncats.io/drug/50LFG02TXD,US Approved Rx 2019,NDA211243,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211243,Possibly Marketed Outside US 1970,NDA211243,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d81a6a79-a74a-44b7-822c-0dfa3036eaed,,
784,236395-14-5,https://drugs.ncats.io/drug/BEA68ZVB2K,US Approved Rx 2023,ANDA211236,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211236,US Approved Rx 2013,NDA022416,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022416,Partial-onset seizures,Approved
785,81147-92-4,https://drugs.ncats.io/drug/MDY902UXSR,US Approved Rx 2022,ANDA214172,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214172,US Approved Rx 1986,NDA019386,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019386,Supraventricular tachycardia; Noncompensatory sinus tachycardia,Approved; Approved
786,119141-88-7,https://drugs.ncats.io/drug/N3PA6559FT,US Approved Rx 2020,ANDA212866,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212866,Possibly Marketed Outside US 1989,ANDA078003,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f0ba9c8-e5f2-4d65-a0e3-19a6541a03b5,Heartburn,Approved
787,29975-16-4,https://drugs.ncats.io/drug/36S3EQV54C,US Approved Rx 1997,ANDA074826,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=074826,US Previously Marketed 1990,PROSOM by ABBOTT,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019080,Insomnia,Approved
788,17916-67-5,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
789,2998-57-4,https://drugs.ncats.io/drug/35LT29625A,US Approved Rx 1981,NDA018045,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018045,US Approved Rx 1981,NDA018045,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018045,Carcinoma of the prostate,Approved
790,50-27-1,https://drugs.ncats.io/drug/FB33469R8E,Possibly Marketed Outside US ,WHO-ATC:G03CA04,https://ginas.ncats.nih.gov/ginas/app/substance/FB33469R8E,Possibly Marketed Outside US 2012,NADA141325,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9b6e29b3-7286-4408-9a44-7d8589d1d958,Urinary tract infections; Atrophic vaginitis; Genital prolapse,Phase IV; Phase III; Phase IV
791,53-16-7,https://drugs.ncats.io/drug/2DI9HA706A,US Approved Rx 1977,ANDA083220,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=083220,US Previously Marketed 1931,Theelin by Parke Davis,https://en.wikipedia.org/wiki/Estrone_(medication),Endometrial hyperplasia/carcinoma; Menopausal and postmenopausal disorder; Ovarian diseases; Precocious puberty; Amenorrhea; Infertility; Breast cancer; Prostate cancer; Obesity; Endometrial cancer; Benign breast disease; Premenstrual syndrome; Menopausal and postmenopausal disorders,Approved; Approved; Natural Metabolite; Natural Metabolite; Natural Metabolite; Natural Metabolite; Natural Metabolite; Natural Metabolite; Natural Metabolite; Natural Metabolite; Natural Metabolite; Phase III; Approved
792,12126-59-9,https://drugs.ncats.io/drug/IU5QR144QX,US Approved Rx 2003,NDA021417,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021417,US Approved Rx 1942,NDA004782,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=004782,,
793,53-16-7,https://drugs.ncats.io/drug/2DI9HA706A,US Approved Rx 1977,ANDA083220,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=083220,US Previously Marketed 1931,Theelin by Parke Davis,https://en.wikipedia.org/wiki/Estrone_(medication),Endometrial hyperplasia/carcinoma; Menopausal and postmenopausal disorder; Ovarian diseases; Precocious puberty; Amenorrhea; Infertility; Breast cancer; Prostate cancer; Obesity; Endometrial cancer; Benign breast disease; Premenstrual syndrome; Menopausal and postmenopausal disorders,Approved; Approved; Natural Metabolite; Natural Metabolite; Natural Metabolite; Natural Metabolite; Natural Metabolite; Natural Metabolite; Natural Metabolite; Natural Metabolite; Natural Metabolite; Phase III; Approved
794,138729-47-2,https://drugs.ncats.io/drug/UZX80K71OE,US Approved Rx 2015,ANDA202929,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202929,US Approved Rx 2004,NDA021476,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021476,Insomnia,Approved
795,58-54-8,https://drugs.ncats.io/drug/M5DP350VZV,US Approved Rx 2019,ANDA211232,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211232,US Approved Rx 1967,NDA016093,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016093,Nephrotic syndrome; Congestive heart failure,Approved; Approved
796,185243-69-0,https://drugs.ncats.io/drug/9d14cfd3,,,,,,,,
797,1262780-97-1,https://drugs.ncats.io/drug/60ME133FJB,US Approved Rx 2017,NDA208325,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208325,US Approved Rx 2017,NDA208325,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208325,Secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis,Approved
798,1173755-55-9,https://drugs.ncats.io/drug/AIW6036FAS,US Approved Rx 2016,NDA206488,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206488,US Approved Rx 2016,NDA206488,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206488,,
799,74-55-5,https://drugs.ncats.io/drug/8G167061QZ,US Approved Rx 1999,ANDA075095,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=075095,US Approved Rx 1967,NDA016320,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016320,Pulmonary tuberculosis,Approved
800,64-17-5,https://drugs.ncats.io/drug/bfe60581,,,,,,,,
801,141-43-5,https://drugs.ncats.io/drug/5KV86114PT,Possibly Marketed Outside US 2008,NDA022032,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6c87a6a-253a-4455-9b7d-62f506da592e,Possibly Marketed Outside US 1980,NADA113232,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d14180ed-329c-464a-a9ac-b7bbf3d59536,Myocardial ischemia,Preclinical
802,113-18-8,https://drugs.ncats.io/drug/6EIM3851UZ,US Previously Marketed 1961,PLACIDYL by ABBVIE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=010021,US Previously Marketed 1955,Placidyl by Abbott,OB NME Appendix 1950-1985,Insomnia,Approved
803,57-63-6,https://drugs.ncats.io/drug/423D2T571U,US Approved Rx 1992,ANDA072693,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=072693,US Previously Marketed 1943,ESTINYL by SCHERING,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=005292,Pregnancy,Approved
804,536-33-4,https://drugs.ncats.io/drug/OAY8ORS3CQ,US Approved Rx 1965,NDA013026,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=013026,US Approved Rx 1965,NDA013026,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=013026,Tuberculosis,Approved
805,77-67-8,https://drugs.ncats.io/drug/5SEH9X1D1D,US Approved Rx 2012,ANDA200892,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200892,US Approved Rx 1960,NDA012380,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012380,Absence epilepsy,Approved
806,86-35-1,https://drugs.ncats.io/drug/46QG38NC4U,US Previously Marketed 1957,PEGANONE by RECORDATI RARE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=010841,US Previously Marketed 1957,PEGANONE by RECORDATI RARE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=010841,Epilepsy,Approved
807,107-21-1,https://drugs.ncats.io/drug/FC72KVT52F,Possibly Marketed Outside US 2020,21 CFR 333A,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ada16013-e7cc-2f13-e053-2995a90ae1e3,Possibly Marketed Outside US 2003,NDA021385,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=821073f7-33f6-464d-baed-f66d97987d6d,,
808,36637-18-0,https://drugs.ncats.io/drug/I6CQM0F31V,US Previously Marketed 1976,DURANEST by DENTSPLY PHARM,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021384,US Previously Marketed 1976,DURANEST by DENTSPLY PHARM,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021384,Pain,Approved
809,2809-21-4,https://drugs.ncats.io/drug/M2F465ROXU,US Previously Marketed 1987,DIDRONEL by MGI PHARMA INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019545,Possibly Marketed Outside US 1965,M006,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89577417-76a0-cb04-e053-2995a90a5733,Heterotopic ossification; Paget’s disease of bone,Approved; Approved
810,41340-25-4,https://drugs.ncats.io/drug/2M36281008,US Approved Rx 2000,ANDA075665,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=075665,US Previously Marketed 1991,LODINE by WYETH PHARMS INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018922,Osteoarthritis; Acute pain; Rheumatoid arthritis,Approved; Approved; Approved
811,33125-97-2,https://drugs.ncats.io/drug/Z22628B598,US Approved Rx 2016,ANDA202354,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202354,US Approved Rx 1982,NDA018227,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018227,Pain,Approved
812,54048-10-1,https://drugs.ncats.io/drug/304GTH6RNH,US Approved Rx 2001,NDA021187,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021187,US Approved Rx 2001,NDA021187,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021187,Pregnancy,Approved
813,33419-42-0,https://drugs.ncats.io/drug/6PLQ3CP4P3,US Approved Rx 1998,ANDA074983,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=074983,US Previously Marketed 1983,VEPESID by CORDEN PHARMA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018768,Refractory testicular tumors; Small-cell lung cancer,Approved; Approved
814,117091-64-2,https://drugs.ncats.io/drug/528XYJ8L1N,US Approved Rx 1998,ANDA074983,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=074983,US Previously Marketed 1983,VEPESID by CORDEN PHARMA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018768,Refractory testicular tumors; Small-cell lung cancer,Approved; Approved
815,269055-15-4,https://drugs.ncats.io/drug/0C50HW4FO1,US Approved Rx 2022,ANDA215402,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215402,US Approved Rx 2008,NDA022187,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022187,HIV-1 infection,Approved
816,1231-93-2,https://drugs.ncats.io/drug/9E01C36A9S,US Approved Rx 2018,ANDA209547,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209547,US Previously Marketed 1966,OVULEN by GD SEARLE LLC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016029,Pregnancy,Approved
817,97-53-0,https://drugs.ncats.io/drug/3T8H1794QW,US Approved Allergenic Extract 1994,BLA103738,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f082b68-dc74-418a-9e6f-b3c285b41d44,US Previously Marketed 1921,Eugenol U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Toothache,Approved
818,84625-35-4,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
819,308064-97-3,https://drugs.ncats.io/drug/2f941257,,,,,,,,
820,159351-69-6,https://drugs.ncats.io/drug/9HW64Q8G6G,US Approved Rx 2021,ANDA205426,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205426,US Approved Rx 2009,NDA022334,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022334,"Advanced hormone receptor-positive, HER2­ negative breast cancer; Neuroendocrine tumors; Advanced renal cell carcinoma",Approved; Approved; Approved
821,1180-71-8,https://drugs.ncats.io/drug/L0F260866S,,,,,,,Neuroblastoma; HIV-1 infection; Colon cancer,Basic research; Basic research; Basic research
822,1256937-27-5,https://drugs.ncats.io/drug/LKC0U3A8NJ,US Approved Rx 2015,BLA125522,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125522,US Approved Rx 2015,BLA125522,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125522,,
823,107868-30-4,https://drugs.ncats.io/drug/NY22HMQ4BX,US Approved Rx 2020,ANDA213547,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213547,US Approved Rx 1999,NDA020753,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020753,Estrogen-receptor positive early breast cancer; Advanced breast cancer in postmenopausal women,Approved; Approved
824,141758-74-9,https://drugs.ncats.io/drug/9P1872D4OL,US Approved Rx 2005,NDA021773,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021773,US Approved Rx 2005,NDA021773,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021773,Type 2 diabetes mellitus,Approved
825,7553-56-2,https://drugs.ncats.io/drug/9679TC07X4,US Approved OTC ,21 CFR 333.210(d) antifungal povidone-iodine,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec333-210.xml,US Previously Marketed 1921,Iodine U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,antiseptic,Approved
826,163222-33-1,https://drugs.ncats.io/drug/EOR26LQQ24,US Approved Rx 2022,ANDA210859,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210859,US Approved Rx 2002,NDA021445,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021445,Homozygous familial sitosterolemia; Homozygous familial hypercholesterolemia; Hyperlipidemia,Approved; Approved; Approved
827,69-72-7,https://drugs.ncats.io/drug/O414PZ4LPZ,US Approved OTC ,21 CFR 358.110(b) wart remover:collodoin-like vehicle salicylic acid,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec358-110.xml,US Previously Marketed 1860,sodium salicylate,https://catalog.hathitrust.org/Record/100782317,Psoriasis; Ichthyosis vulgaris; Keratosis palmaris; Bruises; Arthritis; Strains and sprains; Simple backache,Approved; Approved; Approved; Approved; Approved; Approved; Approved
828,56283-52-4,https://drugs.ncats.io/drug/D7DS8XY15Y,,,,,,,,
829,17493-86-6,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
830,78690-39-8,https://drugs.ncats.io/drug/6O01GMS00P,US Approved Rx 2023,NDA216873,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216873,US Approved Rx 2023,NDA216873,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216873,Pancreatic cancer; Non-small cell lung cancer; Secondary myelofibrosis (post-polycythemia vera and post-essential thrombocythemia); Primary myelofibrosis,Phase III; Phase I; Phase III; Phase III
831,109319-16-6,https://drugs.ncats.io/drug/5PKM8P0G5I,Possibly Marketed Outside US ,Vonvendi by Shire Pharma Canada Ulc [Canada],https://www.drugbank.ca/drugs/DB12872,,,,,
832,64-17-5,https://drugs.ncats.io/drug/bfe60581,,,,,,,,
833,97089-56-0,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
834,104227-87-4,https://drugs.ncats.io/drug/QIC03ANI02,US Approved Rx 1996,NDA020629,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020629,US Previously Marketed 1994,FAMVIR by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020363,Recurrent herpes labialis,Approved
835,76824-35-6,https://drugs.ncats.io/drug/5QZO15J2Z8,US Approved Rx 2023,ANDA218181,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218181,US Previously Marketed 1986,PEPCID by BAUSCH,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019462,Duodenal ulcer; Gastric ulcer; Gastroesophageal reflux disease,Approved; Approved; Approved
836,504-24-5,https://drugs.ncats.io/drug/BH3B64OKL9,US Approved Rx 2018,ANDA206863,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206863,US Approved Rx 2010,NDA022250,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022250,Multiple sclerosis,Approved
837,57-10-3,https://drugs.ncats.io/drug/2V16EO95H1,Possibly Marketed Outside US ,"Sha-lem by Shalem Products, Inc.",https://www.drugbank.ca/drugs/DB03796,Possibly Marketed Outside US 1990,21 CFR 358A,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6eef6b11-20c2-4665-a5dd-cce4e790102e,Respiratory distress syndrome in premature infants,Approved
838,144060-53-7,https://drugs.ncats.io/drug/101V0R1N2E,US Approved Rx 2021,ANDA212924,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212924,US Approved Rx 2009,NDA021856,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021856,Hyperuricemia in patients with gout,Approved
839,25451-15-4,https://drugs.ncats.io/drug/X72RBB02N8,US Approved Rx 2016,ANDA204595,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204595,US Approved Rx 1993,NDA020189,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020189,Epilepsy,Approved
840,72509-76-3,https://drugs.ncats.io/drug/OL961R6O2C,US Approved Rx 2018,ANDA210847,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210847,US Previously Marketed 1991,PLENDIL by ASTRAZENECA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019834,Hypertension,Approved
841,133-11-9,https://drugs.ncats.io/drug/52936SIP7V,US Previously Marketed 1961,PHENY-PAS-TEBAMIN by PHARM RES ASSOC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011695,US Previously Marketed 1959,Pheny-PAS-Tebamin by Purdue Frederick,DeHaen 1940-1975 NMEs,Tuberculosis,Approved
842,43210-67-9,https://drugs.ncats.io/drug/621BVT9M36,Possibly Marketed Outside US ,Canada:FENBENDAZOLE,https://tripod.nih.gov/npc/#Download,Possibly Marketed Outside US 1977,NADA128620,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=859d4e30-d70c-4baf-aa62-0d3feff25057,Cancer; Gastrointestinal parasitic disease,Basic research; Approved
843,458-24-2,https://drugs.ncats.io/drug/2DS058H2CF,US Approved Rx 2020,NDA212102,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212102,US Previously Marketed 1973,Pondimin by Robins,OB NME Appendix 1950-1985,Dravet syndrome; Lennox gastaut syndrome; Seizure disorders; Obesity; Epilepsy,Phase III; Phase II; Phase III; Approved; Phase II
844,49562-28-9,https://drugs.ncats.io/drug/U202363UOS,US Approved Rx 2012,ANDA090715,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=090715,US Previously Marketed 1993,LIPIDIL by ABBVIE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019304,Hypertriglyceridemia; Hypercholesterolemia,Approved; Approved
845,42017-89-0,https://drugs.ncats.io/drug/BGF9MN2HU1,US Approved Rx 2015,ANDA200920,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200920,US Approved Rx 2008,NDA022224,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022224,hypertriglyceridemia,Approved
846,67227-56-9,https://drugs.ncats.io/drug/INU8H2KAWG,US Approved Rx 1997,NDA019922,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019922,US Approved Rx 1997,NDA019922,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019922,Hypertension,Approved
847,29679-58-1,https://drugs.ncats.io/drug/RA33EAC7KY,US Approved Rx 1976,NDA017604,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017604,US Approved Rx 1976,NDA017604,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017604,Rheumatoid arthritis; Pain; Osteoarthritis,Approved; Approved; Approved
848,16397-28-7,https://drugs.ncats.io/drug/W0194S5FOA,Possibly Marketed Outside US ,Lipolin by ICN-Usafarma [Brazil],https://archive.org/details/Pharmaceutical_Manufacturing_Encyclopedia_Vols_12_2nd_Ed,,,,Obesity,Withdrawn
849,437-38-7,https://drugs.ncats.io/drug/UF599785JZ,US Approved Rx 2019,ANDA210762,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210762,US Previously Marketed 1968,INNOVAR by EPIC PHARMA LLC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016049,Pain,Approved
850,119683-68-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
851,171544-35-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
852,1309-38-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
853,286930-02-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
854,83799-24-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
855,25878-23-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
856,873857-62-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
857,121181-53-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
858,98319-26-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
859,162359-55-9,https://drugs.ncats.io/drug/3QN8BYN5QF,US Approved Rx 2022,ANDA208003,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208003,US Approved Rx 2010,NDA022527,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=22527,Multiple sclerosis,Approved
860,50-00-0,https://drugs.ncats.io/drug/T0H3L6C7I5,Possibly Marketed Outside US 2019,HB Triple Play by Wausau Chemical,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=426419d4-5d88-438c-9c10-2541abb6a3fc,Possibly Marketed Outside US 2019,HB Triple Play by Wausau Chemical,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=426419d4-5d88-438c-9c10-2541abb6a3fc,,
861,146-14-5,https://drugs.ncats.io/drug/ZC44YTI8KK,Possibly Marketed Outside US ,"BumP DHA by Centurion Labs, LLC",https://www.drugbank.ca/drugs/DB03147,Possibly Marketed Outside US 2011,EnBrace HR by Jaymac Pharma,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f14fa40-97ab-4ec5-b66b-793d6d1abac9,Vitamin B2 deficiency; Stomatitis; Conjunctivitis,Approved; Approved; Approved
862,146-17-8,https://drugs.ncats.io/drug/7N464URE7E,US Approved Rx 2016,NDA203324,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203324,US Previously Marketed 1947,BEROCCA PN by ROCHE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006071,Vitamin deficiency; Cerebral infarction; Atherosclerosis,Approved; Approved; Approved
863,1206488-21-2,https://drugs.ncats.io/drug/KDQ7F67CVT,,,,,,,,
864,15301-69-6,https://drugs.ncats.io/drug/3E74Y80MEY,US Approved Rx 2004,ANDA076831,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=076831,US Previously Marketed 1970,URISPAS by ORTHO MCNEIL JANSSEN,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016769,Urethritis; Prostatitis; Cystitis,Approved; Approved; Approved
865,54143-55-4,https://drugs.ncats.io/drug/K94FTS1806,US Approved Rx 2020,ANDA210683,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210683,US Previously Marketed 1985,TAMBOCOR by ALVOGEN,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018830,Documented ventricular arrhythmias; Paroxysmal atrial fibrillation,Approved; Approved
866,167933-07-5,https://drugs.ncats.io/drug/37JK4STR6Z,US Approved Rx 2015,NDA022526,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022526,US Approved Rx 2015,NDA022526,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022526,Hypoactive sexual desire disorder,Approved
867,956103-76-7,https://drugs.ncats.io/drug/6W15Z5R0RU,US Approved Rx 2012,NDA202008,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202008,US Approved Rx 2012,NDA202008,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202008,Alzheimer’s disease,Approved
868,50-91-9,https://drugs.ncats.io/drug/039LU44I5M,US Approved Rx 2001,ANDA075837,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=075837,US Previously Marketed 1970,FUDR by HOSPIRA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016929,Gastrointestinal adenocarcinoma metastatic to the liver,Approved
869,86386-73-4,https://drugs.ncats.io/drug/8VZV102JFY,US Approved Rx 2012,ANDA078698,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=078698,US Previously Marketed 1990,DIFLUCAN IN SODIUM CHLORIDE 0.9% by PFIZER,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019950,Cryptococcal meningitis; Vaginal candidiasis,Approved; Approved
870,2022-85-7,https://drugs.ncats.io/drug/D83282DT06,US Approved Rx 2017,ANDA204652,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204652,US Approved Rx 1971,NDA017001,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017001,Systemic candidiasis; Cryptococcal meningitis; Cryptococcus pulmonary infections; Candida urinary system infections; Candida endocarditis,Approved; Approved; Approved; Approved; Approved
871,21679-14-1,https://drugs.ncats.io/drug/P2K93U8740,US Approved Rx 2007,ANDA078393,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=078393,US Previously Marketed 1991,FLUDARA by GENZYME CORP,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020038,Chronic lymphocytic leukemia,Approved
872,127-31-1,https://drugs.ncats.io/drug/U0476M545B,US Approved Rx 2022,ANDA215279,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215279,US Previously Marketed 1955,FLORINEF by CASPER PHARMA LLC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=010060,Addison's disease; Salt-losing adrenogenital syndrome,Approved; Approved
873,1524-88-5,https://drugs.ncats.io/drug/8EUL29XUQT,US Approved Rx 2016,ANDA207133,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207133,US Previously Marketed 1961,Cordran by Lilly,https://books.google.com/books?id=ZiiU-iiF1K8C&newbks=1&newbks_redir=0&dq=hydroxyphenamate&pg=PA367#v=onepage&q=hydroxyphenamate&f=false,Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses,Approved
874,78755-81-4,https://drugs.ncats.io/drug/40P7XK9392,US Approved Rx 2004,ANDA076787,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=076787,US Previously Marketed 1991,ROMAZICON by HOFFMANN LA ROCHE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020073,Benzodiazepine overdose,Approved
875,3385-03-3,https://drugs.ncats.io/drug/78M02AA8KF,US Approved Rx 2002,ANDA074805,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=074805,US Previously Marketed 1981,NASALIDE by IVAX RES,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018148,Perennial or seasonal allergic rhinitis,Approved
876,67-73-2,https://drugs.ncats.io/drug/0CD5FD6S2M,US Approved Rx 1994,ANDA040041,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=040041,US Approved Rx 1961,NDA012787,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012787,Chronic non-infectious uveitis affecting the posterior segment of the eye; Corticosteroid-responsive dermatoses,Approved; Approved
877,356-12-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
878,2321-07-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
879,7782-41-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
880,426-13-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
881,51-21-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
882,54910-89-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
883,76-43-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
884,69-23-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
885,17617-23-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
886,5104-49-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
887,13311-84-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
888,90566-53-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
889,397864-44-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
890,93957-54-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
891,54739-18-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
892,59-30-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
893,97048-13-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
894,146479-72-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
895,146479-72-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
896,7554-65-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
897,160369-77-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
898,114870-03-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
899,50-00-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
900,64-18-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
901,73573-87-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
902,226700-79-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
903,172673-20-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
904,63585-09-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
905,522-40-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
906,77-86-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
907,98048-97-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
908,93390-81-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
909,258516-89-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
910,901119-35-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
911,1655501-53-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
912,158747-02-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
913,6347-01-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
914,3351-86-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
915,977001-75-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
916,129453-61-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
917,110-17-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
918,67-45-8,https://drugs.ncats.io/drug/5J9CPU3RE0,US Previously Marketed 1961,FUROXONE by SHIRE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011270,US Previously Marketed 1957,Tricofuron by Eaton,OB NME Appendix 1950-1985,Bacterial or protozoal enteritis; Bacterial or protozoal diarrhea,Approved; Approved
919,54-31-9,https://drugs.ncats.io/drug/7LXU5N7ZO5,US Approved Rx 2014,ANDA203428,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203428,US Approved Rx 1966,NDA016273,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016273,Hypertension; Edema,Approved; Approved
920,60142-96-3,https://drugs.ncats.io/drug/6CW7F3G59X,US Approved Rx 2007,ANDA078428,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=078428,US Approved Rx 1993,NDA020235,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020235,Restless legs syndrome; Postherpetic neuralgia,Approved; Approved
921,478296-72-9,https://drugs.ncats.io/drug/75OCL1SPBQ,US Approved Rx 2007,ANDA078428,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=078428,US Approved Rx 1993,NDA020235,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020235,Restless legs syndrome; Postherpetic neuralgia,Approved; Approved
922,113662-23-0,https://drugs.ncats.io/drug/15G12L5X8K,US Approved Rx 2013,NDA204781,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204781,US Previously Marketed 1988,MAGNEVIST by BAYER HLTHCARE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019596,"Central nervous system diseases; Breast cancer; Renal artery obstruction; Disruption of the blood brain barrier and abnormal vascularity in brain, spine and associated tissues",Approved; Approved; Approved; Approved
923,770691-21-9,https://drugs.ncats.io/drug/1BJ477IO2L,US Approved Rx 2013,NDA204781,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204781,US Previously Marketed 1988,MAGNEVIST by BAYER HLTHCARE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019596,"Central nervous system diseases; Breast cancer; Renal artery obstruction; Disruption of the blood brain barrier and abnormal vascularity in brain, spine and associated tissues",Approved; Approved; Approved; Approved
924,131410-48-5,https://drugs.ncats.io/drug/84F6U3J2R6,US Approved Rx 2007,NDA022066,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022066,US Approved Rx 1993,NDA020123,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020123,Contrast agent for MRI,Approved
925,201688-00-8,https://drugs.ncats.io/drug/E65RW73PHS,US Approved Rx 2013,NDA204781,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204781,US Previously Marketed 1988,MAGNEVIST by BAYER HLTHCARE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019596,"Central nervous system diseases; Breast cancer; Renal artery obstruction; Disruption of the blood brain barrier and abnormal vascularity in brain, spine and associated tissues",Approved; Approved; Approved; Approved
926,80529-93-7,https://drugs.ncats.io/drug/K2I13DR72L,US Approved Rx 2013,NDA204781,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204781,US Previously Marketed 1988,MAGNEVIST by BAYER HLTHCARE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019596,"Central nervous system diseases; Breast cancer; Renal artery obstruction; Disruption of the blood brain barrier and abnormal vascularity in brain, spine and associated tissues",Approved; Approved; Approved; Approved
927,72573-82-1,https://drugs.ncats.io/drug/QVF9Y6955W,US Approved Rx 2013,NDA204781,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204781,US Previously Marketed 1988,MAGNEVIST by BAYER HLTHCARE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019596,"Central nervous system diseases; Breast cancer; Renal artery obstruction; Disruption of the blood brain barrier and abnormal vascularity in brain, spine and associated tissues",Approved; Approved; Approved; Approved
928,120066-54-8,https://drugs.ncats.io/drug/0199MV609F,US Approved Rx 2003,NDA021489,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021489,US Approved Rx 1992,NDA020131,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020131,"Lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues",Approved
929,131069-91-5,https://drugs.ncats.io/drug/RLM74T3Z9D,US Approved Rx 2013,NDA204781,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204781,US Previously Marketed 1988,MAGNEVIST by BAYER HLTHCARE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019596,"Central nervous system diseases; Breast cancer; Renal artery obstruction; Disruption of the blood brain barrier and abnormal vascularity in brain, spine and associated tissues",Approved; Approved; Approved; Approved
930,135326-11-3,https://drugs.ncats.io/drug/3QJA87N40S,US Approved Rx 2013,NDA204781,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204781,US Previously Marketed 1988,MAGNEVIST by BAYER HLTHCARE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019596,"Central nervous system diseases; Breast cancer; Renal artery obstruction; Disruption of the blood brain barrier and abnormal vascularity in brain, spine and associated tissues",Approved; Approved; Approved; Approved
931,10257-28-0,https://drugs.ncats.io/drug/X2RN3Q8DNE,Possibly Marketed Outside US ,WHO-ATC:V04CE01,https://ginas.ncats.nih.gov/ginas/app/substance/X2RN3Q8DNE,Possibly Marketed Outside US 1995,ANDA074077,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff6b4568-1383-46b6-a1c6-385fc31fb210,,
932,357-70-0,https://drugs.ncats.io/drug/0D3Q044KCA,US Approved Rx 2008,ANDA079028,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=079028,US Previously Marketed 2001,RAZADYNE by JANSSEN PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021224,Alzheimer’s disease,Approved
933,1578199-75-3,https://drugs.ncats.io/drug/55KHL3P693,US Approved Rx 2018,BLA761063,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761063,US Approved Rx 2018,BLA761063,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761063,,
934,7440-55-3,https://drugs.ncats.io/drug/CH46OC8YV4,Possibly Marketed Outside US 2012,NCT01534182: Phase 4 Interventional Completed Relapsing Remitting Multiple Sclerosis,https://clinicaltrials.gov/ct2/show/NCT01534182,,,,,
935,552858-79-4,https://drugs.ncats.io/drug/59UA429E5G,US Approved Rx 2005,BLA125117,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125117,US Approved Rx 2005,BLA125117,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125117,,
936,506-26-3,https://drugs.ncats.io/drug/78YC2MAX4O,Possibly Marketed Outside US ,Canada:GAMMA-LINOLENIC ACID,https://tripod.nih.gov/npc/#Download,Possibly Marketed Outside US 2017,21 CFR 333A,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e2726f7-f199-1c0d-e054-00144ff8d46c,Atopic dermatitis; Mastalgia,Approved; Approved
937,82410-32-0,https://drugs.ncats.io/drug/P9G3CKZ4P5,US Approved Rx 2003,ANDA076222,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=076222,US Previously Marketed 1989,CYTOVENE by CHEPLAPHARM,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019661,"Unknown; Cytomegalovirus retinitis; Cytomegalovirus infectious disease in kidney, heart, and kidney-pancreas transplantation; Cytomegalovirus retinitis; Acute herpetic keratitis",Approved; Approved; Approved; Approved
938,124904-93-4,https://drugs.ncats.io/drug/IX503L9WN0,US Approved Rx 2018,ANDA204246,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204246,US Approved Rx 1999,NDA021057,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021057,Prevent premature ovulation,Approved
939,77-92-9,https://drugs.ncats.io/drug/GQH5A01T0W,,,,,,,,
940,107390-08-9,https://drugs.ncats.io/drug/ODU3ZAZ94J,US Approved Rx 2023,NDA216386,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216386,US Approved Rx 2023,NDA216386,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216386,,
941,64-17-5,https://drugs.ncats.io/drug/bfe60581,,,,,,,,
942,112811-59-3,https://drugs.ncats.io/drug/81485Y3A9A,US Approved Rx 2016,ANDA204227,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204227,US Previously Marketed 1999,Tequin,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=21061,Bacterial conjunctivitis,Approved
943,184475-35-2,https://drugs.ncats.io/drug/S65743JHBS,US Approved Rx 2022,ANDA209532,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209532,US Previously Marketed 2003,IRESSA by ASTRAZENECA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021399,Non-small cell lung cancer,Approved
944,9000-70-8,https://drugs.ncats.io/drug/A7JR5F8DLH,Possibly Marketed Outside US 2010,"Complete Natal DHA by Trigen Laboratories, LLC",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da53ce22-b0a3-4c91-94df-e03693aec841,Possibly Marketed Outside US 2010,"Complete Natal DHA by Trigen Laboratories, LLC",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da53ce22-b0a3-4c91-94df-e03693aec841,,
945,84650-08-8,https://drugs.ncats.io/drug/ODU3ZAZ94J,US Approved Rx 2023,NDA216386,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216386,US Approved Rx 2023,NDA216386,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216386,,
946,95058-81-4,https://drugs.ncats.io/drug/B76N6SBZ8R,US Approved Rx 2011,NDA200795,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200795,US Previously Marketed 1996,GEMZAR by LILLY,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020509,Advanced ovarian cancer; Metastatic breast cancer; Pancreatic cancer; Non-small cell lung cancer,Approved; Approved; Approved; Approved
947,25812-30-0,https://drugs.ncats.io/drug/Q8X02027X3,US Approved Rx 2010,ANDA079072,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=079072,US Approved Rx 1981,NDA018422,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018422,Hyperlipidemia; Coronary heart disease,Approved; Approved
948,175463-14-6,https://drugs.ncats.io/drug/OKR68Y0E4T,US Previously Marketed 2003,FACTIVE by LG CHEM LTD,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021158,US Previously Marketed 2003,FACTIVE by LG CHEM LTD,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021158,Community-acquired pneumonia; Chronic bronchitis,Approved; Approved
949,220578-59-6,https://drugs.ncats.io/drug/8GZG754X6M,US Approved Rx 2017,BLA761060,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761060,US Previously Marketed 2000,Mylotarg,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=21174,,
950,6347-01-9,https://drugs.ncats.io/drug/6YSS42VSEV,US Previously Marketed 1953,Levugen by Mead Johnson,DeHaen 1940-1975 NMEs,US Previously Marketed 1921,fructose,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Pain,Approved
951,446-72-0,https://drugs.ncats.io/drug/DH2M523P0H,Possibly Marketed Outside US ,"Fosteum by Primus Pharmaceuticals, Inc.",https://www.drugbank.ca/drugs/DB01645,Possibly Marketed Outside US 2007,"Fosteum by Primus Pharmaceuticals, Inc.",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=899ea7ce-0996-4635-9545-1e07091cf400,Metabolic syndrome; Colorectal cancer; Cystic fibrosis,Phase III; Phase II; Phase II
952,1403-66-3,https://drugs.ncats.io/drug/T6Z9V48IKG,US Approved Rx 1984,ANDA062533,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=062533,US Previously Marketed 1966,Garamycio by Schering,DeHaen 1940-1975 NMEs,Infection caused by Staphylococcus species; Escherichia coli infections; Infection caused by Proteus species; Infection caused by Klebsiella-Enterobacter-Serratia species; Pseudomonas aeruginosa infection; Infection caused by Citrobacter species; Infections caused by Staphylococcus species; Escherichia coli infections; Infection caused by Citrobacter species,Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved
953,84650-10-2,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
954,1254053-43-4,https://drugs.ncats.io/drug/66D92MGC8M,US Approved Rx 2018,NDA211349,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211349,US Approved Rx 2018,NDA211349,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211349,Acute myeloid leukemia,Approved
955,90045-36-6,https://drugs.ncats.io/drug/19FUJ2C58T,Possibly Marketed Outside US ,"Ginsamin Power by Biogrand Co., Ltd",https://www.drugbank.ca/drugs/DB01381,Possibly Marketed Outside US 1999,M012,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ff48fc-9603-413c-ab7c-2598b3e08f9c,,
956,1095173-27-5,https://drugs.ncats.io/drug/K673DMO5H9,US Approved Rx 2018,NDA210656,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210656,US Approved Rx 2018,NDA210656,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210656,Myelodysplastic syndromes; Solid tumors; Acute myeloid leukemia,Phase II; Phase I; Approved
957,147245-92-9,https://drugs.ncats.io/drug/5M691HL4BO,US Approved Rx 2017,ANDA091646,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=091646,US Approved Rx 1996,NDA020622,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020622,,
958,1365970-03-1,https://drugs.ncats.io/drug/K6BUU8J72P,US Approved Rx 2021,NDA215110,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215110,US Approved Rx 2017,NDA209394,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209394,Chronic hepatitis C,Approved
959,10238-21-8,https://drugs.ncats.io/drug/SX6K58TVWC,,,,,,,Type 2 diabetes mellitus,Approved
960,21187-98-4,https://drugs.ncats.io/drug/G4PX8C4HKV,Possibly Marketed Outside US ,Diamicron Mr by Servier [Canada],https://www.drugbank.ca/drugs/DB01120,,,,Type 2 diabetes mellitus,Approved
961,93479-97-1,https://drugs.ncats.io/drug/6KY687524K,US Approved Rx 2006,NDA021925,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021925,US Approved Rx 1995,NDA020496,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020496,Type 2 diabetes mellitus,Approved
962,29094-61-9,https://drugs.ncats.io/drug/X7WDT95N5C,US Approved Rx 2018,ANDA203499,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203499,US Previously Marketed 1984,GLUCOTROL by PFIZER,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017783,Type 2 diabetes mellitus,Approved
963,9007-92-5,https://drugs.ncats.io/drug/76LA80IG2G,US Approved Rx 2020,ANDA208086,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208086,US Previously Marketed 1960,GLUCAGON by LILLY,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012122,Hypoglycemia,Approved
964,72626-61-0,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
965,9074-87-7,https://drugs.ncats.io/drug/2GFP9BJD79,US Approved OTC ,21 CFR 347.10(t) skin protectant zinc carbonate,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec347-10.xml,US Previously Marketed 1921,Precipitated Zinc Carbonate U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Caries; Ulcerative colitis; Breast cancer; Acute myeloid leukemia; Unknown; Unknown; Poison Ivy dermatitis; Diaper dermatitis; Dysgeusia; Mucositis; Gastrointestinal disorders; Renal insufficiency; Unknown; Unknown; Zinc deficiency,Basic research; Approved; Basic research; Basic research; Approved; Approved; Phase III; Phase III; Approved; Approved; Preclinical
966,76081-94-2,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
967,526-95-4,https://drugs.ncats.io/drug/R4R8J0Q44B,US Approved Rx 1979,NDA017378,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017378,US Approved Rx 1975,NDA017586,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017586,Unknown; Iron deficiency anemia,Approved
968,3416-24-8,https://drugs.ncats.io/drug/N08U5BOQ1K,Possibly Marketed Outside US ,"Glucosamine Sulfate, Chondroitin Sulfate, Ibuprofen by Contract Pharmacal Corp.",https://www.drugbank.ca/drugs/DB01296,Possibly Marketed Outside US 1988,21 CFR 348,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5f76bfc-6601-815a-e053-2995a90ac124,Oral lichen planus; Low back pain; Osteoarthritis of knee,Phase IV; Phase IV; Phase IV
969,2280-44-6,https://drugs.ncats.io/drug/5SL0G7R0OK,US Approved Rx 1986,NDA019445,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019445,US Previously Marketed 1921,dextrose,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Hypoglycemia; Caloric intake deficit,Basic research; Approved
970,64-77-7,https://drugs.ncats.io/drug/982XCM1FOI,US Previously Marketed 1985,TOLBUTAMIDE by PUREPAC PHARM,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=088950,US Previously Marketed 1957,ORINASE by PHARMACIA AND UPJOHN,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=010670,Type 2 diabetes mellitus,Approved
971,492-61-5,https://drugs.ncats.io/drug/J4R00M814D,Possibly Marketed Outside US 2019,M020,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8d420e4b-c778-3ed4-e053-2995a90a59a9,Possibly Marketed Outside US 2013,21 CFR 358H,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab084d44-dfb8-4cde-bfa1-17d72cce686e,,
972,32449-92-6,https://drugs.ncats.io/drug/XE4Y3016M9,US Previously Marketed 1950,Glucurone by Commercial Solvents,DeHaen 1940-1975 NMEs,US Previously Marketed 1950,Glucurone by Commercial Solvents,DeHaen 1940-1975 NMEs,Unknown,
973,56-86-0,https://drugs.ncats.io/drug/3KX376GY7L,US Previously Marketed 1961,GLUTAVENE by TILDEN YATES,https://www.govinfo.gov/content/pkg/FR-1973-12-05/pdf/FR-1973-12-05.pdf,US Previously Marketed 1939,FLANITHIN 325MG by TABLE ROCK,https://www.govinfo.gov/content/pkg/FR-1969-09-12/pdf/FR-1969-09-12.pdf,Delayed gastric emptying; Postoperative heart failure; Nerve damage,Not Provided; Phase III; Phase III
974,56-85-9,https://drugs.ncats.io/drug/0RH81L854J,US Approved Rx 2017,NDA208587,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208587,US Previously Marketed 2004,NUTRESTORE by EMMAUS MEDCL,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021667,Short bowel syndrome,Approved
975,111-30-8,https://drugs.ncats.io/drug/T3C89M417N,Possibly Marketed Outside US ,Canada:GLUTARAL,https://tripod.nih.gov/npc/#Download,Possibly Marketed Outside US 1985,Paraguard by Seachem Laboratories Inc.,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=984f46c0-6651-46c6-b5f2-e86b557953c7,Unknown,
976,70-18-8,https://drugs.ncats.io/drug/GAN16C9B8O,Possibly Marketed Outside US ,"Tobakient by Levins Pharmaceuticals, LLC",https://www.drugbank.ca/drugs/DB00143,Possibly Marketed Outside US 2003,BLA125063,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da,Breast cancer; Back pain from urinating; Free radical toxicit; Parkinson's disease; Cystic fibrosis,Phase II; Not Provided; Not Provided; Phase II; Phase III
977,56-81-5,https://drugs.ncats.io/drug/PDC6A3C0OX,US Approved OTC ,21 CFR 347.10(h) skin protectant glycerin,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec347-10.xml,US Previously Marketed 1921,Glycerin U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Dry skin or hair,Approved
978,611168-24-2,https://drugs.ncats.io/drug/ZH6F1VCV7B,US Approved Rx 2022,ANDA216462,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216462,US Approved Rx 1996,NDA020573,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020573,Late-onset disease; Urea cycle disorders,Approved; Approved
979,57-03-4,https://drugs.ncats.io/drug/9NTI6P3O4X,US Approved Rx 2014,NDA200656,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200656,US Previously Marketed 1921,Sodium Glycerophosphate U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Essential fatty acid deficiency or negative nitrogen balance,Approved
980,123-94-4,https://drugs.ncats.io/drug/258491E1RZ,US Previously Marketed ,"21 CFR 310.545(a)(18)(i)(B) skin protectant:w/ sales less than $25,000 glyceryl stearate",https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-545.xml,Possibly Marketed Outside US 1971,ANDA090256,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ff7fa78-0fca-976f-e053-2995a90a4641,Dry Skin,Approved
981,56-40-6,https://drugs.ncats.io/drug/TE7660XO1C,US Approved OTC ,21 CFR 331.11(f) antacid glycine (aminoacetic acid),https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec331-11.xml,US Previously Marketed 1921,Glycocoll,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Cystic fibrosis; Brain tumor malignancy; Schizophrenia; Malnutrition,Phase II; Natural Metabolite; Phase III; Approved
982,56-40-6,https://drugs.ncats.io/drug/TE7660XO1C,US Approved OTC ,21 CFR 331.11(f) antacid glycine (aminoacetic acid),https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec331-11.xml,US Previously Marketed 1921,Glycocoll,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Cystic fibrosis; Brain tumor malignancy; Schizophrenia; Malnutrition,Phase II; Natural Metabolite; Phase III; Approved
983,79-14-1,https://drugs.ncats.io/drug/0WT12SX38S,US Previously Marketed 2022,glycolic acid,https://www.federalregister.gov/documents/2022/01/27/2022-01558/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal,Possibly Marketed Outside US 1947,NDA006188,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b0c23a2c-b250-4c0d-9b2a-c1483faa2ca0,Acne,Not Provided
984,13283-82-4,https://drugs.ncats.io/drug/A14FB57V1D,US Approved Rx 2022,ANDA212467,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212467,Possibly Marketed Outside US 1961,NDA012827,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bd65ee5e-2000-423c-b0a6-72eb213455c4,Peptic ulcer; Chronic obstructive pulmonary disease,Approved; Approved
985,84775-66-6,https://drugs.ncats.io/drug/2788Z9758H,Possibly Marketed Outside US ,Canada:GLYCYRRHIZA GLABRA,https://tripod.nih.gov/npc/#Download,Possibly Marketed Outside US 1999,M012,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ff48fc-9603-413c-ab7c-2598b3e08f9c,,
986,1405-86-3,https://drugs.ncats.io/drug/6FO62043WK,US Previously Marketed 1921,Ammoniated Glycyrrhizin U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Ammoniated Glycyrrhizin U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Hepatitis B; Autoimmune hepatitis; Chronic hepatitis C; Chronic hepatitis C; Erythema; Cardiomyopathy; Autoimmune hepatitis; Ovarian cancer; Radiodermatitis; Leukemia; Unknown; Unknown; Inflammation,Not Provided; Phase I; Not Provided; Approved; Phase I; Preclinical; Phase I; Basic research; Basic research; Basic research; Basic research
987,7440-57-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
988,476181-74-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
989,9034-40-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
990,65807-02-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
991,1405-97-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
992,109889-09-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
993,7782-42-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
994,1350514-68-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
995,119914-60-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
996,126-07-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
997,90-05-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
998,93-14-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
999,60329-03-5,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
1000,40580-59-4,https://drugs.ncats.io/drug/765C9332T4,US Previously Marketed 1982,HYLOREL by PHARMACIA AND UPJOHN,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018104,US Previously Marketed 1982,HYLOREL by PHARMACIA AND UPJOHN,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018104,Hypertension,Approved
1001,55-65-2,https://drugs.ncats.io/drug/ZTI6C33Q2Q,US Previously Marketed 1985,GUANETHIDINE MONOSULFATE by WATSON LABS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=086114,US Previously Marketed 1960,lsmelin Sulfate by Ciba,DeHaen 1940-1975 NMEs,Hypertension,Approved
1002,29110-47-2,https://drugs.ncats.io/drug/30OMY4G3MK,US Approved Rx 1997,ANDA074796,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=074796,US Previously Marketed 1986,TENEX by PROMIUS PHARMA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019032,Attention deficit hyperactivity disorder; Hypertension,Approved; Approved
1003,113-00-8,https://drugs.ncats.io/drug/JU58VJ6Y3B,US Previously Marketed 1939,GUANIDINE HYDROCHLORIDE by MERCK SHARP DOHME,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=001546,US Previously Marketed 1939,GUANIDINE HYDROCHLORIDE by MERCK SHARP DOHME,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=001546,Eaton-Lambert syndrome,Approved
1004,9000-30-0,https://drugs.ncats.io/drug/E89I1637KE,US Previously Marketed ,21 CFR 310.545(a)(12)(i) laxative:bulk laxative guar gum,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-545.xml,Possibly Marketed Outside US 1974,ANDA080767,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=77bb4ef4-c10e-4acc-8225-651d003f4561,,
1005,1350289-85-8,https://drugs.ncats.io/drug/089658A12D,US Approved Rx 2017,BLA761061,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761061,US Approved Rx 2017,BLA761061,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761061,,
1006,69-72-7,https://drugs.ncats.io/drug/O414PZ4LPZ,US Approved OTC ,21 CFR 358.110(b) wart remover:collodoin-like vehicle salicylic acid,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec358-110.xml,US Previously Marketed 1860,sodium salicylate,https://catalog.hathitrust.org/Record/100782317,Psoriasis; Ichthyosis vulgaris; Keratosis palmaris; Bruises; Arthritis; Strains and sprains; Simple backache,Approved; Approved; Approved; Approved; Approved; Approved; Approved
1007,23092-17-3,https://drugs.ncats.io/drug/320YC168LF,US Previously Marketed 1981,PAXIPAM by SCHERING,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017736,US Previously Marketed 1981,PAXIPAM by SCHERING,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017736,Seizures; Anxiety,Preclinical; Approved
1008,3093-35-4,https://drugs.ncats.io/drug/SI86V6QNEG,US Approved Rx 1974,NDA017556,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017556,US Approved Rx 1974,NDA017556,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017556,Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses,Approved
1009,52-86-8,https://drugs.ncats.io/drug/J6292F8L3D,US Approved Rx 1987,ANDA071131,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=071131,US Previously Marketed 1967,HALDOL by ORTHO MCNEIL,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=015922,Schizophrenia; Tourette's syndrome,Approved; Approved
1010,151-67-7,https://drugs.ncats.io/drug/UQT9G45D1P,US Previously Marketed 1975,HALOTHANE by HOSPIRA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=083254,US Previously Marketed 1958,FLUOTHANE by WYETH AYERST,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011338,Pain,Approved
1011,141758-74-9,https://drugs.ncats.io/drug/9P1872D4OL,US Approved Rx 2005,NDA021773,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021773,US Approved Rx 2005,NDA021773,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021773,Type 2 diabetes mellitus,Approved
1012,9025-56-3,https://drugs.ncats.io/drug/S2MZZ5DR1O,Possibly Marketed Outside US ,Canada:HEMICELLULASE,https://tripod.nih.gov/npc/#Download,Possibly Marketed Outside US 2019,"Stozyme by Chunwoo Pharmaceutical Co., Ltd.",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=96932453-80c2-4a44-e053-2a95a90a7bb6,,
1013,9005-49-6,https://drugs.ncats.io/drug/4QW4AN84NQ,Possibly Marketed Outside US 2020,21 CFR 333A,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7023eea3-cedd-462d-a718-b2277c16b6b6,Possibly Marketed Outside US 2020,21 CFR 333A,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7023eea3-cedd-462d-a718-b2277c16b6b6,,
1014,67-63-0,https://drugs.ncats.io/drug/ND2M416302,US Approved OTC ,21 CFR 344.12 otic:ear drying aid isopropyl alcohol,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec344-12.xml,US Previously Marketed 1921,Rubbing Alcohol,https://books.google.com/books?id=1n4gAQAAMAAJ&newbks=1&newbks_redir=0&dq=alcohol%20rubbing%20usp&pg=PA85#v=onepage&q=alcohol%20rubbing%20usp&f=false,,
1015,520-26-3,https://drugs.ncats.io/drug/E750O06Y6O,US Previously Marketed 1961,CVP WITH VITAMIN K BIOFLAVONOID by USV,https://patents.google.com/patent/US2888381,US Previously Marketed 1921,bioflavonoid,https://catalog.hathitrust.org/Record/100163146,"Metabolic syndrome; Obesity; Osteoporosis, osteopenia; Allergies; Skin Care",Phase II; Phase II; Phase III; Approved; Approved
1016,70-30-4,https://drugs.ncats.io/drug/IWW5FV6NK2,US Approved Rx 1978,NDA017433,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017433,US Previously Marketed 1948,Hexachlorophene by Various Mfrs.,DeHaen 1940-1975 NMEs,Skin infections,Approved
1017,3811-75-4,https://drugs.ncats.io/drug/3483C2H13H,Possibly Marketed Outside US ,WHO-ATC:R02AA18,https://ginas.ncats.nih.gov/ginas/app/substance/3483C2H13H,Possibly Marketed Outside US 2017,M006,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d39ee6a2-5d65-4198-82d9-deb83471f312,,
1018,136-77-6,https://drugs.ncats.io/drug/R9QTB5E82N,US Previously Marketed 1926,hexylresorcinol by Leonard,https://jamanetwork.com/journals/jama/article-abstract/239930,US Previously Marketed 1926,hexylresorcinol by Leonard,https://jamanetwork.com/journals/jama/article-abstract/239930,Respiratory tract infections; Sore throat; Hyperpigmentation,Preclinical; Approved; Preclinical
1019,64-17-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1020,51-45-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1021,71-00-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1022,9008-05-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1023,76712-82-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1024,87-00-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1025,118-56-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1026,8028-66-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1027,9041-92-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1028,61489-71-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1029,6754-58-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1030,102518-79-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1031,9004-61-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1032,9001-54-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1033,461-72-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1034,86-54-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1035,7647-01-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1036,58-93-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1037,125-29-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1038,50-23-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1039,72590-77-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1040,135-09-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1041,7722-84-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1042,466-99-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1043,123-31-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1044,13422-51-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1045,103-86-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1046,127-07-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1047,118-42-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1048,9004-62-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1049,1190-94-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1050,68-96-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1051,618-28-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1052,83-40-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1053,68-88-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1054,101-31-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1055,548-04-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1056,7790-92-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1057,680188-33-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1058,114084-78-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1059,206181-63-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1060,936563-96-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1061,15687-27-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1062,122647-31-8,https://drugs.ncats.io/drug/2436VX1U9B,US Approved Rx 2010,ANDA090643,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=090643,US Approved Rx 1995,NDA020491,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020491,Atrial fibrillation,Approved
1063,130308-48-4,https://drugs.ncats.io/drug/7PG89G35Q7,US Approved Rx 2020,ANDA211501,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211501,US Approved Rx 2011,NDA022150,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022150,Hereditary angioedema,Approved
1064,10417-94-4,https://drugs.ncats.io/drug/AAN7QOV9EA,US Approved Rx 2023,ANDA217844,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217844,Possibly Marketed Outside US 2008,DHA by Mission Pharmacal Company,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=40480393-700d-4afd-8309-704ac8689e85,Hypertriglyceridemia; Major depressive disorder; Alzheimer’s disease,Approved; Phase III; Phase III
1065,58957-92-9,https://drugs.ncats.io/drug/ZRP63D75JW,US Approved Rx 2007,ANDA065288,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=065288,US Previously Marketed 1990,IDAMYCIN by PFIZER,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050661,Acute myeloid leukemia,Approved
1066,1362509-93-0,https://drugs.ncats.io/drug/97RWB5S1U6,US Approved Rx 2015,BLA761025,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761025,US Approved Rx 2015,BLA761025,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761025,,
1067,58186-27-9,https://drugs.ncats.io/drug/HB6PN45W4J,Possibly Marketed Outside US ,EU/1/15/1020/001,https://www.drugbank.ca/drugs/DB09081,Possibly Marketed Outside US 2011,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22729742-a481-40a3-9cba-7bedf054faca,Alzheimer’s disease; Leber’s hereditary optic neuropathy; Duchenne muscular dystrophy; Friedreich ataxia,Approved; Approved; Phase III; Approved
1068,870281-82-6,https://drugs.ncats.io/drug/YG57I8T5M0,US Approved Rx 2014,NDA206545,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206545,US Approved Rx 2014,NDA206545,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206545,Small lymphocytic lymphoma; Follicular B-cell non-Hodgkin lymphoma (FL); Chronic lymphocytic leukemia,Approved; Approved; Approved
1069,54-42-2,https://drugs.ncats.io/drug/LGP81V5245,US Previously Marketed 1963,HERPLEX by ALLERGAN,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=013935,US Previously Marketed 1963,HERPLEX by ALLERGAN,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=013935,Herpes simplex keratitis,Approved
1070,50936-59-9,https://drugs.ncats.io/drug/5W8JGG2651,US Approved Rx 2006,BLA125151,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125151,US Approved Rx 2006,BLA125151,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125151,,
1071,3778-73-2,https://drugs.ncats.io/drug/UM20QQM95Y,US Approved Rx 2011,ANDA076619,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=076619,US Previously Marketed 1987,IFEX by BAXTER HLTHCARE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019763,Germ cell testicular cancer,Approved
1072,133454-47-4,https://drugs.ncats.io/drug/VPO7KJ050N,US Approved Rx 2009,NDA022192,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022192,US Approved Rx 2009,NDA022192,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022192,Schizophrenia,Approved
1073,78919-13-8,https://drugs.ncats.io/drug/JED5K35YGL,US Approved Rx 2024,NDA217933,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217933,US Approved Rx 2004,NDA021779,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021779,Pulmonary arterial hypertension,Approved
1074,152459-95-5,https://drugs.ncats.io/drug/BKJ8M8G5HI,US Approved Rx 2015,ANDA078340,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=078340,US Previously Marketed 2001,GLEEVEC by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021335,Myelodysplastic/myeloproliferative diseases associated with PDGFR; Hypereosinophilic syndrome; Philadelphia chromosome positive chronic myeloid leukemia; Philadelphia chromosome positive acute lymphoblastic leukemia; Aggressive systemic mastocytosis (D816V c-Kit mutation status negative/c-Kit mutational status unknown),Approved; Approved; Approved; Approved; Approved
1075,154248-97-2,https://drugs.ncats.io/drug/Q6U6J48BWY,US Approved Rx 1994,BLA020367,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020367,US Approved Rx 1994,BLA020367,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020367,,
1076,64221-86-9,https://drugs.ncats.io/drug/Q20IM7HE75,US Approved Rx 2011,ANDA090577,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=090577,US Approved Rx 1985,NDA050587,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050587,Bacterial infections; Escherichia coli infections; Staphylococcal infections; Endocarditis; Urinary tract infections; Lower respiratory tract infections,Approved; Approved; Approved; Approved; Approved; Approved
1077,50-49-7,https://drugs.ncats.io/drug/OGG85SX4E4,US Approved Rx 2008,ANDA040751,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=040751,US Previously Marketed 1959,TOFRANIL by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011838,Depression,Approved
1078,99011-02-6,https://drugs.ncats.io/drug/P1QW714R7M,US Approved Rx 2010,NDA022483,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022483,US Previously Marketed 1997,ALDARA by BAUSCH,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020723,Actinic keratosis; External genital and perianal warts/condyloma acuminata; Primary superficial basal cell carcinoma,Approved; Approved; Approved
1079,138660-96-5,https://drugs.ncats.io/drug/HV6MT68KKF,Clinical ,INN:sevirumab [INN],https://ginas.ncats.nih.gov/ginas/app/substance/HV6MT68KKF,,,,,
1080,569658-79-3,https://drugs.ncats.io/drug/J1R33H8X7A,Clinical ,INN:libivirumab [INN],https://ginas.ncats.nih.gov/ginas/app/substance/J1R33H8X7A,,,,,
1081,2618667-99-3,https://drugs.ncats.io/drug/K3CR9VL7SE,Clinical ,INN:silevimig [INN],https://ginas.ncats.nih.gov/ginas/app/substance/K3CR9VL7SE,,,,,
1082,312753-06-3,https://drugs.ncats.io/drug/8OR09251MQ,US Previously Marketed 2015,UTIBRON by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207930,US Previously Marketed 2011,ARCAPTA NEOHALER by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022383,"Airflow obstruction in patients with chronic obstructive pulmonary disease (COPD); Airflow obstruction in patients with chronic obstructive pulmonary disease (COPD),",Approved; Approved
1083,26807-65-8,https://drugs.ncats.io/drug/F089I0511L,US Approved Rx 1996,ANDA074722,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=074722,US Previously Marketed 1983,LOZOL by SANOFI AVENTIS US,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018538,Congestive heart failure; Hypertension,Approved; Approved
1084,860-22-0,https://drugs.ncats.io/drug/L06K8R7DQK,Possibly Marketed Outside US 1995,ANDA065520,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e1904c28-8c19-44da-b395-1e4bd08d6122,Possibly Marketed Outside US 1978,"K-PhosNo. 2 by Beach Products, Inc.",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9f446400-c403-4971-879e-1341f7f7d9da,,
1085,150378-17-9,https://drugs.ncats.io/drug/9MG78X43ZT,US Previously Marketed 1996,CRIXIVAN by MERCK SHARP DOHME,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020685,US Previously Marketed 1996,CRIXIVAN by MERCK SHARP DOHME,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020685,HIV infection,Approved
1086,3599-32-4,https://drugs.ncats.io/drug/IX6J1063HV,US Approved Rx 2007,ANDA040811,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=040811,US Previously Marketed 1959,IC-GREEN by RENEW PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011525,Age-related macular degeneration; Surgery,Approved; Approved
1087,700-06-1,https://drugs.ncats.io/drug/C11E72455F,Clinical 2018,NCT03687073: Phase 1 Interventional Completed Smoking,https://clinicaltrials.gov/ct2/show/NCT03687073,,,,Breast cancer; Cancer; Obesity,Phase III; Phase I; Phase II
1088,53-86-1,https://drugs.ncats.io/drug/XXE1CET956,US Approved Rx 2009,ANDA079175,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=079175,US Previously Marketed 1965,INDOCIN by ZYLA LIFE SCIENCES,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016059,Osteoarthritis; Ankylosing spondylitis; Arthritis; Rheumatoid arthritis,Approved; Approved; Approved; Approved
1089,170277-31-3,https://drugs.ncats.io/drug/B72HH48FLU,US Approved Rx 2019,BLA761086,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761086,US Approved Rx 1998,BLA103772,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103772,,
1090,75567-37-2,https://drugs.ncats.io/drug/7686S50JAH,US Previously Marketed 2019,INGENOL MEBUTATE by PADAGIS ISRAEL,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209018,US Previously Marketed 2012,PICATO by LEO LABS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202833,Actinic keratosis; Unknown,Approved
1091,551-72-4,https://drugs.ncats.io/drug/63GQX5QW03,,,,,,,,
1092,6556-11-2,https://drugs.ncats.io/drug/A99MK953KZ,US Approved Rx 2014,ANDA090892,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=090892,US Previously Marketed 1937,"Niacin by Merck & Co, Inc.",https://archive.org/details/in.ernet.dli.2015.145864,Hyperlipidemia; Atherosclerotic disease; Myocardial infarction,Approved; Approved; Approved
1093,635715-01-4,https://drugs.ncats.io/drug/P93RUU11P7,US Approved Rx 2017,BLA761040,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761040,US Approved Rx 2017,BLA761040,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761040,,
1094,116094-23-6,https://drugs.ncats.io/drug/D933668QVX,US Approved Rx 2000,BLA020986,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020986,US Approved Rx 2000,BLA020986,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020986,diabetes mellitus,Approved
1095,844439-96-9,https://drugs.ncats.io/drug/54Q18076QB,US Approved Rx 2016,BLA208583,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208583,US Previously Marketed 2015,RYZODEG 70/30 by NOVO,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203313,,
1096,169148-63-4,https://drugs.ncats.io/drug/4FT78T86XV,US Approved Rx 2005,BLA021878,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021878,US Approved Rx 2005,BLA021878,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021878,diabetes mellitus,Approved
1097,160337-95-1,https://drugs.ncats.io/drug/2ZM8CX04RZ,US Approved Rx 2015,BLA205692,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205692,US Approved Rx 2000,BLA021081,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021081,type 1 diabetes mellitus; type 2 diabetes mellitus,Approved; Approved
1098,207748-29-6,https://drugs.ncats.io/drug/7XIY785AZD,US Approved Rx 2004,BLA021629,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021629,US Approved Rx 2004,BLA021629,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021629,,
1099,122320-73-4,https://drugs.ncats.io/drug/05V02F2KDG,US Previously Marketed 2007,ROSIGLITAZONE by WATSON LABS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=078023,US Previously Marketed 1999,AVANDIA by WOODWARD,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021071,Type 2 diabetes mellitus,Approved
1100,8049-62-5,https://drugs.ncats.io/drug/2OYE00PC25,US Approved Rx 2023,NDA215830,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215830,US Approved Rx 2023,NDA215830,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215830,,
1101,8049-62-5,https://drugs.ncats.io/drug/2OYE00PC25,US Approved Rx 2023,NDA215830,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215830,US Approved Rx 2023,NDA215830,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215830,,
1102,8049-62-5,https://drugs.ncats.io/drug/2OYE00PC25,US Approved Rx 2023,NDA215830,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215830,US Approved Rx 2023,NDA215830,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215830,,
1103,133107-64-9,https://drugs.ncats.io/drug/GFX7QIS1II,US Approved Rx 1996,BLA020563,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020563,US Approved Rx 1996,BLA020563,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020563,diabetes mellitus,Approved
1104,133107-64-9,https://drugs.ncats.io/drug/GFX7QIS1II,US Approved Rx 1996,BLA020563,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020563,US Approved Rx 1996,BLA020563,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020563,diabetes mellitus,Approved
1105,8049-62-5,https://drugs.ncats.io/drug/2OYE00PC25,US Approved Rx 2023,NDA215830,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215830,US Approved Rx 2023,NDA215830,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215830,,
1106,8049-62-5,https://drugs.ncats.io/drug/2OYE00PC25,US Approved Rx 2023,NDA215830,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215830,US Approved Rx 2023,NDA215830,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215830,,
1107,76543-88-9,https://drugs.ncats.io/drug/47RRR83SK7,Possibly Marketed Outside US ,UK NHS:Interferon alfa-2a,https://tripod.nih.gov/npc/#Download,,,,,
1108,98530-12-2,https://drugs.ncats.io/drug/43K1W2T1M6,US Approved Rx 1986,BLA103132,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103132,US Approved Rx 1986,BLA103132,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103132,,
1109,118390-30-0,https://drugs.ncats.io/drug/56588OP40D,US Previously Marketed 1997,Infergen,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103663,US Previously Marketed 1997,Infergen,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103663,,
1110,145258-61-3,https://drugs.ncats.io/drug/XRO4566Q4R,US Approved Rx 1996,BLA103628,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103628,US Approved Rx 1996,BLA103628,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103628,,
1111,145155-23-3,https://drugs.ncats.io/drug/TTD90R31WZ,US Approved Rx 1993,BLA103471,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103471,US Approved Rx 1993,BLA103471,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103471,,
1112,9008-12-2,https://drugs.ncats.io/drug/70BT6OQT2Q,US Previously Marketed 1953,Bifacton by Organon,DeHaen 1940-1975 NMEs,US Previously Marketed 1953,Bifacton by Organon,DeHaen 1940-1975 NMEs,,
1113,9005-80-5,https://drugs.ncats.io/drug/JOS53KRJ01,US Previously Marketed 1940,INULIN AND SODIUM CHLORIDE by ISO TEX,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=002282,US Previously Marketed 1940,INULIN AND SODIUM CHLORIDE by ISO TEX,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=002282,kidney disease,Approved
1114,8002-46-8,https://drugs.ncats.io/drug/6O01GMS00P,US Approved Rx 2023,NDA216873,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216873,US Approved Rx 2023,NDA216873,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216873,Pancreatic cancer; Non-small cell lung cancer; Secondary myelofibrosis (post-polycythemia vera and post-essential thrombocythemia); Primary myelofibrosis,Phase III; Phase I; Phase III; Phase III
1115,7553-56-2,https://drugs.ncats.io/drug/9679TC07X4,US Approved OTC ,21 CFR 333.210(d) antifungal povidone-iodine,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec333-210.xml,US Previously Marketed 1921,Iodine U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,antiseptic,Approved
1116,92339-11-2,https://drugs.ncats.io/drug/HW8W27HTXX,US Approved Rx 1997,NDA020808,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020808,US Approved Rx 1996,NDA020351,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020351,Cardiovascular diseases,Approved
1117,75-47-8,https://drugs.ncats.io/drug/KXI2J76489,US Previously Marketed 1921,Iodoform U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Iodoform U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Root canal filling; Irritated ears,Not Provided; Not Provided
1118,66108-95-0,https://drugs.ncats.io/drug/4419T9MX03,US Approved Rx 1995,NDA020608,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020608,US Approved Rx 1985,NDA018956,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018956,Spinal cord disease; Urinary system disease; Gastrointestinal disorders; Cardiovascular diseases; Glioma,Approved; Approved; Approved; Approved; Approved
1119,60166-93-0,https://drugs.ncats.io/drug/JR13W81H44,US Approved Rx 1985,NDA018735,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018735,US Approved Rx 1985,NDA018735,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018735,Urinary system disease; Cardiovascular diseases; Glioma,Approved; Approved; Approved
1120,96-83-3,https://drugs.ncats.io/drug/FE9794P71J,US Previously Marketed 1951,TELEPAQUE by GE HEALTHCARE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=008032,US Previously Marketed 1951,TELEPAQUE by GE HEALTHCARE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=008032,Cholelithiasis; Gallbladder disease,Approved; Approved
1121,5587-89-3,https://drugs.ncats.io/drug/F604ZKI910,US Previously Marketed 1962,ORAGRAFIN SODIUM by BRACCO,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012967,US Previously Marketed 1962,ORAGRAFIN SODIUM by BRACCO,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012967,Hyperthyroidism; Graves' hyperthyroidism,Approved; Approved
1122,73334-07-3,https://drugs.ncats.io/drug/712BAC33MZ,US Approved Rx 1995,NDA020220,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020220,US Approved Rx 1995,NDA020220,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020220,Cancer; Cardiovascular diseases; Urinary system disease,Approved; Approved; Approved
1123,2276-90-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1124,87771-40-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1125,59017-64-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1126,107793-72-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1127,477202-00-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1128,22254-24-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1129,138402-11-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1130,97682-44-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1131,9004-66-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1132,7705-08-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1133,50-81-7,https://drugs.ncats.io/drug/PQ6CK8PD0R,US Approved Rx 2018,NDA209381,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209381,US Previously Marketed 1947,BEROCCA PN by ROCHE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006071,Scurvy; Vitamin C deficiency,Approved; Approved
1134,7439-89-6,https://drugs.ncats.io/drug/5ba434dc,,,,,,,,
1135,241479-67-4,https://drugs.ncats.io/drug/60UTO373KE,US Approved Rx 2015,NDA207500,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207500,US Approved Rx 2015,NDA207500,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207500,Invasive aspergillosis; Invasive mucormycosis,Approved; Approved
1136,742049-41-8,https://drugs.ncats.io/drug/VH2L779W8Q,US Approved Rx 2015,NDA207500,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207500,US Approved Rx 2015,NDA207500,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207500,Invasive aspergillosis; Invasive mucormycosis,Approved; Approved
1137,59-63-2,https://drugs.ncats.io/drug/34237V843T,US Approved Rx 1959,NDA011961,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011961,US Approved Rx 1959,NDA011961,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011961,Depression,Approved
1138,530-08-5,https://drugs.ncats.io/drug/YV0SN3276Q,US Previously Marketed 1983,ISOETHARINE HYDROCHLORIDE by ROXANE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=088275,US Previously Marketed 1961,Bronkosol by Sterling,OB NME Appendix 1950-1993,Chronic bronchitis; Emphysema,Approved; Approved
1139,26675-46-7,https://drugs.ncats.io/drug/CYS9AKD70P,US Approved Rx 1999,ANDA075225,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=075225,US Approved Rx 1979,NDA017624,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017624,Pain,Approved
1140,1560-93-6,https://drugs.ncats.io/drug/04R9AW5KWV,,,,,,,,
1141,443-79-8,https://drugs.ncats.io/drug/5HX0BYT4E3,US Previously Marketed ,21 CFR 310.545(a)(20) weight control isoleucine,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-545.xml,Possibly Marketed Outside US 1971,NDA016822,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa89dad1-bf4f-4f7e-ad1b-2431bdf36a2d,Acute infectious diarrhoea; Hyperglycemia; Liver cirrhosis; Burns,Phase II; Not Provided; Phase IV; Approved
1142,503-01-5,https://drugs.ncats.io/drug/Y7L24THH6T,US Previously Marketed 1948,Octin HCl by Knoll,DeHaen 1940-1975 NMEs,US Previously Marketed 1948,Octin HCl by Knoll,DeHaen 1940-1975 NMEs,Migraine; Headache; Neuralgia,Approved; Approved; Approved
1143,54-85-3,https://drugs.ncats.io/drug/V83O1VOZ8L,US Approved Rx 2014,ANDA202610,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202610,US Previously Marketed 1952,NYDRAZID by SANDOZ,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=008662,Tuberculosis,Approved
1144,7683-59-2,https://drugs.ncats.io/drug/L628TT009W,US Approved Rx 2021,ANDA211864,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211864,US Previously Marketed 1948,ISUPREL by SANOFI AVENTIS US,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006328,Bronchospasm occurring during anesthesia; Cardiac arrest; Heart block; Adams-stokes syndrome,Approved; Approved; Approved; Approved
1145,110-27-0,https://drugs.ncats.io/drug/0RE8K4LNJS,Possibly Marketed Outside US ,Resultz by Aralez Pharmaceuticals Canada Inc [Canada],https://www.drugbank.ca/drugs/DB13966,Possibly Marketed Outside US 2000,Excel by United Pet Group,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=447024cb-5965-4f1e-9e8d-d12d9ba3fca0,Unknown,
1146,142-91-6,https://drugs.ncats.io/drug/8CRQ2TH63M,US Previously Marketed ,"21 CFR 310.545(a)(18)(vi)(B) skin protectant:poison ivy/oak/sumac w/ sales less than $25,000 isopropyl palmitate",https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-545.xml,Possibly Marketed Outside US 1996,Hydrocortisone Acetate Pramoxine Hcl by Bryant Ranch Prepack,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=79fae74b-bef2-4e13-a2e9-da68747951eb,Unknown,
1147,652-67-5,https://drugs.ncats.io/drug/WXR179L51S,US Previously Marketed 1974,ISMOTIC by ALCON,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017063,US Previously Marketed 1974,ISMOTIC by ALCON,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017063,Ocular hypertension; Glaucoma,Approved; Approved
1148,87-33-2,https://drugs.ncats.io/drug/IA7306519N,,,,,,,,
1149,16051-77-7,https://drugs.ncats.io/drug/LX1OH63030,US Approved Rx 2018,ANDA207141,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207141,US Previously Marketed 1921,Spirit of Glyceryl Trinitrate U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,,
1150,4759-48-2,https://drugs.ncats.io/drug/EH28UP18IF,US Approved Rx 2019,ANDA211644,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211644,US Previously Marketed 1971,RETIN-A by VALEANT INTL,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016921,,
1151,395-28-8,https://drugs.ncats.io/drug/R15UI3245N,US Previously Marketed 1959,Vasodilan by Mead Johnson,OB NME Appendix 1950-1993,US Previously Marketed 1959,Vasodilan by Mead Johnson,OB NME Appendix 1950-1993,Arteriosclerosis obliterans; Thromboangitis obliterans; Raynaud's disease,Approved; Approved; Approved
1152,873054-44-5,https://drugs.ncats.io/drug/1Y740ILL1Z,US Approved Rx 2018,NDA210491,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210491,US Approved Rx 2012,NDA203188,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203188,Cystic fibrosis,Approved
1153,70288-86-7,https://drugs.ncats.io/drug/8883YP2R6D,US Approved Rx 2019,ANDA210019,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210019,Possibly Marketed Outside US 1984,NADA128409,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d8e1598-f824-415e-927c-dbe70e735f80,Onchocerciasis; Strongyloidiasis of the intestinal tract,Approved; Approved
1154,1448347-49-6,https://drugs.ncats.io/drug/Q2PCN8MAM6,US Approved Rx 2018,NDA211192,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192,US Approved Rx 2018,NDA211192,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192,Relapsed or refractory acute myeloid leukemia; Cholangiocarcinoma,Approved; Phase III
1155,219989-84-1,https://drugs.ncats.io/drug/K27005NP0A,US Approved Rx 2007,NDA022065,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022065,US Approved Rx 2007,NDA022065,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022065,Breast cancer,Approved
1156,1072833-77-2,https://drugs.ncats.io/drug/71050168A2,US Approved Rx 2015,NDA208462,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208462,US Approved Rx 2015,NDA208462,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208462,Multiple myeloma; Bladder cancer; Multiple myeloma; Glioblastoma,Approved; Phase II; Approved; Phase I
1157,1143503-69-8,https://drugs.ncats.io/drug/BTY153760O,US Approved Rx 2016,BLA125521,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125521,US Approved Rx 2016,BLA125521,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125521,,
1158,61789-91-1,https://drugs.ncats.io/drug/724GKU717M,US Previously Marketed ,21 CFR 310.527(a) hair loss prevention jojoba oil,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-527.xml,Possibly Marketed Outside US 2007,21 CFR 333,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d645ab34-1a96-48d1-b9d2-e2dd9e614f78,,
1159,59-01-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1160,1332-58-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1161,8008-20-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1162,6740-88-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1163,65277-42-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1164,22071-15-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1165,74103-06-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1166,34580-13-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1167,501-30-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1168,63-68-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1169,36894-69-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1170,175481-36-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1171,68333-16-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1172,68333-14-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1173,81103-11-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1174,5965-66-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1175,4618-18-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1176,4547-24-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1177,134678-17-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1178,84057-84-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1179,1426055-14-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1180,108736-35-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1181,103577-45-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1182,7439-91-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1183,231277-92-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1184,210589-09-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1185,1223403-58-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1186,130209-82-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1187,860005-21-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1188,143-07-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1189,156028-14-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1190,1510-16-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1191,151-21-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1192,8002-43-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1193,1256388-51-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1194,75706-12-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1195,191732-72-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1196,417716-92-8,https://drugs.ncats.io/drug/EE083865G2,US Approved Rx 2022,NDA213092,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213092,US Approved Rx 2015,NDA206947,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206947,Renal cell cancer; Differentiated thyroid cancer,Approved; Approved
1197,5327-45-7,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
1198,138068-37-8,https://drugs.ncats.io/drug/Y43GF64R34,US Previously Marketed 1998,Refludan,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=20807,US Previously Marketed 1998,Refludan,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=20807,heparin-associated thrombocytopenia,Approved
1199,878672-00-5,https://drugs.ncats.io/drug/09ERP08I3W,US Previously Marketed 2015,ZURAMPIC by IRONWOOD PHARMS INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207988,US Previously Marketed 2015,ZURAMPIC by IRONWOOD PHARMS INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207988,Hyperuricemia,Approved
1200,917389-32-3,https://drugs.ncats.io/drug/1H09Y5WO1F,US Approved Rx 2017,NDA209940,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209940,US Approved Rx 2017,NDA209940,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209940,Cytomegalovirus infection; cytomegalovirus infection,Phase III; Approved
1201,112809-51-5,https://drugs.ncats.io/drug/7LKK855W8I,US Approved Rx 2011,ANDA090289,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=090289,US Approved Rx 1997,NDA020726,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020726,Breast cancer,Approved
1202,61-90-5,https://drugs.ncats.io/drug/GMW67QNF9C,US Previously Marketed ,21 CFR 310.545(a)(20) weight control leucine,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-545.xml,Possibly Marketed Outside US 1971,NDA016822,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa89dad1-bf4f-4f7e-ad1b-2431bdf36a2d,Diamond-Blackfan anemia; Pure red cell aplasia; Non-alcoholic fatty liver disease; Burns,Phase II; Phase II; Phase II; Approved
1203,53714-56-0,https://drugs.ncats.io/drug/EFY6W0M8TG,US Approved Rx 2021,ANDA213829,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213829,US Previously Marketed 1985,LUPRON by ABBVIE ENDOCRINE INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019010,Prostate cancer; Endometriosis; Uterine leiomyomata,Approved; Approved; Approved
1204,1477-40-3,https://drugs.ncats.io/drug/R3B637Y991,Possibly Marketed Outside US ,WHO-ATC:N07BC03,https://ginas.ncats.nih.gov/ginas/app/substance/R3B637Y991,,,,Opioid dependence,Approved
1205,14769-73-4,https://drugs.ncats.io/drug/2880D3468G,US Previously Marketed 1990,ERGAMISOL by JANSSEN PHARMA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020035,US Previously Marketed 1990,ERGAMISOL by JANSSEN PHARMA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020035,Dukes' Stage C colon cancer; Ascariasis; Steroid-sensitive idiopathic nephrotic syndrome,Approved; Not Provided; Not Provided
1206,102767-28-2,https://drugs.ncats.io/drug/44YRR34555,US Approved Rx 2022,ANDA214815,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214815,US Approved Rx 1999,NDA021035,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021035,Partial onset seizures; Juvenile myoclonic epilepsy; Idiopathic generalized epilepsy,Approved; Approved; Approved
1207,33817-09-3,https://drugs.ncats.io/drug/Y24T9BT2Q2,US Approved OTC ,21 CFR 341.20(b)(1) cough/cold:nasal decongestant levmetamfetamine,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec341-20.xml,Possibly Marketed Outside US 2014,21 CFR 341,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=904b7e21-cce5-4b96-afc1-b36f532f98ac,Upper respiratory allergies; Allergic rhinitis; Common cold,Approved; Approved; Approved
1208,47141-42-4,https://drugs.ncats.io/drug/G6317AOI7K,US Approved Rx 1994,ANDA074326,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=074326,US Approved Rx 1985,NDA019219,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019219,Chronic open-angle glaucoma; Ocular hypertension,Approved; Approved
1209,27262-47-1,https://drugs.ncats.io/drug/A5H73K9U3W,US Previously Marketed 1999,CHIROCAINE by PURDUE PHARMA LP,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020997,US Previously Marketed 1999,CHIROCAINE by PURDUE PHARMA LP,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020997,Pain,Approved
1210,79449-98-2,https://drugs.ncats.io/drug/COU3RRH769,US Previously Marketed 1993,LIVOSTIN by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020219,US Previously Marketed 1993,LIVOSTIN by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020219,Seasonal allergic conjunctivitis,Approved
1211,541-15-1,https://drugs.ncats.io/drug/0G389FZZ9M,US Approved Rx 1985,NDA018948,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018948,US Approved Rx 1985,NDA018948,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018948,Systemic primary carnitine deficiency; Ulcerative colitis; Peripheral arterial occlusive disorders; Congestive heart failure,Approved; Phase III; Approved; Phase III
1212,130018-77-8,https://drugs.ncats.io/drug/6U5EA9RT2O,US Approved Rx 2013,ANDA090362,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=090362,Possibly Marketed Outside US 1995,NDA022064,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=371ca86d-7ffd-4f20-b6c6-af0a9ff7362f,Perennial allergic rhinitis; Chronic idiopathic urticaria; Seasonal allergic rhinitis; Dermatitis; Allergic rhinitis; Chronic Idiopathic Urticaria,Approved; Approved; Approved; Phase III; Approved; Approved
1213,59-92-7,https://drugs.ncats.io/drug/46627O600J,US Approved Rx 1993,ANDA074260,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=074260,US Previously Marketed 1970,LARODOPA by ROCHE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016912,Parkinson's disease,Approved
1214,100986-85-4,https://drugs.ncats.io/drug/RIX4E89Y14,US Approved Rx 2011,ANDA090787,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=090787,US Previously Marketed 1996,LEVAQUIN by JANSSEN PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020635,Complicated Skin and Skin Structure Infections; Plague; Chronic bacterial prostatitis; Chronic bronchitis; Urinary tract infections; Pneumonia,Approved; Approved; Approved; Approved; Approved; Approved
1215,31690-09-2,https://drugs.ncats.io/drug/8S95DH25XC,Possibly Marketed Outside US ,Yasmin Plus by Bayer [Canada],https://www.drugbank.ca/drugs/DB11256,Possibly Marketed Outside US 2010,"Zatean-Pn DHA by Trigen Laboratories, LLC",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f6ee5344-98ea-45a5-85be-712ef43a809e,Pregnancy,Approved
1216,23089-26-1,https://drugs.ncats.io/drug/24WE03BX2T,Possibly Marketed Outside US ,"PurpleU BAOBAB FACE by Recipe Co., Ltd.",https://www.drugbank.ca/drugs/DB13153,Possibly Marketed Outside US 2009,21 CFR 333D,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51f03428-f25a-4d6f-affb-71c41effd67b,sunburn; Alzheimer’s disease; Inflammatory pain; Pancreatic cancer,Approved; Basic research; Not Provided; Basic research
1217,89-78-1,https://drugs.ncats.io/drug/YS08XHA860,US Approved OTC ,"21 CFR 346.16(c) anorectal:analgesic, anesthetic, antipruritic menthol",https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec346-16.xml,US Previously Marketed 1921,Menthol U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Itching; Mild pain; Rhinitis; Gastrointestinal endoscopy; Common cold; Pain; Sore throat; Arthritis; Simple backache,Approved; Approved; Approved; Phase III; Approved; Not Provided; Approved; Approved; Approved
1218,96847-54-0,https://drugs.ncats.io/drug/UGM0326TXX,US Approved Rx 2023,ANDA210771,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210771,Possibly Marketed Outside US 2009,ANDA210790,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bcbc5d92-e022-4a0d-ab4d-2b0d7aa68c58,Ischemic stroke; Major depressive disorder,Phase III; Approved
1219,797-63-7,https://drugs.ncats.io/drug/5W7SIA7YZW,US Approved Rx 2015,ANDA201088,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201088,US Previously Marketed 1968,OVRAL-28 by WYETH PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016806,Heavy menstrual bleeding; Fertilization; Pregnancy; Pregnancy,Approved; Approved; Approved; Approved
1220,297-90-5,https://drugs.ncats.io/drug/V7R79HN3XD,US Previously Marketed 1953,Dromoran by Hoffmann-La Roche,DeHaen 1940-1975 NMEs,US Previously Marketed 1953,Dromoran by Hoffmann-La Roche,DeHaen 1940-1975 NMEs,Unknown,
1221,34391-04-3,https://drugs.ncats.io/drug/EDN2NBH5SS,US Approved Rx 2013,ANDA078171,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=078171,US Approved Rx 1999,NDA020837,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020837,Asthma; Chronic obstructive pulmonary disease,Approved; Approved
1222,55-03-8,https://drugs.ncats.io/drug/054I36CPMN,US Approved Rx 2016,ANDA206163,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206163,US Previously Marketed 1953,Synthroid Sodium by Travenol,DeHaen 1940-1975 NMEs,Euthyroid goiters; Hypothyroidism,Approved; Approved
1223,137-58-6,https://drugs.ncats.io/drug/98PI200987,US Approved OTC ,21 CFR 346.10(f) anorectal:local anesthetic lidocaine,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec346-10.xml,US Previously Marketed 1948,XYLOCAINE DENTAL by DENTSPLY PHARM,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021380,Ventricular arrhythmia; Pain,Approved; Approved
1224,1025967-78-5,https://drugs.ncats.io/drug/038E5L962W,US Approved Rx 2023,ANDA215063,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215063,US Approved Rx 2016,NDA208073,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208073,Dry eye syndrome; Allergic conjunctivitis,Approved; Phase II
1225,138-86-3,https://drugs.ncats.io/drug/9MC3I34447,Possibly Marketed Outside US 2016,Younique Royalty Hydrating Day Cream SPF 20 by Younique LLC,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4443398b-4073-448e-e054-00144ff8d46c,Possibly Marketed Outside US 1982,NDA018613,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2024030e-b00d-4fcc-b51d-45dc86933749,Unknown,
1226,851199-59-2,https://drugs.ncats.io/drug/N0TXR0XR5X,US Approved Rx 2012,NDA202811,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202811,US Approved Rx 2012,NDA202811,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202811,Irritable bowel syndrome; Constipation,Approved; Approved
1227,668270-12-0,https://drugs.ncats.io/drug/3X29ZEJ4R2,US Approved Rx 2016,NDA208026,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208026,US Approved Rx 2011,NDA201280,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201280,Type 2 diabetes mellitus,Approved
1228,78-70-6,https://drugs.ncats.io/drug/D81QY6I88E,Possibly Marketed Outside US 2011,21 CFR 333D,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=56f966a1-4317-412f-b5b8-bb7f1d6e0279,Possibly Marketed Outside US 1990,M032,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eb1d6e9e-e7fd-478e-80c0-3a3f529682d7,Flea infestations,Not Provided
1229,154-21-2,https://drugs.ncats.io/drug/BOD072YW0F,US Approved Rx 1964,NDA050317,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050317,US Approved Rx 1964,NDA050317,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050317,Streptococcal infections; Pneumococcal infections; Staphylococcal infections,Approved; Approved; Approved
1230,58-89-9,https://drugs.ncats.io/drug/59NEE7PCAB,US Previously Marketed 1982,SCABENE by STIEFEL,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=086769,US Previously Marketed 1951,Kwell by Reed & Carnrick,OB NME Appendix 1950-1993,Scabies; Lice infestation,Approved; Approved
1231,165800-03-3,https://drugs.ncats.io/drug/ISQ9I6J12J,US Approved Rx 2017,ANDA205154,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205154,US Approved Rx 2000,NDA021131,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021131,Vancomycin-resistant Enterococcus faecium infections; Community-acquired pneumonia; Skin infections; Nosocomial pneumonia,Approved; Approved; Approved; Approved
1232,60-33-3,https://drugs.ncats.io/drug/9KJL21T0QJ,US Previously Marketed 1961,LENIC WITH NIACIN LINOLEIC ACID by CROOKES-BARNES,https://www.govinfo.gov/content/pkg/FR-1973-05-30/pdf/FR-1973-05-30.pdf,US Previously Marketed 1921,linoleic acid,https://catalog.hathitrust.org/Record/100163146,Unknown; Multiple sclerosis; Parenteral Nutrition,Phase I; Approved
1233,463-40-1,https://drugs.ncats.io/drug/0RBV727H71,Possibly Marketed Outside US ,Canada:LINOLENIC ACID,https://tripod.nih.gov/npc/#Download,Possibly Marketed Outside US 1985,"Keradan by Medimetriks Pharmaceuticals, Inc.",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4d5c5b14-9e4f-4d43-a336-e4ae71d34e42,Parenteral Nutrition,Approved
1234,15785-49-6,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
1235,82-76-8,https://drugs.ncats.io/drug/630I4V6051,,,,,,,,
1236,7664-41-7,https://drugs.ncats.io/drug/5138Q19F1X,US Approved Rx 1984,ANDA088366,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=088366,US Previously Marketed 1921,Ammonium Chloride U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Metabolic alkalosis,Approved
1237,204656-20-2,https://drugs.ncats.io/drug/839I73S42A,US Approved Rx 2014,NDA206321,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206321,US Approved Rx 2010,NDA022341,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022341,type 2 diabetes mellitus,Approved
1238,608137-32-2,https://drugs.ncats.io/drug/H645GUL8KJ,US Approved Rx 1976,NDA017078,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017078,US Previously Marketed 1937,Dexedrine by Smith Kline French,https://web.archive.org/web/20091219120223/http://www.medic8.com/medicines/Dexedrine.html,Attention deficit hyperactivity disorder; Moderate to severe binge eating disorder; Attention deficit hyperactivity disorder,Approved; Approved; Approved
1239,76547-98-3,https://drugs.ncats.io/drug/7Q3P4BS2FD,US Approved Rx 2006,ANDA077622,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077622,US Previously Marketed 1987,PRINIVIL by MERCK,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019558,Heart failure; Acute myocardial infarction; Hypertension,Approved; Approved; Approved
1240,11096-63-2,https://drugs.ncats.io/drug/9B7E8Y9D0X,Possibly Marketed Outside US 2021,21 CFR 333A,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb80ef22-bcd2-9276-e053-2995a90a6557,Possibly Marketed Outside US 2021,21 CFR 333A,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb80ef22-bcd2-9276-e053-2995a90a6557,Eye diseases,Approved
1241,7439-93-2,https://drugs.ncats.io/drug/9FN79X2M3F,,,,,,,"Bipolar disorder, manic episodes",Approved
1242,53320-86-8,https://drugs.ncats.io/drug/D703131383,Possibly Marketed Outside US 2019,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4075f9dc-c25f-434f-a3fc-a7f896295c3d,Possibly Marketed Outside US 2004,KeratexKCG by Penleigh Irving Ltd,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ca82b1d-ccd4-4326-b3da-30b45eeb471a,,
1243,320367-13-3,https://drugs.ncats.io/drug/74O62BB01U,US Approved Rx 2016,BLA208471,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208471,US Approved Rx 2016,BLA208471,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208471,Type 2 diabetes mellitus,Approved
1244,90063-60-8,https://drugs.ncats.io/drug/ODU3ZAZ94J,US Approved Rx 2023,NDA216386,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216386,US Approved Rx 2023,NDA216386,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216386,,
1245,53882-12-5,https://drugs.ncats.io/drug/SPU695OD73,US Approved Rx 1993,NDA020191,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020191,US Approved Rx 1993,NDA020191,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020191,Vernal keratitis; Vernal conjunctivitis; Vernal keratoconjunctivitis,Approved; Approved; Approved
1246,31036-80-3,https://drugs.ncats.io/drug/UI82K0T627,US Approved Rx 2018,NDA209229,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209229,US Approved Rx 2018,NDA209229,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209229,Opioid-Related Disorders,Approved
1247,98079-51-7,https://drugs.ncats.io/drug/L6BR2WJD8V,US Previously Marketed 1992,MAXAQUIN by PHARMACIA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020013,US Previously Marketed 1992,MAXAQUIN by PHARMACIA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020013,Uncomplicated urinary tract infections; Chronic bronchitis; Bacterial conjunctivitis,Approved; Approved; Approved
1248,182431-12-5,https://drugs.ncats.io/drug/82KUB0583F,US Approved Rx 2012,NDA203858,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203858,US Approved Rx 2012,NDA203858,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203858,Homozygous familial hypercholesterolemia,Approved
1249,13010-47-4,https://drugs.ncats.io/drug/7BRF0Z81KG,US Approved Rx 1976,NDA017588,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017588,US Approved Rx 1976,NDA017588,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017588,Hodgkin's lymphoma; Brain cancer,Approved; Approved
1250,906-33-2,https://drugs.ncats.io/drug/O4601UER1Z,,,,,,,Unknown; Breast cancer; Constipation; Inflammation,Basic research; Natural Metabolite; Natural Metabolite
1251,1388129-63-2,https://drugs.ncats.io/drug/VQ723R7O8R,Possibly Marketed Outside US ,Afstyla by Csl Behring [Canada],https://www.drugbank.ca/drugs/DB13998,Possibly Marketed Outside US 2016,BLA125591,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51f19873-a63f-4229-9477-5da4ecf31cde,,
1252,53179-11-6,https://drugs.ncats.io/drug/6X9OC3H4II,US Approved Rx 2021,ANDA215579,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215579,US Previously Marketed 1976,IMODIUM by J AND J CONSUMER INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017690,Diarrhea,Approved
1253,192725-17-0,https://drugs.ncats.io/drug/2494G1JF75,US Approved Rx 2021,ANDA091677,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=091677,US Previously Marketed 2000,KALETRA by ABBVIE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021226,HIV infection; HPV positive with high grade squamous intraepithelial lesions,Approved; Phase II
1254,76470-66-1,https://drugs.ncats.io/drug/W72I5ZT78Z,US Previously Marketed 1991,LORABID by KING PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050668,US Previously Marketed 1991,LORABID by KING PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050668,Bacterial infections,Approved
1255,79794-75-5,https://drugs.ncats.io/drug/7AJO3BO7QN,US Approved Rx 2019,ANDA210033,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210033,US Approved Rx 1993,NDA019658,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019658,Upper respiratory allergies,Approved
1256,846-49-1,https://drugs.ncats.io/drug/O26FZP769L,US Approved Rx 1980,NDA018140,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018140,US Approved Rx 1977,NDA017794,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017794,Anxiety,Approved
1257,616202-92-7,https://drugs.ncats.io/drug/637E494O0Z,US Previously Marketed 2019,LORCASERIN HYDROCHLORIDE by ZYDUS PHARMS USA INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209464,US Previously Marketed 2012,BELVIQ,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=22529,Obesity,Approved
1258,1454846-35-5,https://drugs.ncats.io/drug/OSP71S83EU,US Approved Rx 2018,NDA210868,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210868,US Approved Rx 2018,NDA210868,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210868,"Neuroblastoma; Anaplastic Large Cell Lymphoma, ALK-Positive; Non-small cell lung cancer",Phase I; Phase II; Approved
1259,114798-26-4,https://drugs.ncats.io/drug/JMS50MPO89,US Approved Rx 2012,ANDA091541,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=091541,US Approved Rx 1995,NDA020387,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020387,Hypertension; Stroke; Heart failure; Diabetic nephropathy,Phase IV; Phase IV; Approved; Approved
1260,129260-79-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1261,75330-75-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1262,1977-10-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1263,333963-40-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1264,9067-32-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1265,825600-90-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1266,187164-19-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1267,936727-05-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1268,82186-77-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1269,367514-87-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1270,1110766-97-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1271,9034-40-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1272,56973-41-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1273,502-65-8,https://drugs.ncats.io/drug/SB0N2N0WV6,Possibly Marketed Outside US ,"Corvita by Trigen Laboratories, LLC",https://www.drugbank.ca/drugs/DB11231,Possibly Marketed Outside US 2007,"Corvite Free by Vertical Pharmaceuticals, LLC",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61f55a42-a2c3-4aa7-9935-69ada425b211,Prostate cancer; Atherosclerosis; Coronary heart disease,Phase III; Phase III; Phase III
1274,56-87-1,https://drugs.ncats.io/drug/K3Z4F929H6,US Previously Marketed ,21 CFR 310.545(a)(20) weight control lysine hydrochloride,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-545.xml,Possibly Marketed Outside US 1971,NDA016822,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6ea7ec73-403e-4303-8862-6380e2f1fda6,Osteoporosis; Angina pectoris; Herpes simplex infection; Heroin dependence; Anxiety; Patent ductus arteriosus,Natural Metabolite; Natural Metabolite; Natural Metabolite; Natural Metabolite; Natural Metabolite; Approved
1275,9066-59-5,https://drugs.ncats.io/drug/4YRW73H69V,Possibly Marketed Outside US ,Japan:Lysozyme Hydrochloride,https://tripod.nih.gov/npc/#Download,Possibly Marketed Outside US 2012,21 CFR 346,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b607f6a7-f2e2-4af8-8ae5-9d66f1b1fb06,,
1276,108-39-4,https://drugs.ncats.io/drug/GGO4Y809LO,US Previously Marketed ,21 CFR 310.545(a)(22)(iv) antifungal:scalp or nails m-cresol,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-545.xml,Possibly Marketed Outside US 1982,BLA018780,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b519bd83-038c-4ec5-a231-a51ec5cc291f,,
1277,122-46-3,https://drugs.ncats.io/drug/73UDH1DF0R,,,,,,,,
1278,381231-18-1,https://drugs.ncats.io/drug/8680B21W73,US Previously Marketed 2017,MACRILEN by NOVO,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205598,US Previously Marketed 2017,MACRILEN by NOVO,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205598,Growth hormone deficiency,Approved
1279,441798-33-0,https://drugs.ncats.io/drug/Z9K9Y9WMVL,US Approved Rx 2013,NDA204410,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204410,US Approved Rx 2013,NDA204410,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204410,Pulmonary arterial hypertension,Approved
1280,138-39-6,https://drugs.ncats.io/drug/58447S8P4L,US Approved Rx 1969,NDA016763,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016763,US Previously Marketed 1948,Sulfamylon by Winthrop,DeHaen 1940-1975 NMEs,Burn,Approved
1281,74978-16-8,https://drugs.ncats.io/drug/6V88E24N5T,US Approved OTC ,21 CFR 331.11(g)(2) antacid:magnesium-containing magaldrate,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec331-11.xml,US Previously Marketed 1960,Riopan by Ayerst,DeHaen 1940-1975 NMEs,Heartburn; Pain in the upper abdomen; Heartburn; indigestion; Nausea,Approved; Approved; Approved; Approved
1282,7439-95-4,https://drugs.ncats.io/drug/I38ZP9992A,US Approved OTC ,21 CFR 331.11(g)(7) antacid:magnesium-containing magnesium oxide,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec331-11.xml,US Previously Marketed 1921,Magnesium Carbonate U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Bone disease; Bacterial infections; Bronchial spasm; Unknown; Magnesium deficiency; Convulsions; Eclampsia; Unknown; Eclampsia; Preeclampsia; Preparation for colonoscopy; Atrial fibrillation; Unknown; Magnesium deficiency; Unknown; Unknown; Oxaluria; Constipation; Magnesium deficiency; Stroke; Magnesium deficiency; Fibromyalgia; Unknown; Magnesium deficiency; Unknown; Unknown,Basic research; Preclinical; Preclinical; Not Provided; Not Provided; Not Provided; Approved; Approved; Approved; Phase III; Approved; Approved; Approved; Approved; Phase III; Approved; Phase II; Approved
1283,64-17-5,https://drugs.ncats.io/drug/bfe60581,,,,,,,,
1284,121-75-5,https://drugs.ncats.io/drug/U5N7SU872W,US Approved Rx 2012,ANDA091559,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=091559,US Previously Marketed 1982,OVIDE by TARO,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018613,Pediculosis; Scabies,Approved; Approved
1285,6915-15-7,https://drugs.ncats.io/drug/817L1N4CKP,Possibly Marketed Outside US ,Canada:MALIC ACID,https://tripod.nih.gov/npc/#Download,Possibly Marketed Outside US 1942,21 CFR 356,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=989f8509-cd28-48e7-9aa1-baddfbcac95a,Skin injuries; Cisplatin-induced toxicity; Cardiac arrhythmia,Approved; Preclinical; Preclinical
1286,141-82-2,https://drugs.ncats.io/drug/9KX7ZMG0MK,US Previously Marketed 1940,KOAGAMIN PARENTERAL MALONIC ACID by CHATHAM,https://archive.org/details/arizonamedicinej202unse/page/n77?q=koagamin,US Previously Marketed 1940,KOAGAMIN PARENTERAL MALONIC ACID by CHATHAM,https://archive.org/details/arizonamedicinej202unse/page/n77?q=koagamin,,
1287,9050-36-6,https://drugs.ncats.io/drug/7CVR7L4A2D,US Previously Marketed ,21 CFR 310.545(a)(20) weight control maltodextrin,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-545.xml,Possibly Marketed Outside US 1984,NeuroBion by BENARD INDUSTRIES INC,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a55617fa-abea-468d-a5b2-022868fe4b2a,,
1288,155319-91-8,https://drugs.ncats.io/drug/N02W67RKJS,US Previously Marketed 1997,TESLASCAN by IC TARGETS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020652,US Previously Marketed 1997,TESLASCAN by IC TARGETS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020652,Cancer; Myocardial Infarction; Colon cancer; Hepatocellular carcinoma,Withdrawn; Phase II; Phase II; Approved
1289,7439-96-5,https://drugs.ncats.io/drug/42Z2K6ZL8P,US Previously Marketed 1921,Solution of Peptonate of Iron and Manganese N.F.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Solution of Peptonate of Iron and Manganese N.F.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,,
1290,69-65-8,https://drugs.ncats.io/drug/3OWL53L36A,US Approved Rx 2020,NDA202049,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202049,Possibly Marketed Outside US 1955,Levsin by Alaven Pharmaceutical LLC,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32388e18-08de-455c-aad4-9c2264435f0f,Constipation; End-Stage Renal Disease; Cystic fibrosis; Asthma; Acute renal failure; Elevated intraocular pressure; Cerebral edema,Basic research; Approved; Approved; Approved; Approved; Approved; Approved
1291,10262-69-8,https://drugs.ncats.io/drug/2U1W68TROF,US Previously Marketed 1988,MAPROTILINE HYDROCHLORIDE by AM THERAP,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=072131,US Previously Marketed 1980,LUDIOMIL by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017543,Major depressive disorder; Dysthymic disorder,Approved; Approved
1292,376348-65-1,https://drugs.ncats.io/drug/MD6P741W8A,US Approved Rx 2007,NDA022128,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022128,US Approved Rx 2007,NDA022128,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022128,CCR5-tropic HIV-1 infection,Approved
1293,22232-71-9,https://drugs.ncats.io/drug/C56709M5NH,US Previously Marketed 1980,MAZANOR by WYETH AYERST,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017980,US Previously Marketed 1973,SANOREX by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017247,Obesity; Duchenne muscular dystrophy,Approved; Approved
1294,31431-39-7,https://drugs.ncats.io/drug/81G6I5V05I,US Approved Rx 1995,ANDA073580,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=073580,US Previously Marketed 1974,VERMOX by JANSSEN PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017481,Necator americanus infection; Enterobius vermicularis (pinworm) infection; Ascaris lumbricoides infection; Trichuriasis infection,Approved; Approved; Approved; Approved
1295,60-40-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1296,68562-41-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1297,478166-15-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1298,644-62-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1299,569-65-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1300,13422-55-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1301,3380-34-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1302,7704-34-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1303,520-85-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1304,2668-66-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1305,61-68-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1306,51742-87-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1307,3562-63-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1308,131-49-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1309,73-31-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1310,977051-08-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1311,71125-38-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1312,148-82-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1313,19982-08-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1314,58-27-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1315,2124-57-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1316,84082-70-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1317,1490-04-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1318,83-89-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1319,25990-43-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1320,59-47-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1321,100-92-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1322,50-12-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1323,96-88-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1324,196078-29-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1325,57-53-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1326,91-84-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1327,150-76-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1328,15015-80-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1329,60-23-1,https://drugs.ncats.io/drug/5UX2SD1KE2,US Approved Rx 2020,NDA213491,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213491,US Approved Rx 1994,NDA020392,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020392,Nephropathic cystinosis,Approved
1330,50-44-2,https://drugs.ncats.io/drug/PKK6MUZ20G,US Approved Rx 2004,ANDA040528,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=040528,US Previously Marketed 1953,PURINETHOL by STASON PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=009053,Acute lymphoblastic leukemia,Approved
1331,15829-53-5,https://drugs.ncats.io/drug/0I308SWC92,US Approved OTC ,21 CFR 358.710(a)(7) dandruff:dandruff sulfur,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec358-710.xml,US Previously Marketed 1921,Washed Sulphur U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Scalp itching and flaking,Approved
1332,7487-94-7,https://drugs.ncats.io/drug/53GH7MZT1R,US Previously Marketed 1921,Solution of Arsenous and Mercuric Iodide U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Solution of Arsenous and Mercuric Iodide U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,,
1333,7783-36-0,https://drugs.ncats.io/drug/PI950N9DYS,,,,,,,,
1334,96036-03-2,https://drugs.ncats.io/drug/YOP6PX0BAO,US Approved Rx 2016,ANDA205883,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205883,US Approved Rx 1996,NDA050706,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050706,Skin structure infections; Intra-abdominal infections; Bacterial meningitis,Approved; Approved; Approved
1335,89-57-6,https://drugs.ncats.io/drug/4Q81I59GXC,US Approved Rx 2019,ANDA207271,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207271,US Approved Rx 1987,NDA019618,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019618,Ulcerative colitis,Approved
1336,19767-45-4,https://drugs.ncats.io/drug/NR7O1405Q9,US Approved Rx 2010,ANDA090913,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=090913,US Previously Marketed 1987,IFEX/MESNEX KIT by BAXTER HLTHCARE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019763,Ifosfamide-induced hemorrhagic cystitis,Approved
1337,5588-33-0,https://drugs.ncats.io/drug/5XE4NWM740,US Previously Marketed 1970,SERENTIL by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016775,US Previously Marketed 1970,SERENTIL by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016775,Schizophrenia; Psychosis,Approved; Approved
1338,72-33-3,https://drugs.ncats.io/drug/B2V233XGE7,US Previously Marketed 1964,NORINYL 1+50 21-DAY by ACTAVIS LABS UT INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=013625,US Previously Marketed 1957,Enovid by Searle,DeHaen 1940-1975 NMEs,Menstrual cycle disorder; Pregnancy,Approved; Approved
1339,77-41-8,https://drugs.ncats.io/drug/0G76K8X6C0,US Approved Rx 1957,NDA010596,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=010596,US Approved Rx 1957,NDA010596,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=010596,Epilepsy,Approved
1340,74536-44-0,https://drugs.ncats.io/drug/EJQ7M98H5J,Possibly Marketed Outside US 2010,NCT02161653: Phase 4 Interventional Completed Severe Alcoholic Hepatitis,https://clinicaltrials.gov/ct2/show/NCT02161653,,,,Fragile X syndrome; Alcoholic hepatitis; Attention deficit hyperactivity disorder,Phase II; Approved; Phase III
1341,54-49-9,https://drugs.ncats.io/drug/818U2PZ2EH,US Approved Rx 2021,ANDA211304,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211304,US Previously Marketed 1954,ARAMINE by MERCK,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=009509,Acute hypotensive state; Hemorrhage; Shock; Priapism,Approved; Approved; Approved; Not Provided
1342,1665-48-1,https://drugs.ncats.io/drug/1NMA9J598Y,US Approved Rx 2015,ANDA040486,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=040486,US Previously Marketed 1962,SKELAXIN by KING PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=013217,Painful musculoskeletal conditions,Approved
1343,657-24-9,https://drugs.ncats.io/drug/9100L32L2N,US Approved Rx 2006,ANDA077880,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077880,US Previously Marketed 1995,GLUCOPHAGE by EMD SERONO INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020357,Type 2 diabetes mellitus; Cancer,Approved; Phase III
1344,55-92-5,https://drugs.ncats.io/drug/03V657ZD3V,US Approved Rx 1986,NDA019193,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019193,US Approved Rx 1986,NDA019193,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019193,Asthma,Approved
1345,76-99-3,https://drugs.ncats.io/drug/UC6VBE7V1Z,US Approved Rx 2015,ANDA203502,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203502,US Approved Rx 1947,NDA021624,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021624,Detoxification & maintenance treatment of opioid addiction; Pain,Approved; Approved
1346,537-46-2,https://drugs.ncats.io/drug/44RAL3456C,US Approved Rx 2010,ANDA091189,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=091189,US Approved Rx 1943,NDA005378,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=005378,Attention deficit hyperactivity disorder; Exogenous obesity; Unknown,Approved; Approved
1347,91-80-5,https://drugs.ncats.io/drug/A01LX40298,US Previously Marketed 1961,SEMIKON HCL by BEECHAM LABS,https://www.govinfo.gov/content/pkg/FR-1973-03-19/pdf/FR-1973-03-19.pdf,US Previously Marketed 1947,Thenylene HCl by Abbott,DeHaen 1940-1975 NMEs,Unknown,
1348,554-57-4,https://drugs.ncats.io/drug/W733B0S9SD,US Approved Rx 2018,ANDA207438,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207438,US Previously Marketed 1959,NEPTAZANE by LEDERLE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011721,Glaucoma,Approved
1349,100-97-0,https://drugs.ncats.io/drug/J50OIX95QV,US Approved Rx 1967,NDA016151,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016151,US Previously Marketed 1894,Urotropine,https://books.google.com/books?id=MacRAAAAYAAJ&newbks=1&newbks_redir=0&dq=urotropine&pg=RA1-PA426#v=onepage&q=urotropine&f=false,Urinary tract infections,Approved
1350,63-68-3,https://drugs.ncats.io/drug/AE28F7PNPL,US Previously Marketed 1945,Methionine by Various Mfrs.,DeHaen 1940-1975 NMEs,US Previously Marketed 1945,Methionine by Various Mfrs.,DeHaen 1940-1975 NMEs,AIDS vacuolar myelopathy; Skin irritation in incontinent adults and diaper rash in infants; Alkaline urine,Phase III; Not Provided; Approved
1351,532-03-6,https://drugs.ncats.io/drug/125OD7737X,US Approved Rx 2016,ANDA206128,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206128,US Previously Marketed 1957,ROBAXIN by AUXILIUM PHARMS LLC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011011,Muscle spasm,Approved
1352,151-83-7,https://drugs.ncats.io/drug/E5B8ND5IPE,US Approved Rx 1960,NDA011559,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011559,US Approved Rx 1960,NDA011559,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011559,Pain,Approved
1353,59-05-2,https://drugs.ncats.io/drug/YL5FZ2Y5U1,US Approved Rx 2020,ANDA210454,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210454,US Previously Marketed 1953,METHOTREXATE SODIUM by STRIDES PHARMA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=008085,Gestational choriocarcinoma; Breast cancer; Lung cancer; Rheumatoid arthritis,Approved; Approved; Approved; Approved
1354,390-28-3,https://drugs.ncats.io/drug/HUQ1KC1YLI,US Previously Marketed 1949,Vasoxyl by Burroughs Wellcome,DeHaen 1940-1975 NMEs,US Previously Marketed 1949,Vasoxyl by Burroughs Wellcome,DeHaen 1940-1975 NMEs,Fecal incontinence,Approved
1355,298-81-7,https://drugs.ncats.io/drug/U4VJ29L7BQ,US Approved Rx 1986,NDA019600,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019600,US Previously Marketed 1954,8-MOP by VALEANT PHARM INTL,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=009048,"Idiopathic vitiligo; Cutaneous T-cell lymphoma; Severe, recalcitrant, disabling psoriasis",Approved; Approved; Approved
1356,677324-53-7,https://drugs.ncats.io/drug/LR3UXN0193,US Approved Rx 2007,BLA125164,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125164,US Approved Rx 2007,BLA125164,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125164,,
1357,135-07-9,https://drugs.ncats.io/drug/L3H46UAC61,US Previously Marketed 1986,METHYCLOTHIAZIDE by PAR PHARM,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=089136,US Previously Marketed 1960,ENDURON by ABBVIE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012524,Hypertension,Approved
1358,134-20-3,https://drugs.ncats.io/drug/981I0C1E5W,Possibly Marketed Outside US 2024,M020,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51d5862a-8f2c-40c6-a749-5ad6f9420143,Possibly Marketed Outside US 2012,21 CFR 333A,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0dade250-cbaf-47f5-9c31-1b9aa0447cfe,,
1359,72013-76-4,https://drugs.ncats.io/drug/NJX1653L36,Possibly Marketed Outside US ,"Leshcutan by Bensonab, R.A.|Slobodyab, L.B.|Lillickab, L.|Maffiaab, A.|Sullivan, N.",https://www.sciencedirect.com/science/article/pii/S0022347649801983,,,,Bacterial infections; Leishmaniasis,Approved; Approved
1360,9004-67-5,https://drugs.ncats.io/drug/O0GN6F9B2Y,US Approved OTC ,21 CFR 349.12(a)(4) ophthalmic:demulcents methylcellulose,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec349-12.xml,Possibly Marketed Outside US 1978,ANDA084903,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=418a70aa-8480-4748-a1a8-af39f4962bf0,,
1361,555-30-6,https://drugs.ncats.io/drug/M4R0H12F6M,US Approved Rx 1985,ANDA070075,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=070075,US Previously Marketed 1962,ALDOMET by MERCK,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=013400,Type 1 diabetes in DQ8 positive patients with residual beta cell function; Hypertension; Preeclampsia; Hypertension,Approved; Approved; Phase IV; Approved
1362,6014-30-8,https://drugs.ncats.io/drug/2579Z4P04J,US Approved Rx 1985,ANDA070075,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=070075,US Previously Marketed 1962,ALDOMET by MERCK,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=013400,Type 1 diabetes in DQ8 positive patients with residual beta cell function; Hypertension; Preeclampsia; Hypertension,Approved; Approved; Phase IV; Approved
1363,61-73-4,https://drugs.ncats.io/drug/8NAP7826UB,US Approved Rx 2016,NDA204630,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204630,US Previously Marketed 1921,Methylthionine Chloride U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Cancer; Ifosfamide-induced encelophaty; Methemoglobinemia; Dermatologic infections; Septic shock; Alzheimer’s disease,Approved; Approved; Approved; Approved; Phase III; Phase II
1364,113-42-8,https://drugs.ncats.io/drug/W53L6FE61V,US Approved Rx 2021,ANDA211919,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211919,US Approved Rx 1946,NDA006035,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006035,Hemorrhage of the uterus following delivery of the placenta,Approved
1365,70114-87-3,https://drugs.ncats.io/drug/N3K9WO9CMA,,,,,,,,
1366,73232-52-7,https://drugs.ncats.io/drug/RFO6IL3D3M,US Approved Rx 2016,NDA208271,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208271,US Approved Rx 2008,NDA021964,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021964,Opioid-induced constipation,Approved
1367,99-76-3,https://drugs.ncats.io/drug/A2I8C7HI9T,US Previously Marketed ,21 CFR 310.545(a)(22)(ii) antifungal:diaper rash methylparaben,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-545.xml,Possibly Marketed Outside US 1974,E-Z-Paste by E-Z-EM Canada Inc,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=704132ea-4986-0b2c-2dd4-de89c0282a15,Unknown; Psychotic Disorders,Approved
1368,113-45-1,https://drugs.ncats.io/drug/207ZZ9QZ49,US Approved Rx 2018,ANDA210139,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210139,US Approved Rx 1955,NDA010187,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=010187,Attention deficit hyperactivity disorder; Narcolepsy,Approved; Approved
1369,115-38-8,https://drugs.ncats.io/drug/5NC67NU76B,US Previously Marketed 1961,MONOMEB TABLETS METHYLPHENOBARBITAL by WINTHROP,https://books.google.ru/books?id=szDnBwAAQBAJ&pg=PA73&lpg=PA73&dq=MONOMEB+WINTHROP&source=bl&ots=CvuwHrt5J7&sig=ehypR0G6oGIXd_61JjvD5ZLRJ0U&hl=ru&sa=X&ved=2ahUKEwi17a2517rfAhVGCywKHfM5CnIQ6AEwB3oECAkQAQ#v=onepage&q=MONOMEB%20WINTHROP&f=falsehttps://www.sciencedirect.com/science/article/pii/S0095956116336866 ,US Previously Marketed 1921,methylphenobarbital,https://catalog.hathitrust.org/Record/100163146,Anxiety; Epilepsy,Approved; Approved
1370,83-43-2,https://drugs.ncats.io/drug/X4W7ZR7023,US Approved Rx 2004,ANDA040612,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=040612,US Approved Rx 1957,NDA011153,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011153,Congenital adrenal hyperplasia; Rheumatoid arthritis; Contact dermatitis,Approved; Approved; Approved
1371,58-18-4,https://drugs.ncats.io/drug/V9EFU16ZIF,US Approved Rx 2015,ANDA204851,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204851,US Previously Marketed 1938,Oreton-M by Schering,https://archive.org/details/in.ernet.dli.2015.145864,Primary hypogonadism; Delayed puberty,Approved; Approved
1372,7060-82-4,https://drugs.ncats.io/drug/ZMZ79891ZH,US Approved Rx 2016,NDA204630,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204630,US Previously Marketed 1921,Methylthionine Chloride U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Cancer; Ifosfamide-induced encelophaty; Methemoglobinemia; Dermatologic infections; Septic shock; Alzheimer’s disease,Approved; Approved; Approved; Approved; Phase III; Phase II
1373,115-10-6,https://drugs.ncats.io/drug/AM13FS69BX,Possibly Marketed Outside US ,UK NHS:Methoxymethane,https://tripod.nih.gov/npc/#Download,Possibly Marketed Outside US 1993,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=07e93376-9bfa-44ca-acb8-258d6822b1c6,Warts,Approved
1374,361-37-5,https://drugs.ncats.io/drug/XZA9HY6Z98,US Previously Marketed 1962,SANSERT by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012516,US Previously Marketed 1962,SANSERT by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012516,Vascular headaches,Approved
1375,22664-55-7,https://drugs.ncats.io/drug/X39AL81KEB,US Previously Marketed 1989,OPTIPRANOLOL by BAUSCH AND LOMB,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019907,US Previously Marketed 1989,OPTIPRANOLOL by BAUSCH AND LOMB,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019907,Ocular hypertension; Open-angle glaucoma,Approved; Approved
1376,672-87-7,https://drugs.ncats.io/drug/DOQ0J0TPF7,US Approved Rx 1979,NDA017871,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017871,US Approved Rx 1979,NDA017871,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017871,Pheochromocytoma,Approved
1377,364-62-5,https://drugs.ncats.io/drug/L4YEB44I46,US Approved Rx 2020,NDA209388,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209388,US Previously Marketed 1979,REGLAN by HIKMA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017862,Gastroesophageal reflux disease; Diabetic gastroparesis,Approved; Approved
1378,17560-51-9,https://drugs.ncats.io/drug/TZ7V40X7VX,US Approved Rx 2021,ANDA213827,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213827,US Previously Marketed 1973,ZAROXOLYN by I3 PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017386,Congestive heart failure; Hypertension,Approved; Approved
1379,51384-51-1,https://drugs.ncats.io/drug/GEB06NHM23,US Approved Rx 2007,ANDA077739,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077739,US Approved Rx 1978,NDA017963,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017963,Myocardial infarction; Angina pectoris; Hypertension,Approved; Approved; Approved
1380,186018-45-1,https://drugs.ncats.io/drug/TL60C27RLH,US Approved Rx 2014,BLA125390,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125390,US Approved Rx 2014,BLA125390,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125390,,
1381,443-48-1,https://drugs.ncats.io/drug/140QMO216E,US Approved Rx 2016,ANDA208162,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208162,US Previously Marketed 1963,FLAGYL by PFIZER,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012623,Anaerobic bacterial infections; Trichomoniasis; Acute intestinal amebiasis,Approved; Approved; Approved
1382,54-36-4,https://drugs.ncats.io/drug/ZS9KD92H6V,US Approved Rx 1961,NDA012911,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012911,US Approved Rx 1961,NDA012911,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012911,Secondary adrenocortical insufficiency,Approved
1383,31828-71-4,https://drugs.ncats.io/drug/1U511HHV4Z,US Approved Rx 1996,ANDA074450,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=074450,US Previously Marketed 1985,MEXITIL by BOEHRINGER INGELHEIM,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018873,Muscle cramps in amyotrophic lateral sclerosis; Life-threatening arrhythmias; Chronic pain from amputation,Approved; Approved; Phase II
1384,51481-65-3,https://drugs.ncats.io/drug/OH2O403D1G,US Previously Marketed 1987,MEZLIN by BAYER PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=062697,US Previously Marketed 1981,MEZLIN by BAYER PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050549,Bacterial infections,Approved
1385,116644-53-2,https://drugs.ncats.io/drug/27B90X776A,US Previously Marketed 1997,Posicor,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=20689,US Previously Marketed 1997,Posicor,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=20689,"Stable angina, chronic; Glioblastoma multiforme; Hypertension",Withdrawn; Phase I; Withdrawn
1386,235114-32-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1387,22916-47-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1388,59467-70-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1389,42794-76-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1390,120685-11-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1391,84371-65-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1392,72432-03-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1393,72599-27-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1394,64-17-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1395,96847-55-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1396,78415-72-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1397,58066-85-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1398,10118-90-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1399,38304-91-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1400,223673-61-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1401,85650-52-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1402,59122-46-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1403,50-07-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1404,53-19-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1405,65271-80-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1406,106861-44-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1407,68693-11-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1408,103775-10-6,https://drugs.ncats.io/drug/WT87C52TJZ,US Approved Rx 2010,ANDA090416,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=090416,US Previously Marketed 1995,UNIVASC by UCB INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020312,Hypertension; Hypertension,Natural Metabolite; Approved
1409,1159266-37-1,https://drugs.ncats.io/drug/YI437801BE,US Approved Rx 2018,BLA761051,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761051,US Approved Rx 2018,BLA761051,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761051,,
1410,7416-34-4,https://drugs.ncats.io/drug/RT3Y3QMF8N,US Approved Rx 2015,ANDA090453,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=090453,US Previously Marketed 1974,MOBAN by CHARTWELL RX,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017111,Schizophrenia,Approved
1411,7439-98-7,https://drugs.ncats.io/drug/81AH48963U,Possibly Marketed Outside US ,Pro Hers Vanilla by CROWN GENERAL AGENCY INC,https://www.drugbank.ca/drugs/DB11137,Possibly Marketed Outside US 1996,"Strovite Forte Caplet by Everett Laboratories, Inc.",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=add96910-9404-48aa-bb3c-945e321a11ab,,
1412,105102-22-5,https://drugs.ncats.io/drug/8HR4QJ6DW8,US Approved Rx 2017,ANDA207989,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207989,US Previously Marketed 1987,ELOCON by ORGANON,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019543,Dermatoses; Asthma,Approved; Approved
1413,103-16-2,https://drugs.ncats.io/drug/9L2KA76MG5,US Previously Marketed 1952,BENOQUIN by VALEANT PHARM INTL,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=008173,US Previously Marketed 1952,BENOQUIN by VALEANT PHARM INTL,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=008173,Depigmentation; Melanoma,Approved; Preclinical
1414,79-11-8,https://drugs.ncats.io/drug/5GD84Y125G,Possibly Marketed Outside US 2012,21 CFR 333A,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=861ae219-9a28-78a0-e053-2991aa0ad056,Possibly Marketed Outside US 2012,21 CFR 333A,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=861ae219-9a28-78a0-e053-2991aa0ad056,,
1415,2272-11-9,https://drugs.ncats.io/drug/U4RY8MRX7C,US Approved Rx 1988,NDA019357,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019357,US Approved Rx 1988,NDA019357,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019357,Idiopathic achalasia; Esophageal varices,Not Provided; Approved
1416,13537-32-1,https://drugs.ncats.io/drug/IW87A7KU3R,US Approved OTC ,21 CFR 355.10(b)(1) anticaries:dentifrices sodium monolfuorophosphate (gel or paste),https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec355-10.xml,US Previously Marketed 1953,NDK Fluoride Dentrifice by NOK,OB NME Appendix 1950-1993,Anticavity,Approved
1417,158966-92-8,https://drugs.ncats.io/drug/MHM278SD3E,US Approved Rx 2015,ANDA204290,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204290,US Approved Rx 1998,NDA020830,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020830,Asthma; Exercise-induced bronchoconstriction; Seasonal allergic rhinitis; Perennial allergic rhinitis,Approved; Approved; Approved; Approved
1418,31883-05-3,https://drugs.ncats.io/drug/2GT1D0TMX1,US Previously Marketed 1990,ETHMOZINE by SHIRE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019753,US Previously Marketed 1990,ETHMOZINE by SHIRE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019753,Ventricular arrhythmia,Approved
1419,284036-24-4,https://drugs.ncats.io/drug/113E3Z3CJJ,Possibly Marketed Outside US ,EU/1/99/103/008,https://www.drugbank.ca/drugs/DB13999,Possibly Marketed Outside US 2008,BLA125264,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=52e97c7f-8240-4cd6-afd2-c452ab2f6e32,,
1420,57-27-2,https://drugs.ncats.io/drug/76I7G6D29C,US Approved Rx 2011,ANDA202348,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202348,US Previously Marketed 1827,morphine,https://catalog.hathitrust.org/Record/100782317,Pain severe,Approved
1421,1020748-57-5,https://drugs.ncats.io/drug/2NDX4B6N8F,US Approved Rx 2018,BLA761104,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761104,US Approved Rx 2018,BLA761104,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761104,,
1422,151096-09-2,https://drugs.ncats.io/drug/U188XYD42P,US Approved Rx 2017,ANDA208682,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208682,US Previously Marketed 1999,AVELOX by BAYER HLTHCARE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021085,Plague; Community acquired pneumonia; Acute bacterial sinusitis,Approved; Approved; Approved
1423,12650-69-0,https://drugs.ncats.io/drug/D0GX863OA5,US Approved Rx 2022,ANDA214811,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214811,US Previously Marketed 1987,BACTROBAN by GLAXOSMITHKLINE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050591,Secondarily infected traumatic skin lesions,Approved
1424,128794-94-5,https://drugs.ncats.io/drug/9242ECW6R0,US Approved Rx 2009,ANDA065520,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=065520,US Approved Rx 1995,NDA050722,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050722,Organ transplant rejection,Approved
1425,24280-93-1,https://drugs.ncats.io/drug/HU9DX48N0T,US Approved Rx 2009,ANDA065520,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=065520,US Approved Rx 1995,NDA050722,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050722,Organ transplant rejection,Approved
1426,529-44-2,https://drugs.ncats.io/drug/76XC01FTOJ,Possibly Marketed Outside US 2013,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1990f21-e9c9-4600-ac11-db0f7d4237fd,Possibly Marketed Outside US 2013,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1990f21-e9c9-4600-ac11-db0f7d4237fd,Cancer; Diabetes mellitus,Basic research; Basic research
1427,7512-17-6,https://drugs.ncats.io/drug/V956696549,US Previously Marketed 2019,N-acetyl-D-glucosamine,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23,Possibly Marketed Outside US 2005,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=af05f2b7-bd7f-42a0-8042-92a0e07f0c36,Inflammatory bowel disease; Multiple sclerosis; Osteoarthritis,Not Provided; Preclinical; Preclinical
1428,2901-77-1,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
1429,97-78-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1430,525-79-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1431,51022-71-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1432,42924-53-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1433,53-84-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1434,220045-89-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1435,76932-56-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1436,147-52-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1437,65472-88-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1438,20594-83-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1439,916072-89-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1440,389-08-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1441,55096-26-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1442,854601-70-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1443,465-65-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1444,16590-41-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1445,434-22-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1446,835-31-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1447,22204-53-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1448,121679-13-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1449,50-02-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1450,189261-10-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1451,7681-93-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1452,105816-04-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1453,99200-09-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1454,906805-06-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1455,69049-73-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1456,83366-66-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1457,121032-29-9,https://drugs.ncats.io/drug/60158CV180,US Approved Rx 2022,ANDA216934,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216934,US Approved Rx 2005,NDA021877,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021877,T-cell acute lymphoblastic leukemia,Approved
1458,159989-64-7,https://drugs.ncats.io/drug/HO3OGH5D7I,US Approved Rx 2003,NDA021503,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021503,US Previously Marketed 1997,VIRACEPT by AGOURON PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020778,HIV infection,Approved
1459,1404-04-2,https://drugs.ncats.io/drug/I16QD7X297,US Approved OTC ,21 CFR 333.110(d) first aid antibiotic:ointment neomycin sulfate,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec333-110.xml,US Previously Marketed 1951,Mycifradin by Upjohn,DeHaen 1940-1975 NMEs,Bacterial Infection; Hepatic coma,Approved; Approved
1460,59-99-4,https://drugs.ncats.io/drug/3982TWQ96G,US Approved Rx 2019,ANDA212512,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212512,US Previously Marketed 1931,PROSTIGMIN by Valeant,https://trademarks.justia.com/713/22/prostigmin-71322016.html,Myasthenia gravis,Approved
1461,78281-72-8,https://drugs.ncats.io/drug/0J9L7J6V8C,US Approved Rx 2005,NDA021862,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021862,US Approved Rx 2005,NDA021862,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021862,Cataract; Pain,Approved; Approved
1462,698387-09-6,https://drugs.ncats.io/drug/JJH94R3PWB,US Approved Rx 2017,NDA208051,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208051,US Approved Rx 2017,NDA208051,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208051,Breast cancer; Colorectal cancer; Non-small cell lung cancer; HER2-overexpressed/amplified breast cancer,Phase III; Phase II; Phase II; Approved
1463,124584-08-3,https://drugs.ncats.io/drug/P7WI8UL647,US Previously Marketed 2001,NATRECOR by SCIOS LLC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020920,Possibly Marketed Outside US 2001,NDA020920,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44c45bfe-461f-4398-8f20-ea771b2403ee,acutely decompensated heart failure,Approved
1464,1254032-66-0,https://drugs.ncats.io/drug/W6I5QDT7QI,US Approved Rx 2019,NDA208259,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208259,US Approved Rx 2017,NDA208254,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208254,Ocular hypertension; Open-angle glaucoma,Approved; Approved
1465,290297-26-6,https://drugs.ncats.io/drug/7732P08TIR,US Approved Rx 2018,NDA210493,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210493,US Approved Rx 2014,NDA205718,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205718,Nausea and vomiting; Acute and delayed nausea and vomiting,Approved; Approved
1466,129618-40-2,https://drugs.ncats.io/drug/99DK7FVK1H,US Approved Rx 2012,ANDA078584,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=078584,US Previously Marketed 1996,VIRAMUNE by BOEHRINGER INGELHEIM,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020636,HIV-1 infection,Approved
1467,55985-32-5,https://drugs.ncats.io/drug/CZ5312222S,US Approved Rx 2023,ANDA216420,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216420,US Previously Marketed 1988,CARDENE by CHIESI,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019488,Hypertension; Chronic stable angina,Approved; Approved
1468,7440-02-0,https://drugs.ncats.io/drug/7OV03QG267,Possibly Marketed Outside US ,Canada:NICKEL CHLORIDE,https://tripod.nih.gov/npc/#Download,,,,,
1469,98-92-0,https://drugs.ncats.io/drug/25X51I8RD4,US Approved Rx 2001,NDA021265,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021265,US Previously Marketed 1947,BEROCCA PN by ROCHE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006071,Pellagra; Arteriosclerotic syndromes; Ophthalmology,Approved; Not Provided; Not Provided
1470,54-11-5,https://drugs.ncats.io/drug/6M3C89ZY6R,US Approved Rx 2008,ANDA078697,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=078697,US Approved Rx 1984,NDA018612,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018612,Nicotine dependence,Approved
1471,59-67-6,https://drugs.ncats.io/drug/2679MF687A,US Approved Rx 2014,ANDA090892,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=090892,US Previously Marketed 1937,"Niacin by Merck & Co, Inc.",https://archive.org/details/in.ernet.dli.2015.145864,Hyperlipidemia; Atherosclerotic disease; Myocardial infarction,Approved; Approved; Approved
1472,21829-25-4,https://drugs.ncats.io/drug/I9ZF7L6G2L,US Approved Rx 1989,NDA019684,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019684,US Approved Rx 1981,NDA018482,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018482,Chronic stable angina; Vasospastic angina,Approved; Approved
1473,641571-10-0,https://drugs.ncats.io/drug/F41401512X,US Approved Rx 2007,NDA022068,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=22068,US Approved Rx 2007,NDA022068,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=22068,Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML),Approved
1474,63612-50-0,https://drugs.ncats.io/drug/51G6I8B902,US Approved Rx 2016,ANDA207631,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207631,US Approved Rx 1996,NDA020169,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020169,Metastatic prostate cancer,Approved
1475,66085-59-4,https://drugs.ncats.io/drug/57WA9QZ5WH,US Approved Rx 2013,NDA203340,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203340,US Previously Marketed 1988,NIMOTOP by BAYER PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018869,Subarachnoid hemorrhage; Subarachnoid hemorrhage; Subarachnoid hemorrhage,Approved; Approved; Approved
1476,656247-17-5,https://drugs.ncats.io/drug/G6HRD2P839,US Approved Rx 2014,NDA205832,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205832,US Approved Rx 2014,NDA205832,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205832,Idiopathic pulmonary fibrosis,Approved
1477,1038915-60-4,https://drugs.ncats.io/drug/HMC2H89N35,Possibly Marketed Outside US ,Zejula by Glaxosmithkline Inc [Canada],https://www.drugbank.ca/drugs/DB11793,Possibly Marketed Outside US 2017,NDA208447,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c15c7b7e-4b7f-4489-bbbc-884caeee0669,Fallopian tube cancer; Ovarian cancer; Breast cancer; Peritoneal cancer; epithelial ovarian cancer,Phase III; Phase III; Phase III; Phase III; Approved
1478,63675-72-9,https://drugs.ncats.io/drug/4I8HAB65SZ,US Approved Rx 2011,ANDA091001,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=091001,US Approved Rx 1995,NDA020356,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020356,Hypertension,Approved
1479,55981-09-4,https://drugs.ncats.io/drug/SOA12P041N,US Approved Rx 2002,NDA021498,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021498,US Approved Rx 2002,NDA021498,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021498,Diarrhea caused by Giardia lamblia or Cryptosporidium parvum; Rotavirus gastroenteritis; Tuberculosis; Trichomoniasis; Hepatitis B,Approved; Basic research; Basic research; Basic research; Basic research
1480,7697-37-2,https://drugs.ncats.io/drug/411VRN1TV4,US Previously Marketed 1961,VERA-TENSIL R-S POTASSIUM NITRATE by RICHLYN,https://cdn.loc.gov/service/ll/fedreg/fr037/fr037248/fr037248.pdf,US Previously Marketed 1921,Nitric Acid U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Dental Caries,Not Provided
1481,59-87-0,https://drugs.ncats.io/drug/X8XI70B5Z6,US Previously Marketed 1982,ACTIN-N by SHERWOOD MEDCL,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017343,US Previously Marketed 1945,FURACIN by SHIRE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=005795,Infected burns; Skin infections due to skin grafts,Approved; Approved
1482,67-20-9,https://drugs.ncats.io/drug/87367ebd,,,,,,,,
1483,55-63-0,https://drugs.ncats.io/drug/G59M7S0WS3,,,,,,,Angina pectoris; Coronary heart disease; Pulmonary hypertension; Angina pectoris; Hypertensive crises; Heart failure; Angina pectoris; Hypertension; Angina; Heart failure; Myocardial infarction; Angina pectoris; Angina pectoris,Approved; Basic research; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved
1484,15078-28-1,https://drugs.ncats.io/drug/169D1260KM,US Approved Rx 2018,ANDA207141,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207141,US Previously Marketed 1921,Spirit of Glyceryl Trinitrate U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,,
1485,7782-77-6,https://drugs.ncats.io/drug/T2I5UM75DN,US Approved Rx 2012,NDA203922,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203922,US Previously Marketed 1921,Sodium Nitrite U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Cyanide poisoning,Approved
1486,10024-97-2,https://drugs.ncats.io/drug/K50XQU1029,US Approved Rx 2013,NDA206014,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206014,US Previously Marketed 1844,nitrous oxide,https://catalog.hathitrust.org/Record/100782317,Pain,Approved
1487,946414-94-4,https://drugs.ncats.io/drug/31YO63LBSN,US Approved Rx 2015,BLA125527,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125527,US Approved Rx 2014,BLA125554,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554,,
1488,76963-41-2,https://drugs.ncats.io/drug/P41PML4GHR,US Approved Rx 2002,ANDA076178,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=076178,US Previously Marketed 1988,AXID by SMITHKLINE BEECHAM,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019508,Gastroesophageal reflux disease; Gastric ulcer; Duodenal ulcer,Approved; Approved; Approved
1489,1175512-71-6,https://drugs.ncats.io/drug/27Y83O992Q,Possibly Marketed Outside US ,Rebinyn by Novo Nordisk [Canada],https://www.drugbank.ca/drugs/DB13933,,,,,
1490,9016-45-9,https://drugs.ncats.io/drug/283U2KY9DD,,,,,,,,
1491,1314-13-2,https://drugs.ncats.io/drug/SOI2LOH54Z,US Approved OTC ,21 CFR 347.10(t) skin protectant zinc carbonate,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec347-10.xml,US Previously Marketed 1921,Precipitated Zinc Carbonate U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Caries; Ulcerative colitis; Breast cancer; Acute myeloid leukemia; Unknown; Unknown; Poison Ivy dermatitis; Diaper dermatitis; Dysgeusia; Mucositis; Gastrointestinal disorders; Renal insufficiency; Unknown; Unknown; Zinc deficiency,Basic research; Approved; Basic research; Basic research; Approved; Approved; Phase III; Phase III; Approved; Approved; Preclinical
1492,1477-39-0,https://drugs.ncats.io/drug/KU5U13XY7J,Clinical ,INN:noracymethadol,https://tripod.nih.gov/npc/#Download,,,,,
1493,53016-31-2,https://drugs.ncats.io/drug/R0TAY3X631,US Approved Rx 2014,ANDA200910,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200910,US Previously Marketed 2001,ORTHO EVRA by JANSSEN PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021180,Pregnancy; Pregnancy,Approved; Approved
1494,51-41-2,https://drugs.ncats.io/drug/X4W3ENH1CV,US Approved Rx 2018,ANDA210839,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210839,US Approved Rx 1950,NDA007513,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=007513,Hypotension; Cardiac arrest; Systemic inflammatory response syndrome; Neurogenic orthostatic hypotension,Approved; Approved; Phase IV; Approved
1495,68-22-4,https://drugs.ncats.io/drug/T18F433X4S,US Approved Rx 2014,ANDA202996,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202996,US Previously Marketed 1957,Norlutin by Parke-Davis,OB NME Appendix 1950-1985,Endometriosis; Abnormal uterine bleeding; Pregnancy; Secondary amenorrhea,Approved; Approved; Approved; Approved
1496,70458-96-7,https://drugs.ncats.io/drug/N0F8P22L1P,US Previously Marketed 1991,CHIBROXIN by MERCK,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019757,US Previously Marketed 1986,NOROXIN by MERCK,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019384,Urinary tract infections; Conjunctivitis; Prostatitis; Gonorrhea,Approved; Approved; Approved; Approved
1497,811-97-2,https://drugs.ncats.io/drug/DH9E53K1Y8,Possibly Marketed Outside US 2020,21 CFR 333D,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adc4ed21-dfa8-4dad-8e03-e5f07fca03bc,Possibly Marketed Outside US 1981,NDA021457,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=133fb50a-68d3-4d1b-a47a-67d07cc48da5,,
1498,13563-60-5,https://drugs.ncats.io/drug/YFS274763Y,Clinical ,INN:norgesterone,https://tripod.nih.gov/npc/#Download,,,,,
1499,107382-52-5,https://drugs.ncats.io/drug/NKX8DN6TY9,,,,,,,,
1500,797-63-7,https://drugs.ncats.io/drug/5W7SIA7YZW,US Approved Rx 2015,ANDA201088,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201088,US Previously Marketed 1968,OVRAL-28 by WYETH PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016806,Heavy menstrual bleeding; Fertilization; Pregnancy; Pregnancy,Approved; Approved; Approved; Approved
1501,72-69-5,https://drugs.ncats.io/drug/BL03SY4LXB,US Approved Rx 1977,NDA018013,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018013,US Previously Marketed 1964,AVENTYL by RANBAXY,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=014685,Depression; Plaque psoriasis; Gastroesophageal reflux disease,Approved; Phase II; Phase III
1502,303-81-1,https://drugs.ncats.io/drug/17EC19951N,US Previously Marketed 1956,Sodium Albamycin by Upjohn,DeHaen 1940-1975 NMEs,US Previously Marketed 1956,Sodium Albamycin by Upjohn,DeHaen 1940-1975 NMEs,Breast cancer; Psoriasis; Non-small cell lung cancer; Bovine subclinical mastitis caused by Staphylococcus aureus and Streptococcus agalactiae; Staphylococcal Infections,Phase I; Not Provided; Phase II; Approved; Approved
1503,1258984-36-9,https://drugs.ncats.io/drug/5Z9SP3X666,US Approved Rx 2016,NDA209531,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209531,US Approved Rx 2016,NDA209531,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209531,,
1504,1400-61-9,https://drugs.ncats.io/drug/BDF1O1C72E,US Approved Rx 1988,ANDA062838,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=062838,US Previously Marketed 1954,Mycostatin by Squibb,DeHaen 1940-1975 NMEs,,
1505,643-79-8,https://drugs.ncats.io/drug/4P8QP9768A,Possibly Marketed Outside US ,Canada:ORTHO-PHTHALALDEHYDE,https://tripod.nih.gov/npc/#Download,Possibly Marketed Outside US 2022,Safe OPA by Valley Inc.,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89393417-c8a3-46bf-ad89-db7b8c360c85,Metabolic disease; Kidney disease,Approved; Approved
1506,459789-99-2,https://drugs.ncats.io/drug/0462Z4S4OZ,US Approved Rx 2016,NDA207999,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207999,US Approved Rx 2016,NDA207999,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207999,Primary biliary cholangitis,Approved
1507,949142-50-1,https://drugs.ncats.io/drug/O43472U9X8,US Approved Rx 2013,BLA125486,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125486,US Approved Rx 2013,BLA125486,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125486,,
1508,637334-45-3,https://drugs.ncats.io/drug/A10SJL62JY,US Approved Rx 2017,BLA761053,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761053,US Approved Rx 2017,BLA761053,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761053,,
1509,1048016-09-6,https://drugs.ncats.io/drug/7V6HE3DM5A,US Approved Rx 2012,BLA125422,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125422,US Approved Rx 2012,BLA125422,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125422,,
1510,557-61-9,https://drugs.ncats.io/drug/81I2215OVK,Possibly Marketed Outside US ,"Ginsamin Power by Biogrand Co., Ltd",https://www.drugbank.ca/drugs/DB11220,Possibly Marketed Outside US 2010,"Ginsamin Power by Biogrand Co., Ltd",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=79fdfc31-a9fb-4b79-95d9-a792f982bd14,Myocardial ischemia; Atherosclerosis; Parkinsonism,Basic research; Basic research; Basic research
1511,124-07-2,https://drugs.ncats.io/drug/OBL58JN025,US Previously Marketed 1945,Sodium Caprylate by Pennwalt,DeHaen 1940-1975 NMEs,Possibly Marketed Outside US 1942,BLA101138,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=face90dc-a227-3ec2-1645-f74eb9dac68c,Essential tremor,Phase II
1512,5466-77-3,https://drugs.ncats.io/drug/4Y5P7MUD51,US Previously Marketed 1992,SHADE UVAGUARD by BAYER HEALTHCARE LLC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020045,Possibly Marketed Outside US 1984,"NU-DERM SUNFADER  Skin Lightener with Sunscreen (SPF 15) PABA FREE by OMP, INC.",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f439d77f-ec5b-4534-a005-08f2e7af8d0c,Sunburns,Approved
1513,17493-86-6,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
1514,6197-30-4,https://drugs.ncats.io/drug/5A68WGF6WM,US Approved Rx 2006,NDA021501,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021501,Possibly Marketed Outside US 2004,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b67a454-26ba-4049-854c-9335668236cd,Sunburns,Approved
1515,2315-67-5,https://drugs.ncats.io/drug/20CAX7IO75,Possibly Marketed Outside US ,Canada:POLYETHYLENE GLYCOL P-ISOOCTYLPHENYL ETHER,https://tripod.nih.gov/npc/#Download,Possibly Marketed Outside US 2011,21 CFR 333D,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=48782ccf-c030-4478-b9b4-f6868845febd,Unknown,
1516,2315-67-5,https://drugs.ncats.io/drug/20CAX7IO75,Possibly Marketed Outside US ,Canada:POLYETHYLENE GLYCOL P-ISOOCTYLPHENYL ETHER,https://tripod.nih.gov/npc/#Download,Possibly Marketed Outside US 2011,21 CFR 333D,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=48782ccf-c030-4478-b9b4-f6868845febd,Unknown,
1517,83150-76-9,https://drugs.ncats.io/drug/RWM8CCW8GP,US Approved Rx 2005,ANDA075959,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=075959,US Approved Rx 1988,NDA019667,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019667,Vasoactive intestinal peptide tumors (VIPomas); Acromegaly; Carcinoid tumors,Approved; Approved; Approved
1518,6969-49-9,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
1519,679818-59-8,https://drugs.ncats.io/drug/M95KG522R0,US Approved Rx 2009,BLA125326,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125326,US Approved Rx 2009,BLA125326,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125326,,
1520,82419-36-1,https://drugs.ncats.io/drug/A4P49JAZ9H,US Approved Rx 2022,ANDA216130,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216130,US Previously Marketed 1990,FLOXIN by JANSSEN PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019735,Otitis due to bacterial infections; Bacterial conjunctivitis; Bacterial infections; Corneal ulcer due to bacterial infections,Approved; Approved; Approved; Approved
1521,1461-15-0,https://drugs.ncats.io/drug/V0YM2B16TS,Discontinued ,SoftGlo by Hub Pharmaceuticals,https://www.drugbank.ca/drugs/DB11184,,,,Multidrug resistance,Not Provided
1522,132539-06-1,https://drugs.ncats.io/drug/N7U69T4SZR,US Approved Rx 2012,ANDA202050,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202050,US Approved Rx 1996,NDA020592,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020592,Bipolar I disorder; Schizophrenia,Approved; Approved
1523,763113-22-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1524,1024603-93-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1525,112-80-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1526,143-28-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1527,144689-63-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1528,868049-49-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1529,113806-05-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1530,15722-48-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1531,26833-87-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1532,389139-89-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1533,242138-07-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1534,1258226-87-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1535,84494-70-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1536,73590-58-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1537,99614-02-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1538,8008-60-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1539,137598-97-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1540,586-06-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1541,171099-57-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1542,96829-58-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1543,16773-42-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1544,83-98-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1545,196618-13-0,https://drugs.ncats.io/drug/20O93L6F9H,US Approved Rx 2021,ANDA215208,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215208,US Approved Rx 1999,NDA021087,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021087,Influenza virus infections,Approved
1546,1421373-65-0,https://drugs.ncats.io/drug/3C06JJ0Z2O,US Approved Rx 2015,NDA208065,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208065,US Approved Rx 2015,NDA208065,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208065,Metastatic EGFR T790M mutation positive non-small cell lung cancer,Approved
1547,128607-22-7,https://drugs.ncats.io/drug/B0P231ILBK,US Approved Rx 2024,ANDA215574,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215574,US Approved Rx 2013,NDA203505,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203505,Dyspareunia,Approved
1548,7664-41-7,https://drugs.ncats.io/drug/5138Q19F1X,US Approved Rx 1984,ANDA088366,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=088366,US Previously Marketed 1921,Ammonium Chloride U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Metabolic alkalosis,Approved
1549,50-70-4,https://drugs.ncats.io/drug/506T60A25R,US Approved Rx 2020,NDA202049,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202049,Possibly Marketed Outside US 1955,Levsin by Alaven Pharmaceutical LLC,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32388e18-08de-455c-aad4-9c2264435f0f,Constipation; End-Stage Renal Disease; Cystic fibrosis; Asthma; Acute renal failure; Elevated intraocular pressure; Cerebral edema,Basic research; Approved; Approved; Approved; Approved; Approved; Approved
1550,64-17-5,https://drugs.ncats.io/drug/bfe60581,,,,,,,,
1551,50-37-3,https://drugs.ncats.io/drug/8NA5SWF92O,Clinical ,INN:lysergide,https://tripod.nih.gov/npc/#Download,,,,Anxiety,Phase II
1552,23593-75-1,https://drugs.ncats.io/drug/G07GZ97H65,US Approved OTC ,21 CFR 333.210(g) antifungal clotrimazole,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec333-210.xml,US Previously Marketed 1975,LOTRIMIN by SCHERING PLOUGH,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017619,Tinea corporis; Vaginal yeast infections; Tinea cruris; Tinea pedis,Approved; Approved; Approved; Approved
1553,7722-84-1,https://drugs.ncats.io/drug/BBX060AN9V,US Approved OTC ,21 CFR 344.1 otic:earwax removal aid carbamide peroxide 6.5% (in anhydrous glycerin),https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec344-10.xml,US Previously Marketed 1921,Hydrogen Peroxide ,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Gingivitis; Skin infections; Seborrheic keratoses,Approved; Approved; Approved
1554,50-70-4,https://drugs.ncats.io/drug/506T60A25R,US Approved Rx 2020,NDA202049,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202049,Possibly Marketed Outside US 1955,Levsin by Alaven Pharmaceutical LLC,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32388e18-08de-455c-aad4-9c2264435f0f,Constipation; End-Stage Renal Disease; Cystic fibrosis; Asthma; Acute renal failure; Elevated intraocular pressure; Cerebral edema,Basic research; Approved; Approved; Approved; Approved; Approved; Approved
1555,630-60-4,https://drugs.ncats.io/drug/5ACL011P69,Possibly Marketed Outside US ,WHO-ATC:C01AC01,https://ginas.ncats.nih.gov/ginas/app/substance/5ACL011P69,,,,Atrial fibrillation; Atrial flutter; Cardiac arrhythmia; Unknown,Approved; Approved; Approved
1556,9006-59-1,https://drugs.ncats.io/drug/B05Y6V2CZS,Possibly Marketed Outside US 2013,NCT01981083: Phase 4 Interventional Unknown status Protein-Energy Malnutrition,https://clinicaltrials.gov/ct2/show/NCT01981083,,,,,
1557,15690-55-8,https://drugs.ncats.io/drug/3JU1DU3652,US Approved Rx 1999,ANDA075528,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=075528,US Previously Marketed 1967,CLOMID by SANOFI AVENTIS US,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016131,Ovulatory dysfunction,Approved
1558,66-79-5,https://drugs.ncats.io/drug/UH95VD7V76,US Approved Rx 2017,ANDA207147,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207147,US Previously Marketed 1962,PROSTAPHLIN by APOTHECON,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050118,Infections caused by penicillinase-producing staphylococci,Approved
1559,144-62-7,https://drugs.ncats.io/drug/9E7R5L6H31,US Previously Marketed 1922,Oxalic acid,https://books.google.com/books?id=slZKAAAAMAAJ&newbks=1&newbks_redir=0&dq=%22oxalic%20acid%22%20therapeutic&pg=PA804#v=onepage&q=%22oxalic%20acid%22%20therapeutic&f=false,US Previously Marketed 1922,Oxalic acid,https://books.google.com/books?id=slZKAAAAMAAJ&newbks=1&newbks_redir=0&dq=%22oxalic%20acid%22%20therapeutic&pg=PA804#v=onepage&q=%22oxalic%20acid%22%20therapeutic&f=false,,
1560,61825-94-3,https://drugs.ncats.io/drug/04ZR38536J,US Approved Rx 2017,ANDA205529,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205529,US Previously Marketed 2002,ELOXATIN by SANOFI AVENTIS US,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021492,Carcinoma of the colon or rectum; Colon cancer,Approved; Approved
1561,53-39-4,https://drugs.ncats.io/drug/7H6TM3CT4L,US Previously Marketed 2007,OXANDROLONE by UPSHER SMITH LABS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=078033,US Previously Marketed 1964,Anavar by Searle,OB NME Appendix 1950-1985,Protein catabolism; Osteoporosis,Approved; Approved
1562,21256-18-8,https://drugs.ncats.io/drug/MHJ80W9LRB,US Approved Rx 2001,ANDA075855,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=075855,US Approved Rx 1992,NDA018841,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018841,Rheumatoid arthritis; Osteoarthritis; Juvenile rheumatoid arthritis,Approved; Approved; Approved
1563,604-75-1,https://drugs.ncats.io/drug/6GOW6DWN2A,US Approved Rx 1988,ANDA071814,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=071814,US Previously Marketed 1965,SERAX by ALPHARMA US PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=015539,Acohol withdrawal; Anxiety,Approved; Approved
1564,28721-07-5,https://drugs.ncats.io/drug/VZI5B1W380,US Approved Rx 2000,NDA021014,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021014,US Approved Rx 2000,NDA021014,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021014,Bipolar disorder; Partial seizures,Phase III; Approved
1565,94-07-5,https://drugs.ncats.io/drug/PEG5DP7434,US Previously Marketed 1931,Sympatol,https://en.wikipedia.org/wiki/Synephrine,US Previously Marketed 1931,Sympatol,https://en.wikipedia.org/wiki/Synephrine,Obesity,Approved
1566,64211-45-6,https://drugs.ncats.io/drug/C668Q9I33J,US Approved Rx 2016,ANDA205076,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205076,US Approved Rx 1988,NDA019828,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019828,Tinea corporis; Tinea cruris; Tinea pedis; Tinea (pityriasis) versicolor,Approved; Approved; Approved; Approved
1567,9032-53-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1568,27025-41-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1569,4350-09-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1570,131-57-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1571,99-43-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1572,5633-20-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1573,8031-14-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1574,76-42-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1575,1491-59-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1576,434-07-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1577,76-41-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1578,79-57-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1579,50-56-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1580,150-13-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1581,100-09-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1582,99-96-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1583,18979-53-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1584,98-67-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1585,33069-62-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1586,21245-02-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1587,571190-30-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1588,162394-19-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1589,144598-75-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1590,199739-10-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1591,188039-54-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1592,223751-74-4,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
1593,57-10-3,https://drugs.ncats.io/drug/2V16EO95H1,Possibly Marketed Outside US ,"Sha-lem by Shalem Products, Inc.",https://www.drugbank.ca/drugs/DB03796,Possibly Marketed Outside US 1990,21 CFR 358A,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6eef6b11-20c2-4665-a5dd-cce4e790102e,Respiratory distress syndrome in premature infants,Approved
1594,135729-61-2,https://drugs.ncats.io/drug/5D06587D6R,US Approved Rx 2018,ANDA205648,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205648,US Previously Marketed 2003,ALOXI by HELSINN HLTHCARE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021372,Postoperative nausea and vomiting; Chemotherapy induced nausea and vomiting,Approved; Approved
1595,606-04-2,https://drugs.ncats.io/drug/UA8U0KJM72,US Previously Marketed 1961,NEO BROMTH PAMABROM by BRAYTEN,https://cdn.loc.gov/service/ll/fedreg/fr037/fr037132/fr037132.pdf,US Previously Marketed 1952,Pamabrom by Brayten,DeHaen 1940-1975 NMEs,Menstrual relief,Not Provided
1596,40391-99-9,https://drugs.ncats.io/drug/OYY3447OMC,US Approved Rx 2002,ANDA075841,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=075841,US Previously Marketed 1991,AREDIA by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020036,Osteolytic bone metastases of breast cancer; Paget's disease; Malignant hypercalcemia,Approved; Approved; Approved
1597,41753-43-9,https://drugs.ncats.io/drug/7413S0WMH6,Possibly Marketed Outside US ,Unknown,https://clinicaltrials.gov/ct2/show/NCT02413099,,,,Ischemic heart disease; Vascular dementia; Male infertility; Erectile dysfunction,Basic research; Phase II; Phase IV; Phase IV
1598,11061-68-0,https://drugs.ncats.io/drug/1Y17CTI5SR,US Approved Rx 2019,BLA208157,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208157,US Approved Rx 1982,BLA018780,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018780,Diabetes mellitus,Approved
1599,53608-75-6,https://drugs.ncats.io/drug/78b12638,,,,,,,,
1600,16974-53-1,https://drugs.ncats.io/drug/J76UF062FS,US Approved Rx 1990,ANDA072760,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=072760,US Previously Marketed 1972,PAVULON by ORGANON USA INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017015,Pain,Approved
1601,339177-26-3,https://drugs.ncats.io/drug/6A901E312A,US Approved Rx 2006,BLA125147,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125147,US Approved Rx 2006,BLA125147,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125147,,
1602,404950-80-7,https://drugs.ncats.io/drug/9647FM7Y3Z,US Previously Marketed 2015,FARYDAK by SECURA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205353,US Previously Marketed 2015,FARYDAK by SECURA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205353,Multiple myeloma,Approved
1603,16816-67-4,https://drugs.ncats.io/drug/7K81IL792L,Possibly Marketed Outside US ,Japan:Pantethine,https://tripod.nih.gov/npc/#Download,Possibly Marketed Outside US 2000,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=422d83f6-011b-4a4c-9a7b-50288536938f,Cardiovascular diseases,Approved
1604,16485-10-2,https://drugs.ncats.io/drug/WV9CM0O67Z,US Approved Rx 2000,NDA021163,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021163,US Previously Marketed 1947,BEROCCA PN by ROCHE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006071,Skin moisturizer; SUNBURN,Basic research; Approved
1605,102625-70-7,https://drugs.ncats.io/drug/D8TST4O562,US Approved Rx 2014,ANDA202052,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202052,US Approved Rx 2000,NDA020987,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020987,Erosive esophagitis associated with gastroesophageal reflux disease; Zollinger-Ellison syndrome,Approved; Approved
1606,79-83-4,https://drugs.ncats.io/drug/19F5HK2737,US Previously Marketed 1993,VITAPED by HOSPIRA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020176,US Previously Marketed 1937,Calcium pentothate,https://books.google.com/books?newbks=1&newbks_redir=0&id=LlpLAAAAMAAJ&dq=dispensatory+pantothenate&focus=searchwithinvolume&q=pantothenate,Acne; Systemic lupus erythematosus; Osteoarthrosis; Rheumatoid arthritis; Pernicious anemia,Not Provided; Not Provided; Not Provided; Not Provided; Approved
1607,9001-73-4,https://drugs.ncats.io/drug/A236A06Y32,US Previously Marketed 1921,Caroid,https://books.google.com/books?id=-Uk2AQAAMAAJ&newbks=1&newbks_redir=0&dq=papain%20first%20marketed&pg=RA1-PA446#v=onepage&q=papain%20first%20marketed&f=false,US Previously Marketed 1921,Caroid,https://books.google.com/books?id=-Uk2AQAAMAAJ&newbks=1&newbks_redir=0&dq=papain%20first%20marketed&pg=RA1-PA446#v=onepage&q=papain%20first%20marketed&f=false,,
1608,58-74-2,https://drugs.ncats.io/drug/DAA13NKG2Q,Possibly Marketed Outside US ,"Papaverine Hydrochloride by AMERICAN REGENT, INC.",https://www.drugbank.ca/drugs/DB01113,Possibly Marketed Outside US 1995,"Papaverine Hydrochloride by American Regent, Inc.",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9e5e2ce4-7a57-4c61-a826-64c8d11d038e,Spasm of smooth muscle,Approved
1609,103-90-2,https://drugs.ncats.io/drug/362O9ITL9D,US Approved Rx 2018,ANDA210644,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210644,US Previously Marketed 1950,Trigesic by Squibb,DeHaen 1940-1975 NMEs,Common cold; Backache; Headache; Arthritis; Fever,Approved; Approved; Approved; Approved; Approved
1610,7440-23-5,https://drugs.ncats.io/drug/9NEZ333N27,US Previously Marketed 1921,Sodium Indigotindisulphonate U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Sodium Indigotindisulphonate U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,,
1611,9002-64-6,https://drugs.ncats.io/drug/N19A0T0E5J,US Approved Rx 2015,BLA125511,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125511,US Approved Rx 2015,BLA125511,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125511,Hypoparathyroidism; Postmenopausal osteoporosis,Approved; Approved
1612,131918-61-1,https://drugs.ncats.io/drug/6702D36OG5,US Approved Rx 2017,ANDA203897,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203897,US Approved Rx 1998,NDA020819,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020819,Secondary hyperparathyroidism associated with chronic kidney disease,Approved
1613,1216941-48-8,https://drugs.ncats.io/drug/OU2YM37K86,US Previously Marketed 2016,VIEKIRA XR by ABBVIE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208624,US Previously Marketed 2014,VIEKIRA PAK (COPACKAGED) by ABBVIE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206619,Chronic hepatitis C virus (genotype 4) infection,Approved
1614,7542-37-2,https://drugs.ncats.io/drug/61JJC8N5ZK,US Approved Rx 2007,ANDA065173,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=065173,US Previously Marketed 1960,Humatin by Parke-Davis,DeHaen 1940-1975 NMEs,Hepatic coma; Intestinal amebiasis,Approved; Approved
1615,61869-08-7,https://drugs.ncats.io/drug/41VRH5220H,US Approved Rx 2005,ANDA076618,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=076618,US Previously Marketed 1992,Paxil by SmithKline,OB NME Appendix 1950-1993,Generalized anxiety disorder; Social anxiety disorder; Post-traumatic stress disorder; Major depressive disorder; Obsessive-compulsive disorder; Panic disorder,Approved; Approved; Approved; Approved; Approved; Approved
1616,396091-73-9,https://drugs.ncats.io/drug/98H1T17066,US Approved Rx 2012,NDA200677,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200677,US Approved Rx 2012,NDA200677,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200677,Cushing’s disease,Approved
1617,1208912-84-8,https://drugs.ncats.io/drug/7T97I3787N,US Approved Rx 2015,NDA205739,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205739,US Approved Rx 2015,NDA205739,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205739,,
1618,1420706-45-1,https://drugs.ncats.io/drug/50FKX8CB2Y,US Approved Rx 2018,NDA210922,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210922,US Approved Rx 2018,NDA210922,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210922,,
1619,444731-52-6,https://drugs.ncats.io/drug/7RN5DR86CK,US Approved Rx 2023,ANDA217713,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217713,US Approved Rx 2009,NDA022465,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022465,Soft tissue sarcoma; Renal cell carcinoma,Approved; Approved
1620,9000-69-5,https://drugs.ncats.io/drug/47EQO8LE7H,US Previously Marketed 1961,CREMOSUXIDINE PECTIN by MSD,https://www.govinfo.gov/content/pkg/FR-1972-12-27/pdf/FR-1972-12-27.pdf,US Previously Marketed 1921,pectin,https://catalog.hathitrust.org/Record/100163146,,
1621,130167-68-9,https://drugs.ncats.io/drug/HW3H7D91F6,US Previously Marketed 1990,ADAGEN by LEADIANT BIOSCI INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019818,US Previously Marketed 1990,ADAGEN by LEADIANT BIOSCI INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019818,,
1622,222716-86-1,https://drugs.ncats.io/drug/3HP012Q0FH,US Previously Marketed 2004,MACUGEN by BAUSCH AND LOMB INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021756,US Previously Marketed 2004,MACUGEN by BAUSCH AND LOMB INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021756,Age-related macular degeneration,Approved
1623,130167-69-0,https://drugs.ncats.io/drug/7D96IR0PPM,US Approved Rx 1994,BLA103411,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103411,US Approved Rx 1994,BLA103411,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103411,,
1624,208265-92-3,https://drugs.ncats.io/drug/3A58010674,US Approved Rx 2019,BLA761045,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761045,US Approved Rx 2002,BLA125031,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125031,,
1625,215647-85-1,https://drugs.ncats.io/drug/G8RGG88B68,US Approved Rx 2001,BLA103949,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103949,US Approved Rx 2001,BLA103949,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103949,,
1626,1211327-92-2,https://drugs.ncats.io/drug/I8309403R0,US Approved Rx 2014,BLA125499,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125499,US Approved Rx 2014,BLA125499,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125499,,
1627,885051-90-1,https://drugs.ncats.io/drug/R581OT55EA,US Approved Rx 2010,BLA125293,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125293,US Approved Rx 2010,BLA125293,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125293,,
1628,1585984-95-7,https://drugs.ncats.io/drug/N6UAH27EUV,US Approved Rx 2018,BLA761079,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761079,US Approved Rx 2018,BLA761079,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761079,,
1629,218620-50-9,https://drugs.ncats.io/drug/N824AOU5XV,US Approved Rx 2003,BLA021106,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021106,US Approved Rx 2003,BLA021106,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021106,,
1630,1374853-91-4,https://drugs.ncats.io/drug/DPT0O3T46P,US Approved Rx 2014,BLA125514,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,US Approved Rx 2014,BLA125514,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,,
1631,137281-23-3,https://drugs.ncats.io/drug/04Q9AIZ7NO,US Approved Rx 2022,ANDA090384,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=090384,US Approved Rx 2004,NDA021677,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021677,Nonsquamous non-small cell lung cancer; Malignant pleural mesothelioma,Approved; Approved
1632,69372-19-6,https://drugs.ncats.io/drug/2C09NV773M,US Previously Marketed 1999,ALAMAST by SANTEN,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021079,US Previously Marketed 1999,ALAMAST by SANTEN,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021079,Bronchial asthma; Allergic rhinitis,Approved; Approved
1633,2152-34-3,https://drugs.ncats.io/drug/7GAQ2332NK,US Previously Marketed 1975,CYLERT by ABBOTT,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016832,US Previously Marketed 1975,CYLERT by ABBOTT,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016832,Attention deficit hyperactivity disorder,Approved
1634,38363-40-5,https://drugs.ncats.io/drug/78W62V43DY,US Previously Marketed 1987,LEVATOL by AUXILIUM PHARMS LLC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018976,US Previously Marketed 1987,LEVATOL by AUXILIUM PHARMS LLC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018976,Hypertension,Approved
1635,39809-25-1,https://drugs.ncats.io/drug/359HUE8FJC,US Approved Rx 1996,NDA020629,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020629,US Previously Marketed 1994,FAMVIR by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020363,Recurrent herpes labialis,Approved
1636,771431-20-0,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
1637,61-33-6,https://drugs.ncats.io/drug/Q42T66VG0C,US Approved Rx 1953,NDA050138,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050138,US Previously Marketed 1943,Penicillin G Sodium by Various Mfrs.,DeHaen 1940-1975 NMEs,Actinomycosis; Sepsis; Anthrax; Botulism; Diphtheria,Approved; Approved; Approved; Approved; Approved
1638,87-08-1,https://drugs.ncats.io/drug/Z61I075U2W,US Approved Rx 1968,ANDA060456,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=060456,US Previously Marketed 1955,V-Cillin by Lilly,DeHaen 1940-1975 NMEs,Pneumococcal infections; Staphylococcal infections; Streptococcal infections,Approved; Approved; Approved
1639,460-73-1,https://drugs.ncats.io/drug/TA9UOF49CY,Possibly Marketed Outside US 2014,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aec3924f-3da2-486a-bd4e-59ded15c12b0,Possibly Marketed Outside US 2014,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aec3924f-3da2-486a-bd4e-59ded15c12b0,,
1640,100-33-4,https://drugs.ncats.io/drug/673LC5J4LQ,US Approved Rx 1984,NDA019264,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019264,US Approved Rx 1984,NDA019264,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019264,"Pneumocystis jiroveci pneumonia (PJP) in high-risk, HIV-infected patients",Approved
1641,359-83-1,https://drugs.ncats.io/drug/RP4A60D26L,US Approved Rx 2001,ANDA075735,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=075735,US Previously Marketed 1967,TALWIN by HOSPIRA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016194,Pain,Approved
1642,67-43-6,https://drugs.ncats.io/drug/7A314HQM0I,US Previously Marketed 2004,PENTETATE ZINC TRISODIUM by HAMELN PHARMA PLUS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021751,Possibly Marketed Outside US 1965,M006,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89577417-76a0-cb04-e053-2995a90a5733,"Internal contamination with plutonium, americium, or curium; Acne; Contamination with plutonium, americium, or curium",Approved; Approved; Withdrawn
1643,54-95-5,https://drugs.ncats.io/drug/WM5Z385K7T,US Previously Marketed 1950,PARA HYCODAN PENTYLENETETRAZOL by ENDO,"Federal Register v.37 (1972), page 2852, retrieved from: https://books.google.ru/books?id=VNfjJrqyk_8C",US Previously Marketed 1929,Metrazol by Knoll,https://books.google.com/books?id=2QJtAAAAMAAJ&q=metrazol&dq=metrazol&hl=en&newbks=1&newbks_redir=0&sa=X&ved=2ahUKEwiTueXIhv_mAhVOpFkKHSgHAgUQ6AEwAHoECAAQAg,Narcolepsy without cataplexy; Idiopathic hypersomnia,Phase II; Phase II
1644,76-74-4,https://drugs.ncats.io/drug/I4744080IR,US Approved Rx 1973,ANDA083246,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=083246,US Previously Marketed 1921,calcium pentobarbital,https://catalog.hathitrust.org/Record/100163146,Insomnia; Convulsive episodes; Anxiety,Approved; Approved; Approved
1645,37319-17-8,https://drugs.ncats.io/drug/914032762Y,US Approved Rx 1996,NDA020193,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020193,US Approved Rx 1996,NDA020193,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020193,Interstitial cystitis,Approved
1646,53910-25-1,https://drugs.ncats.io/drug/395575MZO7,US Approved Rx 1991,NDA020122,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020122,US Approved Rx 1991,NDA020122,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020122,Hairy cell leukemia,Approved
1647,6493-05-6,https://drugs.ncats.io/drug/SD6QCT3TSU,US Approved Rx 1999,ANDA075191,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=075191,US Previously Marketed 1984,TRENTAL by VALIDUS PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018631,Intermittent claudication,Approved
1648,77-23-6,https://drugs.ncats.io/drug/32C726X12W,US Previously Marketed 1955,Toclase by Pfizer,DeHaen 1940-1975 NMEs,US Previously Marketed 1955,Toclase by Pfizer,DeHaen 1940-1975 NMEs,Cough,Phase I
1649,608-73-1,https://drugs.ncats.io/drug/5477B350EK,,,,,,,,
1650,73049-73-7,https://drugs.ncats.io/drug/0K9R94573C,Possibly Marketed Outside US 2022,ANDA204469,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2467e332-e95b-4291-9473-b3594c348fbc,Possibly Marketed Outside US 1995,21 CFR 333E,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=311663b8-0652-4b56-86ef-92e3caa81558,,
1651,330600-85-6,https://drugs.ncats.io/drug/9ZS94HQO3B,US Approved Rx 2014,NDA206426,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206426,US Approved Rx 2014,NDA206426,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206426,Influenza virus infections,Approved
1652,380917-97-5,https://drugs.ncats.io/drug/H821664NPK,US Approved Rx 2016,NDA208277,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208277,US Approved Rx 2012,NDA202834,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202834,Epilepsy,Approved
1653,14034-78-7,https://drugs.ncats.io/drug/HC4C3M1FO2,US Previously Marketed 1921,Sodium Perborate U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Sodium Perborate U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,,
1654,76-19-7,https://drugs.ncats.io/drug/CK0N3WH0SR,US Approved Rx 2001,NDA021064,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021064,Possibly Marketed Outside US 1997,NDA020899,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=46bcf276-d423-408a-a410-f11383406a94,Heart Diseases,Approved
1655,66104-22-1,https://drugs.ncats.io/drug/24MJ822NZ9,US Previously Marketed 1988,PERMAX by VALEANT PHARM INTL,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019385,US Previously Marketed 1988,PERMAX by VALEANT PHARM INTL,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019385,Parkinson's disease; Pituitary Pars Intermedia Dysfunction (Equine Cushing’s Disease) in horses,Withdrawn; Approved
1656,82834-16-0,https://drugs.ncats.io/drug/Y5GMK36KGY,US Approved Rx 2009,ANDA079070,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=079070,US Previously Marketed 1993,ACEON by SYMPLMED PHARMS LLC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020184,Parkinson's disease; Stable coronary artery disease; Hypertension; Unknown; Unknown; Unknown,Not Provided; Approved; Approved
1657,52645-53-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1658,726169-73-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1659,58-39-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1660,380610-27-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1661,8007-00-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1662,57-42-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1663,60-80-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1664,94-78-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1665,634-03-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1666,51-71-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1667,64-04-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1668,82-88-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1669,86-21-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1670,50-06-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1671,108-95-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1672,77-09-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1673,59-96-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1674,122-09-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1675,50-60-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1676,63-91-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1677,1821-12-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1678,59-42-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1679,33987-92-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1680,48115-38-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1681,92-12-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1682,57-41-0,https://drugs.ncats.io/drug/6158TKW0C5,US Approved Rx 2006,ANDA040684,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=040684,US Previously Marketed 1938,Dilantin by Parke-Davis,http://triggered.edina.clockss.org/ServeContent?rft_id=info:doi/10.1124/mi.9.5.1,Seizures; Status epilepticus,Approved; Approved
1683,89531-62-4,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
1684,1334474-30-4,https://drugs.ncats.io/drug/7CMB6B4449,,,,,,,,
1685,1446756-47-3,https://drugs.ncats.io/drug/394XK0IH40,Possibly Marketed Outside US ,EnLyte by Jaymac Pharmaceuticals Llc,https://www.drugbank.ca/drugs/DB00144,Possibly Marketed Outside US 2011,EnBrace HR by Jaymac Pharma,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f14fa40-97ab-4ec5-b66b-793d6d1abac9,,
1686,92128-87-5,https://drugs.ncats.io/drug/2OYE00PC25,US Approved Rx 2023,NDA215830,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215830,US Approved Rx 2023,NDA215830,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215830,,
1687,7664-38-2,https://drugs.ncats.io/drug/E4GA8884NN,US Approved Rx 2011,ANDA079247,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=079247,US Previously Marketed 1921,Ammonium Phosphate N.F.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Hypophosphatemia; Hyperphosphatemia; Sore muscles & joints; Fatigue; Nausea; Lose body protein; Occasional sleeplessness; Hypophosphatemia,Natural Metabolite; Natural Metabolite; Not Provided; Not Provided; Not Provided; Approved; Not Provided; Approved
1688,7723-14-0,https://drugs.ncats.io/drug/TYV5CW74LV,,,,,,,,
1689,57-47-6,https://drugs.ncats.io/drug/9U1VM840SP,US Previously Marketed 1921,Physostigmine Salicylate U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Physostigmine Salicylate U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Glaucoma,Approved
1690,83-86-3,https://drugs.ncats.io/drug/7IGF0S7R8I,US Previously Marketed 1962,Reneal by Squibb,DeHaen 1940-1975 NMEs,US Previously Marketed 1962,Reneal by Squibb,DeHaen 1940-1975 NMEs,Cancer; Bipolar disorder; Aortic valve calcification; Skin Care; Iron deficiency anemia; Manic depression; Bipolar disorder,Preclinical; Phase I; Phase III; Approved; Not Provided; Phase I; Phase I
1691,336622-97-0,https://drugs.ncats.io/drug/3M9T3AX86F,,,,,,,,
1692,79083-00-4,https://drugs.ncats.io/drug/MLF3D1712D,US Approved Rx 1983,ANDA087954,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=087954,US Previously Marketed 1940,Synkamin by Parke-Davis,DeHaen 1940-1975 NMEs,Hypoprothrombinemia; Hemorrhagic disease of newborn; Vitamin K deficiency; Hypoprothrombinemia,Approved; Approved; Approved; Approved
1693,554-62-1,https://drugs.ncats.io/drug/GIN46U9Q2Q,Possibly Marketed Outside US ,"P1P AC Repair Ampoule by Phytos Co., Ltd.",https://www.drugbank.ca/drugs/DB14119,Possibly Marketed Outside US 2002,M020,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4bfbfac7-6738-4996-a152-95dfbd759154,Metabolic syndrome; Acne vulgaris; Hyperpigmentation; Skin Care,Phase II; Phase II; Basic research; Approved
1694,1353900-92-1,https://drugs.ncats.io/drug/2WU922TK3L,US Approved Rx 2017,NDA209394,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209394,US Approved Rx 2017,NDA209394,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209394,Chronic hepatitis C,Approved
1695,98-98-6,https://drugs.ncats.io/drug/QZV2W997JQ,,,,,,,Binge eating disorder; Type 2 diabetes mellitus,Phase II; Phase I
1696,10040-34-3,https://drugs.ncats.io/drug/95D580798S,US Approved Rx 2017,NDA209589,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209589,US Previously Marketed 2012,PREPOPIK by FERRING PHARMS INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202535,cleansing of the colon; Unknown,Approved
1697,98-79-3,https://drugs.ncats.io/drug/SZB83O1W42,Possibly Marketed Outside US ,part333D,https://www.drugbank.ca/drugs/DB03088,Possibly Marketed Outside US 2002,21 CFR 333D,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=190e3e37-ad29-4e94-840a-fa982fcdaab4,Dry skin; Acne; Halitosis; Seborrhea,Approved; Approved; Phase I; Approved
1698,92-13-7,https://drugs.ncats.io/drug/01MI4Q9DI3,US Approved Rx 2019,ANDA210384,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210384,US Previously Marketed 1921,Pilocarpine Hydrochloride U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Sjogren's syndrome; Head and neck cancer; Acute angle-closure glaucoma; Ocular hypertension; Open-angle glaucoma,Approved; Approved; Approved; Approved; Approved
1699,706779-91-1,https://drugs.ncats.io/drug/JZ963P0DIK,US Approved Rx 2024,ANDA214493,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214493,US Approved Rx 2016,NDA207318,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207318,Parkinson's disease,Approved
1700,137071-32-0,https://drugs.ncats.io/drug/7KYV510875,US Approved Rx 2018,ANDA209345,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209345,Possibly Marketed Outside US 2001,NDA021302,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e4027e5a-0f9b-4070-b196-f60172f45c4c,Atopic dermatitis,Approved
1701,74150-27-9,https://drugs.ncats.io/drug/34AP3BBP9T,Possibly Marketed Outside US ,Pimobendan by CBSCHEM LIMITED,https://www.drugbank.ca/drugs/DB11450,Possibly Marketed Outside US 2007,NADA141273,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5441e5b2-cdc0-477a-bd9a-ec5f8d912281,Heart failure,Approved
1702,2062-78-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1703,13523-86-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1704,111025-46-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1705,52212-02-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1706,61477-96-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1707,7280-37-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1708,51-03-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1709,7491-74-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1710,38677-81-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1711,53179-13-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1712,50650-76-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1713,36322-90-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1714,147511-69-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1715,62354-43-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1716,1154757-24-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1717,467426-54-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1718,110078-46-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1719,18378-89-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1720,518-28-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1721,9000-55-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1722,71-23-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1723,3055-99-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1724,9012-76-4,https://drugs.ncats.io/drug/7SRJ3W89J8,Possibly Marketed Outside US 2020,M020,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b3f01646-d3d8-446d-993d-526287fb8b44,Possibly Marketed Outside US 2018,M020,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=118fd112-4085-4a76-bb64-46c57b3a6377,,
1725,56-81-5,https://drugs.ncats.io/drug/PDC6A3C0OX,US Approved OTC ,21 CFR 347.10(h) skin protectant glycerin,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec347-10.xml,US Previously Marketed 1921,Glycerin U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Dry skin or hair,Approved
1726,53637-25-5,https://drugs.ncats.io/drug/2OYE00PC25,US Approved Rx 2023,NDA215830,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215830,US Approved Rx 2023,NDA215830,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215830,,
1727,53637-25-5,https://drugs.ncats.io/drug/2OYE00PC25,US Approved Rx 2023,NDA215830,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215830,US Approved Rx 2023,NDA215830,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215830,,
1728,691397-13-4,https://drugs.ncats.io/drug/6SG11EPD3Z,Excipient ,,https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm?event=browseByLetter.page&Letter=P,,,,,
1729,133029-32-0,https://drugs.ncats.io/drug/DT9D8Z79ET,Possibly Marketed Outside US ,part333A,https://www.drugbank.ca/drugs/DB15677,Possibly Marketed Outside US 2010,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5996f9b2-18c1-4c8f-a0ab-eca180db61ad,,
1730,9003-97-8,https://drugs.ncats.io/drug/W25LM17A4W,US Previously Marketed 1960,Sorboquel by White (Schering),DeHaen 1940-1975 NMEs,US Previously Marketed 1960,Sorboquel by White (Schering),DeHaen 1940-1975 NMEs,,
1731,68424-04-4,https://drugs.ncats.io/drug/VH2XOU12IE,Possibly Marketed Outside US 1970,"O-Cal FA multivitamin by Pharmics, Inc.",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3b24458b-6d48-4cc6-8233-81f173277cb8,Possibly Marketed Outside US 1960,ANDA040424,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=48115c9e-c82f-438d-b178-dce1b73687db,,
1732,9002-88-4,https://drugs.ncats.io/drug/T23R5E6AK8,,,,,,,,
1733,1404-26-8,https://drugs.ncats.io/drug/J2VZ07J96K,US Approved OTC ,21 CFR 333.120 first aid antibiotic:ointment polymyxin b sulfate (combination only),https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec333-120.xml,US Previously Marketed 1951,Aerosporin by Burroughs Wellcome,DeHaen 1940-1975 NMEs,"Acute Infections due to Pseudomonas aeruginosa; Sepsis; Meningeal infections due to H influenzae; Urinary tract infections, E.coli",Approved; Approved; Approved; Approved
1734,75345-27-6,https://drugs.ncats.io/drug/6716Z5YR3G,Possibly Marketed Outside US ,Canada:POLYQUATERNIUM-1,https://tripod.nih.gov/npc/#Download,Possibly Marketed Outside US 2003,21 CFR 349,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ca4d2c43-632d-447d-89bb-4809a3c13f41,,
1735,9005-64-5,https://drugs.ncats.io/drug/59IO08SBZU,Possibly Marketed Outside US 2023,ANDA075357,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a919196-024d-8aee-e063-6294a90a555d,Possibly Marketed Outside US 2023,ANDA075357,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a919196-024d-8aee-e063-6294a90a555d,,
1736,9005-65-6,https://drugs.ncats.io/drug/6OZP39ZG8H,US Approved OTC ,21 CFR 349.12(d)(4) ophthalmic:demulcents polysorbate 80,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec349-12.xml,US Previously Marketed 1949,Olothorb by Merck Sharp & Dohme,DeHaen 1940-1975 NMEs,Dry eye syndrome,Approved
1737,28210-41-5,https://drugs.ncats.io/drug/ZSL2FB6GXN,US Approved Rx 1998,ANDA040029,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=040029,Possibly Marketed Outside US 1953,NDA022556,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e8248ad-f213-401c-9c0a-1e32e7341345,,
1738,346-18-9,https://drugs.ncats.io/drug/36780APV5N,US Previously Marketed 1980,MINIZIDE by PFIZER,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017986,US Previously Marketed 1961,RENESE by PFIZER,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012845,Edema; Hypertension,Approved; Approved
1739,68258-82-2,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
1740,9002-89-5,https://drugs.ncats.io/drug/J1DZU42714,Possibly Marketed Outside US 2002,ANDA206654,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f6a1a792-141b-42e8-8bd1-884e4408eb8a,Possibly Marketed Outside US 2002,ANDA206654,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f6a1a792-141b-42e8-8bd1-884e4408eb8a,,
1741,19171-19-8,https://drugs.ncats.io/drug/D2UX06XLB5,US Approved Rx 2013,NDA204026,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204026,US Approved Rx 2013,NDA204026,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204026,Multiple myeloma,Approved
1742,943319-70-8,https://drugs.ncats.io/drug/4340891KFS,US Approved Rx 2012,NDA203469,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203469,US Approved Rx 2012,NDA203469,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203469,Headache; Philadelphia chromosome positive acute lymphoblastic leukemia; Chronic myeloid leukemia,Discontinued; Approved; Approved
1743,69004-04-2,https://drugs.ncats.io/drug/JPW84AS66U,Possibly Marketed Outside US ,Canada:PONAZURIL,https://tripod.nih.gov/npc/#Download,Possibly Marketed Outside US 2015,NADA141188,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f26dfd14-238b-48f6-90ba-b44524973602,Coccidiosis; Equine protozoal myeloencephalitis,Basic research; Approved
1744,129069-19-8,https://drugs.ncats.io/drug/KE3U2023NP,US Approved Rx 1999,BLA020744,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020744,US Approved Rx 1999,BLA020744,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020744,,
1745,87806-31-3,https://drugs.ncats.io/drug/Y3834SIK5F,US Approved Rx 2003,NDA021525,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021525,US Approved Rx 1995,NDA020451,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020451,Microinvasive endobronchial nonsmall cell lung cancer; Esophageal cancer; Barrett’s esophagus; Completely or partially obstructing endobronchial nonsmall cell lung cancer,Approved; Approved; Approved; Approved
1746,171228-49-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1747,7440-09-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1748,7722-64-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1749,9003-39-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1750,25655-41-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1751,146464-95-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1752,6735-59-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1753,104632-26-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1754,151126-32-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1755,140-65-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1756,53-43-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1757,150322-43-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1758,81093-37-0,https://drugs.ncats.io/drug/KXO2KT9N0G,US Approved Rx 2006,ANDA076341,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=076341,US Previously Marketed 1991,PRAVACHOL by BRISTOL MYERS SQUIBB,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019898,Coronary heart disease; Dysbetalipoproteinemia; Mixed dyslipidemia; Hypercholesterolemia,Approved; Approved; Approved; Approved
1759,55268-74-1,https://drugs.ncats.io/drug/6490C9U457,US Approved Rx 1982,NDA018714,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018714,Possibly Marketed Outside US 1981,NADA111607,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=641f1874-ad52-40fd-9c63-2ca537a6e147,Schistosoma mekongi infection; Schistosoma hematobium infection; Schistosoma japonicum infection; Clonorchis sinensis/Opisthorchis viverrini,Approved; Approved; Approved; Approved
1760,19216-56-9,https://drugs.ncats.io/drug/XM03YJ541D,US Approved Rx 2021,ANDA214608,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214608,US Approved Rx 1976,NDA017442,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017442,Prostatic hyperplasia; Post-traumatic headache; Hypertension,Phase IV; Phase IV; Approved
1761,73771-04-7,https://drugs.ncats.io/drug/V901LV1K7D,US Approved Rx 2007,ANDA077236,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077236,US Previously Marketed 1991,DERMATOP by VALEANT PHARMS NORTH,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019568,Dermatoses,Approved
1762,50-24-8,https://drugs.ncats.io/drug/9PHQ9Y1OLM,US Approved Rx 2022,ANDA216715,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216715,US Previously Marketed 1955,Meticortelone by Schering,DeHaen 1940-1975 NMEs,Iritis; Herpes zoster keratitis; Superficial punctate keratitis; Allergic conjunctivitis; Acne rosacea; Inflammation and pain; Anaphylaxis; Brain edema; Acute asthma attack; Pulmonary edema; Rheumatoid arthritis; Primary or secondary adrenocortical insufficiency; Rheumatic diseases; Allergic states; Mycosis fungoides; Acute leukemia; Multiple sclerosis; Uveitis; Hematologic disorders; Symptomatic sarcoidosis,Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved; Approved
1763,53-03-2,https://drugs.ncats.io/drug/VB0R961HZT,US Approved Rx 1976,ANDA085162,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=085162,US Previously Marketed 1955,METICORTEN by SCHERING,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=009766,Atopic dermatitis; Severe erythema multiforme (Stevens-Johnson syndrome); Crohn's disease; Congenital adrenal hyperplasia; Aggressive lymphoma; Diamond-Blackfan anemia,Approved; Approved; Approved; Approved; Approved; Approved
1764,148553-50-8,https://drugs.ncats.io/drug/55JG375S6M,US Approved Rx 2019,ANDA207623,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207623,US Approved Rx 2004,NDA021723,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021723,Partial onset seizures; Fibromyalgia; Postherpetic neuralgia; Diabetic peripheral neuropathy,Approved; Approved; Approved; Approved
1765,145-13-1,https://drugs.ncats.io/drug/73R90F7MQ8,US Previously Marketed 1950,Natolone by National (MerrellNational),DeHaen 1940-1975 NMEs,US Previously Marketed 1950,Natolone by National (MerrellNational),DeHaen 1940-1975 NMEs,Schizophrenia; Spatial memory disorder; Autism; Obsessive-compulsive disorder; Schizophrenia; Major depressive disorder; Marijuana dependence; Bipolar disorder,Preclinical; Preclinical; Phase II; Phase II; Phase IV; Phase IV; Phase II; Phase IV
1766,721-50-6,https://drugs.ncats.io/drug/046O35D44R,US Approved Rx 2003,ANDA076453,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=076453,US Approved Rx 1965,NDA021383,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021383,Pain,Approved
1767,90-34-6,https://drugs.ncats.io/drug/MVR3634GX1,US Approved Rx 2014,ANDA204476,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204476,US Approved Rx 1952,NDA008316,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=008316,Plasmodium vivax malaria; Plasmodium vivax malaria,Approved; Approved
1768,125-33-7,https://drugs.ncats.io/drug/13AFD7670Q,US Approved Rx 2008,ANDA040866,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=040866,US Approved Rx 1954,NDA009170,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=009170,Focal epileptic seizures; Psychomotor epileptic seizures; Grand mal epileptic seizures,Approved; Approved; Approved
1769,57-66-9,https://drugs.ncats.io/drug/PO572Z7917,US Approved Rx 2008,ANDA040618,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=040618,US Previously Marketed 1951,BENEMID by MERCK,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=007898,Gouty arthritis; Gout,Approved; Approved
1770,51-06-9,https://drugs.ncats.io/drug/L39WTC366D,US Approved Rx 1986,ANDA089069,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=089069,US Previously Marketed 1950,PRONESTYL by APOTHECON,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=007335,Ventricular tachycardia,Approved
1771,59-46-1,https://drugs.ncats.io/drug/4Z8Y51M438,US Previously Marketed 1954,TETRACYN by PFIZER,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=060285,US Previously Marketed 1905,Novocaine,https://books.google.com/books?id=HEMfAQAAIAAJ&lpg=PA588&ots=mRz14jeh0L&dq=alypin%20discovery%201905&pg=PA588#v=onepage&q=alypin%20discovery%201905&f=false,Pain,Approved
1772,671-16-9,https://drugs.ncats.io/drug/35S93Y190K,US Approved Rx 1969,NDA016785,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016785,US Approved Rx 1969,NDA016785,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016785,Hodgkin's lymphoma; Glioblastoma multiforme; Anaplastic astrocytoma,Approved; Approved; Approved
1773,58-38-8,https://drugs.ncats.io/drug/YHP6YLT61T,US Approved Rx 2023,ANDA217478,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217478,US Previously Marketed 1956,COMPAZINE by GLAXOSMITHKLINE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=010571,Dengue fever; Nausea; Vomiting; Generalized non-psychotic anxiety; Schizophrenia,Preclinical; Approved; Approved; Approved; Approved
1774,77-37-2,https://drugs.ncats.io/drug/C6QE1Q1TKR,US Previously Marketed 1955,KEMADRIN by MONARCH PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=009818,US Previously Marketed 1955,KEMADRIN by MONARCH PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=009818,Postencephalitic parkinsonism; Idiopathic Parkinson's disease; Arteriosclerotic parkinsonism,Approved; Approved; Approved
1775,92-62-6,https://drugs.ncats.io/drug/CY3RNB3K4T,US Previously Marketed 1919,Proflavine,https://books.google.com/books?id=Mp0hAQAAMAAJ&lpg=PA1443&ots=_xoaFHPs4k&dq=proflavine%20first%20marketed&pg=PA1443#v=onepage&q=proflavine%20first%20marketed&f=false,US Previously Marketed 1919,Proflavine,https://books.google.com/books?id=Mp0hAQAAMAAJ&lpg=PA1443&ots=_xoaFHPs4k&dq=proflavine%20first%20marketed&pg=PA1443#v=onepage&q=proflavine%20first%20marketed&f=false,Head and neck cancer; Colon polyps; Genital herpes; Gram-positive bacterial infections; Barrett’s esophagus; Cervical cancer,Not Provided; Phase I; Phase II; Approved; Phase II; Phase I
1776,57-83-0,https://drugs.ncats.io/drug/4G7DS2Q64Y,US Approved Rx 1998,NDA020843,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020843,US Previously Marketed 1934,Proluton,https://archive.org/details/newnonofficialre39coun,Amenorrhea; Abnormal uterine bleeding,Approved; Approved
1777,500-92-5,https://drugs.ncats.io/drug/S61K3P7B2V,US Approved Rx 2011,ANDA091211,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=091211,US Previously Marketed 1947,Chloroguanide by Squibb,DeHaen 1940-1975 NMEs,Plasmodium falciparum malaria; Plasmodium falciparum malaria,Approved; Approved
1778,4305-67-3,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
1779,60-87-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1780,54063-53-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1781,74-98-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1782,298-50-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1783,79-09-4,https://drugs.ncats.io/drug/JHU490RVYR,US Previously Marketed 1921,sodium propionate,https://catalog.hathitrust.org/Record/100163146,US Previously Marketed 1921,sodium propionate,https://catalog.hathitrust.org/Record/100163146,,
1784,2078-54-8,https://drugs.ncats.io/drug/YI7VU623SF,US Approved Rx 2018,ANDA205067,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205067,US Approved Rx 1989,NDA019627,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019627,Pain,Approved
1785,64-17-5,https://drugs.ncats.io/drug/bfe60581,,,,,,,,
1786,525-66-6,https://drugs.ncats.io/drug/9Y8NXQ24VQ,US Approved Rx 1987,ANDA070690,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=070690,US Previously Marketed 1967,INDERAL by WYETH PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016418,Angina pectoris; hypertension; Hypertrophic subaortic stenosis; Migraine,Approved; Approved; Approved; Approved
1787,57-55-6,https://drugs.ncats.io/drug/6DC9Q167V3,US Approved OTC ,21 CFR 349.12(d)(5) ophthalmic:demulcents propylene glycol,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec349-12.xml,US Previously Marketed 1961,VOSOL PROPYLENE GLYCOL by WAMPOLE LABS,https://www.govinfo.gov/content/pkg/FR-1972-12-14/pdf/FR-1972-12-14.pdf,Dryness of the eye,Approved
1788,101-40-6,https://drugs.ncats.io/drug/LQU92IU8LL,US Approved OTC ,21 CFR 341.20(b)(9) cough/cold:nasal decongestant propylhexedrine,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec341-20.xml,US Previously Marketed 1949,Benzedrex by Smith Kline & French,DeHaen 1940-1975 NMEs,Nasal congestion,Approved
1789,94-13-3,https://drugs.ncats.io/drug/Z8IX2SC1OH,US Previously Marketed ,21 CFR 310.545(a)(22)(ii) antifungal:diaper rash propylparaben,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-545.xml,Possibly Marketed Outside US 1961,NDA012911,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a27d0ef-83a7-4e1c-9430-46a3326ee8d8,Gram-positive bacterial skin infections; Fungal skin infections; Gram-negative bacterial skin infections; dermatitis,Basic research; Basic research; Basic research; Approved
1790,51-52-5,https://drugs.ncats.io/drug/721M9407IY,US Approved Rx 2023,ANDA208867,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208867,US Approved Rx 1947,NDA006188,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006188,Hyperthyroidism,Approved
1791,9012-00-4,https://drugs.ncats.io/drug/72G3UY6T4N,US Approved Rx 1987,ANDA089454,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=089454,US Previously Marketed 1950,PROTAMINE SULFATE by LILLY,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006460,,
1792,75847-73-3,https://drugs.ncats.io/drug/69PN84IO1A,US Approved Rx 2001,ANDA075727,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=075727,US Approved Rx 1985,NDA018998,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018998,Hypertension; Asymptomatic left ventricular dysfunction; Heart failure,Approved; Approved; Approved
1793,60202-16-6,https://drugs.ncats.io/drug/3Z6S89TXPW,Possibly Marketed Outside US ,Octaplex by Octapharma Pharmazeutika Produktionsges M B H [Canada],https://www.drugbank.ca/drugs/DB11312,Possibly Marketed Outside US 2007,BLA125234,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=926914a9-78b2-40ea-b37d-2a55c09bf275,,
1794,81-07-2,https://drugs.ncats.io/drug/FST467XS7D,US Previously Marketed 1921,Benzosulphinide U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Benzosulphinide U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Unknown,
1795,50-70-4,https://drugs.ncats.io/drug/506T60A25R,US Approved Rx 2020,NDA202049,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202049,Possibly Marketed Outside US 1955,Levsin by Alaven Pharmaceutical LLC,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32388e18-08de-455c-aad4-9c2264435f0f,Constipation; End-Stage Renal Disease; Cystic fibrosis; Asthma; Acute renal failure; Elevated intraocular pressure; Cerebral edema,Basic research; Approved; Approved; Approved; Approved; Approved; Approved
1796,103658-53-3,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
1797,24305-27-9,https://drugs.ncats.io/drug/5Y5F15120W,US Previously Marketed 1978,THYREL TRH by FERRING,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018087,US Previously Marketed 1976,THYPINONE by ABBOTT,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017638,Primary hypothyroidism; Thyroid Diseases,Phase II; Approved
1798,438-60-8,https://drugs.ncats.io/drug/4NDU154T12,US Approved Rx 2012,ANDA202220,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202220,US Previously Marketed 1967,VIVACTIL by TEVA WOMENS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016012,Mental depression,Approved
1799,499-67-2,https://drugs.ncats.io/drug/B4OB0JHI1X,US Approved Rx 1971,ANDA080027,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=080027,US Previously Marketed 1953,OPHTHAINE by APOTHECON,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=008883,Pain,Approved
1800,179474-81-8,https://drugs.ncats.io/drug/0A09IUW5TP,US Approved Rx 2018,NDA210166,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210166,US Approved Rx 2018,NDA210166,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210166,"Constipation, chronic",Approved
1801,90-82-4,https://drugs.ncats.io/drug/7CUC9DDI9F,US Approved OTC ,21 CFR 341.20(a)(3) cough/cold:nasal decongestant pseudoephedrine sulfate,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec341-20.xml,US Previously Marketed 1961,DISOPHROL by SCHERING,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012394,Nasal congestion,Approved
1802,117060-54-5,https://drugs.ncats.io/drug/M7KVR1LSN0,,,,,,,,
1803,1332-09-8,https://drugs.ncats.io/drug/NT5NN5KL16,US Previously Marketed 1921,Pumice N.F.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Pumice N.F.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,,
1804,85865-74-3,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
1805,15686-83-6,https://drugs.ncats.io/drug/4QIH0N49E7,US Approved OTC ,21 CFR 357.110 anthelmintic pyrantel pamoate,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec357-110.xml,US Previously Marketed 1971,Antiminth by Roerig (Pfizer),OB NME Appendix 1950-1985,Strongyloidiasis; Pinworm infection; Large roundworms infection; Tapeworm infection,Approved; Approved; Approved; Approved
1806,98-96-4,https://drugs.ncats.io/drug/2KNI5N06TI,US Approved Rx 1971,ANDA080157,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=080157,US Previously Marketed 1955,Pyrazinamide by Merck (Merck Sharp & Dohme),OB NME Appendix 1950-1985,Tuberculosis,Approved
1807,8003-34-7,https://drugs.ncats.io/drug/e4443c7a,,,,,,,,
1808,155-97-5,https://drugs.ncats.io/drug/19QM69HH21,US Approved Rx 1955,NDA009830,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=009830,US Approved Rx 1955,NDA009830,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=009830,Myasthenia gravis,Approved
1809,66-72-8,https://drugs.ncats.io/drug/3THM379K8A,Possibly Marketed Outside US 2019,21 CFR 347,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c17ee80-ceac-53e9-e053-2995a90a8193,Possibly Marketed Outside US 2019,21 CFR 347,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c17ee80-ceac-53e9-e053-2995a90a8193,,
1810,54-47-7,https://drugs.ncats.io/drug/F06SGE49M6,Possibly Marketed Outside US ,Dexivite by Lifsa Drugs Llc,https://www.drugbank.ca/drugs/DB00114,Possibly Marketed Outside US 2011,EnLyte by Jaymac Pharma,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e83b2dd3-a9a0-40bc-ade4-6cd4db433b06,Tardive dyskinesia; Metabolic syndrome; Type 2 diabetes mellitus,Phase II; Phase II; Phase II
1811,65-23-6,https://drugs.ncats.io/drug/KV2JZ1BI6Z,US Approved Rx 2016,NDA209661,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209661,US Previously Marketed 1947,BEROCCA PN by ROCHE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006071,West syndrome; Pyridoxine deficiency; Pyridoxine-dependent epilepsy,Approved; Approved; Approved
1812,58-14-0,https://drugs.ncats.io/drug/Z3614QOX8W,US Approved Rx 2021,ANDA211271,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211271,US Approved Rx 1953,NDA008578,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=008578,Toxoplasmosis; Malaria; Acute malaria,Approved; Approved; Approved
1813,13463-41-7,https://drugs.ncats.io/drug/R953O2RHZ5,US Approved OTC ,21 CFR 358.710(a)(2) dandruff:dandruff (wash-off) pyrithione zinc,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec358-710.xml,US Previously Marketed 1961,Head & Shoulders Shampoo by Proctor and Gamble,OB NME Appendix 1950-1985,Seborrhea; Acute myeloid leukemia,Approved; Preclinical
1814,9004-70-0,https://drugs.ncats.io/drug/KYR8BR2X6O,US Previously Marketed 1921,Pyroxylin U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Pyroxylin U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,,
1815,127-17-3,https://drugs.ncats.io/drug/8558G7RUTR,Possibly Marketed Outside US 2020,21 CFR 333A,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0923fbdc-b85a-4113-a07f-715820fffa3f,Possibly Marketed Outside US 1987,21 CFR 349,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45ac4335-3ecd-4a03-865e-82dd9cd3c715,Coronary Disease; Blood Transfusion,Phase II; Approved
1816,36735-22-5,https://drugs.ncats.io/drug/JF8V0828ZI,US Approved Rx 1985,NDA018708,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018708,US Approved Rx 1985,NDA018708,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018708,Insomnia,Approved
1817,117-39-5,https://drugs.ncats.io/drug/9IKM0I5T1E,US Previously Marketed 1953,Quertine by Abbott,DeHaen 1940-1975 NMEs,US Previously Marketed 1953,Quertine by Abbott,DeHaen 1940-1975 NMEs,Thromboembolism; Chronic obstructive pulmonary disease; Acute mountain sickness,Phase III; Phase I; Phase III
1818,111974-69-7,https://drugs.ncats.io/drug/BGL0JSY5SI,US Approved Rx 2012,ANDA201109,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201109,US Approved Rx 1997,NDA020639,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020639,Schizophrenia; Bipolar disorder; Major depressive disorder,Approved; Approved; Approved
1819,85441-61-8,https://drugs.ncats.io/drug/RJ84Y44811,US Approved Rx 2011,ANDA201356,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201356,US Previously Marketed 1991,ACCUPRIL by PFIZER PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019885,Hypertension,Approved
1820,56-54-2,https://drugs.ncats.io/drug/ITX08688JL,US Approved Rx 2010,NDA021879,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021879,US Previously Marketed 1921,Quinidine N.F.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Ventricular arrhythmia; Plasmodium falciparum malaria; Atrial fibrillation,Approved; Approved; Approved
1821,72402-53-0,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
1822,120138-50-3,https://drugs.ncats.io/drug/23OW28RS7P,US Approved Rx 1999,NDA050747,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050747,US Approved Rx 1999,NDA050747,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050747,Complicated skin and skin structure infections caused by Staphylococcus aureus or Streptococcus pyogenes,Approved
1823,117976-89-3,https://drugs.ncats.io/drug/32828355LL,US Approved Rx 2013,ANDA076824,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=076824,US Approved Rx 1999,NDA020973,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020973,Zollinger-Ellison syndrome; Erosive or ulcerative gastroesophageal reflux disease; Duodenal ulcer,Approved; Approved; Approved
1824,53214-57-6,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
1825,329-65-7,https://drugs.ncats.io/drug/GR0L9S3J0F,US Approved OTC ,21 CFR 341.16(g) cough/cold:bronchodilator racepinephrine hydrochloride,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec341-16.xml,Possibly Marketed Outside US 2000,21 CFR 341,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd1b35c7-b23b-4b95-8162-df3d263fe32e,Asthma; Bronchiolitis,Approved; Approved
1826,15623-45-7,https://drugs.ncats.io/drug/8BR2SOL3L1,Possibly Marketed Outside US ,WHO-ATC:V10XX03,https://ginas.ncats.nih.gov/ginas/app/substance/8BR2SOL3L1,,,,,
1827,84449-90-1,https://drugs.ncats.io/drug/YX9162EO3I,US Approved Rx 2016,ANDA206384,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206384,US Approved Rx 1997,NDA020815,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020815,Breast cancer in postmenopausal women with osteoporosis; Breast cancer in postmenopausal women at high risk for invasive breast cancer; Osteoporosis in postmenopausal women,Approved; Approved; Approved
1828,518048-05-0,https://drugs.ncats.io/drug/22VKV8053U,US Approved Rx 2013,NDA205786,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205786,US Approved Rx 2007,NDA022145,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022145,HIV-1 infection,Approved
1829,196597-26-9,https://drugs.ncats.io/drug/901AS54I69,US Approved Rx 2005,NDA021782,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021782,US Approved Rx 2005,NDA021782,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021782,Insomnia,Approved
1830,87333-19-5,https://drugs.ncats.io/drug/L35JN3I7SJ,US Approved Rx 2005,ANDA076549,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=076549,US Approved Rx 1991,NDA019901,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019901,Congestive heart failure; Hypertension; Myocardial infarction,Approved; Approved; Approved
1831,947687-13-0,https://drugs.ncats.io/drug/D99YVK4L0X,US Approved Rx 2014,BLA125477,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125477,US Approved Rx 2014,BLA125477,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125477,,
1832,347396-82-1,https://drugs.ncats.io/drug/ZL1R02VT79,US Approved Rx 2006,BLA125156,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125156,US Approved Rx 2006,BLA125156,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125156,,
1833,82530-72-1,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
1834,128345-62-0,https://drugs.ncats.io/drug/7AJ51I17KG,US Approved Rx 2007,ANDA077405,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077405,US Previously Marketed 1983,ZANTAC 150 by GLAXO GRP LTD,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018703,Zollinger-Ellison syndrome; Duodenal ulcer; Gastroesophageal reflux disease; Gastric ulcer,Approved; Approved; Approved; Approved
1835,95635-55-5,https://drugs.ncats.io/drug/A6IEZ5M406,US Approved Rx 2020,ANDA211745,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211745,US Previously Marketed 2006,RANEXA by MENARINI INTL,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021526,Angina,Approved
1836,90106-07-3,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
1837,465499-11-0,https://drugs.ncats.io/drug/GG1LBM463S,US Previously Marketed 1999,RAPLON by ORGANON USA INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020984,US Previously Marketed 1999,RAPLON by ORGANON USA INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020984,Skeletal muscle relaxation,Withdrawn
1838,136236-51-6,https://drugs.ncats.io/drug/003N66TS6T,US Approved Rx 2019,ANDA206153,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206153,US Approved Rx 2006,NDA021641,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021641,Idiopathic Parkinson's disease,Approved
1839,134774-45-1,https://drugs.ncats.io/drug/08GY9K1EUO,US Approved Rx 2002,BLA103946,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103946,US Approved Rx 2002,BLA103946,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103946,,
1840,8063-17-0,https://drugs.ncats.io/drug/b140e130,,,,,,,,
1841,1803171-55-2,https://drugs.ncats.io/drug/C3VX249T6L,US Approved Rx 2018,BLA761108,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761108,US Approved Rx 2018,BLA761108,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761108,,
1842,313348-27-5,https://drugs.ncats.io/drug/7AXV542LZ4,US Approved Rx 2008,NDA022161,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022161,US Approved Rx 2008,NDA022161,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022161,Radionuclide myocardial perfusion imaging,Approved
1843,755037-03-7,https://drugs.ncats.io/drug/24T2A1DOYB,US Approved Rx 2012,NDA203085,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203085,US Approved Rx 2012,NDA203085,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203085,Colorectal cancer; Gastrointestinal stromal tumor,Approved; Approved
1844,132875-61-7,https://drugs.ncats.io/drug/P10582JYYK,US Approved Rx 2020,ANDA210594,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210594,US Approved Rx 1996,NDA020630,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020630,Pain,Approved
1845,9001-98-3,https://drugs.ncats.io/drug/VT6PI051PW,US Previously Marketed 1921,Rennin N.F.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Rennin N.F.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,,
1846,135062-02-1,https://drugs.ncats.io/drug/668Z8C33LU,US Approved Rx 2013,ANDA201189,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201189,US Previously Marketed 1997,PRANDIN by GEMINI LABS LLC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020741,Type 2 diabetes mellitus,Approved
1847,50-55-5,https://drugs.ncats.io/drug/8B1QWR724A,US Previously Marketed 1982,SANDRIL by LILLY,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=009376,US Previously Marketed 1954,SERPASIL by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=009434,Hypertension; Agitated psychotic states,Approved; Approved
1848,241473-69-8,https://drugs.ncats.io/drug/35A26E427H,US Approved Rx 2016,BLA761033,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761033,US Approved Rx 2016,BLA761033,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761033,,
1849,108-46-3,https://drugs.ncats.io/drug/YUL4LO94HK,US Approved OTC ,21 CFR 333.310(b) acne resorcinol (when combined with sulfur),https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec333-310.xml,US Previously Marketed 1894,Resorcinol,https://www.google.com/books/edition/The_New_England_Journal_of_Medicine/4641AQAAMAAJ?hl=en&gbpv=1&dq=RESORCINOL%20treatment&pg=PA241&printsec=frontcover&bsq=RESORCINOL%20treatment,Psoriasis; Acne,Approved; Approved
1850,102-29-4,https://drugs.ncats.io/drug/YL6O37RD1S,US Approved OTC ,21 CFR 333.310(c) acne resorcinol monoacetate (when combined with sulfur),https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec333-310.xml,US Previously Marketed 1906,Euresol by Knoll & Co,https://www.google.com/books/edition/Journal_of_the_American_Medical_Associat/Xc0-AQAAMAAJ?hl=en&gbpv=1&dq=euresol&pg=PA1194&printsec=frontcover&bsq=euresol,Acne,Approved
1851,501-36-0,https://drugs.ncats.io/drug/Q369O8926L,Possibly Marketed Outside US ,"Co-Balamin by Home Aide Diagnostics, Inc.",https://www.drugbank.ca/drugs/DB02709,Possibly Marketed Outside US 2011,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58fd7b0c-4b4b-4705-b325-49fbfbac889a,Osteoarthritis of knee; Seasonal allergic rhinitis; Type 2 diabetes mellitus,Phase III; Phase III; Phase III
1852,224452-66-8,https://drugs.ncats.io/drug/4MG6O8991R,US Approved Rx 2007,NDA022055,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022055,US Approved Rx 2007,NDA022055,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022055,Impetigo due to Staphylococcus aureus; Impetigo due to Streptococcus pyogenes,Approved; Approved
1853,133652-38-7,https://drugs.ncats.io/drug/DQA630RIE9,US Approved Rx 1998,BLA103786,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103786,Possibly Marketed Outside US 1996,BLA103786,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e7b63b16-d911-478b-a445-b690a1360b48,,
1854,150812-12-7,https://drugs.ncats.io/drug/12G01I6BBU,US Previously Marketed 2011,POTIGA by GLAXOSMITHKLINE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022345,US Previously Marketed 2011,POTIGA by GLAXOSMITHKLINE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022345,Partial-onset seizures,Approved
1855,11103-57-4,https://drugs.ncats.io/drug/81G40H8B0T,US Approved Rx 2001,NDA021265,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021265,US Previously Marketed 1947,BEROCCA PN by ROCHE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006071,Vitamin A deficiency; Maternal morbidity; Maternal mortality; Measles; Vitamin A deficiency; Skin aging; Skin photodamage,Phase III; Phase III; Phase III; Approved; Approved; Phase IV; Phase II
1856,864750-70-9,https://drugs.ncats.io/drug/G2AE2VE07O,US Approved Rx 2018,NDA210598,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210598,US Approved Rx 2018,NDA210598,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210598,Chronic obstructive pulmonary disease,Approved
1857,501-94-0,https://drugs.ncats.io/drug/1AK4MU3SNX,Clinical 2016,NCT02783989: Not Applicable Interventional Completed Cardiovascular Disease,https://clinicaltrials.gov/ct2/show/NCT02783989,,,,,
1858,36791-04-5,https://drugs.ncats.io/drug/49717AWG6K,US Approved Rx 2006,ANDA077743,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077743,US Approved Rx 1985,NDA018859,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018859,Chronic hepatitis C; Respiratory syncytial virus infection,Approved; Approved
1859,1211441-98-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1860,83-88-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1861,10257-32-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1862,141-22-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1863,72559-06-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1864,13292-46-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1865,61379-65-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1866,80621-81-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1867,501081-76-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1868,500287-72-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1869,1744-22-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1870,13392-28-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1871,49697-38-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1872,625115-55-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1873,105462-24-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1874,106266-06-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1875,26652-09-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1876,155213-67-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1877,174722-31-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1878,366789-02-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1879,123441-03-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1880,144034-80-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1881,119302-91-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1882,162011-90-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1883,162401-32-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1884,552292-08-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1885,128517-07-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1886,267639-76-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1887,91374-21-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1888,84057-95-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1889,632-99-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1890,84696-47-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1891,11121-48-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1892,122320-73-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1893,3650-09-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1894,287714-41-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1895,99755-59-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1896,8031-67-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1897,283173-50-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1898,106308-44-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1899,1417412-83-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1900,153-18-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1901,941678-49-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1902,81-07-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1903,554-62-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1904,85897-35-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1905,149709-62-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1906,133865-89-1,https://drugs.ncats.io/drug/90ENL74SIG,US Approved Rx 2017,NDA207145,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207145,US Approved Rx 2017,NDA207145,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207145,Parkinson's disease,Approved
1907,18559-94-9,https://drugs.ncats.io/drug/QF8SVZ843E,US Approved Rx 2013,ANDA078171,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=078171,US Approved Rx 1999,NDA020837,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020837,Asthma; Chronic obstructive pulmonary disease,Approved; Approved
1908,183990-46-7,https://drugs.ncats.io/drug/X88E147FCU,Possibly Marketed Outside US 2017,NDA213051,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98,Possibly Marketed Outside US 2017,NDA213051,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98,,
1909,9007-12-9,https://drugs.ncats.io/drug/DF35I47HCM,Possibly Marketed Outside US 2020,NCT04445857: Phase 4 Interventional Completed Analgesia,https://clinicaltrials.gov/ct2/show/NCT04445857,,,,,
1910,65-45-2,https://drugs.ncats.io/drug/EM8BM710ZC,US Previously Marketed 1943,Salicylamide by Various Mfrs.,DeHaen 1940-1975 NMEs,US Previously Marketed 1943,Salicylamide by Various Mfrs.,DeHaen 1940-1975 NMEs,Arthritis; Common cold,Approved; Approved
1911,87-17-2,https://drugs.ncats.io/drug/LHP8NEY345,US Previously Marketed 1946,Salicylanilide by Various Mfrs.,DeHaen 1940-1975 NMEs,US Previously Marketed 1946,Salicylanilide by Various Mfrs.,DeHaen 1940-1975 NMEs,Tinea capitis,Approved
1912,69-72-7,https://drugs.ncats.io/drug/O414PZ4LPZ,US Approved OTC ,21 CFR 358.110(b) wart remover:collodoin-like vehicle salicylic acid,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec358-110.xml,US Previously Marketed 1860,sodium salicylate,https://catalog.hathitrust.org/Record/100782317,Psoriasis; Ichthyosis vulgaris; Keratosis palmaris; Bruises; Arthritis; Strains and sprains; Simple backache,Approved; Approved; Approved; Approved; Approved; Approved; Approved
1913,89365-50-4,https://drugs.ncats.io/drug/2I4BC502BT,US Approved Rx 2020,ANDA203433,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203433,US Previously Marketed 1994,SEREVENT by GLAXOSMITHKLINE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020236,Asthma; Exercise-induced bronchospasm; Chronic obstructive pulmonary disease,Approved; Approved; Approved
1914,552-94-3,https://drugs.ncats.io/drug/V9MO595C9I,US Previously Marketed ,21 CFR 310.545(a)(23)(i) internal analgesic salsalate,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-545.xml,Possibly Marketed Outside US 1995,"Salsalate by Caraco Pharmaceutical Laboratories, Ltd.",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=90813662-c27e-4541-86a5-70b435533b69,Rheumatoid arthritis; Osteoarthritis; Type 2 diabetes mellitus,Approved; Approved; Phase III
1915,84775-83-7,https://drugs.ncats.io/drug/U3HSK5JC0Q,Possibly Marketed Outside US 2022,21 CFR 355,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc1c793b-b636-f13a-e053-2995a90ace61,Possibly Marketed Outside US 2007,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9096881-929d-4b70-9d60-a40528b74e44,,
1916,122575-21-7,https://drugs.ncats.io/drug/745X144DZY,US Previously Marketed 1997,QUADRAMET by LANTHEUS MEDICAL,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020570,US Previously Marketed 1997,QUADRAMET by LANTHEUS MEDICAL,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020570,Pain relief,Approved
1917,122575-21-7,https://drugs.ncats.io/drug/745X144DZY,US Previously Marketed 1997,QUADRAMET by LANTHEUS MEDICAL,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020570,US Previously Marketed 1997,QUADRAMET by LANTHEUS MEDICAL,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020570,Pain relief,Approved
1918,62989-33-7,https://drugs.ncats.io/drug/EGX657432I,US Approved Rx 2022,ANDA215420,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215420,US Approved Rx 2007,NDA022181,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022181,Phenylketonuria,Approved
1919,127779-20-8,https://drugs.ncats.io/drug/L3JE09KZ2F,US Previously Marketed 2004,INVIRASE by HOFFMANN-LA ROCHE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021785,US Previously Marketed 1995,Invirase,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=20628,HIV infection,Approved
1920,1035654-66-0,https://drugs.ncats.io/drug/94O110CX2E,US Approved Rx 2018,NDA209521,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209521,US Approved Rx 2018,NDA209521,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209521,Inflammatory lesions of non-nodular moderate to severe acne vulgaris,Approved
1921,83869-56-1,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
1922,1189541-98-7,https://drugs.ncats.io/drug/NU90V55F8I,US Approved Rx 2017,BLA761037,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761037,US Approved Rx 2017,BLA761037,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761037,,
1923,361442-04-8,https://drugs.ncats.io/drug/8I7IO46IVQ,US Approved Rx 2023,ANDA205972,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205972,US Previously Marketed 2009,Onglyza,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=22350,Type 2 diabetes mellitus,Approved
1924,85-83-6,https://drugs.ncats.io/drug/I35E9QU96C,Possibly Marketed Outside US ,Canada:SCARLET RED,https://tripod.nih.gov/npc/#Download,Possibly Marketed Outside US 1962,RED-KOTE Veterinary Scarlet-Red Oil by H. W. Naylor Company Inc.,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eed276d1-4aea-c7ed-95b7-a03f29a763c0,Lacerations; Slow healing ulcers; Abrasions; Burn,Basic research; Basic research; Basic research; Basic research
1925,7432-28-2,https://drugs.ncats.io/drug/G01BQC0879,,,,,,,Alzheimer’s disease; Drug-induced liver injury; Allergic asthma; Breast cancer,Preclinical; Preclinical; Preclinical; Basic research
1926,51-34-3,https://drugs.ncats.io/drug/DL48G20X8X,US Approved Rx 2020,ANDA212342,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212342,US Previously Marketed 1899,Hyoscine,https://en.wikipedia.org/wiki/Hyoscine,Postoperative nausea and vomiting; Depression; Motion sickness,Approved; Phase IV; Approved
1927,1276027-63-4,https://drugs.ncats.io/drug/K4YTU42T8G,US Approved Rx 2015,BLA125561,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125561,US Approved Rx 2015,BLA125561,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125561,,
1928,125-40-6,https://drugs.ncats.io/drug/P0078O25A9,US Previously Marketed 1973,SODIUM BUTABARBITAL by IVAX SUB TEVA PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=083484,US Previously Marketed 1939,BUTISOL SODIUM by MYLAN SPECIALITY LP,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=000793,Sleeplessness,Approved
1929,3366-95-8,https://drugs.ncats.io/drug/R3459K699K,US Approved Rx 2017,NDA209363,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209363,US Approved Rx 2017,NDA209363,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209363,Giardiasis; Bacterial vaginosis,Approved; Approved
1930,76-73-3,https://drugs.ncats.io/drug/1P7H87IN75,US Previously Marketed 1982,SECOBARBITAL SODIUM by VITARINE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=086273,US Previously Marketed 1929,secobarbital,https://archive.org/details/newnonofficialre39coun,Insomnia; Preoperative sedation,Approved; Approved
1931,1393-25-5,https://drugs.ncats.io/drug/88C55N56UU,US Previously Marketed 1981,SECRETIN-FERRING by FERRING,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018290,US Previously Marketed 1981,SECRETIN-FERRING by FERRING,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018290,Exocrine pancreatic insufficiency; Gastrinoma,Approved; Approved
1932,1229022-83-6,https://drugs.ncats.io/drug/DLG4EML025,US Approved Rx 2023,BLA761349,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761349,US Approved Rx 2015,BLA125504,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125504,,
1933,14611-51-9,https://drugs.ncats.io/drug/2K1V7GP655,US Approved Rx 1997,ANDA074871,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=074871,US Previously Marketed 1989,SELEGILINE HYDROCHLORIDE by SOMERSET,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019334,Bipolar depression; Cognitive disorders; Cocaine-related disorders; Parkinson's disease; Major depressive disorder,Approved; Phase II; Phase III; Approved; Approved
1934,7783-08-6,https://drugs.ncats.io/drug/HV0Y51NC4J,Possibly Marketed Outside US ,"Corvita by Trigen Laboratories, LLC",https://www.drugbank.ca/drugs/DB11068,Possibly Marketed Outside US 2011,"Corvita by Trigen Laboratories, LLC",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c920c091-1eef-49e1-a697-eb5bf6aae145,Liver cirrhosis; Alzheimer’s disease,Not Provided; Basic research
1935,7783-00-8,https://drugs.ncats.io/drug/F6A27P4Q4R,US Approved Rx 2020,NDA209376,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209376,Possibly Marketed Outside US 1964,NADA030315,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=74620a2d-a633-4af7-9a29-9da71623e450,,
1936,7782-49-2,https://drugs.ncats.io/drug/H6241UJ22B,Possibly Marketed Outside US ,V & M Vitamin and Mineral Supplement by Garden State Nutritionals [Canada],https://www.drugbank.ca/drugs/DB11135,Possibly Marketed Outside US 1996,"Strovite Forte Caplet by Everett Laboratories, Inc.",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=add96910-9404-48aa-bb3c-945e321a11ab,,
1937,1464-42-2,https://drugs.ncats.io/drug/J9V40V4PKZ,,,,,,,Lung cancer; Colorectal cancer,Phase II; Phase II
1938,1187-56-0,https://drugs.ncats.io/drug/P6708E7555,US Previously Marketed 1976,SELENOMETHIONINE SE 75 by GE HEALTHCARE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017257,US Previously Marketed 1973,SETHOTOPE by BRACCO,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017047,Investigate methionine metabolism,Approved
1939,475086-01-2,https://drugs.ncats.io/drug/5EXC0E384L,US Approved Rx 2021,NDA214275,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214275,US Approved Rx 2015,NDA207947,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207947,Pulmonary arterial hypertension,Approved
1940,910463-68-2,https://drugs.ncats.io/drug/53AXN4NNHX,US Approved Rx 2020,NDA213182,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213182,US Approved Rx 2017,NDA209637,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637,Type 2 diabetes mellitus,Approved
1941,517-43-1,https://drugs.ncats.io/drug/9VK7V8762D,Possibly Marketed Outside US ,part334,https://www.drugbank.ca/drugs/DB11365,Possibly Marketed Outside US 1998,21 CFR 334,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3277678-c1c5-4722-afcc-994f6b6253f6,,
1942,8013-11-4,https://drugs.ncats.io/drug/51e4a495,,,,,,,,
1943,8049-97-6,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
1944,56-45-1,https://drugs.ncats.io/drug/452VLY9402,Possibly Marketed Outside US ,Clinimix by Baxter Laboratories [Canada],https://www.drugbank.ca/drugs/DB00133,Possibly Marketed Outside US 1971,NDA016822,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa89dad1-bf4f-4f7e-ad1b-2431bdf36a2d,Hereditary sensory and autonomic neuropathy type 1; Amyotrophic lateral sclerosis; Alzheimer’s disease; Burns,Phase II; Phase II; Phase II; Approved
1945,86168-78-7,https://drugs.ncats.io/drug/89243S03TE,US Previously Marketed 1997,GEREF by EMD SERONO INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020443,US Previously Marketed 1990,GEREF by EMD SERONO,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019863,growth hormone deficiency,Approved
1946,50-67-9,https://drugs.ncats.io/drug/333DO1RDJY,Possibly Marketed Outside US 2021,"NCT04597190: Phase 4 Interventional Active, not recruiting PTSD",https://clinicaltrials.gov/ct2/show/NCT04597190,,,,,
1947,99592-32-2,https://drugs.ncats.io/drug/72W71I16EG,US Approved Rx 2003,NDA021385,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021385,US Approved Rx 2003,NDA021385,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021385,Interdigital tinea pedis,Approved
1948,79617-96-2,https://drugs.ncats.io/drug/QUC7NX6WMB,US Approved Rx 2014,ANDA202825,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202825,US Approved Rx 1991,NDA019839,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019839,Phobic disorders; Major depressive disorder; Post-traumatic stress disorder; Premenstrual dysphoric disorder; Panic disorder; Obsessive-compulsive disorder,Approved; Approved; Approved; Approved; Approved; Approved
1949,52757-95-6,https://drugs.ncats.io/drug/941N5DUU5C,US Approved Rx 2018,ANDA210464,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210464,US Previously Marketed 1998,RENAGEL by GENZYME,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020926,,
1950,28523-86-6,https://drugs.ncats.io/drug/38LVP0K73A,US Approved Rx 2007,ANDA078650,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=078650,US Approved Rx 1995,NDA020478,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020478,Pain,Approved
1951,305838-77-1,https://drugs.ncats.io/drug/D2YCN1I522,Possibly Marketed Outside US 2010,21 CFR 348,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9ef2e9e-8b09-4797-8a14-03cca5bd1059,Possibly Marketed Outside US 2010,21 CFR 348,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9ef2e9e-8b09-4797-8a14-03cca5bd1059,,
1952,119-53-9,https://drugs.ncats.io/drug/L7J6A1NE81,US Previously Marketed 1921,Benzoin U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Benzoin U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Unknown,
1953,106650-56-0,https://drugs.ncats.io/drug/WV5EC51866,US Previously Marketed 1997,MERIDIA by ABBOTT,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020632,US Previously Marketed 1997,MERIDIA by ABBOTT,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020632,Obesity,Withdrawn
1954,139755-83-2,https://drugs.ncats.io/drug/3M7OB98Y7H,US Approved Rx 2013,ANDA078380,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=078380,US Approved Rx 1998,NDA020895,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020895,Erectile dysfunction; Pulmonary arterial hypertension,Approved; Approved
1955,7440-21-3,https://drugs.ncats.io/drug/Z4152N8IUI,Possibly Marketed Outside US ,"Calcium Complex High Grade by New Spirit Naturals, Inc. [Canada]",https://www.drugbank.ca/drugs/DB12982,Possibly Marketed Outside US 1996,M005,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2096e241-3ed3-49cd-88c4-71db1fd2934a,Scarring,Approved
1956,7631-86-9,https://drugs.ncats.io/drug/0b3ebd14,,,,,,,,
1957,160970-54-7,https://drugs.ncats.io/drug/CUZ39LUY82,US Approved Rx 2018,ANDA210687,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210687,US Approved Rx 2008,NDA022206,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022206,Benign prostatic hyperplasia,Approved
1958,541502-14-1,https://drugs.ncats.io/drug/T4H8FMA7IM,US Approved Rx 2014,BLA125496,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125496,Possibly Marketed Outside US 2014,BLA125496,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=451f535b-8b6b-4ecf-9f19-d921b72eea39,,
1959,7440-22-4,https://drugs.ncats.io/drug/Q3A5NLA4B5,,,,,,,,
1960,65666-07-1,https://drugs.ncats.io/drug/U946SH95EE,Possibly Marketed Outside US ,Milk Thistle Plus Turmeric by Puresource Inc. [Canada],https://www.drugbank.ca/drugs/DB14375,Possibly Marketed Outside US 2010,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d5756fa-02cc-4caf-938d-f3c14f5cbd34,,
1961,923604-59-5,https://drugs.ncats.io/drug/9WS5RD66HZ,US Previously Marketed 2013,OLYSIO by JANSSEN PRODS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205123,US Previously Marketed 2013,OLYSIO by JANSSEN PRODS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205123,Chronic hepatitis C,Approved
1962,8050-81-5,https://drugs.ncats.io/drug/2OYE00PC25,US Approved Rx 2023,NDA215830,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215830,US Approved Rx 2023,NDA215830,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215830,,
1963,1219013-68-9,https://drugs.ncats.io/drug/U50VWW6XH6,Possibly Marketed Outside US ,Nuwiq by Octapharma Pharmazeutika Produktionsges M B H [Canada],https://www.drugbank.ca/drugs/DB09108,Possibly Marketed Outside US 2015,BLA125555,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6cb51f8-3acd-412c-93ec-41a8017dff3e,,
1964,79902-63-9,https://drugs.ncats.io/drug/AGG2FN16EV,US Approved Rx 2007,ANDA078103,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=078103,US Approved Rx 1991,NDA019766,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019766,Coronary heart disease mortality and cardiovascular events; Hyperlipidemia; Homozygous and heterozygous familial hypercholesterolemia; Unknown,Approved; Approved; Approved
1965,25126-32-3,https://drugs.ncats.io/drug/M03GIQ7Z6P,US Approved Rx 1976,NDA017697,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017697,US Approved Rx 1976,NDA017697,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017697,Pancreas disorders; Gallbladder disease,Approved; Approved
1966,188265-33-0,https://drugs.ncats.io/drug/T432289GYZ,US Approved Rx 2006,NDA021902,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021902,Possibly Marketed Outside US 1992,21 CFR 358A,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94fc4999-0186-4d3d-91ad-962423ccfb74,,
1967,917381-47-6,https://drugs.ncats.io/drug/8Q622VDR18,Possibly Marketed Outside US ,WHO-ATC:L03AX17,https://ginas.ncats.nih.gov/ginas/app/substance/8Q622VDR18,Possibly Marketed Outside US 2010,BLA125197,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8309b497-5d4e-4408-ac0c-2452c11c8a35,,
1968,53123-88-9,https://drugs.ncats.io/drug/W36ZG6FT64,US Approved Rx 2020,ANDA208691,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208691,Possibly Marketed Outside US 1999,NDA021083,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3275b824-3f82-4151-2ab2-0036a9ba0acc,Lymphangioleiomyomatosis,Approved
1969,486460-32-6,https://drugs.ncats.io/drug/QFP0P1DV7Z,US Approved Rx 2007,NDA022044,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022044,US Approved Rx 2006,NDA021995,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=21995,Type 2 diabetes mellitus,Approved
1970,64-17-5,https://drugs.ncats.io/drug/bfe60581,,,,,,,,
1971,7440-23-5,https://drugs.ncats.io/drug/9NEZ333N27,US Previously Marketed 1921,Sodium Indigotindisulphonate U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Sodium Indigotindisulphonate U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,,
1972,737-31-5,https://drugs.ncats.io/drug/V5403H8VG7,US Approved Rx 2022,ANDA214201,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214201,US Previously Marketed 1954,HYPAQUE by GE HEALTHCARE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=009561,Urinary system disease; Gastrointestinal disorders,Approved; Approved
1973,502-85-2,https://drugs.ncats.io/drug/7G33012534,US Approved Rx 2023,NDA214755,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214755,US Approved Rx 2002,NDA021196,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021196,Narcolepsy,Approved
1974,1190307-88-0,https://drugs.ncats.io/drug/WJ6CA3ZU8B,US Approved Rx 2016,NDA208341,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208341,US Approved Rx 2013,NDA204671,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204671,Chronic hepatitis C,Approved
1975,67-63-0,https://drugs.ncats.io/drug/ND2M416302,US Approved OTC ,21 CFR 344.12 otic:ear drying aid isopropyl alcohol,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec344-12.xml,US Previously Marketed 1921,Rubbing Alcohol,https://books.google.com/books?id=1n4gAQAAMAAJ&newbks=1&newbks_redir=0&dq=alcohol%20rubbing%20usp&pg=PA85#v=onepage&q=alcohol%20rubbing%20usp&f=false,,
1976,3380-34-5,https://drugs.ncats.io/drug/4NM5039Y5X,US Previously Marketed 1997,COLGATE TOTAL by COLGATE PALMOLIVE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020231,US Previously Marketed 1969,P-300 Antibacterial by Colgate-Palmolive,OB NME Appendix 1950-1993,Bacterial infections,Approved
1977,242478-37-1,https://drugs.ncats.io/drug/A8910SQJ1U,US Approved Rx 2024,ANDA204374,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204374,US Approved Rx 2004,NDA021518,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021518,"Overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency",Approved
1978,218949-48-5,https://drugs.ncats.io/drug/MQG94M5EEO,US Approved Rx 2010,BLA022505,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=22505,US Approved Rx 2010,BLA022505,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=22505,HIV-associated lipodystrophy,Approved
1979,956697-53-3,https://drugs.ncats.io/drug/0RLU3VTK5M,US Approved Rx 2015,NDA205266,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205266,US Approved Rx 2015,NDA205266,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205266,Basal cell carcinoma,Approved
1980,284461-73-0,https://drugs.ncats.io/drug/9ZOQ3TZI87,US Approved Rx 2022,ANDA216073,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216073,US Approved Rx 2005,NDA021923,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021923,Hepatocellular carcinoma; Renal cell carcinoma; Differentiated thyroid carcinoma,Approved; Approved; Approved
1981,110-44-1,https://drugs.ncats.io/drug/X045WJ989B,Possibly Marketed Outside US 1966,NDA012750,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9bae0d9-c2d9-49bd-92d4-a90281f35540,Possibly Marketed Outside US 1952,NDA008697,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ce19944-dd88-4a7b-84ca-b07f4ec23bad,Acne,Approved
1982,6184-06-1,https://drugs.ncats.io/drug/38Y76163XT,Clinical ,INN:sorbinicate,https://tripod.nih.gov/npc/#Download,,,,,
1983,12441-09-7,https://drugs.ncats.io/drug/6O92ICV9RU,Possibly Marketed Outside US 2012,"TL-Select DHA by Trigen Laboratories, Inc.",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0e91f52-a38e-4f8a-acd3-d229e4eaf299,Possibly Marketed Outside US 1986,NDA019600,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae951dc4-9031-43bf-943c-cb2366951f23,,
1984,1338-43-8,https://drugs.ncats.io/drug/06XEA2VD56,Possibly Marketed Outside US 2009,21 CFR 333C,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb58c46f-d405-4b45-b947-39f177624df5,Possibly Marketed Outside US 1972,ANDA061621,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e142a363-a8b8-40b9-ae9d-28777367e718,,
1985,50-70-4,https://drugs.ncats.io/drug/506T60A25R,US Approved Rx 2020,NDA202049,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202049,Possibly Marketed Outside US 1955,Levsin by Alaven Pharmaceutical LLC,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32388e18-08de-455c-aad4-9c2264435f0f,Constipation; End-Stage Renal Disease; Cystic fibrosis; Asthma; Acute renal failure; Elevated intraocular pressure; Cerebral edema,Basic research; Approved; Approved; Approved; Approved; Approved; Approved
1986,3930-20-9,https://drugs.ncats.io/drug/A6D97U294I,US Approved Rx 2001,ANDA075500,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=075500,US Approved Rx 1992,NDA019865,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019865,Atrial fibrillation; Atrial flutter; Ventricular arrhythmia,Approved; Approved; Approved
1987,8030-76-0,https://drugs.ncats.io/drug/1DI56QDM62,Possibly Marketed Outside US ,IQQU Acne Serum by Iqqu Usa Co.,https://www.drugbank.ca/drugs/DB14161,Possibly Marketed Outside US 1996,ANDA091226,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0a0feb6-84f0-4693-a11f-eb4f7ae0a87d,hypertension,Preclinical
1988,110871-86-8,https://drugs.ncats.io/drug/Q90AGA787L,US Previously Marketed 1996,ZAGAM by MYLAN,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020677,US Previously Marketed 1996,ZAGAM by MYLAN,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020677,Chronic bronchitis; Community-acquired pneumonia,Approved; Approved
1989,1695-77-8,https://drugs.ncats.io/drug/93AKI1U6QF,US Previously Marketed 1971,Trobicin by Upjohn,OB NME Appendix 1950-1993,US Previously Marketed 1971,Trobicin by Upjohn,OB NME Appendix 1950-1993,Acute gonorrheal urethritis; Acute gonorrheal urethritis; Acute gonorrheal urethritis,Approved; Approved; Approved
1990,84961-60-4,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
1991,168316-95-8,https://drugs.ncats.io/drug/XPA88EAP6V,US Approved Rx 2011,NDA022408,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022408,US Approved Rx 2011,NDA022408,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022408,Pediculosis,Approved
1992,52-01-7,https://drugs.ncats.io/drug/27O7W4T232,US Approved Rx 2016,ANDA203512,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203512,US Approved Rx 1960,NDA012151,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012151,Essential hypertension; Discrete aldosterone-producing adrenal adenomas; Congestive heart failure,Approved; Approved; Approved
1993,112-80-1,https://drugs.ncats.io/drug/2UMI9U37CP,US Previously Marketed 1921,Oleic Acid U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Oleic Acid U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Obesity; Colorectal cancer; Type 2 diabetes mellitus; Atherosclerosis; Unknown,Phase I; Phase II; Phase I; Phase I
1994,111-01-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1995,111-02-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1996,2892-62-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1997,302-96-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1998,9005-25-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
1999,3056-17-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2000,57-11-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2001,123-94-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2002,9000-36-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2003,58543-16-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2004,57817-89-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2005,83-48-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2006,471-34-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2007,9002-01-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2008,57-92-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2009,4480-58-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2010,18883-66-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2011,7440-24-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2012,304-55-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2013,110-15-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2014,54182-58-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2015,56038-13-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2016,8047-67-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2017,57-50-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2018,56030-54-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2019,343306-71-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2020,68373-14-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2021,61318-90-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2022,127-71-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2023,144-80-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2024,68-35-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2025,2447-57-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2026,127-69-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2027,144-82-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2028,723-46-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2029,63-74-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2030,144-83-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2031,599-79-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2032,72-14-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2033,57-96-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2034,7134-11-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2035,7704-34-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2036,7664-93-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2037,2551-62-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2038,38194-50-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2039,68238-36-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2040,103628-46-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2041,557795-19-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2042,40828-46-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2043,1339940-90-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2044,1030377-33-3,https://drugs.ncats.io/drug/081L192FO9,US Approved Rx 2014,NDA204569,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204569,US Approved Rx 2014,NDA204569,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204569,Sleep-onset insomnia,Approved
2045,306-40-1,https://drugs.ncats.io/drug/J2R869A8YF,US Approved Rx 2021,NDA215143,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215143,US Approved Rx 1952,NDA008453,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=008453,Skeletal muscle relaxation,Approved
2046,1332-37-2,https://drugs.ncats.io/drug/1K09F3G675,US Approved OTC ,21 CFR 347.10(c) skin protectant calamine,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec347-10.xml,US Previously Marketed 1921,Saccharated Ferric Oxide N.F.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Iron deficiency anemia; Radioactive cesium and/or radioactive or non-radioactive thallium internal contamination; Pain; Unknown; Chronic kidney disease; Unknown; Unknown; Unknown; Dental diseases; Parenteral Nutrition; Iron deficiency,Approved; Approved; Approved; Approved; Basic research; Approved; Approved
2047,2016-63-9,https://drugs.ncats.io/drug/ZTY15D026H,Possibly Marketed Outside US ,WHO-ATC:R03DA08,https://ginas.ncats.nih.gov/ginas/app/substance/ZTY15D026H,,,,,
2048,321-64-2,https://drugs.ncats.io/drug/4VX7YNB537,US Previously Marketed 1993,COGNEX by SHIONOGI INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020070,US Previously Marketed 1993,COGNEX by SHIONOGI INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020070,Alzheimer’s disease,Approved
2049,104987-11-3,https://drugs.ncats.io/drug/Y5L2157C4J,US Approved Rx 1994,NDA050708,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050708,US Approved Rx 1994,NDA050708,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050708,Organ rejection; Atopic dermatitis,Approved; Phase III
2050,171596-29-5,https://drugs.ncats.io/drug/742SXX0ICT,US Approved Rx 2019,ANDA206285,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206285,US Approved Rx 2003,NDA021368,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021368,Benign prostatic hyperplasia; Erectile dysfunction,Approved; Approved
2051,106635-80-7,https://drugs.ncats.io/drug/262P8GS9L9,US Approved Rx 2018,NDA210607,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210607,US Approved Rx 2018,NDA210607,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210607,Malaria,Approved
2052,209860-87-7,https://drugs.ncats.io/drug/1O6WQ6T7G3,US Approved Rx 2022,ANDA209040,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209040,US Approved Rx 2012,NDA202514,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202514,Unknown; Glaucoma; Ocular hypertension,Approved; Approved
2053,2055491-00-2,https://drugs.ncats.io/drug/8ZHS5657EH,US Approved Rx 2018,BLA761116,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761116,US Approved Rx 2018,BLA761116,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761116,,
2054,1207456-01-6,https://drugs.ncats.io/drug/9QHX048FRV,US Approved Rx 2018,NDA211651,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651,US Approved Rx 2018,NDA211651,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651,Unknown; Ovarian cancer; Breast cancer,Phase III; Approved
2055,308076-02-0,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
2056,37228-64-1,https://drugs.ncats.io/drug/N69L6LM4QU,,,,,,,,
2057,1187560-31-1,https://drugs.ncats.io/drug/07730V90L6,Possibly Marketed Outside US ,WHO-ATC:L01XX51,https://ginas.ncats.nih.gov/ginas/app/substance/07730V90L6,Possibly Marketed Outside US 2015,BLA125518,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=64ffb680-ea8c-42fc-9649-9e8c0eb77ddb,,
2058,10540-29-1,https://drugs.ncats.io/drug/094ZI81Y45,US Approved Rx 2005,NDA021807,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021807,US Previously Marketed 1977,NOLVADEX by ASTRAZENECA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017970,Reduction in breast cancer incidence; Breast cancer; Ductal carcinoma in situ,Approved; Approved; Approved
2059,106133-20-4,https://drugs.ncats.io/drug/G3P28OML5I,US Approved Rx 2013,ANDA202433,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202433,US Approved Rx 1997,NDA020579,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020579,Benign prostatic hyperplasia,Approved
2060,1401-55-4,https://drugs.ncats.io/drug/28F9E0DJY6,US Previously Marketed 1921,Tannic Acid U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Tannic Acid U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Alzheimer’s disease; Pain; Addisonian anemia,Preclinical; Not Provided; Approved
2061,175591-23-8,https://drugs.ncats.io/drug/H8A007M585,US Approved Rx 2008,NDA022304,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022304,US Approved Rx 2008,NDA022304,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022304,Pain,Approved
2062,526-83-0,https://drugs.ncats.io/drug/W4888I119H,US Approved OTC ,21 CFR 331.11(m) antacid:tartrate-containing tartrate (acid or salt),https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec331-11.xml,US Previously Marketed 1921,Tartaric Acid U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,skin cleasing,Approved
2063,12225-21-7,https://drugs.ncats.io/drug/JQ6BLH9FR7,Possibly Marketed Outside US 2023,NDA216956,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=65171e4a-d136-4abc-b08c-c40c1b486ff6,Possibly Marketed Outside US 2018,21 CFR 331,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3495102f-55d2-4a94-8d55-f46f49e00c27,,
2064,609799-22-6,https://drugs.ncats.io/drug/SHS4PU80D9,US Approved Rx 2023,ANDA211654,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211654,US Approved Rx 2014,NDA205677,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205677,"Sleep disorders, circadian rhythm",Approved
2065,107-35-7,https://drugs.ncats.io/drug/1EQV5MLY3D,Possibly Marketed Outside US ,Smofkabiven Electrolyte Free by Fresenius Kabi [Canada],https://www.drugbank.ca/drugs/DB01956,Possibly Marketed Outside US 1984,NDA019018,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1d88fbe0-eb97-4964-8a78-88940064f8f0,Prehypertension; Fatigue; Hepatitis; Congestive heart failure; Psychotic disorder,Phase III; Approved; Approved; Approved; Phase III
2066,81-24-3,https://drugs.ncats.io/drug/5E090O0G3Z,Possibly Marketed Outside US ,Regubil by Laboratoire Riva Inc [Canada],https://www.drugbank.ca/drugs/DB04348,,,,Type 2 diabetes mellitus; Obesity,Phase II; Phase II
2067,174671-46-6,https://drugs.ncats.io/drug/K124A4EUQ3,US Approved Rx 2020,ANDA212256,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212256,US Approved Rx 2014,NDA204427,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204427,Onychomycosis,Approved
2068,118292-40-3,https://drugs.ncats.io/drug/81BDR9Y8PS,US Approved Rx 2019,NDA211882,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211882,US Approved Rx 1997,NDA020600,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020600,Facial acne vulgaris; Plaque psoriasis; Unknown,Approved; Approved
2069,89786-04-9,https://drugs.ncats.io/drug/SE10G96M8W,US Approved Rx 2010,ANDA065362,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=065362,US Previously Marketed 1993,ZOSYN by WYETH PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050684,Female pelvic infections; Skin and skin structure infections; Pneumonia; Intra-abdominal infections; Complicated urinary tract infections,Approved; Approved; Approved; Approved; Approved
2070,7440-43-9,https://drugs.ncats.io/drug/00BH33GNGH,Possibly Marketed Outside US ,Canada:CADMIUM METALLICUM,https://tripod.nih.gov/npc/#Download,Possibly Marketed Outside US 2018,"EBV/CFS Plus by Deseret Biologicals, Inc.",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1c744874-554e-4039-b72c-24bb59e5021f,Unknown,
2071,178959-14-3,https://drugs.ncats.io/drug/IV7T84QA4T,US Previously Marketed 1998,ACUTECT by CIS BIO INTL SA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020887,US Previously Marketed 1998,ACUTECT by CIS BIO INTL SA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020887,Deep Vein Thrombosis,Approved
2072,856866-72-3,https://drugs.ncats.io/drug/97HLQ82NGL,US Approved Rx 2014,NDA205436,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205436,US Approved Rx 2014,NDA205436,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205436,Skin bacterial infections; Staphylococcal skin infections; Skin infections; Unknown,Approved; Approved; Approved
2073,197922-42-2,https://drugs.ncats.io/drug/7M19191IKG,US Approved Rx 2012,NDA203441,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203441,US Approved Rx 2012,NDA203441,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203441,Short bowel syndrome,Approved
2074,145158-71-0,https://drugs.ncats.io/drug/458VC51857,US Previously Marketed 2002,ZELNORM by ALFASIGMA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021200,US Previously Marketed 2002,ZELNORM by ALFASIGMA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021200,Constipation,Approved
2075,402957-28-2,https://drugs.ncats.io/drug/655M5O3W0U,US Previously Marketed 2011,INCIVEK by VERTEX PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201917,US Previously Marketed 2011,INCIVEK by VERTEX PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201917,Chronic hepatitis C,Approved
2076,372151-71-8,https://drugs.ncats.io/drug/XK134822Z0,US Approved Rx 2013,NDA022407,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022407,US Approved Rx 2009,NDA022110,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022110,Hospital-acquired and ventilator-associated bacterial pneumonia,Approved
2077,3424-98-4,https://drugs.ncats.io/drug/2OC4HKD3SF,US Previously Marketed 2006,TYZEKA by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022011,US Previously Marketed 2006,TYZEKA by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022011,Chronic hepatitis B,Approved
2078,191114-48-4,https://drugs.ncats.io/drug/KI8H7H19WL,US Previously Marketed 2004,KETEK by SANOFI AVENTIS US,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021144,US Previously Marketed 2004,KETEK by SANOFI AVENTIS US,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021144,Acute bacterial sinusitis; Acute bacterial exacerbation of chronic bronchitis; Community-acquired pneumonia,Approved; Approved; Approved
2079,122946-43-4,https://drugs.ncats.io/drug/124I3FE35T,Possibly Marketed Outside US 2009,NCT01093469: Phase 4 Interventional Completed Atopic Dermatitis,https://clinicaltrials.gov/ct2/show/NCT01093469,,,,,
2080,144701-48-4,https://drugs.ncats.io/drug/U5SYW473RQ,US Approved Rx 2017,ANDA208605,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208605,US Approved Rx 1998,NDA020850,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020850,Cardiovascular diseases; Hypertension,Approved; Approved
2081,1137608-69-5,https://drugs.ncats.io/drug/3T25U84H4U,US Approved Rx 2017,NDA208794,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208794,US Approved Rx 2017,NDA208794,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208794,Carcinoid syndrome,Approved
2082,846-50-4,https://drugs.ncats.io/drug/CHB1QD2QSS,US Approved Rx 2023,ANDA217875,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217875,US Approved Rx 1981,NDA018163,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018163,Insomnia,Approved
2083,85622-93-1,https://drugs.ncats.io/drug/YF1K15M17Y,US Approved Rx 2014,ANDA201742,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201742,US Previously Marketed 1999,TEMODAR by MERCK SHARP DOHME,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021029,Refractory anaplastic astrocytoma; Glioblastoma multiforme; Cancer,Approved; Approved; Basic research
2084,162635-04-3,https://drugs.ncats.io/drug/624KN6GM2T,US Approved Rx 2007,NDA022088,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022088,US Approved Rx 2007,NDA022088,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022088,Advanced renal cell carcinoma,Approved
2085,191588-94-0,https://drugs.ncats.io/drug/WGD229O42W,US Approved Rx 2000,BLA103909,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103909,US Approved Rx 2000,BLA103909,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103909,,
2086,29767-20-2,https://drugs.ncats.io/drug/957E6438QA,US Previously Marketed 1992,VUMON by HQ SPECLT PHARMA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020119,US Previously Marketed 1992,VUMON by HQ SPECLT PHARMA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020119,Refractory childhood acute lymphoblastic leukemia,Approved
2087,379270-37-8,https://drugs.ncats.io/drug/EL9943AG5J,US Approved Rx 2018,NDA022142,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022142,US Approved Rx 2001,NDA021356,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021356,HBV infections; HIV-1 infection; HIV-1 infection; Hepatitis B,Approved; Approved; Basic research; Phase II
2088,201341-05-1,https://drugs.ncats.io/drug/F4YU4LON7I,US Approved Rx 2018,NDA022142,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022142,US Approved Rx 2001,NDA021356,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021356,HBV infections; HIV-1 infection; HIV-1 infection; Hepatitis B,Approved; Approved; Basic research; Phase II
2089,63590-64-7,https://drugs.ncats.io/drug/8L5014XET7,US Approved Rx 1998,ANDA074823,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=074823,US Previously Marketed 1987,HYTRIN by ABBOTT,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019057,Benign prostatic hyperplasia; Hypertension,Approved; Approved
2090,91161-71-6,https://drugs.ncats.io/drug/G7RIW8S0XP,US Approved Rx 2006,NDA021958,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021958,US Previously Marketed 1992,LAMISIL by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020192,Onychomycosis,Approved
2091,23031-25-6,https://drugs.ncats.io/drug/N8ONU3L3PG,US Approved Rx 2009,ANDA078630,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=078630,US Previously Marketed 1974,BRICANYL by SANOFI AVENTIS US,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017466,Asthma,Approved
2092,67915-31-5,https://drugs.ncats.io/drug/0KJ2VE664U,US Approved Rx 2004,NDA021735,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021735,US Previously Marketed 1987,TERAZOL 7 by JANSSEN PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019579,Vulvovaginal candidiasis; HIV infection,Approved; Phase I
2093,50679-08-8,https://drugs.ncats.io/drug/7BA5G9Y06Q,US Previously Marketed 1985,Seldane by Dow,OB NME Appendix 1950-1993,US Previously Marketed 1985,Seldane by Dow,OB NME Appendix 1950-1993,,
2094,163451-81-8,https://drugs.ncats.io/drug/1C058IKG3B,US Approved Rx 2020,ANDA209677,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209677,US Approved Rx 1998,NDA020905,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020905,Multiple sclerosis; Active rheumatoid arthritis,Approved; Approved
2095,52232-67-4,https://drugs.ncats.io/drug/10T9CSU89I,US Approved Rx 2023,ANDA211097,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211097,US Previously Marketed 1987,PARATHAR by SANOFI AVENTIS US,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019498,Postmenopausal Osteoporosis,Approved
2096,8006-39-1,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
2097,218949-48-5,https://drugs.ncats.io/drug/MQG94M5EEO,US Approved Rx 2010,BLA022505,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=22505,US Approved Rx 2010,BLA022505,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=22505,HIV-associated lipodystrophy,Approved
2098,968-93-4,https://drugs.ncats.io/drug/6J9BLA949Q,US Previously Marketed 1970,TESLAC by BRISTOL MYERS SQUIBB,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016118,US Previously Marketed 1969,TESLAC by BRISTOL MYERS SQUIBB,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016119,Breast cancer,Approved
2099,58-22-0,https://drugs.ncats.io/drug/3XMK78S47O,US Approved Rx 2017,ANDA204255,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204255,US Previously Marketed 1937,Oreton-F by Schering,https://archive.org/details/in.ernet.dli.2015.145864,Hypogonadism,Approved
2100,718635-93-9,https://drugs.ncats.io/drug/8OBZ1M4V3V,US Approved Rx 2023,NDA214520,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214520,US Approved Rx 2023,NDA214520,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214520,,
2101,94-24-6,https://drugs.ncats.io/drug/0619F35CGV,US Approved OTC ,21 CFR 346.10(i) anorectal:local anesthetic tetracaine hydrochloride,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec346-10.xml,US Previously Marketed 1932,tetracaine,https://archive.org/details/newnonofficialre39coun,Rapid and short-acting topical ophthalmic anesthetic,Approved
2102,16960-16-0,https://drugs.ncats.io/drug/72YY86EA29,US Approved Rx 2012,ANDA202147,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202147,US Approved Rx 1970,NDA016750,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016750,Adrenocortical insufficiency,Approved
2103,60-54-8,https://drugs.ncats.io/drug/F8VB5M810T,US Approved OTC ,21 CFR 333.110(f) first aid antibiotic:ointment tetracycline hydrochloride,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec333-110.xml,US Previously Marketed 1953,ACHROMYCIN by LEDERLE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050273,Bacterial infections,Approved
2104,9005-27-0,https://drugs.ncats.io/drug/875Y4127EA,Possibly Marketed Outside US ,Volulyte by Fresenius Kabi [Canada],https://www.drugbank.ca/drugs/DB09106,Possibly Marketed Outside US 1991,BN890105,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f90664e-f2ec-47ea-bfec-7be2bf2dc28c,,
2105,66-40-0,https://drugs.ncats.io/drug/5AV7G7EIEE,US Previously Marketed 1947,Etamon Chloride by Parke-Davis,DeHaen 1940-1975 NMEs,US Previously Marketed 1947,Etamon Chloride by Parke-Davis,DeHaen 1940-1975 NMEs,Hypertension; Disease of mental health,Not Provided; Not Provided
2106,84-22-0,https://drugs.ncats.io/drug/S9U025Y077,US Approved OTC ,21 CFR 349.18(d) ophthalmic:vasoconstrictor tetrahydrozoline hydrochloride,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec349-18.xml,US Previously Marketed 1954,Tyzine by Pfizer,OB NME Appendix 1950-1985,Nasal congestion,Approved
2107,1152311-62-0,https://drugs.ncats.io/drug/8RW88Y506K,US Approved Rx 2018,NDA210491,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210491,US Approved Rx 2018,NDA210491,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210491,Cystic fibrosis,Approved
2108,50-35-1,https://drugs.ncats.io/drug/4Z8R6ORS6L,US Approved Rx 1998,NDA020785,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020785,US Approved Rx 1998,NDA020785,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020785,Erythema nodosum leprosum; Multiple myeloma,Approved; Approved
2109,3081-61-6,https://drugs.ncats.io/drug/8021PR16QO,Possibly Marketed Outside US 2013,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ba70ab3-a7ce-4096-ace4-09b78a83c792,Possibly Marketed Outside US 2013,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ba70ab3-a7ce-4096-ace4-09b78a83c792,Schizophrenia; Anxiety; Attention deficit hyperactivity disorder,Phase III; Approved; Phase II
2110,83-67-0,https://drugs.ncats.io/drug/OBD445WZ5P,US Previously Marketed 1921,Theobromine Sodio-Salicylate U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Theobromine Sodio-Salicylate U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Acute bronchitis; Hypertension; Angina pectoris,Phase III; Approved; Approved
2111,58-55-9,https://drugs.ncats.io/drug/0I55128JYK,US Approved Rx 1983,ANDA087943,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=087943,US Previously Marketed 1921,Theophylline U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,,
2112,60-56-0,https://drugs.ncats.io/drug/554Z48XN5E,US Approved Rx 2007,ANDA040734,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=040734,US Previously Marketed 1950,TAPAZOLE by KING PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=007517,Hyperthyroidism,Approved
2113,70-16-6,https://drugs.ncats.io/drug/4ABT0J945J,US Approved Rx 2012,ANDA091623,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=091623,US Previously Marketed 1947,BEROCCA PN by ROCHE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006071,Thiamine deficiency,Approved
2114,1420-55-9,https://drugs.ncats.io/drug/8ETK1WAF6R,US Previously Marketed 1963,TORECAN by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=013247,US Previously Marketed 1961,TORECAN by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012753,Vomiting; Nausea,Approved; Approved
2115,1077-28-7,https://drugs.ncats.io/drug/73Y7P0K73Y,Possibly Marketed Outside US ,"Canada:LIPOIC ACID, ALPHA",https://tripod.nih.gov/npc/#Download,Possibly Marketed Outside US 2001,"Strovite OneCaplets by Exeltis USA, Inc.",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b9b71fa4-89c7-4f5b-8174-950649434ba5,Type 2 diabetes mellitus; Nonalcoholic steatohepatitis; Stress (tako-tsubo) cardiomyopathy; Subchorionic hematoma; Carpal tunnel syndrome; Women infertility,Phase IV; Phase IV; Phase IV; Phase IV; Phase IV; Phase IV
2116,54-64-8,https://drugs.ncats.io/drug/2225PI3MOV,US Previously Marketed ,21 CFR 310.545(a)(27)(i) antimicrobial:first aid antiseptic thimerosal,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-545.xml,Possibly Marketed Outside US 1947,BLA101062,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=600e54ad-af13-462f-8a2d-2c3f7d91a8cd,Influenza virus infections; Diaper rash,Approved; Withdrawn
2117,76-75-5,https://drugs.ncats.io/drug/JI8Z5M7NA3,US Previously Marketed 1959,PENTOTHAL by ABBOTT,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011679,US Previously Marketed 1934,thiopental,https://archive.org/details/newnonofficialre39coun,Pain,Approved
2118,50-52-2,https://drugs.ncats.io/drug/N3D6TG58NI,US Approved Rx 1983,ANDA088004,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=088004,US Previously Marketed 1962,MELLARIL by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011808,Schizophrenia,Approved
2119,52-24-4,https://drugs.ncats.io/drug/905Z5W3GKH,US Approved Rx 2018,ANDA210337,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210337,US Previously Marketed 1959,THIOTEPA by IMMUNEX,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011683,Superficial papillary carcinoma of the urinary bladder; Breast adenocarcinoma; Adenocarcinoma of the ovary,Approved; Approved; Approved
2120,91-85-0,https://drugs.ncats.io/drug/R79646H5Z8,US Approved OTC ,21 CFR 341.12(l) cough/cold:antihistamine thonzylamine hydrochloride,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec341-12.xml,US Previously Marketed 1948,Neohetramine HCl by Nepera (Warner/ Chilcolt),DeHaen 1940-1975 NMEs,Tuberculosis; Runny nose; Nasal congestion; Itching; Sneezing,Preclinical; Approved; Approved; Approved; Approved
2121,72-19-5,https://drugs.ncats.io/drug/2ZD004190S,US Previously Marketed ,21 CFR 310.545(a)(20) weight control threonine,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-545.xml,Possibly Marketed Outside US 1971,NDA016822,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa89dad1-bf4f-4f7e-ad1b-2431bdf36a2d,Multiple sclerosis; Spasticity; Amyotrophic lateral sclerosis; Burns,Phase II; Phase II; Phase II; Approved
2122,108-95-2,https://drugs.ncats.io/drug/339NCG44TV,US Approved Allergenic Extract 1941,BLA103888,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d756bf9e-2e57-48a4-897a-ec1d96472dec,US Previously Marketed 1921,Phenol U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Unknown; Sore throat; Onychocryptosis,Approved; Approved
2123,9002-04-4,https://drugs.ncats.io/drug/6K15ABL77G,Possibly Marketed Outside US ,TachoSil by Takeda [Canada],https://www.drugbank.ca/drugs/DB11571,Possibly Marketed Outside US 1998,BLA103980,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b3f69e25-1b87-4507-81fa-582ea084673d,,
2124,869858-13-9,https://drugs.ncats.io/drug/SCK81AMR7R,Possibly Marketed Outside US ,Recothrom by Baxter Laboratories [Canada],https://www.drugbank.ca/drugs/DB11572,Possibly Marketed Outside US 2008,BLA125248,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=54885644-e51e-4263-aadb-366abaeb56a3,,
2125,89-83-8,https://drugs.ncats.io/drug/3J50XA376E,US Previously Marketed 1921,Thymol U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Thymol U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Gingivitis; Cataract,Not Provided; Basic research
2126,194100-83-9,https://drugs.ncats.io/drug/AVX3D5A4LM,US Approved Rx 1998,BLA020898,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020898,US Approved Rx 1998,BLA020898,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020898,,
2127,148-79-8,https://drugs.ncats.io/drug/N1Q45E87DT,US Previously Marketed 1967,MINTEZOL by MERCK SHARP DOHME,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016097,US Previously Marketed 1967,MINTEZOL by MERCK SHARP DOHME,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016097,Strongyloidiasis; Cutaneous larva migrans; Trichinosis; Visceral larva migrans,Approved; Approved; Approved; Approved
2128,115103-54-3,https://drugs.ncats.io/drug/Z80I64HMNP,US Approved Rx 2011,ANDA077555,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077555,US Approved Rx 1997,NDA020646,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020646,Partial seizures; Cocaine-related disorders; Anxiety,Approved; Phase II; Phase III
2129,274693-27-5,https://drugs.ncats.io/drug/GLH0314RVC,US Approved Rx 2023,ANDA208567,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208567,US Approved Rx 2011,NDA022433,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022433,Myocardial infarction; Acute coronary syndrome,Approved; Approved
2130,34787-01-4,https://drugs.ncats.io/drug/F93UJX4SWT,US Previously Marketed 1986,TIMENTIN by GLAXOSMITHKLINE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=062691,US Previously Marketed 1976,TICAR by GLAXOSMITHKLINE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050497,Skin and soft tissue infections; Sepsis; Intra-abdominal infections; Infections of the female pelvis and genital tract; Acute and chronic respiratory tract infections,Approved; Approved; Approved; Approved; Approved
2131,55142-85-3,https://drugs.ncats.io/drug/OM90ZUW7M1,US Approved Rx 1999,ANDA075089,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=075089,US Previously Marketed 1991,TICLID by ROCHE PALO,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019979,Coronary artery disease; Thrombotic stroke,Approved; Approved
2132,220620-09-7,https://drugs.ncats.io/drug/70JE2N95KR,US Approved Rx 2019,ANDA206335,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206335,US Approved Rx 2005,NDA021821,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021821,Complicated skin and skin structure infections; Community-acquired bacterial pneumonia; Complicated intra-abdominal infections,Approved; Approved; Approved
2133,9031-11-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2134,1326244-10-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2135,89987-06-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2136,26839-75-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2137,148159-84-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2138,9005-49-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2139,65899-73-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2140,154-42-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2141,1953-02-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2142,3313-26-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2143,136310-93-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2144,183204-74-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2145,174484-41-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2146,144494-65-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2147,7440-32-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2148,51322-75-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2149,32986-56-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2150,41708-72-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2151,477600-75-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2152,1156-19-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2153,59-98-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2154,64-77-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2155,134308-13-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2156,26171-23-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2157,2398-96-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2158,124937-51-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2159,119-53-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2160,150683-30-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2161,56-40-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2162,137-58-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2163,97240-79-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2164,123948-87-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2165,56211-40-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2166,89778-26-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2167,192391-48-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2168,114899-77-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2169,123154-38-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2170,871700-17-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2171,87679-37-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2172,1197-18-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2173,53902-12-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2174,3721-26-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2175,180288-69-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2176,1018448-65-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2177,157283-68-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2178,19794-93-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2179,81846-19-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2180,302-79-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2181,102-76-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2182,124-94-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2183,76-25-5,https://drugs.ncats.io/drug/F446C597KA,US Approved Rx 2017,ANDA207730,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207730,US Previously Marketed 1958,TRIAMCINOLONE ACETONIDE by MYLAN,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011601,Perennial allergic rhinitis; Sympathetic ophthalmia; Uveitis; Seasonal allergic rhinitis; Temporal arteritis,Approved; Approved; Approved; Approved; Approved
2184,5611-51-8,https://drugs.ncats.io/drug/I7GT1U99Y9,US Approved Rx 2017,ANDA207730,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207730,US Previously Marketed 1958,TRIAMCINOLONE ACETONIDE by MYLAN,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011601,Perennial allergic rhinitis; Sympathetic ophthalmia; Uveitis; Seasonal allergic rhinitis; Temporal arteritis,Approved; Approved; Approved; Approved; Approved
2185,396-01-0,https://drugs.ncats.io/drug/WS821Z52LQ,US Approved Rx 1964,NDA013174,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=013174,US Approved Rx 1964,NDA013174,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=013174,Edema associated with congestive heart failure,Approved
2186,28911-01-5,https://drugs.ncats.io/drug/1HM943223R,US Approved Rx 2020,ANDA214219,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214219,US Approved Rx 1982,NDA017892,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017892,Insomnia,Approved
2187,90131-68-3,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
2188,133-67-5,https://drugs.ncats.io/drug/Q58C92TUN0,US Previously Marketed 1977,TRICHLOREX by LANNETT,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=085630,US Previously Marketed 1960,NAQUA by SCHERING,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012265,Hypertension,Approved
2189,76-03-9,https://drugs.ncats.io/drug/5V2JDO056X,US Previously Marketed 2022,trichloroacetic acid,https://www.federalregister.gov/documents/2022/01/27/2022-01558/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal,Possibly Marketed Outside US 2010,TRI-CHLOR by Gordon Laboratories,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d929f1d6-3234-491c-b084-644c91e61302,Anal high-grade squamous intraepithelial lesions; Melasma,Basic research; Phase III
2190,101-20-2,https://drugs.ncats.io/drug/BGG1Y1ED0Y,US Previously Marketed ,21 CFR 310.545(a)(27)(viii) antimicrobial:personnel hand wash triclocarban,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-545.xml,Possibly Marketed Outside US 2009,21 CFR 333,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b3598ec2-9432-4870-bf1b-0f79c301b6ae,Skin bacterial infections,Withdrawn
2191,3380-34-5,https://drugs.ncats.io/drug/4NM5039Y5X,US Previously Marketed 1997,COLGATE TOTAL by COLGATE PALMOLIVE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020231,US Previously Marketed 1969,P-300 Antibacterial by Colgate-Palmolive,OB NME Appendix 1950-1993,Bacterial infections,Approved
2192,112-24-3,https://drugs.ncats.io/drug/SJ76Y07H5F,US Approved Rx 2019,ANDA211554,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211554,US Approved Rx 1985,NDA019194,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019194,Wilson's disease; Macular edema,Approved; Phase II
2193,117-89-5,https://drugs.ncats.io/drug/214IZI85K3,US Approved Rx 1981,ANDA085789,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=085789,US Previously Marketed 1959,STELAZINE by GLAXOSMITHKLINE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011552,Schizophrenia; Non psychotic anxiety,Approved; Approved
2194,146-54-3,https://drugs.ncats.io/drug/RO16TQF95Y,US Previously Marketed 1958,VESPRIN by APOTHECON,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011325,US Previously Marketed 1957,VESPRIN by BRISTOL MYERS SQUIBB,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011123,Psychosis,Approved
2195,70-00-8,https://drugs.ncats.io/drug/RMW9V5RW38,US Approved Rx 2015,NDA207981,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207981,US Approved Rx 1980,NDA018299,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018299,Keratoconjunctivitis,Approved
2196,6217-54-5,https://drugs.ncats.io/drug/ZAD9OKH9JC,Possibly Marketed Outside US ,Ultra Omega 3 by Liberty Bioscience LLC,https://www.drugbank.ca/drugs/DB03756,Possibly Marketed Outside US 2007,"DHA by Exeltis USA, Inc",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0e273e2-0876-4830-a903-282085be7f32,Alzheimer’s disease; Coronary heart disease; Age-related macular degeneration; Pregnancy,Approved; Approved; Phase III; Phase III
2197,144-11-6,https://drugs.ncats.io/drug/6RC5V8B7PO,US Approved Rx 1974,ANDA084364,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=084364,US Previously Marketed 1949,ARTANE by LEDERLE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006773,Parkinson's disease; Extrapyramidal disorders caused by central nervous system drugs,Approved; Approved
2198,13647-35-3,https://drugs.ncats.io/drug/L0FPV48Q5R,US Previously Marketed 1984,MODRASTANE by BIOENVISION,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018719,US Previously Marketed 1984,MODRASTANE by BIOENVISION,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018719,Post-menopausal breast cancer; Cushing’s disease; Conn’s syndrome; Pituitary-dependent hyperadrenocorticism,Approved; Approved; Approved; Approved
2199,138-56-7,https://drugs.ncats.io/drug/W2X096QY97,US Approved Rx 2003,ANDA076546,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=076546,US Previously Marketed 1959,Tigan by Hoffmann-La Roche,OB NME Appendix 1950-1985,Postoperative nausea and vomiting; Nausea associated with gastroenteritis,Approved; Approved
2200,738-70-5,https://drugs.ncats.io/drug/AN164J8Y0X,US Approved Rx 1973,NDA017377,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017377,US Approved Rx 1973,NDA017377,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017377,Urinary tract infections,Approved
2201,52128-35-5,https://drugs.ncats.io/drug/UPN4ITI8T4,US Previously Marketed 1993,NEUTREXIN by MEDIMMUNE ONCOLOGY,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020326,US Previously Marketed 1993,NEUTREXIN by MEDIMMUNE ONCOLOGY,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020326,Pneumocystis carinii pneumonia; Colorectal cancer; Pancreatic cancer; Refractory acute leukemia,Approved; Phase II; Phase II; Phase II
2202,3564-75-8,https://drugs.ncats.io/drug/9K5931C1H5,US Approved Rx 2006,ANDA077361,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077361,US Previously Marketed 1979,SURMONTIL by ODYSSEY PHARMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016792,Depression,Approved
2203,3902-71-4,https://drugs.ncats.io/drug/Y6UY8OV51T,US Previously Marketed 1964,TRISORALEN by VALEANT PHARM INTL,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012697,US Previously Marketed 1964,TRISORALEN by VALEANT PHARM INTL,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012697,Vitiligo,Approved
2204,91-81-6,https://drugs.ncats.io/drug/3C5ORO99TY,US Previously Marketed 1976,TRIPELENNAMINE HYDROCHLORIDE by WATSON LABS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=085188,US Previously Marketed 1948,PBZ by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=005914,Hives; Rashes; Sneezing,Approved; Approved; Approved
2205,486-12-4,https://drugs.ncats.io/drug/2L8T9S52QM,US Approved OTC ,21 CFR 341.12(m) cough/cold:antihistamine triprolidine hydrochloride,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec341-12.xml,US Previously Marketed 1958,ACTIDIL by GLAXOSMITHKLINE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011110,Allergy; Common cold,Approved; Approved
2206,57773-63-4,https://drugs.ncats.io/drug/9081Y98W2V,US Approved Rx 2000,NDA020715,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020715,US Approved Rx 2000,NDA020715,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020715,Advanced prostate cancer,Approved
2207,68917-73-7,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
2208,97322-87-7,https://drugs.ncats.io/drug/I66ZZ0ZN0E,US Previously Marketed 1997,PRELAY by SANKYO,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020719,US Previously Marketed 1997,PRELAY by SANKYO,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020719,Liposarcoma; Polycystic ovary syndrome; Type 2 diabetes mellitus,Phase II; Phase III; Withdrawn
2209,102-71-6,https://drugs.ncats.io/drug/9O3K93S3TK,US Previously Marketed ,21 CFR 310.545(a)(18)(iv) skin protectant:fever blister/cold sore trolamine,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-545.xml,Possibly Marketed Outside US 1952,NDA007936,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6a621a9c-7380-4a9f-ac54-75b48fe8518e,Impacted cerumen; Sunburns,Withdrawn; Approved
2210,2751-09-9,https://drugs.ncats.io/drug/C4DZ64560D,US Previously Marketed 1958,TAO by PFIZER,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050332,US Previously Marketed 1958,TAO by PFIZER,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050332,Upper and lower respiratory tract infections,Approved
2211,77-86-1,https://drugs.ncats.io/drug/023C2WHX2V,US Previously Marketed 1965,THAM-E by HOSPIRA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=013025,US Previously Marketed 1965,THAM-E by HOSPIRA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=013025,Metabolic acidosis,Approved
2212,1508-75-4,https://drugs.ncats.io/drug/N0A3Z5XTC6,US Approved Rx 1994,ANDA040067,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=040067,Possibly Marketed Outside US 1959,ANDA084306,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57165763-29dc-4812-b840-a8a5086416f3,Eye diseases,Approved
2213,47608-32-2,https://drugs.ncats.io/drug/T4Y8ORK057,US Approved Rx 2010,ANDA091575,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=091575,US Previously Marketed 2004,SANCTURA by ALLERGAN,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021595,Overactive bladder,Approved
2214,147059-72-1,https://drugs.ncats.io/drug/9F388J00UK,US Previously Marketed 1997,TROVAN PRESERVATIVE FREE by PFIZER,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020760,US Previously Marketed 1997,TROVAN PRESERVATIVE FREE by PFIZER,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020760,Complicated skin and skin structure infections; Pneumonia; Intra-abdominal infections; Complicated intra-abdominal infections; Skin infections; Pneumonia; Gynecologic infections; Nosocomial pneumonia,Approved; Approved; Approved; Withdrawn; Withdrawn; Withdrawn; Withdrawn; Withdrawn
2215,72-57-1,https://drugs.ncats.io/drug/I2ZWO3LS3M,US Approved Rx 2004,NDA021670,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021670,US Approved Rx 2004,NDA021670,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021670,Glaucoma; Idiopathic epiretinal membranes; Cataract,Not Provided; Not Provided; Approved
2216,9002-07-7,https://drugs.ncats.io/drug/V6GZ69J3FW,,,,,,,,
2217,73-22-3,https://drugs.ncats.io/drug/8DUH1N11BX,US Previously Marketed ,21 CFR 310.545(a)(20) weight control tryptophan,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-545.xml,Possibly Marketed Outside US 1971,NDA016822,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa89dad1-bf4f-4f7e-ad1b-2431bdf36a2d,Anxiety; Depression,Approved; Approved
2218,57-95-4,https://drugs.ncats.io/drug/W9YXS298BM,US Previously Marketed 1947,TUBOCURARINE CHLORIDE by HOSPIRA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006095,US Previously Marketed 1945,TUBOCURARINE CHLORIDE by BRISTOL MYERS SQUIBB,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=005657,Myasthenia gravis,Approved
2219,1192451-26-5,https://drugs.ncats.io/drug/969NZA3X9T,Possibly Marketed Outside US ,Zonovate by Novo Nordisk [Canada],https://www.drugbank.ca/drugs/DB09109,,,,,
2220,8006-64-2,https://drugs.ncats.io/drug/C5H0QJ6V7F,US Previously Marketed 1921,Oil of Turpentine U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Oil of Turpentine U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,,
2221,1401-69-0,https://drugs.ncats.io/drug/YEF4JXN031,Possibly Marketed Outside US ,Canada:TYLOSIN PHOSPHATE,https://tripod.nih.gov/npc/#Download,Possibly Marketed Outside US 2009,Tylosin Phosphate by Biovet Joint Stock Company,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=59e7addc-2891-44da-ac7d-27f36447c463,Calf diphtheria; Bovine respiratory complex,Approved; Approved
2222,25301-02-4,https://drugs.ncats.io/drug/Y27PUL9H56,US Previously Marketed 1961,ALEVAIRE TYLOXAPOL by BREON,https://cdn.loc.gov/service/ll/fedreg/fr038/fr038045/fr038045.pdf,US Previously Marketed 1953,Triton by Winthrop,DeHaen 1940-1975 NMEs,Pulmonary immaturity,Approved
2223,27293-82-9,https://drugs.ncats.io/drug/4F05V145YR,US Previously Marketed 1969,BILOPAQUE by GE HEALTHCARE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=013731,US Previously Marketed 1969,BILOPAQUE by GE HEALTHCARE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=013731,Cholelithiasis,Approved
2224,60-18-4,https://drugs.ncats.io/drug/42HK56048U,US Previously Marketed 1961,TPN by INTL MINERALS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=008378,US Previously Marketed 1961,TPN by INTL MINERALS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=008378,Negative nitrogen balance,Approved
2225,303-98-0,https://drugs.ncats.io/drug/EJ27X76M46,Possibly Marketed Outside US ,Watkins Coq10 by Watkins Incorporated [Canada],https://www.drugbank.ca/drugs/DB09270,Possibly Marketed Outside US 1993,21 CFR 352,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31454764-6b51-4f4e-ba25-b6ab932855e0,Progressive supranuclear palsy; Atypical parkinsonian syndrome corticobasal degeneration; Parkinson's disease; Coronary artery disease patients under statin therapy,Phase III; Phase III; Phase III; Phase III
2226,126784-99-4,https://drugs.ncats.io/drug/YF7V70N02B,US Approved Rx 2010,NDA022474,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022474,US Approved Rx 2010,NDA022474,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022474,Pregnancy,Approved
2227,98651-66-2,https://drugs.ncats.io/drug/9P6159HM7T,US Approved Rx 2004,ANDA076994,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=076994,US Previously Marketed 1990,ULTRAVATE by SUN PHARM INDS INC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019967,Corticosteroid-responsive dermatoses,Approved
2228,869113-09-7,https://drugs.ncats.io/drug/7AN603V4JV,US Approved Rx 2017,NDA209482,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209482,US Approved Rx 2013,NDA203975,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203975,Chronic obstructive pulmonary disease,Approved
2229,112-38-9,https://drugs.ncats.io/drug/K3D86KJ24N,US Approved OTC ,21 CFR 333.210(f) antifungal undecylenic acid,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec333-210.xml,US Previously Marketed 1945,Desenex Sol. by Pennwalt,DeHaen 1940-1975 NMEs,Tinea corporis; Herpes labialis; Itching; Tinea pedis,Approved; Phase III; Approved; Approved
2230,4076-02-2,https://drugs.ncats.io/drug/690VN2L7TK,Possibly Marketed Outside US ,"DIMAVAL by Petrunkin, V.E.",https://www.ncbi.nlm.nih.gov/pubmed/20664538 | https://www.ncbi.nlm.nih.gov/pubmed/24178900,,,,Mercury poisoning,Approved
2231,120373-24-2,https://drugs.ncats.io/drug/5M161S5O5P,US Previously Marketed 2000,RESCULA by SUCAMPO PHARMA LLC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021214,US Previously Marketed 2000,RESCULA by SUCAMPO PHARMA LLC,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021214,Ocular hypertension; Open-angle glaucoma,Approved; Approved
2232,57-13-6,https://drugs.ncats.io/drug/8W8T17847W,US Previously Marketed 1921,urea,https://catalog.hathitrust.org/Record/100163146,US Previously Marketed 1921,urea,https://catalog.hathitrust.org/Record/100163146,Ichthyosis; Keratosis; Eczema,Approved; Approved; Approved
2233,4105-38-8,https://drugs.ncats.io/drug/2WP61F175M,US Approved Rx 2015,NDA208169,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208169,US Approved Rx 2015,NDA208169,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208169,"Toxicity Due to Chemotherapy (fluorouracil); Toxicity Due to Chemotherapy (capecitabine); Orotic aciduria, hereditary; Overdose of capecitabine or fluorouracil; Hereditary orotic aciduria",Approved; Approved; Approved; Approved; Approved
2234,63-39-8,https://drugs.ncats.io/drug/UT0S826Z60,Possibly Marketed Outside US 2023,BLA125734,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24610d9f-0c5a-4f55-93b3-d456300bfd5d,Possibly Marketed Outside US 2023,BLA125734,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24610d9f-0c5a-4f55-93b3-d456300bfd5d,,
2235,97048-13-0,https://drugs.ncats.io/drug/W9BB98U6HP,US Approved Rx 2002,BLA021484,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021484,US Previously Marketed 1986,METRODIN by SERONO,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019415,,
2236,9039-53-6,https://drugs.ncats.io/drug/83G67E21XI,US Previously Marketed 1978,KINLYTIC by MICROBIX BIOSYSTEMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021846,US Previously Marketed 1978,KINLYTIC by MICROBIX BIOSYSTEMS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021846,,
2237,128-13-2,https://drugs.ncats.io/drug/724L30Y2QR,US Approved Rx 2019,ANDA212452,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212452,US Approved Rx 1987,NDA019594,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019594,Primary biliary cirrhosis,Approved
2238,84012-40-8,https://drugs.ncats.io/drug/ODU3ZAZ94J,US Approved Rx 2023,NDA216386,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216386,US Approved Rx 2023,NDA216386,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216386,,
2239,815610-63-0,https://drugs.ncats.io/drug/FU77B4U5Z0,US Approved Rx 2009,BLA125261,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125261,US Approved Rx 2009,BLA125261,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125261,,
2240,1360457-46-0,https://drugs.ncats.io/drug/1C75676F8V,US Approved Rx 2017,NDA209776,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209776,US Approved Rx 2017,NDA209776,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209776,Urinary tract infections; Pneumonia,Approved; Phase III
2241,76-60-8,https://drugs.ncats.io/drug/8YGN0Y942M,,,,,,,,
2242,410527-75-2,https://drugs.ncats.io/drug/0UHG2WF4HP,Clinical ,USAN:MAVEROPEPIMUT-S COMPONENT A16L [USAN],https://ginas.ncats.nih.gov/ginas/app/substance/0UHG2WF4HP,,,,,
2243,124832-26-4,https://drugs.ncats.io/drug/MZ1IW7Q79D,US Approved Rx 2019,ANDA210774,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210774,US Approved Rx 1982,NDA018604,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018604,Cold sores; Genital herpes; Herpes zoster infections; Herpes simplex infection; Herpes zoster infections,Approved; Approved; Approved; Approved; Approved
2244,1025504-45-3,https://drugs.ncats.io/drug/54K37P50KH,US Approved Rx 2017,NDA209241,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209241,US Approved Rx 2017,NDA209241,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209241,Neurological disorders; tardive dyskinesia,Phase I; Approved
2245,181695-72-7,https://drugs.ncats.io/drug/2919279Q3W,US Previously Marketed 2001,BEXTRA by GD SEARLE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021341,US Previously Marketed 2001,BEXTRA by GD SEARLE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021341,"Pain, postoperative; Primary dysmenorrhea; Rheumatoid arthritis; Osteoarthritis",Approved; Withdrawn; Withdrawn; Withdrawn
2246,81397-67-3,https://drugs.ncats.io/drug/80VUN7L00C,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,US Approved Rx 2024,NDA216165,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216165,,
2247,175865-60-8,https://drugs.ncats.io/drug/GCU97FKN3R,US Approved Rx 2003,ANDA076222,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=076222,US Previously Marketed 1989,CYTOVENE by CHEPLAPHARM,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019661,"Unknown; Cytomegalovirus retinitis; Cytomegalovirus infectious disease in kidney, heart, and kidney-pancreas transplantation; Cytomegalovirus retinitis; Acute herpetic keratitis",Approved; Approved; Approved; Approved
2248,72-18-4,https://drugs.ncats.io/drug/HG18B9YRS7,US Previously Marketed ,21 CFR 310.545(a)(20) weight control valine,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-545.xml,Possibly Marketed Outside US 1971,NDA016822,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa89dad1-bf4f-4f7e-ad1b-2431bdf36a2d,Central fatigue; Burns,Natural Metabolite; Approved
2249,76584-70-8,https://drugs.ncats.io/drug/644VL95AO6,US Approved Rx 2020,ANDA213181,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213181,US Previously Marketed 1964,Virac by Ruson,OB NME Appendix 1950-1985,"Migraine; Bipolar disorder, manic episodes; Epilepsy",Approved; Approved; Approved
2250,99-66-1,https://drugs.ncats.io/drug/614OI1Z5WI,US Approved Rx 2020,ANDA213181,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213181,US Previously Marketed 1964,Virac by Ruson,OB NME Appendix 1950-1985,"Migraine; Bipolar disorder, manic episodes; Epilepsy",Approved; Approved; Approved
2251,56124-62-0,https://drugs.ncats.io/drug/2C6NUM6878,US Approved Rx 2019,ANDA206430,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206430,Possibly Marketed Outside US 1981,ANDA206430,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8739ae02-e4c5-0fa2-e053-2a91aa0a1b74,Bladder cancer,Approved
2252,137862-53-4,https://drugs.ncats.io/drug/80M03YXJ7I,US Approved Rx 1998,NDA020818,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020818,US Previously Marketed 1996,DIOVAN by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020665,Chronic heart failure with reduced ejection fraction; Unknown; Heart failure; Myocardial infarction; Hypertension,Approved; Approved; Approved; Approved
2253,7440-62-2,https://drugs.ncats.io/drug/00J9J9XKDE,Possibly Marketed Outside US ,Multi-actin by Ahmed's Sunforce International Products Inc. [Canada],https://www.drugbank.ca/drugs/DB13971,Possibly Marketed Outside US 1961,ADELGADINA by ProMex LLC,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5aa95d0-8001-40ef-beea-e98449649a81,Unknown,
2254,1404-90-6,https://drugs.ncats.io/drug/6Q205EH1VU,US Approved Rx 2016,ANDA091532,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=091532,US Previously Marketed 1958,Vancocin by Lilly,DeHaen 1940-1975 NMEs,Severe infections caused by susceptible strains of methicillin-resistant staphylococci; Bacterial endocarditis,Approved; Approved
2255,443913-73-3,https://drugs.ncats.io/drug/YO460OQ37K,US Approved Rx 2011,NDA022405,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022405,US Approved Rx 2011,NDA022405,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022405,Thyroid cancer,Approved
2256,121-33-5,https://drugs.ncats.io/drug/CHI530446X,US Previously Marketed 1921,Vanillin U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,US Previously Marketed 1921,Vanillin U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Parkinson's disease; Premature newborns; Toxoplasmosis; Alzheimer’s disease,Preclinical; Phase I; Preclinical; Preclinical
2257,224785-90-4,https://drugs.ncats.io/drug/UCE6F4125H,US Approved Rx 2012,ANDA091347,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=091347,Possibly Marketed Outside US 2003,NDA021400,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a01def95-c0ef-43b9-bd9e-5565b2385ad3,Erectile dysfunction,Approved
2258,249296-44-4,https://drugs.ncats.io/drug/W6HS99O8ZO,US Approved Rx 2023,ANDA201962,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201962,US Previously Marketed 2006,CHANTIX by PF PRISM CV,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021928,Nicotine dependence,Approved
2259,150683-30-0,https://drugs.ncats.io/drug/21G72T1950,US Approved Rx 2018,NDA204441,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204441,US Approved Rx 2009,NDA022275,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022275,Hypervolemic and euvolemic hyponatremia,Approved
2260,50700-72-6,https://drugs.ncats.io/drug/7E4PHP5N1D,US Approved Rx 2010,ANDA090243,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=090243,US Previously Marketed 1981,Isoptin by Knoll,OB NME Appendix 1950-1985,Postoperative complications,Approved
2261,943609-66-3,https://drugs.ncats.io/drug/9RV78Q2002,US Approved Rx 2014,BLA125476,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125476,US Approved Rx 2014,BLA125476,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125476,,
2262,7440-43-9,https://drugs.ncats.io/drug/00BH33GNGH,Possibly Marketed Outside US ,Canada:CADMIUM METALLICUM,https://tripod.nih.gov/npc/#Download,Possibly Marketed Outside US 2018,"EBV/CFS Plus by Deseret Biologicals, Inc.",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1c744874-554e-4039-b72c-24bb59e5021f,Unknown,
2263,884604-91-5,https://drugs.ncats.io/drug/23HYE36B0I,US Approved Rx 2010,BLA022575,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022575,US Approved Rx 2010,BLA022575,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022575,,
2264,1377049-84-7,https://drugs.ncats.io/drug/KCU0C7RS7Z,US Approved Rx 2021,NDA214187,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214187,US Approved Rx 2016,NDA208341,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208341,Hepatitis C,Approved
2265,918504-65-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2266,1257044-40-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2267,93413-69-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2268,52-53-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2269,129497-78-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2270,1638194-78-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2271,5536-17-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2272,68506-86-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2273,503068-34-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2274,163521-12-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2275,865-21-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2276,57-22-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2277,71486-22-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2278,42971-09-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2279,879085-55-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2280,123-31-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2281,1406-18-4,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2282,50-81-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2283,12001-79-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2284,184362-10-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2285,618385-01-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2286,1646819-03-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2287,757971-58-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2288,188416-29-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2289,149647-78-9,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2290,508233-74-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2291,1535212-07-7,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2292,81-81-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2293,7732-18-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2294,7647-14-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2295,30655-48-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2296,8027-33-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2297,121-54-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2298,11138-66-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2299,437-74-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2300,127-40-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2301,87-99-0,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2302,526-36-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2303,10257-31-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2304,146-48-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2305,107753-78-6,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2306,7481-89-2,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2307,151319-34-5,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2308,139110-80-8,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2309,144-68-3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2310,107452-89-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2311,30516-87-1,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
2312,111406-87-2,https://drugs.ncats.io/drug/V1L22WVE2S,US Approved Rx 2020,ANDA211390,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211390,Possibly Marketed Outside US 1996,NDA020471,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aee65202-fddb-497f-9f11-17cc727cb157,Asthma,Approved
2313,7440-66-6,https://drugs.ncats.io/drug/J41CSQ7QDS,US Approved OTC ,21 CFR 333.110(a) first aid antibiotic:ointment bacitracin,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec333-110.xml,US Previously Marketed 1921,Zinc U.S.P.,https://www.gutenberg.org/files/41778/41778-h/41778-h.htm,Skin diseases; Infection; Superficial infections of the external eye and its adnexa caused by susceptible bacteria,Approved; Approved; Approved
2314,146939-27-7,https://drugs.ncats.io/drug/6UKA5VEJ6X,US Approved Rx 2012,ANDA077565,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077565,US Approved Rx 2001,NDA020825,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020825,Schizophrenia; Bipolar disorder,Approved; Approved
2315,7440-67-7,https://drugs.ncats.io/drug/C6V6S92N3C,US Previously Marketed ,21 CFR 310.502(a) certain drugs zirconium,https://www.gpo.gov/fdsys/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5-sec310-502.xml,,,,,
2316,17141-74-1,https://drugs.ncats.io/drug/D652ZWF066,US Approved Rx 2018,NDA207078,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207078,US Approved Rx 2018,NDA207078,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207078,,
2317,118072-93-8,https://drugs.ncats.io/drug/70HZ18PH24,US Approved Rx 2013,ANDA091363,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=091363,US Previously Marketed 2001,ZOMETA by NOVARTIS,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021223,Postmenopausal osteoporosis; Hypercalcemia; Prostate cancer with bone metastasis; Renal osteodystrophy; Disuse osteoporosis,Approved; Approved; Approved; Approved; Approved
2318,139264-17-8,https://drugs.ncats.io/drug/2FS66TH3YW,US Approved Rx 2016,ANDA205074,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205074,US Previously Marketed 1997,ZOMIG by IPR,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020768,Migraine with aura; Migraine without aura,Approved; Approved
2319,82626-48-0,https://drugs.ncats.io/drug/7K383OQI23,US Approved Rx 2016,ANDA201509,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201509,US Approved Rx 1992,NDA019908,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019908,Insomnia,Approved
2320,68291-97-4,https://drugs.ncats.io/drug/459384H98V,US Approved Rx 2006,ANDA077634,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077634,US Approved Rx 2000,NDA020789,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020789,Epilepsy,Approved
